(12) STANDARD PATENT (11) Application No. **AU 2009209304 B2**
(19) AUSTRALIAN PATENT OFFICE

(54) Title
Compounds and compositions as kinase inhibitors

(51) International Patent Classification(s)
C07D 471/04 (2006.01) ***A61K 31/4375*** (2006.01)

(21) Application No: **2009209304** (22) Date of Filing: **2009.01.27**

(87) WIPO No: **WO09/097287**

(30) Priority Data

(31) Number	(32) Date	(33) Country
61/053,091	**2008.05.14**	**US**
61/025,665	**2008.02.01**	**US**

(43) Publication Date: **2009.08.06**
(44) Accepted Journal Date: **2012.04.12**

(71) Applicant(s)
IRM LLC

(72) Inventor(s)
Wu, Xu;Che, Jianwei;Okram, Barun;Jin, Qihui;Jin, Yunho;Yan, S. Frank;Ding, Qiang;Uno, Tetsuo;Liu, Yahua;Hao, Xueshi

(74) Agent / Attorney
Davies Collison Cave, 1 Nicholson Street, Melbourne, VIC, 3000

(56) Related Art
WO 2006/112666 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 August 2009 (06.08.2009)

PCT

(10) International Publication Number
WO 2009/097287 A8

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/4375* (2006.01)

(21) International Application Number:
PCT/US2009/032148

(22) International Filing Date:
27 January 2009 (27.01.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/025,665 1 February 2008 (01.02.2008) US
61/053,091 14 May 2008 (14.05.2008) US

(71) Applicant *(for all designated States except US)*: **IRM LLC** [US/US]; 131 Front Street, P.O. Box 2899, Hamilton, HM LX (BM).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OKRAM, Barun** [IN/US]; 9116 Judicial Drive, Unit #4151, San Diego, California 92122 (US). **UNO, Tetsuo** [JP/US]; 4495 Shorepointe Way, San Diego, California 92130 (US). **DING, Qiang** [CN/US]; 9045 Judicial Drive, Apt. 1208, San Diego, California 92122 (US). **LIU, Yahua** [CN/US]; 7548 Charmant Drive, #1414, San Diego, California 92122 (US). **JIN, Yunho** [KR/US]; 13447 Tiverton Road, San Diego, California 92130 (US). **JIN, Qihui** [CN/US]; 4526 Vereda Mar De Ponderosa, San Diego, California 92130 (US). **WU, Xu** [CN/US]; 12631 El Camino Real, #2309, San Diego, California 92130 (US). **CHE, Jianwei** [CN/US]; 7188 Arroyo Grande Road, San Diego, California 92129 (US). **YAN, S. Frank** [CN/CN]; 396 Ling Zhao Road, No. 4, Room 402, Shanghai 200124 (CN). **HAO, Xueshi** [CN/US]; 3937 Nobel Drive, #135, San Diego, California 92122 (US).

(74) Agents: **RAYMOND, Daniel E.** et al.; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the revised international search report:
1 October 2009

(48) Date of publication of this corrected version:
14 January 2010

(15) Information about Corrections:
see Notice of 14 January 2010

Previous Correction:
see Notice of 1 October 2009

(54) Title: COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS

(57) Abstract: The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat o prevent diseases or disorders associated with abnormal or deregulated kinase activity,particulary Syk,ZAP70,KDR,FMS,FLT3,c-Kit,RET,TrkA,TrkB,TrkC-GR-1R,Alk,c- FMS.or combinations thereof.

WO 2009/097287 A8

COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 61/025,665, filed February 1, 2008 and U.S. Provisional Patent Application No. 61/053,091, filed May 14, 2008. The disclosure of the priority applications is incorporated herein by reference in their entirety and for all purposes.

FIELD OF THE INVENTION

[0002] The invention relates to protein kinase inhibitors, and methods of using such compounds.

BACKGROUND OF THE INVENTION

[0003] Protein kinases (PK) are a large set of structurally related phosphoryl transferases having highly conserved structures and catalytic functions. Protein kinases are enzymatic components of the signal transduction pathways which catalyze the transfer of the terminal phosphate from ATP to the hydroxy group of tyrosine, serine and/or threonine residues of proteins, and are therefore categorized into families by the substrates they phosphorylate: Protein Tyrosine Kinases (PTK), and Protein Serine/Threonine Kinases.

[0004] Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes, wherein protein kinases are key mediators of cellular signals leading to the production of growth factors and cytokines. The overexpression or inappropriate expression of normal or mutant protein kinases plays a significant role in the development of many diseases and disorders including, central nervous system disorders such as Alzheimer's, inflammatory disorders such as arthritis, bone diseases such as osteoporosis, metabolic disorders such as diabetes, blood vessel proliferative disorders such as angiogenesis, autoimmune diseases such as rheumatoid arthritis, ocular diseases, cardiovascular disease, atherosclerosis, cancer, thrombosis, psoriasis, restenosis, schizophrenia, pain sensation, transplant rejection and infectious diseases such as viral, and fungal infections.

[0005] Examples of protein-tyrosine kinases include, but are not limited to, Irk, IGFR-1, Zap-70, Bmx, Btk, CHK (Csk homologous kinase), CSK (C-terminal Src Kinase), Itk-1, Src (c-Src, Lyn, Fyn, Lck, Syk, Hck, Yes, Blk, Fgr and Frk), Tec, Txk/Rlk, Abl, EGFR (EGFR-1/ErbB-1, ErbB-2/NEU/HER-2, ErbB-3 and ErbB-4), FAK, FGF1R (also FGFR1 or FGR-1), FGF2R (also FGR-2), MET (also Met-I or c-MET), PDGFR (.alpha. and .beta.), Tie-1, Tie-2 (also Tek-1 or Tek), VEGFR1 (also FLT-1), VEGFR2 (also KDR), FLT-3, FLT-4, c-KIT, JAK1, JAK2, JAK3, TYK2, LOK, RET, TRKA, PYK2, ALK (Anaplastic Lymphoma Kinase), EPHA (1-8), EPHB (1-6), RON, Fes, Fer or EPHB4 (also EPHB4-1).

[0006] Examples of protein-serine/threonine kinases include, but are not limited to, Ark, ATM (1-3),

CamK (1-IV), CamKK, Chk1 and 2 (Checkpoint kinases), CKI, CK2, Erk, IKK-I (also IKK-ALPHA or CHUK), IKK-2 (also IKK-BETA), Ilk, Jnk (1-3), LimK (1 and 2), MLK3Raf (A, B, and C), CDK (1-10), PKC (including all PKC subtypes), Plk (1-3), NIK, Pak (1-3), PDK1, PKR, RhoK, RIP, RIP-2, GSK3 (.alpha. and .beta.), PKA, P38, Erk (1-3), PKB (including all PKB subtypes) (also AKT-1, AKT-2, AKT-3 or AKT3-1), IRAK1, FRK, SGK, TAK1 or Tp1-2 (also COT).

SUMMARY OF THE INVENTION

[0007] The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors.

[0008] In one aspect, the present invention provides compounds having Formula (I), and the pharmaceutically acceptable salts, pharmaceutically acceptable solvates (e.g. hydrates), the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixture of isomers thereof:



(I)

wherein:

R^1 is $-NR^6R^7$, $(CH_2)_nR^{19}$, L^3R^{19}, R^{20}, C_6-C_{14}aryl, C_3-C_8cycloalkyl, C_2-C_{14}heterocycloalkyl or C_3-C_{13}heteroaryl, wherein the C_6-C_{14}aryl, C_3-C_8cycloalkyl, C_2-C_{14}heterocycloalkyl and C_3-C_{13}heteroaryl of R^1 is optionally substituted with 1 to 3 substituents independently selected from halogen, nitro, cyano, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkylthio, hydroxyl-C_1-C_6alkyl, halo-substituted-C_1-C_6alkyl, halo-substituted-C_1-C_6alkoxy, C_3-C_{12}cycloalkyl, C_2-C_{14}heterocycloalkyl, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, $-X^2S(O)_{0-2}R^{17}$, $-X^2S(O)_{0-2}X^2R^{19}$, $-X^2NR^{17}R^{17}$, $-X^2NR^{17}C(O)R^{17}$, $-X^2C(O)NR^{17}R^{17}$, $-X^2NR^{17}C(O)R^{19}$, $-X^2C(O)NR^{17}R^{19}$, $-X^2C(O)R^{19}$, $-X^2NR^17X^2R^{19}$ and $-X^2OX^2R^{19}$; wherein,

X^2 is a bond or C_1-C_4alkylene;

L^3 is a bond, C_1-C_6alkyl or C_1-C_6alkoxy; wherein the C_1-C_6alkyl and C_1-C_6alkoxy groups of L^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, –CN, $-C_1$-C_6alkyl, C_1-C_6alkoxy, $–OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $–C(O)N(R^{12})_2$, $–N(R^{12})C(O)R^{13}$, C_2-C_{14}heterocycloalkyl, $–S(O)_2R^{13}$, $–S(O)_2 N(R^{12})_2$, R^{13}, $-(C(R^{12})_2)_nR^{13}$, $-(C(R^{12})_2)_nR^{14}$, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy;

R^{17} is H or C_1-C_6alkyl; and

R^{19} is R^{20}, C_3-C_{12}cycloalkyl, C_2-C_{14}heterocycloalkyl, C_6-C_{14}aryl or C_3-C_{13}heteroaryl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_{12}cycloalkyl and

C_2-C_{14}heterocycloalkyl of R^{19} are optionally substituted with 1 to 3 radicals independently selected from halogen, nitro, cyano, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkylthio, hydroxyl-C_1-C_6alkyl, halo-substituted-C_1-C_6alkyl, and halo-substituted-C_1-C_6alkoxy;

R^2 and R^3 are independently selected from H, $(CH_2)_nR^{11}$, $-C(O)R^{12}$, $-CR^{12}=NOCR^{12}$, $-NR^8R^{10}$, halogen, R^{20}, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_1-C_6alkoxy, C_1-C_6alkylthio, hydroxyl-C_1-C_6alkyl, halo-substituted-C_1-C_6alkyl, and halo-substituted-C_1-C_6alkoxy, C_6-C_{14}aryl, C_3-C_{13}heteroaryl and C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_3-C_{13}heteroaryl, and C_2-C_{14}heterocycloalkyl of R^2 and R^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-NO_2$, $-OR^{12}$, $-OR^{10}$, =O, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-NR^{12}C(O)N(R^{12})_2$, $-NHS(O)_2R^{13}$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy;

R^4 is H, C_1-C_6alkyl or $-(CR^{12}R^{12})_nR^{11}$;

R^5 is H or C_1-C_6alkyl;

R^6 is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_1-C_6alkyl, C_3-C_8cycloalkyl, halo-substituted C_1-C_6alkyl, $-(CH_2)_nR^9$, R^{20}, $-L^3R^9$ or $-Y^1$-L^1-R^{14}, wherein,

Y^1 is arylene, heteroarylene or heterocycloalkylene, and

L^1- is a bond, -O-, -C(O)-, $-C(O)N(R^{11})$-, $-(C(R^{12})_2)_n$- or $-O(CH_2)_n$-;

and wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, halo-substituted C_1-C_6alkyl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^6 and Y^1 are optionally substituted with 1 to 3 substituents independently selected from, halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^7 is H or C_1-C_6 alkyl;

R^8 is H or C_1-C_6 alkyl;

R^9 is R^{20}, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or Y^2-L^2-R^{14}, wherein,

Y^2 is bond, arylene, heteroarylene or heterocycloalkylene, and

L^2- is a bond, -O-, or -O$(CH_2)_n$-;

and wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl of R^9 and Y^2 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, =O, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^{10} is halo-substituted C_1-C_6alkyl, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or -$(CH_2)_nR^{11}$, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^{10} are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, hydroxl, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^{11} is $-N(R^{12})_2$, $-OR^{13}$, R^{20}, $-C(O)N(R^{12})_2$, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl, or C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl of R^{11} are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

each R^{12} is independently selected from H, C_1-C_8alkyl, C_2-C_6alkene, halo-substituted C_1-C_6alkyl and C_3-C_8cycloalkyl, or each R^{12} is independently a C_1-C_6alkyl that together with N they are attached to form a heterocycloalkyl;

R^{13} is H, C_1-C_6alkyl, C_3-C_8cycloalkyl, halo-substituted C_1-C_6alkyl or C_2-C_{14}heterocycloalkyl;

R^{14} is H, halogen, OR^{13}, R^{20}, -CN, $-S(O)_2N(R^{12})_2$, $-S(O)_2R^{13}$, $-C(O)N(R^{12})_2$, $N(R^{12})_2$, C_1-C_6alkyl, halo-substituted C_1-C_6alkyl, C_6-C_{14}aryl, heteroaryl or C_2-C_{14}heterocycloalkyl, wherein the C_2-C_{14}heterocycloalkyl, C_6-C_{14}aryl and C_3-C_{13}heteroaryl are optionally substituted with 1-3 substituents independently selected from halogen, -CN, C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_8cycloalkyl, $-OR^{13}$, $-C(O)R^{13}$, $OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)(C(R^{12})_2)_nR^{16}$, $-C(O)N(R^{12})_2$, heterocycloalkyl, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, $-NHS(O)_2R^{13}$, R^{13}, R^{10}, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $-(C(R^{12})_2)_nR^{16}$, halo-substituted C_1-C_6alkyl, C_2-C_6alkenyl, -CN, halogen, R^{10},

R^{15} is H, C_1-C_6alkyl, C_2-C_6alkenyl, -CN, halogen, R^{10};

R^{16} is H, halogen, OR^{13}, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, -CN, $-S(O)_2N(R^{12})_2$, $-S(O)_2R^{13}$, $C(O)N(R^{12})_2$, $-NR^{12}C(O)(R^{12})$, halo-substituted C_1-C_6alkyl, or C_2-C_{14}heterocycloalkyl;

R^{20} is

R^{20} is  ,  or  , and

each n is independently 1, 2, 3, 4, 5 or 6.

[0009] In certain embodiments of the compounds of Formula (I) are compounds of Formula (Ia):



(Ia).

[0009a] In one aspect the present invention provides a compound of Formula (Ia), pharmaceutically acceptable salt, pharmaceutically acceptable solvate thereof :



Formula

(Ia).

wherein:

R^2 and R^3 are independently selected from H, $(CH_2)_nR^{11}$, $-C(O)R^{12}$, $-CR^{12}=NOCR^{12}$, $-NR^8R^{10}$, halogen, R^{20}, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_1-C_6alkoxy, C_1-C_6alkylthio, hydroxyl-C_1-C_6alkyl, halo-substituted-C_1-C_6alkyl, and halo-substituted-C_1-C_6alkoxy, C_6-C_{14}aryl, C_3-C_{13}heteroaryl and C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_3-C_{13}heteroaryl, and C_2-C_{14}heterocycloalkyl of R^2 and R^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-NO_2$, $-OR^{12}$, $-OR^{10}$, =O, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-NR^{12}C(O)N(R^{12})_2$, $-NHS(O)_2R^{13}$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$,$-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy;

R^4 is H, C_1-C_6alkyl or $-(CR^{12}R^{12})_nR^{11}$;

R^5 is H or C_1-C_6alkyl;

R^6 is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_1-C_6alkyl, C_3-C_8cycloalkyl, halo-substituted C_1-C_6alkyl, $-(CH_2)_nR^9$, R^{20}, $-L^3R^9$ or $-Y^1$-L^1-R^{14}, wherein,

Y^1 is arylene, heteroarylene or heterocycloalkylene, and

L^1- is a bond, -O-, -C(O)-, $-C(O)N(R^{11})$-, $-(C(R^{12})_2)_n$- or $-O(CH_2)_n$-;

L^3 is a bond, C_1-C_6alkyl or C_1-C_6alkoxy; wherein the C_1-C_6alkyl and C_1-C_6alkoxy groups of L^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, –CN, -C_1-C_6alkyl, C_1-C_6alkoxy, -OR^{13}, -$C(O)R^{13}$, -$OC(O)R^{13}$, -$C(O)OR^{13}$, -$N(R^{12})_2$, –$C(O)N(R^{12})_2$, -$N(R^{12})C(O)R^{13}$, C_2-C_{14}heterocycloalkyl, –$S(O)_2R^{13}$, –$S(O)_2$ $N(R^{12})_2$, R^{13}, -$(C(R^{12})_2)_nR^{13}$, -$(C(R^{12})_2)_nR^{14}$, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy;

and wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, halo-substituted C_1-C_6alkyl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^6 and Y^1 are optionally substituted with 1 to 3 substituents independently selected from, halogen, -CN, –OR^{12}, –OR^{10}, -$C(O)R^{12}$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{11})_2$, -$N(R^{12})_2$, -$N(R^{12}R^{10})$, -$N(R^{12}R^{11})$, -$(CR^{12}R^{12})_nR^{11}$, -SR^8, –$NR^{12}C(O)N(R^{12})_2$, -$C(O)N(R^{12}R^{10})$, –$N(R^{12})C(O)R^{13}$, –$C(O)N(R^{11})_2$, –$C(O)N(R^{12})_2$, -$(CR^{12}R^{12})_nR^{11}$, -$(CH_2)_nR^{12}$, -$(CH_2)_nR^{13}$, -$O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, -$O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, –$S(O)_2R^{12}$, –$S(O)_2N(R^{11})_2$, –$S(O)_2N(R^{12})_2$, R^{12}, R^{10}, -OR^{13}, -$C(O)R^{13}$, -$OC(O)R^{13}$, -$C(O)OR^{13}$, –$S(O)_2R^{13}$, –R^{13}, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^7 is H or C_1-C_6 alkyl;

R^8 is H or C_1-C_6 alkyl;

R^9 is R^{20}, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or Y^2-L^2-R^{14}, wherein,

Y^2 is bond, arylene, heteroarylene or heterocycloalkylene, and

L^2- is a bond, -O-, or -$O(CH_2)_n$-;

and wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl of R^9 and Y^2 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, =O, –OR^{12}, –OR^{10}, -$C(O)R^{12}$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{11})_2$, -$N(R^{12})_2$, -$N(R^{12}R^{10})$, -$N(R^{12}R^{11})$, -$(CR^{12}R^{12})_nR^{11}$, -SR^8, –$NR^{12}C(O)N(R^{12})_2$, -$C(O)N(R^{12}R^{10})$, -$N(R^{12})C(O)R^{13}$, –$C(O)N(R^{11})_2$, –$C(O)N(R^{12})_2$, -$(CR^{12}R^{12})_nR^{11}$, -$(CH_2)_nR^{12}$, -$(CH_2)_nR^{13}$, -$O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, -$O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, –$S(O)_2R^{12}$,

$-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^{10} is halo-substituted C_1-C_6alkyl, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or $-(CH_2)_nR^{11}$, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^{10} are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, hydroxl, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^{11} is $-N(R^{12})_2$, $-OR^{13}$, R^{20}, $-C(O)N(R^{12})_2$, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl, or C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl of R^{11} are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

each R^{12} is independently selected from H, C_1-C_6alkyl, C_2-C_6alkene, halo-substituted C_1-C_6alkyl and C_3-C_8cycloalkyl, or each R^{12} is independently a C_1-C_6alkyl that together with N they are attached to form a heterocycloalkyl;

R^{13} is H, C_1-C_6 alkyl, C_3-C_8cycloalkyl, halo-substituted C_1-C_6 alkyl or C_2-C_{14}heterocycloalkyl;

R^{14} is H, halogen, OR^{13}, R^{20}, -CN, $-S(O)_2N(R^{12})_2$, $-S(O)_2R^{13}$, $-C(O)N(R^{12})_2$, $N(R^{12})_2$, C_1-C_6alkyl, halo-substituted C_1-C_6alkyl, C_6-C_{14}aryl, heteroaryl or C_2-C_{14}heterocycloalkyl, wherein the C_2-C_{14}heterocycloalkyl, C_6-C_{14}aryl and C_3-C_{13}heteroaryl are optionally substituted with 1-3 substituents independently selected from halogen, –CN, C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_8cycloalkyl, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)(C(R^{12})_2)_nR^{16}$, $-C(O)N(R^{12})_2$, heterocycloalkyl, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, $-NHS(O)_2R^{13}$, R^{13}, R^{10}, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $-(C(R^{12})_2)_nR^{16}$, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy;

R^{15} is H, C_1-C_6alkyl, C_2-C_6alkenyl, -CN, halogen, R^{10},

R^{16} is H, halogen, OR^{13}, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, -CN, $-S(O)_2N(R^{12})_2$, $-S(O)_2R^{13}$, $C(O)N(R^{12})_2$, $-NR^{12}C(O)(R^{12})$, halo-substituted C_1-C_6alkyl, or C_2-C_{14}heterocycloalkyl;

R^{20} is  ,  or  , and

each n is independently 1, 2, 3, 4, 5 or 6.

[00010] In certain embodiments of the compounds of Formulas (I) and Formula (a), R^6 is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl or C_3-C_8cycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{15}heteroaryl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14}heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted

C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy. In other embodiments R^6 is





, or , wherein,

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^8 is H or C_1-C_6 alkyl;

n is 1, 2, 3 or 4, and

p is 0, 1, 2 or 3.

[00011] In other embodiments R^6 is





or , wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^8 is H or C_1-C_6 alkyl;

n is 1, 2, 3 or 4, and

p is 0, 1, 2 or 3.

[00012] In other embodiments of the aforementioned R^6, R^{21} is halogen, –CN, -C_1-C_6 alkyl, C_1-C_6alkoxy, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)N(R^{12})_2$, C_2-C_{14}heterocycloalkyl, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, R^{13}, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $-(CH_2)_nR^{14}$, halo-substituted C_1-C_6 alkyl or halo-substituted C_1-C_6alkoxy.

[00013] In certain embodiments of the compounds of Formulas (I) and Formula (Ia), R^6 is $-(CH_2)_nR^9$, where R^9 is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_8cycloalkyl or C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and n is 1, 2, 3 or 4.

[00014] In certain embodiments of the compounds of Formulas (I) and Formula (Ia), R^6 is $-L^3R^9$, where R^9 is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_8cycloalkyl or C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-

C_{13}heteroaryl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and n is 1, 2, 3 or 4.

[00015] In other embodiments of the compounds of Formulas (I) and Formula (Ia), L^3 is a C_1-C_6alkyl or C_1-C_6alkoxy; wherein the C_1-C_6alkyl and C_1-C_6alkoxy groups of L^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, -C_1-C_6alkyl, $-OR^{13}$, $-N(R^{12})_2$, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy. In other embodiments of such L^3, R^{13} is H or C_1-C_6 alkyl.

[00016] In other embodiments of the aforementioned embodiments, R^9 is



wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^8 is H or C_1-C_6 alkyl;

n is 1, 2, 3 or 4;

m is 1, 2, 3 or 4, and

p is 0, 1, 2 or 3.

[00017] In certain embodiments of such R^9, R^{21} is halogen, –CN, -C_1-C_6 alkyl, C_1-C_6alkoxy, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)N(R^{12})_2$, C_2-C_{14}heterocycloalkyl, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, R^{13}, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $-(CH_2)_nR^{14}$, halo-substituted C_1-C_6 alkyl or halo-substituted C_1-C_6alkoxy.

[00018] In certain embodiments of the compounds of Formulas (I) and Formula (Ia), R^6 is $-Y^1$-L^1-R^{14}, whereY^1 is arylene and R^{14} is C_2-C_{14}heterocycloalkyl optionally substituted with 1-3 substituents

independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and n is 1, 2, 3 or 4. In certain embodiments of the compounds of Formulas (I) and Formula (Ia), R^6 is $-Y^1$-L^1-R^{14}, where Y^1 is phenylene and R^{14} is heterocycloalkyl optionally substituted with 1-3 substituents independently selected from halogen, -CN, $-C_1$-C_6alkyl, C_1-C_6alkoxy, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)N(R^{12})_2$, C_2-C_{14}heterocycloalkyl, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, R^{13}, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $-(CH_2)_nR^{14}$, halo-substituted C_1-C_6 alkyl and halo-substituted C_1-C_6alkoxy.

[00019] In certain embodiments of the compounds of Formulas (I) and Formula (Ia), R^6 is $-(CH_2)_nR^9$ and R^9 is Y^2-L^2-R^{14}, wherein Y^2 is arylene and R^{14} is C_2-C_{14}heterocycloalkyl optionally substituted with 1-3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and n is 1, 2, 3 or 4. In certain embodiments, Y^2 is phenylene.

[00020] In certain embodiments of the compounds of Formulas (I) and Formula (Ia), R^6 is C_1-C_6alkyl or halo-substituted C_1-C_6alkyl, wherein the C_1-C_6alkyl and halo-substituted C_1-C_6alkyl of R^6 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and n is 1, 2, 3 or 4.

[00021] In certain embodiments of the compounds of Formulas (I) and Formula (Ia), R^2 is H, $(CH_2)_nR^{11}$, $-C(O)R^{12}$, $-CR^{12}$=NOCR^{12}, halogen, R^{20}, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_1-C_6alkoxy, C_1-C_6alkylthio, hydroxyl-C_1-C_6alkyl, halo-substituted-C_1-C_6alkyl, and halo-substituted-C_1-C_6alkoxy, C_6-C_{14}aryl, C_3-C_{13}heteroaryl and C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_3-C_{13}heteroaryl, and C_2-C_{14}heterocycloalkyl of R^2 and R^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-NO_2$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, -

$C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and n is 1, 2, 3 or 4.

[00022] In certain embodiments of the compounds of Formulas (I) and Formula (Ia), R^2 H, halogen, R^{20},



, wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, -

$(CH_2)_nR^{12}$, -$(CH_2)_nR^{13}$, -O$(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, -O$(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, –$S(O)_2R^{12}$, –$S(O)_2N(R^{11})_2$, –$S(O)_2N(R^{12})_2$, R^{12}, R^{10}, -OR^{13}, -$C(O)R^{13}$, -$OC(O)R^{13}$, -$C(O)OR^{13}$, –$S(O)_2R^{13}$, –R^{13}, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^8 is H or C_1-C_6 alkyl;

n is 1, 2, 3 or 4;

m is 1, 2, or 3 and

p is 0, 1, 2 or 3.

[00023] In certain embodiments of such R^2, R^{21} is –OR^{12}, -$C(O)R^{12}$, -$N(R^{12})_2$, -$(CH_2)_nR^{13}$, R^{10}, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, hydroxyl-C_1-C_6alkyl or halo-substituted C_1-C_6alkyl.

[00024] Also provided herein are compounds of Formulas (I) and Formula (Ia), wherein the compound of Formula (I) or Formula (Ia) are compounds of Formula (Ib):



(Ib)

wherein,

R^{21} is halogen, -CN, –OR^{12}, –OR^{10}, -$C(O)R^{12}$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{11})_2$, -$N(R^{12})_2$, -$N(R^{12}R^{10})$, -$N(R^{12}R^{11})$, -$(CR^{12}R^{12})_nR^{11}$, -SR^8, –$NR^{12}C(O)N(R^{12})_2$, -$C(O)N(R^{12}R^{10})$, –$N(R^{12})C(O)R^{13}$, –$C(O)N(R^{11})_2$, –$C(O)N(R^{12})_2$, -$(CR^{12}R^{12})_nR^{11}$, -$(CH_2)_nR^{12}$, -$(CH_2)_nR^{13}$, -O$(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, -O$(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, –$S(O)_2R^{12}$, –$S(O)_2N(R^{11})_2$, –$S(O)_2N(R^{12})_2$, R^{12}, R^{10}, -OR^{13}, -$C(O)R^{13}$, -$OC(O)R^{13}$, -$C(O)OR^{13}$, –$S(O)_2R^{13}$, –R^{13}, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

n is 1, 2, 3 or 4, and

p is 0, 1, 2 or 3.

[00025] In certain embodiments of such compounds of Formula (Ib), R^{21} is halogen, -CN, -NO_2, –OR^{12}, -$C(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{12})_2$, –$NR^{12}C(O)N(R^{12})_2$, -$C(O)N(R^{12}R^{10})$, –$C(O)N(R^{12})_2$, -$(CR^{12}R^{12})_nR^{11}$, $(CH_2)_nR^{14}$, -O$(CH_2)_nR^{14}$, –$S(O)_2R^{12}$, –$S(O)_2N(R^{12})_2$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, hydroxyl-C_1-C_6alkyl or halo-substituted C_1-C_6alkyl. In other embodiments of such compounds of Formula (Ib), each R^{12} is independently selected from H, C_1-C_6alkyl and C_3-C_8cycloalkyl, or each R^{12} is independently a C_1-C_6alkyl that together with N they are attached form a heterocycloalkyl. In other embodiments of such compounds of Formula (Ib), R^{10} is C_3-C_8cycloalkyl or -$(CH_2)_nR^{11}$. In other embodiments of such

compounds of Formula (Ib), R^{11} is C_3-C_8cycloalkyl or C_2-C_{14}heterocycloalkyl. In other embodiments of such compounds of Formula (Ib),R^{14} is -OR^{13}, -CN, $N(R^{12})_2$, halo-substituted C_1-C_6alkyl, C_6-C_{14}aryl, C_3-C_{13}heteroaryl or C_2-C_{14}heterocycloalkyl, wherein the C_2-C_{14}heterocycloalkyl, C_6-C_{14}aryl and C_3-C_{13}heteroaryl are optionally substituted with 1-3 substituents independently selected from halogen and C_1-C_6alkyl.

[00026] Also provided herein are compounds of Formulas (I) and Formula (Ia), wherein the compound of Formula (I) or Formula (Ia) are compounds of Formula (Ic):



(Ic).

[00027] In certain embodiments of such compounds of Formula (Ic), R^{10} is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or -$(CH_2)_nR^{11}$, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^{10} are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, –OR^{12}, –OR^{10}, -$C(O)R^{12}$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{11})_2$, -$N(R^{12})_2$, -$N(R^{12}R^{10})$, -$N(R^{12}R^{11})$, -$(CR^{12}R^{12})_nR^{11}$, -SR^8, –$NR^{12}C(O)N(R^{12})_2$, -$C(O)N(R^{12}R^{10})$, –$N(R^{12})C(O)R^{13}$, –$C(O)N(R^{11})_2$, –$C(O)N(R^{12})_2$, -$(CR^{12}R^{12})_nR^{11}$, -$(CH_2)_nR^{12}$, -$(CH_2)_nR^{13}$, -$O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, -$O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, –$S(O)_2R^{12}$, –$S(O)_2N(R^{11})_2$, –$S(O)_2N(R^{12})_2$, R^{12}, R^{10}, -OR^{13}, -$C(O)R^{13}$, -$OC(O)R^{13}$, -$C(O)OR^{13}$, –$S(O)_2R^{13}$, –R^{13}, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and n is 1, 2, 3 or 4. In certain embodiments R^{10} is



, wherein:

R^{21} is halogen, -CN, –OR^{12}, –OR^{10}, -$C(O)R^{12}$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{11})_2$, -$N(R^{12})_2$, -$N(R^{12}R^{10})$, -$N(R^{12}R^{11})$, -$(CR^{12}R^{12})_nR^{11}$, -SR^8, –$NR^{12}C(O)N(R^{12})_2$, -$C(O)N(R^{12}R^{10})$, –$N(R^{12})C(O)R^{13}$, –$C(O)N(R^{11})_2$, –$C(O)N(R^{12})_2$, -$(CR^{12}R^{12})_nR^{11}$, -$(CH_2)_nR^{12}$, -$(CH_2)_nR^{13}$, -$O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, -$O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, –$S(O)_2R^{12}$, –$S(O)_2N(R^{11})_2$, –$S(O)_2N(R^{12})_2$, R^{12}, R^{10}, -OR^{13}, -$C(O)R^{13}$, -$OC(O)R^{13}$, -$C(O)OR^{13}$, –$S(O)_2R^{13}$, –R^{13}, C_2-

C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy; R^8 is H or C_1-C_6 alkyl; n is 1, 2, 3 or 4; m is 1, 2, or 3 and p is 0, 1, 2 or 3.

[00028] In certain embodiments of such compounds of Formula (Ic), R^{10} is -$(CH_2)_nR^{11}$. In certain embodiments of such compounds of Formula (Ic), R^{11} is -$N(R^{12})_2$, -OR^{13}, -$C(O)N(R^{12})_2$, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl, or C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^{10} are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, –OR^{12}, –OR^{10}, -$C(O)R^{12}$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{11})_2$, -$N(R^{12})_2$, -$N(R^{12}R^{10})$, -$N(R^{12}R^{11})$, -$(CR^{12}R^{12})_nR^{11}$, -SR^8, –$NR^{12}C(O)N(R^{12})_2$, -$C(O)N(R^{12}R^{10})$, –$N(R^{12})C(O)R^{13}$, –$C(O)N(R^{11})_2$, –$C(O)N(R^{12})_2$, -$(CR^{12}R^{12})_nR^{11}$, -$(CH_2)_nR^{12}$, -$(CH_2)_nR^{13}$, -$O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, -$O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, –$S(O)_2R^{12}$, –$S(O)_2N(R^{11})_2$, –$S(O)_2N(R^{12})_2$, R^{12}, R^{10}, -OR^{13}, -$C(O)R^{13}$, -$OC(O)R^{13}$, -$C(O)OR^{13}$, –$S(O)_2R^{13}$, –R^{13}, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and n is 1, 2, 3 or 4.

[00029] In certain embodiments of such compounds of Formula (Ic), R^{11} is R^{11} is -$N(R^{12})_2$,



or



, wherein:

R^{21} is halogen, -CN, –OR^{12}, –OR^{10}, -$C(O)R^{12}$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{11})_2$, -$N(R^{12})_2$, -$N(R^{12}R^{10})$, -$N(R^{12}R^{11})$, -$(CR^{12}R^{12})_nR^{11}$, -SR^8, –$NR^{12}C(O)N(R^{12})_2$, -$C(O)N(R^{12}R^{10})$, –$N(R^{12})C(O)R^{13}$, –$C(O)N(R^{11})_2$, –$C(O)N(R^{12})_2$, -$(CR^{12}R^{12})_nR^{11}$, -$(CH_2)_nR^{12}$, -$(CH_2)_nR^{13}$, -$O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, -$O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, –$S(O)_2R^{12}$, –$S(O)_2N(R^{11})_2$, –$S(O)_2N(R^{12})_2$, R^{12}, R^{10}, -OR^{13}, -$C(O)R^{13}$, -$OC(O)R^{13}$, -$C(O)OR^{13}$, –$S(O)_2R^{13}$, –R^{13}, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy; n is 1, 2, 3 or 4, and p is 0, 1, 2 or 3

[00030] Also provided herein are compounds of Formulas (I) and Formula (Ia), wherein the compound of Formula (I) or Formula (Ia) are compounds of Formula (Id):



(Id)

wherein:

R^{21} is halogen, -CN, –OR^{12}, –OR^{10}, -$C(O)R^{12}$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{11})_2$, -$N(R^{12})_2$, -$N(R^{12}R^{10})$, -$N(R^{12}R^{11})$, -$(CR^{12}R^{12})_nR^{11}$, -SR^8, –$NR^{12}C(O)N(R^{12})_2$, -$C(O)N(R^{12}R^{10})$, –$N(R^{12})C(O)R^{13}$, –$C(O)N(R^{11})_2$, –$C(O)N(R^{12})_2$, -$(CR^{12}R^{12})_nR^{11}$, -$(CH_2)_nR^{12}$, -$(CH_2)_nR^{13}$, -

$O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy; n is 1, 2, 3 or 4, and p is 0, 1, 2 or 3.

[00031] In certain embodiments of the aforementioned compounds, R^{15} is H, halogen, C_2-C_6alkenyl, -CN,  ,  or  , wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-NHS(O)_2R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, R^8 is H or C_1-C_6 alkyl; n is 1, 2, 3 or 4, and p is 0, 1, 2 or 3.

[00032] In certain embodiments of the aforementioned compounds, R^{15} is H. In certain embodiments of the aforementioned compounds, R^4 is H.

[00033] Also provided herein are compounds of Formulas (I) and Formula (Ia), wherein the compound of Formula (I) or Formula (Ia) are compounds of Formula (Ie):



(Ie).

[00034] In certain embodiments of the aforementioned compounds, R^3 is H, -CN, halogen, C_2-C_6 alkenyl,



wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy; n is 1, 2, 3 or 4, and p is 0, 1, 2 or 3.

[00035] In certain embodiments of the aforementioned compounds, The compound of any of claims 1-30, wherein R^8 is H. In certain embodiments of the aforementioned compounds, R^3 is H. In certain embodiments of the aforementioned compounds, R^5 is H. In certain embodiments of the aforementioned compounds, R^2 is H or halogen.

[00036] In another aspect, the present invention provides compounds of Formula (I) selected from: 7-chloro-5-(4-morpholinophenylamino)pyrido[4,3-d]pyrimidin-4(3H)-one, 3-(morpholin-4-yl)-N-(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)benzamide; 8-amino-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-(morpholin-4-yl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; N-(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)oxane-4-carboxamide 6-[(dimethylamino)methyl]-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(dimethylamino)methyl]-8-{[3-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-phenylethyl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-(morpholin-4-yl)phenyl]amino}-6-(2-phenylethyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[3-(trifluoromethyl)phenyl]-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminoethyl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopropyl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-phenyl-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-(pyridin-3-yl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-[2-(8-amino-1-oxo-1,2-dihydro-2,7-naphthyridin-3-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione; 6-(3-aminopropyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopropyl)-8-{[3-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[3-(dimethylamino)propyl]phenyl}amino)-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; N-(3-methoxypropyl)-4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)amino]benzene-1-sulfonamide; 6-phenyl-8-{[3-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopropyl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-

naphthyridin-1-one; 8-amino-3-(2-aminoethyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-aminobutyl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-aminobutyl)-8-{[3-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopropyl)-8-{[4-methyl-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-(morpholin-4-yl)phenyl]amino}-6-(pyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-3-(3-aminopropyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-phenyl-8-{[4-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopropyl)-8-{[4-methoxy-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopropyl)-8-[(3,5-dimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopropyl)-8-[(3,4-dimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopropyl)-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopropyl)-8-{[3-fluoro-4-(piperazin-1-ylmethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(3-bromophenyl)amino]-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-cyclohexyl-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-cyclohexyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-methoxyphenyl)amino]-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-phenyl-8-{[2-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[3-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(2-aminoethyl)amino]-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(2-aminoethyl)amino]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopropyl)-8-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(3R)-piperidin-3-ylamino]-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[(3R)-piperidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[(3S)-piperidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[(3S)-pyrrolidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-{[(1S,2S)-2-aminocyclohexyl]amino}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[(3R)-pyrrolidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-{[(1S,2R)-2-aminocyclohexyl]amino}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-(piperidin-3-yloxy)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(2-aminoethyl)amino]-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-[(3S)-piperidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(benzylamino)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(2-aminoethyl)amino]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl 4-[4-({3-[(2-aminoethyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]piperidine-1-carboxylate; 6-[(2-aminoethyl)amino]-8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-

1-one; 8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(pyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 2-(1-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzamide; 8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-{[(1S,2S)-2-aminocyclohexyl]amino}-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(2-aminoethyl)amino]-8-{[3-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopiperidin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-{[(3-chlorophenyl)methyl]amino}-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(3R)-3-aminopyrrolidin-1-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-1-yl)phenyl]amino}-6-(pyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(2-aminoethyl)amino]-2-methyl-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-(pyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-chlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-({3-[(2-aminoethyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-(4-chlorophenyl)benzamide; 6-(3-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl 4-{4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)amino]phenyl}piperidine-1-carboxylate; 6-phenyl-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-hydroxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(2-aminoethyl)amino]-8-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-(1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3,5-dimethyl-1H-pyrazol-4-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-(1-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzonitrile 6-(4-methoxypyridin-3-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 3-(1-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzamide; 8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3,5-dimethyl-1,2-oxazol-4-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(furan-3-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-({3-[(2-aminoethyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]-1,4-thiomorpholine-1,1-dione; 8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-{4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-

yl)amino]phenyl}-1,4-thiomorpholine-1,1-dione; 6-(4-chlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-chlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3,4-dichlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-fluorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[3-(aminomethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[4-(piperazin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-(1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-(1H-pyrazol-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-hydroxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-hydroxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-hydroxypyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-(1-propyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[1-(1,3-dioxolan-2-ylmethyl)-1H-pyrazol-4-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-[4-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]acetic acid 6-(3,5-dimethyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}amino)-6-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}amino)-6-(3-hydroxyphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}amino)-6-(6-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1H-pyrazol-4-yl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-benzyl-1H-pyrazol-4-yl)-8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-fluorophenyl)amino]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-fluorophenyl)amino]-5-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 5-bromo-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-chloro-5-(pyridin-3-yl)-1,2-dihydro-2,7-

naphthyridin-1-one; 6-(3,5-dimethyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzonitrile 5-(furan-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)amino]-N-propylbenzamide; 4-({3-[(2-aminoethyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-propylbenzamide; 4-(4-{[3-(4-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)-1,4-thiomorpholine-1,1-dione; 6-[2-(3-fluorophenyl)pyrrolidin-1-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methoxypyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-({3-[6-(morpholin-4-yl)pyridin-3-yl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]-1,4-thiomorpholine-1,1-dione; 6-(4-methoxypyridin-3-yl)-8-{[4-(piperidin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[3-(dimethylamino)propyl]phenyl}amino)-6-(4-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(1-propyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(3-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(3-fluorophenyl)pyrrolidin-1-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-[4-(1-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]acetic acid 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(piperazin-1-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methylpiperazin-1-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-(piperidin-4-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[4-(piperidin-1-yl)piperidin-1-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-{[2-(morpholin-4-yl)ethyl]amino}-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-(6-aminopyridin-3-yl)-8-[(4-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 5-(6-aminopyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-(2-chloropyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-[4-(aminomethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-4-yl)benzamide; 5-iodo-8-[(4-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-methoxyphenyl)amino]-5-(3-phenylprop-1-yn-1-yl)-1,2-dihydro-2,7-

naphthyridin-1-one; 5-phenyl-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(2-chlorophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(3-chlorophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(4-chlorophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(2-methoxyphenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(3-methoxyphenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(4-methoxyphenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-benzyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-(phenylamino)-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-benzyl-1H-pyrazol-4-yl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-[1-(1,3-dioxolan-2-ylmethyl)-1H-pyrazol-4-yl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-methyl-1H-pyrazol-4-yl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(furan-3-yl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-[8-oxo-1-(phenylamino)-7,8-dihydro-2,7-naphthyridin-4-yl]furan-2-carbaldehyde 8-(phenylamino)-5-(pyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(2-chlorophenyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-chlorophenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N-[2-(morpholin-4-yl)ethyl]-4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)amino]benzamide; N,N-diethyl-4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)amino]benzamide; 6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(phenylamino)-5-[3-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-(phenylamino)-5-[4-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 5-(6-aminopyridin-3-yl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-[6-(morpholin-4-yl)pyridin-3-yl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(phenylamino)-5-[6-(piperazin-1-yl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 5-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(3-aminophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(4-aminophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(3-fluorophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(4-fluorophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 4-[8-oxo-1-(phenylamino)-7,8-dihydro-2,7-naphthyridin-4-yl]benzamide; 8-(phenylamino)-5-[(1E)-3-phenylprop-1-en-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 5-[(E)-2-(2,4-difluorophenyl)ethenyl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 5-[(E)-2-cyclohexylethenyl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(phenylamino)-5-[(E)-2-[3-(trifluoromethyl)phenyl]ethenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-tert-butylpiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 3-[8-oxo-1-(phenylamino)-

7,8-dihydro-2,7-naphthyridin-4-yl]benzonitrile 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[(2,2,2-trifluoroethyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methylpiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-ylcarbonyl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-phenyl-8-{[4-(piperazin-1-ylcarbonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-{[3-(4-methylpiperazin-1-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-[2-(morpholin-4-yl)ethyl]benzamide; 4-({3-[(2-aminoethyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-[2-(morpholin-4-yl)ethyl]benzamide; 4-{[3-(4-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-[2-(morpholin-4-yl)ethyl]benzamide; 6-(2-methoxyphenyl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-ethoxyphenyl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[2-(propan-2-yloxy)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-fluoro-2-methoxyphenyl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-{[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-{[4-(piperidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-{[4-(1-methylpiperidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-aminopropyl)-8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 5-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-[(E)-2-(3-methoxyphenyl)ethenyl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 4-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1,4-thiomorpholine-1,1-dione; 6-(4-acetylpiperazin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[4-(piperidin-1-yl)piperidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-hydroxypiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[4-(morpholin-4-yl)piperidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 4-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1,4-thiomorpholin-1-one; 6-(2-methoxypyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N-ethyl-4-(4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxamide 6-(5-methoxypyridin-3-yl)-8-({4-[1-(propan-2-yl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-cyclopentylpiperidin-4-

yl)phenyl]amino}-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl}amino)-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-({4-[1-(3-oxobutyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 3-[4-(4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]propanenitrile 4-[(8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl)amino]-N-phenylbenzamide; 4-{[4-(1-methyl-1H-pyrazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-phenylbenzamide; 4-{[4-(1-methyl-1H-pyrazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide; 4-{[3-(4-methylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide; 4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide; N-(2-hydroxyethyl)-4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 4-{[3-(cyclopropylamino)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide; 8-({4-[3-(dimethylamino)propyl]phenyl}amino)-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-fluorophenyl)amino]-5-(furan-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[(2,2,2-trifluoroethyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; N-cyclopropyl-4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-chloro-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(1H-indazol-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(1H-indol-6-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(1H-indol-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(3-fluoropyridin-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(6-fluoropyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(2-methoxypyridin-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(6-fluoro-5-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 5-bromo-6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-hydroxypiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4,4-difluoropiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[3-(trifluoromethyl)piperidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[4-(hydroxymethyl)piperidin-1-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-({8-oxo-3-[(3R)-piperidin-3-ylamino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide; 6-(3-methoxyphenyl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[3-(trifluoromethoxy)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[2-(morpholin-4-yl)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(ethanesulfonyl)piperidin-4-yl]phenyl}amino)-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-

naphthyridin-1-one; ethyl 3-[4-(4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]propanoate 6-(3,3-difluoropiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[2-(trifluoromethyl)pyrrolidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[4-(trifluoromethyl)piperidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3,3-difluoropyrrolidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-fluoropiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-bromo-6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(3S)-3-fluoropyrrolidin-1-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-chloro-6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-4-iodo-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-ylcarbonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-iodo-6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-chloro-6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-{1-[(4-fluorophenyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-4-yl}furan-2-carbonitrile 6-(2-aminopyrimidin-5-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethoxypyrimidin-5-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[4-(propan-2-yl)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methanesulfonylpyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; ethyl 5-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carboxylate; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(morpholin-4-yl)pyrazin-2-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(4-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(2-methoxyphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-fluoropyridin-3-yl)-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[1-(1-methanesulfonylpiperidin-4-yl)-1H-pyrazol-4-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[1-(1-acetylpiperidin-4-yl)-1H-pyrazol-4-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N,2-dimethyl-2-(4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-

dihydro-2,7-naphthyridin-1-yl]amino}phenyl)propanamide 4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide; 8-{[4-(4-hydroxypiperidin-1-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; N-cyclopentyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 4-({8-oxo-3-[(2,2,2-trifluoroethyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-propylbenzamide; N,2-dimethyl-2-[4-({8-oxo-3-[(2,2,2-trifluoroethyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]propanamide 8-[(4-fluorophenyl)amino]-5-(3-phenylpropyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1-oxo-1,2-dihydro-2,7-naphthyridine-4-carbonitrile 1-(benzylamino)-8-oxo-7,8-dihydro-2,7-naphthyridine-4-carbonitrile 6-(4-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-chloro-8-{[4-(pyridin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-chloro-8-[(4-{2H,3H-imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-chloro-8-{[4-(1H-imidazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-chloro-8-{[4-(1,3-oxazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methanesulfonylpyridin-3-yl)-8-{[4-(pyridin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2H,3H-imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)amino]-6-(5-methanesulfonylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1H-imidazol-4-yl)phenyl]amino}-6-(5-methanesulfonylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(6-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carbonitrile 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-[6-(piperidin-1-yl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(2-aminoethyl)amino]-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(oxan-4-yl)phenyl]amino}-6-[(3R)-piperidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-chlorophenyl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(3aS,6aS)-octahydropyrrolo[3,4-c]pyrrol-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-4-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-fluorophenyl)amino]-5-(3-hydroxy-3-phenylpropyl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-6-(3,3-difluoropyrrolidin-1-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one; N-cyclopentyl-4-({8-oxo-3-[(2,2,2-trifluoroethyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide; 6-(2-methylpyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(dimethylamino)pyrimidin-5-yl]-8-{[4-(morpholin-4-

yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carbonitrile N-methyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 4-{[3-(2,6-dimethylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide; 4-({3-[2-(dimethylamino)pyrimidin-5-yl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-methylbenzamide; 8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-6-[4-(propan-2-yl)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 2-(4-{[3-(5-methanesulfonylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)-N,2-dimethylpropanamide 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(3,3-difluoropyrrolidin-1-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-chloro-8-[(2-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-chloro-8-[(2-methyl-3-oxo-2,3-dihydro-1H-isoindol-5-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-[(2-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-[(2-methyl-3-oxo-2,3-dihydro-1H-isoindol-5-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 3-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(2,6-difluoropyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-{imidazo[1,2-a]pyridin-6-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(5-fluoropyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 3-[(3-chloro-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl)amino]-N-methylbenzamide; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(6-fluoro-2-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-{[4-(1,3-oxazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-{1H-pyrrolo[2,3-b]pyridin-5-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-2-carbonitrile 6-(6-fluoro-2-methylpyridin-3-yl)-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,6-difluoropyridin-3-yl)-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-N-methylpyridine-2-carboxamide 6-chloro-8-{[4-(1-methanesulfonylpiperidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-chloro-8-{[4-(1-methanesulfonylpyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-chloro-8-{[4-(1-methylpyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-chloro-6-(5-methoxypyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3,3-difluoropyrrolidin-1-yl)-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-({3-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-methylbenzamide; 4-{[3-(1-methyl-1H-pyrazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide; 4-({3-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-oxo-7,8-dihydro-2,7-

naphthyridin-1-yl}amino)-N-propylbenzamide; 4-[(3-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl)amino]-N-propylbenzamide; 4-({8-oxo-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-propylbenzamide; 4-{[3-(3-methyl-1H-pyrazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide; N-methyl-4-{[3-(1-methyl-1H-pyrazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; N-methyl-4-({3-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide; N-methyl-4-[(3-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl)amino]benzamide; N-methyl-4-({8-oxo-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide; N,2-dimethyl-2-[4-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]propanamide N-ethyl-2-methyl-2-[4-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]propanamide N,N,2-trimethyl-2-[4-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]propanamide 6-{1-[2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl]-1H-pyrazol-4-yl}-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(5-methanesulfonylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; N-methyl-4-({8-oxo-3-[(2,2,2-trifluoroethyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide; N,N-dimethyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 4-{[3-(5-methanesulfonylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide; 6-(2-aminopyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methanesulfonylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide; N-methyl-4-{[3-(4-methylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; N-tert-butyl-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carboxamide N-tert-butyl-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carboxamide 8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(4-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpyrrolidin-3-yl)phenyl]amino}-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-{[4-(1-methylpyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,6-dimethylpyridin-3-yl)-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 5-bromo-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-5-(3-hydroxy-3-phenylpropyl)-1,2-dihydro-2,7-naphthyridin-1-one; N-methyl-4-{[8-oxo-3-(2-oxopyrrolidin-1-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; N-methyl-4-{[8-oxo-3-(2-oxopiperidin-1-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 8-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-6-(2-oxopyrrolidin-1-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 6-{[2-(difluoromethane)sulfonylphenyl]amino}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-{[2-(propane-2-sulfonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-{[3-(2,4-dimethoxypyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N,2-dimethylbenzamide; 4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N,2-dimethylbenzamide; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(5-methanesulfonylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpiperidin-3-yl)phenyl]amino}-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 5-chloro-6-(5-methoxypyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}phenyl)amino]-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-[1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; N-methyl-4-({8-oxo-3-[1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide; 8-{[4-(oxan-4-yl)phenyl]amino}-6-[1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl}amino)-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3,3-difluoropiperidin-1-yl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpyrrolidin-3-yl)phenyl]amino}-6-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methanesulfonylacetyl)piperidin-4-yl]phenyl}amino)-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[5-(propane-2-sulfonyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-[5-(propane-2-sulfonyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; N-methyl-4-{[8-oxo-3-(2-oxoazepan-1-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 6-(3,3-difluoropyrrolidin-1-yl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-6-(3-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}amino)-6-(3-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 2-{[1-({6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]amino}benzene-1-sulfonamide; 4-({8-oxo-3-[(2-sulfamoylphenyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-propylbenzamide; N,2-dimethyl-4-({8-oxo-3-[(2-sulfamoylphenyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide;

2-[(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzamide; 6-[(4-fluoro-2-methylphenyl)amino]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-{[2-(propane-2-sulfonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methanesulfonylphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-{[3-(3-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide; N-ethyl-3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide; 8-{[4-(1-methanesulfonylpyrrolidin-3-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 3-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzene-1-sulfonamide; 6-[5-(ethanesulfonyl)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[5-(ethanesulfonyl)pyridin-3-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[5-(ethanesulfonyl)pyridin-3-yl]-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-({3-[5-(ethanesulfonyl)pyridin-3-yl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-methylbenzamide; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(propane-2-sulfonyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[5-(ethanesulfonyl)pyridin-3-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 2,2-dimethyl-6-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one; 2,2-dimethyl-7-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one; 7-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]-3,4-dihydro-2H-1,4-benzoxazin-3-one; 2,2-dimethyl-6-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]-3,4-dihydro-2H-1,4-benzoxazin-3-one; N-methyl-2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzamide; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(2-methylpyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,3-dihydro-1H-indol-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-methyl-1H-pyrazol-4-yl)-8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 3-(1-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide; 6-(3-methanesulfonylphenyl)-8-[4-(morpholin-4-yl)phenoxy]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylsulfanyl)pyrimidin-5-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-{[2-(morpholin-4-yl)ethyl]amino}pyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-methyl-1H-pyrazol-4-

yl)-8-{[6-(piperidin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methoxypyridin-3-yl)-8-{[6-(piperidin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-acetyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(1E)-1-(methoxyimino)ethyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-[(1-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 2-[(1-{[4-(oxan-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 2-[(1-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 2-{[1-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]amino}benzene-1-sulfonamide; tert-butyl 4-(4-{[8-oxo-3-(1,3,5-trimethyl-1H-pyrazol-4-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate; 5-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-sulfonamide; 5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-sulfonamide; 5-(1-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-sulfonamide; 5-[1-({4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]pyridine-3-sulfonamide; 5-(1-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-sulfonamide; N-methyl-4-{[8-oxo-3-(5-sulfamoylpyridin-3-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-ethenyl-6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyridin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-(pyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 4-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-3,4-dihydro-2H-1,4-benzothiazine-1,1-dione; N-methyl-2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; N-ethyl-2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 6-[(2-methanesulfonylphenyl)amino]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-[(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 6-(2-aminopyrimidin-5-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 2-({1-[(2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl}amino)benzene-1-sulfonamide; 4-methoxy-2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; N,N,2-trimethyl-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide; 3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-N-(propan-2-yl)benzene-1-sulfonamide; N-cyclopropyl-3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide; 8-{[4-

(1-acetylpiperidin-4-yl)phenyl]amino}-6-(3-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 4-{[3-(3-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]oxy}benzonitrile 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(3-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methanesulfonylphenyl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N-[3-(1-{[2-methoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)phenyl]methanesulfonamide; 2-hydroxy-N-[3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)phenyl]ethane-1-sulfonamido 8-{[2-methoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}-6-(2-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,6-dimethoxypyridin-3-yl)-8-{[2-methoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methanesulfonylphenyl)-8-{[2-methoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylsulfanyl)pyrimidin-5-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-fluoropyridin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-(pyrimidin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-ethyl-1,3-thiazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methylpyridin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methylpyridin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylsulfanyl)pyrimidin-4-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-(4-{[3-(2-aminopyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)-N,2-dimethylpropanamide 2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]ethane-1-sulfonamide; 2-methyl-6-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; N,N-dimethyl-2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 2,2-dimethyl-6-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one; N,2-dimethyl-2-[4-({8-oxo-3-[(2-sulfamoylphenyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]propanamide 2-[(1-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]-6-methylbenzene-1-sulfonamide; 6-(2-aminopyrimidin-5-yl)-8-{[4-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 3-{[3-(2-aminopyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzene-1-sulfonamide; 2,2-dimethyl-6-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one; N-methyl-3-({8-oxo-3-[(2-sulfamoylphenyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzene-1-sulfonamide; 6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-chlorophenyl)-8-({3-[2-(morpholin-4-

yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; N-ethoxy-4-{[3-(4-methylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 2-[(1-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 2-methyl-6-[(1-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 4-methyl-2-[(1-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 6-(1-methyl-1H-pyrazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-methyl-1H-pyrazol-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-methoxy-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide; 2-methoxy-N-methyl-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide; tert-butyl 3-(4-{[3-(4-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)pyrrolidine-1-carboxylate; 6-(4-methanesulfonylphenyl)-8-{[4-(pyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl 4-(4-{[3-(4-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate; 6-(4-methanesulfonylphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({3-[2-(morpholin-4-yl)-2-oxoethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({4-methyl-3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3-hydroxy-4-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 3-{[3-(2-aminopyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide; 6-(2-methylpyrimidin-5-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-methyl-3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-6-(2-methylpyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methylpyridin-3-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,6-dimethylpyridin-3-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-(2-phenyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methanesulfonyl-4-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methanesulfonyl-4-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methanesulfonyl-4-methylpyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methanesulfonyl-4-methylpyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[3-(2-hydroxypropan-2-yl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[4-(2-hydroxypropan-2-yl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[3-methanesulfonyl-4-(morpholin-4-ylmethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-

dihydro-2,7-naphthyridin-1-one; 6-[3-methanesulfonyl-4-(pyrrolidin-1-ylmethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-ethoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methanesulfonyl-4-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N-[5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridin-2-yl]acetamide 6-(4-methoxypyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-4-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-4-methylpyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 2-methyl-6-[(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; N-methyl-2-[(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-(1H-pyrazol-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 4-chloro-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 4,6-dichloro-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-(pyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[5-(propan-2-yloxy)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[5-methyl-6-(methylamino)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-methoxy-N-methyl-3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-(1-propyl-1H-pyrazol-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[1-(2-phenylethyl)-1H-pyrazol-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[1-(propan-2-yl)-1H-pyrazol-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-benzyl-1H-pyrazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-tert-butyl-1H-pyrazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-sulfonamide; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[5-(trifluoromethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-[5-(trifluoromethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(trifluoromethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-fluoropyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-fluoropyridin-3-yl)-8-{[4-(piperidin-4-

yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(methylamino)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3,3-difluoropyrrolidin-1-yl)-8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-amino-4-methoxypyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N,2-dimethyl-2-(4-{[3-(2-methylpyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)propanamide 2-methyl-6-{[8-oxo-1-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-7,8-dihydro-2,7-naphthyridin-3-yl]amino}benzene-1-sulfonamide; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[5-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[5-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-fluoropyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-{[3-(6-fluoropyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide; 6-[6-(methylamino)pyridin-3-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(ethylamino)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methanesulfonyl-4-methoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methanesulfonyl-4-methylphenyl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N-[5-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridin-2-yl]acetamide 8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-6-[(2,2,2-trifluoroethyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; N-methyl-2-{[8-oxo-1-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-7,8-dihydro-2,7-naphthyridin-3-yl]amino}benzene-1-sulfonamide; 6-(2-amino-4-methoxypyrimidin-5-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-{[4-methyl-3-(methylamino)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methylpyrimidin-5-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-(pyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-aminopyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-2-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-[(1-{[4-(4-ethoxypiperidin-1-yl)-3-fluorophenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 6-(3,3-difluoropyrrolidin-1-yl)-8-{[4-(4-ethoxypiperidin-1-yl)-3-fluorophenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-

4-yl)phenyl]amino}-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3,3-difluoropyrrolidin-1-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 2-[(1-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 6-(3,3-difluoropyrrolidin-1-yl)-8-{[5-methyl-6-(morpholin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3,3-difluoropyrrolidin-1-yl)-8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(pyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-aminopyrazin-2-yl)-8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 4-{[3-(5-aminopyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide; 6-(6-methoxypyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methoxypyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-amino-4-methoxypyrimidin-5-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({4-[(2-methyl-1H-imidazol-1-yl)methyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3-methoxy-4-phenylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-{[3-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(4-{2-[3-(dimethylamino)pyrrolidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-butyl-1H-pyrazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[1-(2-hydroxyethyl)-1H-pyrazol-5-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; ethyl 2-[5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]acetate 6-(2-methylpyrimidin-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyridin-2-yl)-8-({4-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyridin-2-yl)-8-({4-[1-(propan-2-yl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-amino-1,3-thiazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylamino)-1,3-thiazol-4-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methoxypyridin-3-yl)-8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-(1H-pyrazol-3-yl)-1,2-dihydro-2,7-

naphthyridin-1-one; 8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-[5-methyl-6-(methylamino)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-6-ylamino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-({5-methyl-6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(4-ethoxypiperidin-1-yl)-3-fluorophenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 4-{[3-(2-aminopyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-(1-methylpiperidin-4-yl)benzamide; N-(1-methylpiperidin-4-yl)-4-{[3-(2-methylpyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 6-(2-aminopyrimidin-5-yl)-8-({4-[3-(dimethylamino)pyrrolidin-1-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[3-(dimethylamino)pyrrolidin-1-yl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethoxypyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N-methyl-3-{[3-(2-methylpyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzene-1-sulfonamide; 2-methoxy-N-methyl-4-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide; 6-(6-hydrazinylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[6-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-hydroxy-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({5-methyl-6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; ethyl 4-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1,3-thiazole-2-carboxylate; 6-[2-(methanesulfonylmethyl)-1,3-thiazol-4-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl N-{2-[4-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1,3-thiazol-2-yl]ethyl}carbamate 6-[2-(2-aminoethyl)-1,3-thiazol-4-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methylpyridin-2-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-

methylpyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-amino-4-methylpyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-amino-6-methylpyrimidin-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-{methyl[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-(morpholin-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(1-methylpiperidin-4-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-amino-4-methylpyrimidin-5-yl)-8-({4-[3-(dimethylamino)pyrrolidin-1-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-aminopyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-{5H-pyrrolo[2,3-b]pyrazin-2-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-aminopyridin-2-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-{5H-pyrrolo[2,3-b]pyrazin-2-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethyl-1,3-thiazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethyl-1,3-thiazol-5-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-[4-(propane-2-sulfonyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N,N-dimethyl-4-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide; tert-butyl 4-[4-({8-oxo-3-[4-(propane-2-sulfonyl)phenyl]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]piperidine-1-carboxylate; tert-butyl 4-[4-({3-[4-(dimethylsulfamoyl)phenyl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]piperidine-1-carboxylate; tert-butyl 4-(4-{[3-(3-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate; 6-(5-amino-6-methylpyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridazin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl}amino)-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-4-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-4-phenyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-(2-chlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-

naphthyridin-1-one; 6-(1-methyl-1H-pyrazol-4-yl)-8-{methyl[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(2-aminopyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-{[4-(1-methanesulfonylpyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N-methyl-3-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzene-1-sulfonamide; 6-(2-aminopyrimidin-5-yl)-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[5-methyl-6-(methylamino)pyridin-3-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(propan-2-yloxy)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 4-methoxy-N-methyl-3-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide; 6-[3-methanesulfonyl-4-(pyrrolidin-1-ylmethyl)phenyl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[3-methanesulfonyl-4-(morpholin-4-ylmethyl)phenyl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(propan-2-ylamino)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-methyl-1H-imidazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-2-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-(1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl 6-{[3-(4-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-1,2,3,4-tetrahydroisoquinoline-2-carboxylate; 6-(4-methanesulfonylphenyl)-8-(1,2,3,4-tetrahydroisoquinolin-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-[4-(propane-2-sulfonyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 4-(1-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-N,N-dimethylbenzene-1-sulfonamide; 6-[6-(4-methyl-1H-imidazol-1-yl)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(2-ethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; benzyl 4-{1-[(4-{1-[(tert-butoxy)carbonyl]piperidin-4-yl}phenyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl}piperazine-1-carboxylate; 8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-{[(1S,2R)-2-aminocyclohexyl]amino}-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methylpyrazin-2-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-

yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-{[4-(2-methylpyridin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(6-amino-5-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-{[4-(4-methoxyphenyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-amino-4-methylpyrimidin-5-yl)-2-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-6-ylamino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methanesulfinyl-2-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(2-methanesulfonylethyl)({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl})amino]-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(4-methanesulfonylpiperazin-1-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)-2-methoxy-5-methylphenyl]amino}-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-6-ylamino)-6-[5-(propan-2-yloxy)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-6-ylamino)-6-[3-methanesulfonyl-4-(pyrrolidin-1-ylmethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-6-ylamino)-6-[3-methanesulfonyl-4-(morpholin-4-ylmethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-6-ylamino)-6-[6-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-6-ylamino)-6-[5-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 3-(1-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-4-methoxy-N-methylbenzene-1-sulfonamide; 4-(1-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-2-methoxy-N-methylbenzene-1-sulfonamide; 6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-6-ylamino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[5-methyl-6-(methylamino)pyridin-3-yl]-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-[2-(propan-2-yloxy)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-[2-(propan-2-yloxy)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-[5-methyl-6-(methylamino)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1H-indazol-6-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-benzyl-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-methoxyphenyl)methyl]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-6-(2-aminopyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methanesulfonylpiperazin-1-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(2-oxo-2,3-dihydro-1H-indol-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(2-oxo-2,3-dihydro-1H-indol-6-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(methylamino)pyridin-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(propylamino)pyridin-2-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(propan-2-ylamino)pyridin-2-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-{6-[(3-methoxypropyl)amino]pyridin-2-yl}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(dimethylamino)pyridin-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-8-{methyl[6-(morpholin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-(2,6-dimethylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-methyl-6-(1-methyl-1H-pyrazol-4-yl)-8-{methyl[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-{methyl[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 4-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]pyridine-3-sulfonamide; 6-(6-methoxypyrazin-2-yl)-8-({3-methyl-4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 2-(4-{[3-(6-amino-5-methylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)-N,2-dimethylpropanamide 8-[(4-{2-[3-(dimethylamino)pyrrolidin-1-yl]ethyl}phenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-hydroxy-3-methylphenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-amino-6-methylpyrimidin-4-yl)-8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-(2,6-dichlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methoxypyridin-3-yl)-8-[(4-methanesulfonylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-methanesulfonylphenyl)amino]-6-[6-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-{imidazo[1,2-a]pyridin-6-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1H-indazol-6-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-{imidazo[1,2-a]pyridin-6-yl}-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-{1H-pyrrolo[2,3-b]pyridin-5-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-methylpyridin-

3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-fluoro-2-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-fluoro-2-methylpyridin-3-yl)-8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-fluoro-2-methylpyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-(4-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(4-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridin-3-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methoxypyrazin-2-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridin-3-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-(6-methoxypyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(ethylamino)pyridin-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-2-methyl-8-{methyl[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(furan-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-5-ylamino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(4-hydroxyphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(pyrimidin-5-yl)-8-{[3-(trifluoromethyl)phenyl]methyl}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[4-(dimethylamino)phenyl]-8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(4-fluoro-2-methylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(4-fluoro-3-methoxyphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[4-(benzyloxy)phenyl]-8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-fluoropyridin-3-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(methylamino)pyridin-3-yl]-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(ethylamino)pyridin-3-yl]-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-

yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 2-methyl-6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-{[4-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(3-methoxy-4-phenylphenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-{[4-(2-methylpyridin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-[(4-{2-[3-(dimethylamino)pyrrolidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-{[4-(2-methylpyridin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-{[4-(4-hydroxypiperidin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(2-aminopyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-2-sulfonamide; N-methyl-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-2-sulfonamide; 6-(3-methoxypyrazin-2-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(3-methoxy-4-methylphenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-methyl-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 2-methyl-8-(methylamino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-6-(2-aminopyrimidin-5-yl)-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-(methylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(2-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methanesulfonylphenyl)-8-{[3-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-[2-(methylsulfanyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-[(2-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(3-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methanesulfonylphenyl)-8-{[3-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-[(2-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[4-(2-hydroxypropan-2-yl)phenyl]-8-(1H-indazol-5-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-(1H-indazol-5-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-5-ylamino)-6-[5-(propan-2-yloxy)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-fluoropyridin-3-yl)-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-6-ylamino)-6-[6-

(methylamino)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(ethylamino)pyridin-3-yl]-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-[2-(dimethylamino)ethyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-{[4-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N-methyl-3-{[3-(2-methyl-1,3-thiazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 3-{[3-(2-methyl-1,3-thiazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide; 6-(2-methyl-1,3-thiazol-4-yl)-8-{[6-(piperidin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; N-(3-methoxypropyl)-4-{[3-(6-methoxypyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzene-1-sulfonamide; 6-(6-amino-5-methylpyridin-3-yl)-8-({4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-ethyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-({3-chloro-4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-fluoropyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-[6-(methylamino)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(ethylamino)pyridin-3-yl]-8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-5-ylamino)-6-[3-methanesulfonyl-4-(pyrrolidin-1-ylmethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-5-ylamino)-6-[3-methanesulfonyl-4-(morpholin-4-ylmethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-5-ylamino)-6-[5-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-5-ylamino)-6-[5-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[4-(2-hydroxypropan-2-yl)phenyl]-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3-methoxy-4-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 2-(2-methanesulfonylethyl)-8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl}amino)-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-chloro-2-(2-methanesulfonylethyl)-8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-chloro-8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-2-(2-methanesulfonylethyl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-2-(2-methanesulfonylethyl)-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; 2-(2-methanesulfonylethyl)-6-(4-

methanesulfonylphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-chloro-2-(2-methanesulfonylethyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl 4-(4-{[7-(2-methanesulfonylethyl)-3-(4-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate; tert-butyl 4-(4-{[3-chloro-7-(2-methanesulfonylethyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate; 6-(6-methoxypyridin-2-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridin-2-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methoxypyrazin-2-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-methoxypyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(3-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-(3-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-(1H-indazol-6-ylamino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(pyrimidin-5-yl)-8-[(2,2,2-trifluoroethyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-[(2,2,2-trifluoroethyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-[2-(dimethylamino)ethyl]-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-4-methylpyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-({6-[(2S)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({6-[(2S)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-(2-methoxyethyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-[2-(dimethylamino)ethyl]-6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(2-aminopyrimidin-5-yl)-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridin-2-yl)-8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(6-methoxypyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(3-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethoxypyrimidin-5-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethoxypyrimidin-5-yl)-8-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-

dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethoxypyrimidin-5-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-({4-[2-(4-ethylpiperazin-1-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethoxypyrimidin-5-yl)-8-({4-[2-(4-ethylpiperazin-1-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(4-ethylpiperazin-1-yl)ethyl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(5-amino-6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-({4-[2-(4-ethylpiperazin-1-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-[(4-{2-[4-(morpholin-4-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-[(4-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2S)-2-methylmorpholin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-({3-methyl-4-[(2S)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-{6-[2-(pyrrolidin-1-yl)ethoxy]pyridin-2-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-ethoxypyrimidin-5-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(4-methylpiperazin-1-yl)pyridin-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(morpholin-4-yl)pyridin-2-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(pyrrolidin-1-yl)pyridin-2-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-ethoxypyrimidin-5-yl)-8-({6-[(2S)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-ethoxypyrimidin-5-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-ethoxypyrimidin-5-yl)-8-({3-methyl-4-[(2S)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-({[4-(morpholin-4-yl)phenyl]methyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-({3-methyl-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-aminopyridin-3-yl)-8-{[4-(oxan-4-yloxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylamino)pyrimidin-5-yl]-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylamino)pyrimidin-5-yl]-8-[(4-{2-[4-(morpholin-4-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylamino)pyrimidin-

5-yl]-8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(oxan-4-yloxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylamino)pyrimidin-5-yl]-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-(2-methoxyethyl)-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-[(2-methyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]phenyl}amino)-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(4-{2-[4-(dimethylamino)piperidin-1-yl]ethyl}phenyl)amino]-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(2-methylpyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl}phenyl)amino]-6-(2-methyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-({[4-(morpholin-4-yl)phenyl]methyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-{[2-(propane-2-sulfonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methyl-1,3-thiazol-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-{[2-(methylsulfanyl)phenyl]amino}-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methylpyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(3-phenoxyphenyl)amino]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyridin-2-yl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(2-ethoxyphenyl)amino]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-[(3-methyl-1H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-[(3-methyl-1H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(3-methyl-1H-indazol-6-yl)amino]-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(3-methyl-1H-indazol-6-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl]-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-[6-(morpholin-4-yl)pyridin-2-yl]-1,2-dihydro-

2,7-naphthyridin-1-one; 6-[6-(dimethylamino)pyridin-2-yl]-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(3-methoxypyrazin-2-yl)-8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-[(5-methoxy-2-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-{[2-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-{[2-methoxy-5-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-[(2-methoxy-5-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; N-(3-{[1-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]amino}-4-methoxyphenyl)acetamide 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-{[2-methoxy-4-(phenylamino)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(5-chloro-2-methoxyphenyl)amino]-8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-[(2-methoxy-5-nitrophenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-{[3-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(3-methoxy-4-phenylphenyl)amino]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-[(3-methoxy-4-phenylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-[(2-methyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-{[6-(oxan-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-6-(3-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethoxypyrimidin-5-yl)-8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethoxypyrimidin-5-yl)-8-{[3-methyl-4-(2-methylmorpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methylpyrazin-2-yl)-8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-{[3-methyl-4-(2-methylmorpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-yl)-2-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-

yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-{6-[2-(pyrrolidin-1-yl)ethoxy]pyridin-2-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-yl)-8-({3-methyl-4-[(2S)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[4-(dimethylamino)piperidin-1-yl]ethyl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(oxan-4-yloxy)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; N-{4-[1-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]phenyl}acetamide 8-({2-[(2R)-2-methylmorpholin-4-yl]pyrimidin-5-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl}phenyl)amino]-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-6-(2-methyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[4-(dimethylamino)piperidin-1-yl]ethyl}phenyl)amino]-6-(2-methyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[1-(propan-2-yl)piperidin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-yl)-8-({6-[(2S)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-methyl-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[6-(piperazin-1-yl)pyridin-3-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[4-(morpholin-4-yl)piperidin-1-yl]ethyl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(3-fluoropropyl)piperidin-4-yl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(3-fluoropropyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methoxyethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-{[3-methyl-4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-({3-methyl-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-

5-yl)-8-({4-[1-(3-fluoropropyl)piperidin-4-yl]-3-methylphenyl}amino)-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-({3-methyl-4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyridin-2-yl)-8-[(4-{2-[4-(morpholin-4-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyridin-2-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyridin-2-yl)-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-[(4-{2-[4-(morpholin-4-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-[(2-methyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-(2-methyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6,8-bis(phenylsulfanyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-fluoro-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-fluoro-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[4-(dimethylamino)piperidin-1-yl]ethyl}phenyl)amino]-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl}phenyl)amino]-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylamino)pyrimidin-5-yl]-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(3-fluoropropyl)piperidin-4-yl]phenyl}amino)-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methylpyrimidin-5-yl)-8-{[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-{[3-methyl-4-(oxan-4-yl)phenyl]amino}-1,2-

dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-({2-methyl-5-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({2-methyl-5-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 4-{[3-(6-methoxypyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N,2-dimethylbenzamide; 8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-[(4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methyl-1,3-thiazol-4-yl)-8-{[4-(oxan-4-yloxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(3-fluoropropyl)piperidin-4-yl]phenyl}amino)-6-(2-methyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyridin-2-yl)-8-{[4-(oxan-4-yloxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(3-fluoropropyl)piperidin-4-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methyl-1,3-thiazol-2-yl)-8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methyl-1,3-thiazol-2-yl)-8-{[4-(oxan-4-yloxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-(4-methyl-1,3-thiazol-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methyl-1,3-thiazol-2-yl)-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-methyl-1,3-thiazol-2-yl)-8-({2-[(2R)-2-methylmorpholin-4-yl]pyrimidin-5-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-fluoro-5-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-fluoro-5-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-fluoro-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-fluoro-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[6-(1-methylpiperidin-4-yl)pyridin-3-yl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-{[6-(1-methylpiperidin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,6-dimethylphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl 4-(4-{[3-(2-butoxyphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate; 6-(2-butoxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl 4-(4-{[3-(2-ethoxy-5-methylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate; 6-(2-ethoxy-5-methylphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl 4-(4-{[8-oxo-3-(2-propoxyphenyl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate; 8-{[4-(piperidin-4-

yl)phenyl]amino}-6-(2-propoxyphenyl)-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl 4-[4-({8-oxo-3-[2-(propan-2-yloxy)phenyl]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]piperidine-1-carboxylate; 8-{[4-(piperidin-4-yl)phenyl]amino}-6-[2-(propan-2-yloxy)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl 4-(4-{[8-oxo-3-(2-phenoxyphenyl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate; 6-(2-phenoxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[2-(methylamino)pyrimidin-5-yl]-8-[(4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-yl)-8-({3-methyl-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-yl)-8-({3-methyl-4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-(2-methanesulfonylethyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-({6-[(2S)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 4-{[3-(6-methoxypyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide; 8-({4-[1-(2,3-dihydroxypropyl)piperidin-4-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyridin-2-yl)-8-[(4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; N,2-dimethyl-4-{[3-(6-methylpyridin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide; 6-(2-aminopyrimidin-5-yl)-8-[(3-chlorophenyl)amino]-2-(2-methoxyethyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-(2-methoxyethyl)-8-[(3-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methoxypyrazin-2-yl)-2-(2-methoxyethyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3-methoxyphenyl)amino]-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3-methylphenyl)amino]-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3-chlorophenyl)amino]-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(1-methyl-1H-pyrazol-4-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(2-methanesulfonyl-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(2-methanesulfonyl-1,2,3,4-

tetrahydroisoquinolin-6-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(2,2-dimethylmorpholin-4-yl)-3-methylphenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(2,2-dimethylmorpholin-4-yl)-3-methylphenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethoxypyrimidin-5-yl)-8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-{[4-(pyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,4-dimethoxypyrimidin-5-yl)-8-({4-[1-(2-methoxyethyl)pyrrolidin-3-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methoxyethyl)pyrrolidin-3-yl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[6-(oxan-4-yl)pyridin-3-yl]amino}-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-({4-[1-(4,4,4-trifluorobutyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-ethylpyrrolidin-3-yl)phenyl]amino}-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 4-(4-methoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; N-methyl-4-(8-{[4-(morpholin-4-yl)phenyl]amino}-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzamide; 8-{[4-(morpholin-4-yl)phenyl]amino}-4-[3-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 4-[3-(dimethylamino)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-(4-chlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(morpholin-4-yl)phenyl]amino}-4-[4-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-ethyl-8-{[4-(1-ethylpyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2,6-dimethoxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; tert-butyl 4-(4-{[3-(2,6-dimethoxyphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate; 8-{[2-(3-methylbutoxy)phenyl]amino}-6-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-(3-methylbutoxy)phenyl]amino}-6-{[2-(propane-2-sulfonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-(3-methylbutoxy)phenyl]amino}-6-(pyridin-3-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-(3-methylbutoxy)phenyl]amino}-6-{[3-(piperidin-1-ylmethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(2-methoxy-5-phenoxyphenyl)amino]-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-(3-methylbutoxy)phenyl]amino}-6-{[3-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-(3-methylbutoxy)phenyl]amino}-6-{[2-(methylsulfanyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-(3-methylbutoxy)phenyl]amino}-6-[3-(pyrrolidin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 5-(1-{[2-

(3-methylbutoxy)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carbonitrile 6-{2-[(dimethylamino)methyl]phenyl}-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-(3-methylbutoxy)phenyl]amino}-6-[3-(morpholin-4-ylcarbonyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 4-methoxy-3-(1-{[2-(3-methylbutoxy)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzaldehyde 6-(2,6-dimethoxyphenyl)-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-ethoxypyridin-3-yl)-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 3-methoxy-2-(1-{[2-(3-methylbutoxy)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzonitrile 3-methoxy-2-(1-{[2-(3-methylbutoxy)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzamide; 2-methyl-5-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 3-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide; 8-{[2-(3-methylbutoxy)phenyl]amino}-6-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-(3-methylbutoxy)phenyl]amino}-6-[4-(piperazin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-{[4-(4-aminopiperidin-1-yl)pyridin-3-yl]amino}-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-(3-methylbutoxy)phenyl]amino}-6-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 3-methoxy-2-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)benzamide; 6-{2-[(dimethylamino)methyl]phenyl}-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-chloro-6-methoxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(1-methyl-1H-pyrazol-4-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-[(1-methyl-1H-pyrazol-4-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridin-2-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-4-methylpyridin-2-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 1-[2-(4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)ethyl]piperidine-3-carboxylic acid 8-{[1-(piperidin-4-yl)-1H-pyrazol-4-yl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 1-[2-(4-{[3-(2-methoxypyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)ethyl]piperidine-3-carboxylic acid 6-(6-amino-5-methylpyridin-3-yl)-8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-6-(2-methylpyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-cyclopropylpiperidin-4-yl)-3-methylphenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-cyclopropylpiperidin-4-yl)-3-

methylphenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 4-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-[2-methyl-4-(trifluoromethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-(4-methoxy-2-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-(5-methoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[6-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-[6-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methylpyridin-3-yl)-8-{[4-(piperidin-4-yl)-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-{[4-(piperidin-4-yl)-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-cyclopropylpiperidin-4-yl)-3-methylphenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(2,2-dimethylmorpholin-4-yl)-3-methylphenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)-3-(trifluoromethyl)phenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 1-[2-(4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)ethyl]piperidine-4-carboxylic acid 1-[2-(4-{[3-(2-methoxypyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)ethyl]piperidine-4-carboxylic acid 8-({6-[1-(2-methoxyethyl)piperidin-4-yl]pyridin-3-yl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-{[1-(piperidin-4-yl)-1H-pyrazol-4-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({6-[1-(2-methoxyethyl)piperidin-4-yl]pyridin-3-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-hydroxypyrimidin-5-yl)-8-{[1-(piperidin-4-yl)-1H-pyrazol-4-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-amino-5-methylpyridin-3-yl)-8-{[6-(oxan-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[(3-fluorophenyl)methyl]amino}-6-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(1-methyl-1H-pyrazol-4-yl)amino]-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one; 3-[4-(2-methyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]propanenitrile 6-(2-aminopyrimidin-5-yl)-8-[(3-methoxyphenyl)amino]-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-(3-chloro-2-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(oxan-4-yl)-1,3-thiazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(piperidin-3-yl)-1,3-thiazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(2-

aminoethyl)-1,3-thiazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[2-(pyridin-3-yl)-1,3-thiazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-methyl-4-[6-(piperazin-1-yl)pyridin-3-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(piperidin-4-yl)-3-(trifluoromethyl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1-methylpiperidin-4-yl)-3-(trifluoromethyl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 5-[1-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]pyridine-2-carbonitrile 6-(6-methoxypyridin-2-yl)-8-({4-[1-(4,4,4-trifluorobutyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methoxyethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(6-methoxypyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methoxyethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 2-(2-aminoethyl)-6-(2-aminopyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-6-(6-methoxypyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(5-amino-6-methylpyrazin-2-yl)-8-({4-[1-(2-methoxyethyl)piperidin-4-yl]-3-methylphenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{1-[2-(dimethylamino)acetyl]pyrrolidin-3-yl}phenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrimidin-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyridin-2-yl)-8-({3-methyl-4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 4-phenyl-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 4-(4-methoxyphenyl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 4-(4-chlorophenyl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-4-[4-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-4-[3-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 4-[3-(dimethylamino)phenyl]-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 4-(4-methoxy-2-methylphenyl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 4-[2-methyl-4-(trifluoromethyl)phenyl]-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 4-(1-methyl-1H-pyrazol-4-yl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-

naphthyridin-1-one; 4-(5-methoxypyridin-3-yl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-methyl-6-(pyrimidin-4-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(1-methyl-1H-pyrazol-4-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 3-[4-(4-{[3-(2-methoxypyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-2-methylphenyl)piperidin-1-yl]propanenitrile 6-(2-aminopyrimidin-5-yl)-2-(2-hydroxy-3-methoxypropyl)-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-[3-(dimethylamino)propyl]-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 2-[4-(2-methyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]acetonitrile 2-[4-(2-methyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]acetamide 8-({4-[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3-methoxyphenyl)amino]-2-(3-methoxypropyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3,5-dimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3,5-dimethoxyphenyl)amino]-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3,4,5-trimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(hydroxymethyl)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(hydroxymethyl)pyridin-3-yl]-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[4-(1,2-dimethylpiperidin-4-yl)-3-fluorophenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(2-methylphenyl)amino]-6-[3-(pyrrolidin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(2-methoxyphenyl)amino]-6-[3-(pyrrolidin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(2-ethoxyphenyl)amino]-6-[3-(pyrrolidin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-(propan-2-yloxy)phenyl]amino}-6-[3-(pyrrolidin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3,5-dimethoxyphenyl)amino]-2-(2-methoxyethyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3,5-dimethoxyphenyl)amino]-2-[2-(dimethylamino)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one; 8-({1-[1-(2-methoxyethyl)piperidin-4-yl]-1H-pyrazol-4-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({1-[1-(2-methanesulfonylethyl)piperidin-4-yl]-1H-pyrazol-4-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-[(1-methyl-1H-pyrazol-4-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-[(3,4,5-trimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;

4-[6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl]-N-methylbenzamide; 6-(4-ethylpiperazin-1-yl)-4-(4-methoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 4-(4-chlorophenyl)-6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-4-[4-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-4-[3-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one; 4-[3-(dimethylamino)phenyl]-6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-4-(4-methoxy-2-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-4-[2-methyl-4-(trifluoromethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-4-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(4-ethylpiperazin-1-yl)-4-(5-methoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-methyl-6-(pyridin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}phenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{1-[2-(ethylamino)acetyl]piperidin-4-yl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{1-[2-(ethylamino)acetyl]piperidin-4-yl}phenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; N-[3-(2-aminopyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]-4-fluorobenzamide; 4-fluoro-N-[3-(6-methoxypyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]benzamide; 6-(2-amino-6-methylpyrimidin-4-yl)-8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-(2-hydroxyethyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-[(dimethylamino)methyl]-1H-indazol-6-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-[(dimethylamino)methyl]-1H-indazol-6-yl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({3-[(dimethylamino)methyl]-1H-indazol-6-yl}amino)-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(2-methanesulfonyl-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(2-methanesulfonyl-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-methyl-6-[(5-methylpyridin-2-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-methyl-6-[(3-methylpyridin-2-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(1-amino-7-methyl-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]pyridine-3-carbonitrile 6-[(1-amino-7-methyl-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]pyridine-3-carboxamide 8-amino-2-methyl-6-[(1-methyl-1H-pyrazol-3-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-methyl-6-(1,3-thiazol-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-methyl-6-(pyridazin-3-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-

amino-2-methyl-6-(pyrazin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-benzyl-6-(pyrimidin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-methyl-6-(pyrimidin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 2-[4-(4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-1H-pyrazol-1-yl)piperidin-1-yl]acetonitrile 8-({4-[1-(2,3-dihydroxypropyl)piperidin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2,3-dihydroxypropyl)piperidin-4-yl]phenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-({1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-({1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-2-(2-methoxyethyl)-1,2-dihydro-2,7-naphthyridin-1-one; 2-[6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-1-oxo-1,2-dihydro-2,7-naphthyridin-2-yl]acetonitrile 8-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-methoxypyrimidin-5-yl)-8-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-2-[2-(dimethylamino)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-2-(2-hydroxy-3-methoxypropyl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-({4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-({1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-8-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]amino}-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one; N-methyl-2-[4-(2-methyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]acetamide 8-[(2-acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-{[2-(2-methoxyethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(pyrimidin-5-yl)-8-{[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-6-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-{imidazo[1,2-a]pyrimidin-6-yl}-2-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-{8-methylimidazo[1,2-a]pyrazin-6-yl}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-

dihydro-2,7-naphthyridin-1-one; 6-{imidazo[1,2-a]pyrimidin-6-yl}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 2-({1-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}-3-methylphenyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl}amino)-6-methylbenzene-1-sulfonamide; 2-{[1-({4-[1-(2-methoxyethyl)piperidin-4-yl]-3-methylphenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]amino}-6-methylbenzene-1-sulfonamide; 8-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}-3-methylphenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}-3-methylphenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{1-[2-(ethylamino)acetyl]piperidin-4-yl}-3-methylphenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(4-{1-[2-(ethylamino)acetyl]piperidin-4-yl}-3-methylphenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 8-[(6-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}pyridin-3-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(6-methoxypyrazin-2-yl)-8-({4-[2-(4-methylpiperazin-1-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-2-methyl-8-(propan-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 6-(2-aminopyrimidin-5-yl)-2-methyl-8-(propan-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-benzyl-6-(pyrimidin-4-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-benzyl-6-(pyridin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-benzyl-6-[(5-methylpyridin-2-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-benzyl-6-[(3-methylpyridin-2-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-benzyl-6-(pyridazin-3-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one; 4-{6-[(2-methoxyethyl)amino]-8-{[4-(morpholin-4-yl)phenyl]amino}-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl}-N-methylbenzamide; 6-[(2-methoxyethyl)amino]-4-(4-methoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-benzyl-6-[(1-methyl-1H-pyrazol-3-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one; 6-[(2-methoxyethyl)amino]-4-(5-methoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 6-{8-methylimidazo[1,2-a]pyridin-6-yl}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one; 8-amino-2-benzyl-6-(pyrazin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one, and 8-{[4-(morpholin-4-yl)phenyl]amino}-6-{1H,2H,3H-pyrrolo[2,3-b]pyridin-5-yl}-1,2-dihydro-2,7-naphthyridin-1-one.

[00037] In another aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), and a pharmaceutically acceptable carrier. In certain embodiments, such pharmaceutical compositions are formulated for intravenous, oral administration, rectal administration inhalation, nasal administration, topical administration, ophthalmic administration or otic administration. In other embodiments, such pharmaceutical composition are formulated as tablets, a pills, capsules, a liquid, an inhalant, a nasal spray solution, a suppository, a solution, an emulsion, an ointment, eye drops or ear drops.

[00038] In another aspect, the present invention provides a medicament for treating a Syk-mediated

disease or condition in a patient comprising a therapeutically effective amount of a compound of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e).

[00039] In another aspect, the present invention provides the use of a compound of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e) in the manufacture of a medicament for treating a Syk-mediated disease or condition.

[00040] In another aspect, the present invention provides methods for modulating a protein kinase, comprising administering to a system or a subject in need thereof, a therapeutically effective amount of a compound of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts or pharmaceutical compositions thereof, thereby modulating the protein kinase. In certain embodiments, the protein kinase is Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, IGR-1R, Alk, c-FMS, TrkA, TrkB, TrkC kinases, or a combination thereof. In other embodiments the protein kinase is Syk. In certain embodiments of such methods, the compounds of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts or pharmaceutical compositions thereof, inhibit protein kinases. In certain embodiments, the protein kinases inhibited by compounds of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts or pharmaceutical compositions thereof are Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, IGR-1R, Alk, c-FMS, TrkA, TrkB, TrkC kinases, or a combination thereof. In other embodiments the Syk.protein kinase is inhibited by compounds of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts or pharmaceutical compositions thereof.

[00041] In another aspect, the present invention provides methods for modulating a protein kinase, comprising administering to a system or a subject in need thereof, a therapeutically effective amount of a compound of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts, pharmaceutical compositions or medicaments thereof, thereby modulating the protein kinase. In certain embodiments, the protein kinase is Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, IGR-1R, Alk, c-FMS, TrkA, TrkB, TrkC kinases, or a combination thereof. In other embodiments the protein kinase is Syk. In certain embodiments of such methods, the compound of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts, pharmaceutical compositions or medicaments thereof, inhibit protein kinases. In certain embodiments, the protein kinases inhibited by compounds of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts, pharmaceutical compositions or medicaments thereof are Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, IGR-1R, Alk, c-FMS, TrkA, TrkB, TrkC kinases, or a combination thereof. In other embodiments the Syk.protein kinase is inhibited by compounds of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts, pharmaceutical compositions or medicaments thereof.

[00042] In another aspect, the present invention provides methods for treating a Syk mediated disease or condition comprising administering to a system or a subject in need of such treatment a therapeutically effective amount of a compound of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts, pharmaceutical compositions or medicaments thereof, thereby treating such Syk mediated diseases or conditions. In certain embodiments such Syk mediated diseases or conditions are inflammatory diseases or

conditions, respiratory diseases or autoimmune diseases or conditions. In certain embodiments such Syk mediated diseases or conditions are asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohns disease, bronchitis, dermatitis, allergic rhinitis, psoriasis, scleroderma, urticaria, rheumatoid arthritis, multiple sclerosis, cancer, breast cancer, HIV or lupus.

[00043] In another aspect, the present invention provides methods for treating a Syk mediated disease or condition comprising administering to a system or a subject in need of such treatment a therapeutically effective amount of a compound of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts, pharmaceutical compositions or medicaments thereof in combination with a second therapeutic agent, thereby treating such Syk mediated diseases or conditions. In certain embodiments such Syk mediated diseases or conditions are inflammatory diseases or conditions, respiratory diseases or autoimmune diseases or conditions. In certain embodiments such Syk mediated diseases or conditions are asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohns disease, bronchitis, dermatitis, allergic rhinitis, psoriasis, scleroderma, urticaria, rheumatoid arthritis, multiple sclerosis, cancer, breast cancer, HIV or lupus.

[00044] In the above methods for using the compounds of the invention, a compound of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts, pharmaceutical compositions or medicaments thereof is administered to a system comprising cells or tissues. In certain embodiments, a compound of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts, pharmaceutical compositions or medicaments thereof is administered to a human or animal subject.

[00045] In another aspect, the present invention provides methods for treating a cell-proliferative disease or condition comprising administering to a system or a subject in need of such treatment a therapeutically effective amount of a compound of Formulas (I), (Ia), (Ib), (Ic), I(d) or I(e), or pharmaceutically acceptable salts, pharmaceutical compositions or medicaments thereof, wherein the cell-proliferative disease or condition is lymphoma, osteosarcoma, melanoma, breast cancer, renal cancer, prostate cancer, colorectal cancer, thyroid cancer, ovarian cancer, pancreatic cancer, neuronal cancer, lung cancer, uterine cancer or gastrointestinal cancer.

[00046] In another aspect, the present invention provides a compound having the structure



.

[00047] In another aspect, the present invention provides a compound having the structure



[00048] In another aspect, the present invention provides a compound having the structure



[00049] In another aspect, the present invention provides a compound having the structure



[00050] In another aspect, the present invention provides a compound having the structure



DETAILED DESCRIPTION OF THE INVENTION

Definitions

[00051] The term "alkenyl", as used herein, refers to a partially unsaturated branched or straight chain hydrocarbon having at least one carbon-carbon double bond. Atoms oriented about the double bond are in either the cis (Z) or trans (E) conformation. As used herein, the terms "C_2-C_4alkenyl", "C_2-C_5alkenyl", "C_2-C_6alkenyl", "C_2-C_7alkenyl", and "C_2-C_8alkenyl" refer to an alkyenyl group containing at least 2, and at most 4, 5, 6, 7 or 8 carbon atoms, respectively. Non-limiting examples of alkenyl groups, as used herein, include

ethenyl, propenyl, allyl (2-propenyl), butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl and the like.

[00052] The term "alkyl", as used herein, refers to a saturated branched or straight chain hydrocarbon. As used herein, the terms "C_1-C_3alkyl", "C_1-C_4alkyl", "C_1-C_5alkyl", "C_1-C_6alkyl", "C_1-C_7alkyl" and "C_1-C_8alkyl" refer to an alkyl group containing at least 1, and at most 3, 4, 5, 6, 7 or 8 carbon atoms, respectively. Non-limiting examples of alkyl groups as used herein include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, hexyl, heptyl, octyl, nonyl, decyl and the like.

[00053] The term "alkylene", as used herein, refers to a saturated branched or straight chain divalent hydrocarbon radical, wherein the radical is derived by the removal of one hydrogen atom from each of two carbon atoms. As used herein, the terms "C_1-C_3alkylene", "C_1-C_4alkylene", "C_1-C_5alkylene", and "C_1-C_6alkylene" refer to an alkylene group containing at least 1, and at most 3, 4, 5 or 6 carbon atoms respectively. Non-limiting examples of alkylene groups as used herein include, methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, sec-butylene, t-butylene, n-pentylene, isopentylene, hexylene and the like.

[00054] The term "alkynyl", as used herein, refers to a partially unsaturated branched or straight chain hydrocarbon radical having at least one carbon-carbon triple bond. As used herein, the terms "C_2-C_4alkynyl", "C_2-C_5alkynyl", "C_2-C_6alkynyl", "C_2-C_7alkynyl", and "C_2-C_8alkynyl" refer to an alkynyl group containing at least 2, and at most 4, 5, 6, 7 or 8 carbon atoms, respectively. Non-limiting examples of alkynyl groups, as used herein, include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl and the like.

[00055] The term "alkoxy", as used herein, refers to the group $-OR_a$, where R_a is an alkyl group as defined herein. As used herein, the terms "C_1-C_3alkoxy", "C_1-C_4alkoxy", "C_1-C_5alkoxy", "C_1-C_6alkoxy", "C_1-C_7alkoxy" and "C_1-C_8alkoxy" refer to an alkoxy group wherein the alkyl moiety contains at least 1, and at most 3, 4, 5, 6, 7 or 8, carbon atoms. Non-limiting examples of alkoxy groups, as used herein, include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, pentoxy, hexoxy, heptoxy, and the like.

[00056] The term "aryl", as used herein, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. An aryl group may contain one or more substituents and thus may be "optionally substituted". Unless otherwise defined herein, suitable substituents on the unsaturated carbon atom of an aryl group are generally selected from halogen; -R, -OR, -SR, $-NO_2$, -CN, $-N(R)_2$, -NRC(O)R, -NRC(S)R, $-NRC(O)N(R)_2$, -N RC(S)N$(R)_2$, $-NRCO_2R$, -NRNRC(O)R, $-NRNRC(O)N(R)_2$, $-NRNRCO_2R$, -C(O)C(O)R, $-C(O)CH_2C(O)R$, $-CO_2R$, $-C(O)R^{\circ}$, -C(S)R, $-C(O)N(R)_2$, $-C(S)N(R)_2$, -

$OC(O)N(R)_2$, -OC(O)R, -C(O)N(OR)R, -C(NOR)R, $-S(O)_2R$, $-S(O)_3R$, $-SO_2N(R)_2$, -S(O)R, $-NRSO_2N(R)_2$, $-NRSO_2R$, -N(OR)R, $-C(=NH)-N(R)_2$, $-P(O)_2R$, $-PO(R)_2$, $-OPO(R)_2$, $-(CH_2)_{0-2}NHC(O)R$, phenyl (Ph) optionally substituted with R, -O(Ph) optionally substituted with R, $-(CH_2)_{1-2}(Ph)$, optionally substituted with R, or –CH=CH(Ph), optionally substituted with R, wherein each independent occurrence of R is selected from hydrogen, optionally substituted C_1-C_6alkyl, optionally substituted C_1-C_6alkoxy, an unsubstituted 5-6 membered heteroaryl, phenyl, -O(Ph), or $–CH_2(Ph)$, or two independent occurrences of R, on the same substituent or different substituents, taken together with the atom(s) to which each R is bound, to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Non-limiting examples of aryl groups, as used herein, include phenyl, naphthyl, fluorenyl, indenyl, azulenyl, anthracenyl and the like.

[00057] The term “arylene”, as used means a divalent radical derived from an aryl group.

[00058] The term “cyano”, as used herein, refers to a -CN group.

[00059] The term “cycloalkyl”, as used herein, refers to a saturated or partially unsaturated, monocyclic, fused bicyclic, fused tricyclic or bridged polycyclic ring assembly. As used herein, the terms "C_3-C_5 cycloalkyl", "C_3-C_6 cycloalkyl", "C_3-C_7 cycloalkyl", "C_3-C_8 cycloalkyl , "C_3-C_9 cycloalkyl and "C_3-C_{10} cycloalkyl refer to a cycloalkyl group wherein the saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly contain at least 3, and at most 5, 6, 7, 8, 9 or 10, carbon atoms. Non-limiting examples of cycloalkyl groups, as used herein, include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, decahydronaphthalenyl, 2,3,4,5,6,7-hexahydro-1H-indenyl and the like.

[00060] The term “cyclic heterodionyl”, as used herein, refers to a heteroaryl compound bearing two carbonyl substituents. Non-limiting examples of cyclic heterodionyl, as used herein, include thiazolidinyl diones, oxazolidinyl diones and pyrrolidinyl diones.

[00061] The term “halogen”, as used herein, refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).

[00062] The term "halo”, as used herein, refers to the halogen radicals: fluoro (-F), chloro (-Cl), bromo (-Br), and iodo (-I).

[00063] The terms “haloalkyl” or “halo-substituted alkyl”, as used herein, refers to an alkyl group as defined herein, substituted with at least one halo group or combinations thereof. Non-limiting examples of such branched or straight chained haloalkyl groups, as used herein, include methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl substituted with one or more halo groups or combinations thereof, including, but not limited to, trifluoromethyl, pentafluoroethyl, and the like.

[00064] The term "halo-substituted alkenyl", as used herein, refers to an alkenyl group as defined above, substituted with at least one halo group or combinations thereof. Non-limiting examples of such branched or straight chained haloalkenyl groups, as used herein, include ethenyl, propenyl, allyl (2-propenyl), butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl and the like substituted with one or more halo groups or combinations thereof.

[00065] The term "halo-substituted alkynyl", as used herein, refers to an alkynyl group as defined above, substituted with at least one halo group or combinations thereof. Non-limiting examples of such branched or straight chained haloalkynyl groups, as used herein, include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl and the like substituted with one or more halo groups or combinations thereof.

[00066] The term "haloalkoxy", as used herein, refers to an alkoxy group as defined above, substituted with one or more halo group or combinations thereof. Non-limiting examples of such branched or straight chained haloalkynyl groups, as used herein, includemethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, pentoxy, hexoxy, heptoxy and the like substituted with one or more groups or combinations thereof.

[00067] The term "heteroalkyl", as used herein, refers to refers to an alkyl group as defined herein wherein one or more carbon atoms are independently replaced by one or more of oxygen, sulfur, nitrogen, or combinations thereof.

[00068] The term "heteroaryl", as used herein, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms selected from nitrogen, oxygen and sulfur, and wherein each ring in the system contains 3 to 7 ring members. Unless otherwise defined above and herein, suitable substituents on the unsaturated carbon atom of a heteroaryl group are generally selected from from halogen; -R, -OR, -SR, $-NO_2$, -CN, $-N(R)_2$, -NRC(O)R, -NRC(S)R, $-NRC(O)N(R)_2$, -N RC(S)$N(R)_2$, $-NRCO_2R$, -NRNRC(O)R, $-NRNRC(O)N(R)_2$, $-NRNRCO_2R$, $-C(O)C(O)R$, $-C(O)CH_2C(O)R$, $-CO_2R$, $-C(O)R^{\circ}$, -C(S)R, $-C(O)N(R)_2$, $-C(S)N(R)_2$, $-OC(O)N(R)_2$, -OC(O)R, -C(O)N(OR)R, -C(NOR)R, $-S(O)_2R$, $-S(O)_3R$, $-SO_2N(R)_2$, -S(O)R, $-NRSO_2N(R)_2$, $-NRSO_2R$, -N(OR)R, $-C(=NH)-N(R)_2$, $-P(O)_2R$, $-PO(R)_2$, $-OPO(R)_2$, $-(CH_2)_{0-2}NHC(O)R$, phenyl (Ph) optionally substituted with R, -O(Ph) optionally substituted with R, $-(CH_2)_{1-2}(Ph)$, optionally substituted with R, or –CH=CH(Ph), optionally substituted with R, wherein each independent occurrence of R is selected from hydrogen, optionally substituted C_1-C_6alkyl, optionally substituted C_1-C_6alkoxy, an unsubstituted 5-6 membered heteroaryl, phenyl, -O(Ph), or $–CH_2(Ph)$, or two independent occurrences of R, on the same substituent or different substituents, taken together with the atom(s) to which each R is bound, to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected

from nitrogen, oxygen, or sulfur. Non-limiting examples of heteroaryl groups, as used herein, include benzofuranyl, benzofurazanyl, benzoxazolyl, benzopyranyl, benzthiazolyl, benzothienyl, benzazepinyl, benzimidazolyl, benzothiopyranyl, benzo[1,3]dioxole, benzo[b]furyl, benzo[b]thienyl, cinnolinyl, furazanyl, furyl, furopyridinyl, imidazolyl, indolyl, indolizinyl, indolin-2-one, indazolyl, isoindolyl, isoquinolinyl, isoxazolyl, isothiazolyl, 1,8-naphthyridinyl, oxazolyl, oxaindolyl, oxadiazolyl, pyrazolyl, pyrrolyl, phthalazinyl, pteridinyl, purinyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, quinoxalinyl, quinolinyl, quinazolinyl, 4H-quinolizinyl, thiazolyl, thiadiazolyl, thienyl, triazinyl,triazolyl and tetrazolyl.

[00069] The term "heterocycloalkyl", as used herein, refers to a cycloalkyl, as defined herein, wherein one or more of the ring carbons are replaced by a moiety selected from -O-, -N=, -NR-, -C(O)-, -S-, -S(O) - or -$S(O)_2$-, wherein R is hydrogen, C_1-C_8alkyl or a nitrogen protecting group, with the proviso that the ring of said group does not contain two adjacent O or S atoms. Non-limiting examples of heterocycloalkyl groups, as used herein, include morpholino, pyrrolidinyl, pyrrolidinyl-2-one, piperazinyl, piperidinyl, piperidinylone, 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl, 2H-pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, 1,3-dioxolanyl, 2-imidazolinyl, imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, 1,4-dioxanyl, 1,4-dithianyl, thiomorpholinyl, azepanyl, hexahydro-1,4-diazepinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, thioxanyl, azetidinyl, oxetanyl, thietanyl, oxepanyl, thiepanyl, 1,2,3,6-tetrahydropyridinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, , dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, and 3-azabicyclo[4.1.0]heptanyl.

[00070] The term "heteroatom", as used herein, refers to one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon.

[00071] The term "hydroxyl", as used herein, refers to the group -OH.

[00072] The term "hydroxyalkyl", as used herein refers to an alkyl group as defined herein substituted with at least one hydroxyl, hydroxyl being as defined herein. Non-limiting examples of branched or straight chained "C_1-C_6 hydroxyalkyl groups as used herein include methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl substituted independently with one or more hydroxyl groups.

[00073] The term "isocyanato", as used herein, refers to a –N=C=O group.

[00074] The term "isothiocyanato", as used herein, refers to a –N=C=S group.

[00075] The term "mercaptyl", as used herein, refers to an (alkyl)S- group.

[00076] The term "optionally substituted", as used herein, means that the referenced group may or may not be substituted with one or more additional group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, hydroxyl, alkoxy, mercaptyl, , cyano, halo, carbonyl, thiocarbonyl, isocyanato, thiocyanato, isothiocyanato, nitro, perhaloalkyl, perfluoroalkyl, and

amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. Non-limiting examples of optional substituents include, halo, –CN, , –OR, -C(O)R, -OC(O)R, -C(O)OR, , OC(O)NHR, –C(O)N($R)_2$, -SR-, -S(=O)R, -S(=O)$_2$R, -NHR, -N($R)_2$,- NHC(O)-, NHC(O)O-, -C(O)NH-, S(=O)$_2$NHR, –S(O)$_2$ N($R)_2$, -NHS(=O)$_2$, -NHS(O)$_2$R, C_1-C_6 alkyl, C_1-C_6 alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo-substituted C_1-C_6alkyl, halo-substituted C_1-C_6alkoxy, where each R is independently selected from H, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, halo-substituted C_1-C_6alkyl, halo-substituted C_1-C_6alkoxy.

[00077] The term "solvate", as used herein, refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of Formula (I), or a salt thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Non-limiting examples of suitable solvents include water, acetone, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Non-liniting examples of suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid.

[00078] The term "acceptable" with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.

[00079] The term "administration" or "administering" of the subject compound means providing a compound of the invention and prodrugs thereof to a subject in need of treatment.

[00080] The term "bone disease,` as used herein, refers to a disease or condition of the bone, including, but not limited to, inapproriate bone remodeling, loss or gain, osteopenia, osteomalacia, osteofibrosis, and Paget's disease.

[00081] The term "cardiovascular disease," as used herein refers to diseases affecting the heart or blood vessels or both, including but not limited to: arrhythmia; atherosclerosis and its sequelae; angina; myocardial ischemia; myocardial infarction; cardiac or vascular aneurysm; vasculitis, stroke; peripheral obstructive arteriopathy of a limb, an organ, or a tissue; reperfusion injury following ischemia of the brain, heart or other organ or tissue; endotoxic, surgical, or traumatic shock; hypertension, valvular heart disease, heart failure, abnormal blood pressure; shock; vasoconstriction (including that associated with migraines); vascular abnormality, inflammation, insufficiency limited to a single organ or tissue.

[00082] The term "cancer," as used herein refers to an abnormal growth of cells which tend to proliferate in an uncontrolled way and, in some cases, to metastasize (spread). The types of cancer include, but is not limited to, solid tumors (such as those of the bladder, bowel, brain, breast, endometrium, heart, kidney, lung, lymphatic tissue (lymphoma), ovary, pancreas or other endocrine organ (thyroid), prostate, skin (melanoma) or hematological tumors (such as the leukemias).

[00083] The term "carrier," as used herein, refers to chemical compounds or agents that facilitate the

incorporation of a compound described herein into cells or tissues.

[00084] The terms "co-administration" or "combined administration" or the like as used herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.

[00085] The term "dermatological disorder," as used herein refers to a skin disorder. Such dermatological disorders include, but are not limited to, proliferative or inflammatory disorders of the skin such as, atopic dermatitis, bullous disorders, collagenoses, contact dermatitis eczema, Kawasaki Disease, rosacea, Sjogren-Larsso Syndrome, and urticaria.

[00086] The term "diluent"as used herein, refers to chemical compounds that are used to dilute a compound described herein prior to delivery. Diluents can also be used to stabilize compounds described herein.

[00087] The terms "effective amount" or "therapeutically effective amount," as used herein, refer to a sufficient amount of a compound described herein being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate "effective" amount in any individual case may be determined using techniques, such as a dose escalation study.

[00088] The terms "enhance" or "enhancing," as used herein, means to increase or prolong either in potency or duration a desired effect. Thus, in regard to enhancing the effect of therapeutic agents, the term "enhancing" refers to the ability to increase or prolong, either in potency or duration, the effect of other therapeutic agents on a system. An "enhancing-effective amount," as used herein, refers to an amount adequate to enhance the effect of another therapeutic agent in a desired system.

[00089] The terms "fibrosis" or "fibrosing disorder," as used herein, refers to conditions that follow acute or chronic inflammation and are associated with the abnormal accumulation of cells and/or collagen and include but are not limited to fibrosis of individual organs or tissues such as the heart, kidney, joints, lung, or skin, and includes such disorders as idiopathic pulmonary fibrosis and cryptogenic fibrosing alveolitis.

[00090] The term "iatrogenic", as used herein, means a condition, disorder, or disease created or worsened by medical or surgical therapy.

[00091] The term "inflammatory disorders", as used herein, refers to those diseases or conditions that

are characterized by one or more of the signs of pain (dolor, from the generation of noxious substances and the stimulation of nerves), heat (calor, from vasodilatation), redness (rubor, from vasodilatation and increased blood flow), swelling (tumor, from excessive inflow or restricted outflow of fluid), and loss of function (functio laesa, which may be partial or complete, temporary or permanent). Inflammation takes many forms and includes, but is not limited to, inflammation that is one or more of the following: acute, adhesive, atrophic, catarrhal, chronic, cirrhotic, diffuse, disseminated, exudative, fibrinous, fibrosing, focal, granulomatous, hyperplastic, hypertrophic, interstitial, metastatic, necrotic, obliterative, parenchymatous, plastic, productive, proliferous, pseudomembranous, purulent, sclerosing, seroplastic, serous, simple, specific, subacute, suppurative, toxic, traumatic, and/or ulcerative. Inflammatory disorders further include, without being limited to those affecting the blood vessels (polyarteritis, temporarl arteritis); joints (arthritis: crystalline, osteo-, psoriatic, reactive, rheumatoid, Reiter's); gastrointestinal tract (Disease,); skin (dermatitis); or multiple organs and tissues (systemic lupus erythematosus).

[00092] The term "Kinase Panel", as used herein, refers to is a list of kinases including but not limited to Abl(human), Abl(T315I), JAK2, JAK3, ALK, JNK1α1, ALK4, KDR, Aurora-A, Lck, Blk, MAPK1, Bmx, MAPKAP-K2, BRK, MEK1, CaMKII(rat), Met, CDK1/cyclinB, p70S6K, CHK2, PAK2, CK1, PDGFRα, CK2, PDK1, c-Kit, Pim-2, C-Raf, PKA(h), CSK, PKBα, Src, PKCα, DYRK2, Plk3, EGFR, ROCK-I, Fes, Ron, FGFR-3, Ros, Flt3, SAPK2α, Fms, SGK, Fyn, SIK, GSK3β, Syk, IGFR, Tie-2, IKKß, TrkB, IR, WNK3, IRAK4, ZAP-70, ITK, AMPK(rat), LIMK1, Rsk2, Axl, LKB1, SAPK2β, BrSK2, Lyn (h), SAPK3, BTK, MAPKAP-K3, SAPK4, CaMKIV, MARK1, Snk, CDK2/cyclinA, MINK, SRPK1, CDK3/cyclinE, MKK4(m), TAK1, CDK5/p25, MKK6(h), TBK1, CDK6/cyclinD3, MLCK, TrkA, CDK7/cyclinH/MAT1, MRCKβ, TSSK1, CHK1, MSK1, Yes, CK1d, MST2, ZIPK, c-Kit (D816V), MuSK, DAPK2, NEK2, DDR2, NEK6, DMPK, PAK4, DRAK1, PAR-1Bα, EphA1, PDGFRβ, EphA2, Pim-1, EphA5, PKBβ, EphB2, PKCβI, EphB4, PKCδ, FGFR1, PKCη, FGFR2, PKCθ, FGFR4, PKD2, Fgr, PKG1β, Flt1, PRK2, Hck, PYK2, HIPK2, Ret, IKKα, RIPK2, IRR, ROCK-II(human), JNK2α2, Rse, JNK3, Rsk1(h), PI3 Kγ, PI3 Kδ and PI3-Kβ.

[00093] The term "modulate," as used herein, means to interact with a target either directly or indirectly so as to alter the activity of the target, including, by way of example only, to enhance the activity of the target, to inhibit the activity of the target, to limit the activity of the target, or to extend the activity of the target.

[00094] The term "modulator," as used herein, refers to a molecule that interacts with a target either directly or indirectly. The interactions include, but are not limited to, the interactions of an agonist and an antagonist.

[00095] The terms "neurogenerative disease" or "nervous system disorder," as used herein, refers to

conditions that alter the structure or function of the brain, spinal cord or peripheral nervous system, including but not limited to Alzheimer's Disease, cerebral edema, cerebral ischemia, multiple sclerosis, neuropathies, Parkinson's Disease, those found after blunt or surgical trauma (including post-surgical cognitive dysfunction and spinal cord or brain stem injury), as well as the neurological aspects of disorders such as degenerative disk disease and sciatica. The acronym "CNS" refers to disorders of the central nervous system (brain and spinal cord).

[00096] The terms "ocular disease" or "ophthalmic disease," as used herein, refer to diseases which affect the eye or eyes and potentially the surrounding tissues as well. Ocular or ophthalmic diseases include, but are not limited to, conjunctivitis, retinitis, scleritis, uveitis, allergic conjuctivitis, vernal conjunctivitis, pappillary conjunctivitis.

[00097] The term "pharmaceutically acceptable," as used herein, refers a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compounds described herein. Such materials are administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

[00098] The term "pharmaceutically acceptable salt", as used herein, refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compounds described herein.

[00099] The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of Formula I and a coagent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of Formula I and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of 3 or more active ingredients.

[000100] The term "pharmaceutical composition", as used herein, refers to a mixture of a compound described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.

[000101] The term "prodrug", as used herein, refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. Prodrugs are bioavailable by oral administration whereas the parent is not. Prodrugs improve solubility in pharmaceutical compositions over the parent drug. A non-limiting example of a prodrug of the

compounds described herein is a compound described herein administered as an ester which is then metabolically hydrolyzed to a carboxylic acid, the active entity, once inside the cell. A further example of a prodrug is a short peptide bonded to an acid group where the peptide is metabolized to reveal the active moiety.

[000102] The term "respiratory disease," as used herein, refers to diseases affecting the organs that are involved in breathing, such as the nose, throat, larynx, trachea, bronchi, and lungs. Respiratory diseases include, but are not limited to, asthma, adult respiratory distress syndrome and allergic (extrinsic) asthma, non-allergic (intrinsic) asthma, acute severe asthma, chronic asthma, clinical asthma, nocturnal asthma, allergen-induced asthma, aspirin-sensitive asthma, exercise-induced asthma, isocapnic hyperventilation, child-onset asthma, adult-onset asthma, cough-variant asthma, occupational asthma, steroid-resistant asthma, seasonal asthma, seasonal allergic rhinitis, perennial allergic rhinitis, chronic obstructive pulmonary disease, including chronic bronchitis or emphysema, pulmonary hypertension, interstitial lung fibrosis and/or airway inflammation and cystic fibrosis, and hypoxia.

[000103] The term "subject" or "patient", as used herein, encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, humans, chimpanzees, apes monkeys, cattle, horses, sheep, goats, swine; rabbits, dogs, cats, rats, mice, guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like.

[000104] The term "Syk inhibitor", as used herein, refers to a compound which inhibits the Syk receptor.

[000105] The term "Syk mediated disease" or a "disorder or disease or condition mediated by inappropriate Syk activity", as used herein, refers to any disease state mediated or modulated by Syk kinase mechanisms. Such disease states include, but are not limited to, inflammatory, respiratory diseases and autoimmune diseases, such as, by way of example only, asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDs), ulcerative colitis, Crohns disease, bronchitis, dermatitis, allergic rhinitis, psorasis, scleroderma, urticaria, rheumatoid arthritis, multiple sclerosis, cancer, HIV and lupus.

[000106] The term "therapeutically effective amount", as used herein, refers to any amount of a compound which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.

[000107] The terms "treat", "treating" or "treatment," as used herein, refers to methods of alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, arresting the

development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.

[000108] The compound names provided herein were obtained using ChemDraw Ultra 10.0 (CambridgeSoft®) or JChem version 5.0.3 (ChemAxon).

[000109] Other objects, features and advantages of the methods and compositions described herein will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments, are given by way of illustration only.

Description of the Preferred Embodiments

[000110] The present invention provides compounds and pharmaceutical compositions thereof, which are protein kinase inhibitors. The present invention provides compounds, pharmaceutical compositions and methods for the treatment and/or prevention of protein kinase related diseases or conditions/disorders, including disease or conditions/disorders associated with abnormal or deregulated protein kinase activity. In certain embodiments, such protein kinases are Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-1R, Alk and/or c-FMS. In certain embodiments the compounds and pharmaceutical compositions of the present invention are inhibitors of Syk, ZAP70, KDR, FMS, FLT3, c-Kit and/or RET protein kinases. In other embodiments, the compounds and pharmaceutical compositions of the present invention are used to treat and/or prevent diseases and conditions related to, or mediated by, Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET or a combination thereof. In certain embodiments the compounds and pharmaceutical compositions of the present invention are inhibitors of Syk, TrkA, TrkB, TrkC, IGR-1R, Alk and/or c-FMS protein kinases. In other embodiments, the compounds and pharmaceutical compositions of the present invention are used to treat and/or prevent diseases and conditions related to, or mediated by, Syk, TrkA, TrkB, TrkC, IGR-1R, Alk, c-FMS or a combination thereof.

[000111] The protein kinase inhibitors of the present invention are compounds having Formula (I), and pharmaceutically acceptable salts, solvates, N-oxides, prodrugs and isomers thereof:



(I)

wherein:

R^1 is $-NR^6R^7$, $(CH_2)_nR^{19}$, L^3R^{19}, R^{20}, C_6-C_{14}aryl, C_3-C_8cycloalkyl, C_2-C_{14}heterocycloalkyl or C_3-C_{13}heteroaryl, wherein the C_6-C_{14}aryl, C_3-C_8cycloalkyl, C_2-C_{14}heterocycloalkyl and

C_3-C_{13}heteroaryl of R^1 is optionally substituted with 1 to 3 substituents independently selected from halogen, nitro, cyano, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkylthio, hydroxyl-C_1-C_6alkyl, halo-substituted-C_1-C_6alkyl, halo-substituted-C_1-C_6alkoxy, C_3-C_{12}cycloalkyl, C_2-C_{14}heterocycloalkyl, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, $-X^2S(O)_{0-2}R^{17}$, $-X^2S(O)_{0-2}X^2R^{19}$, $-X^2NR^{17}R^{17}$, $-X^2NR^{17}C(O)R^{17}$, $-X^2C(O)NR^{17}R^{17}$, $-X^2NR^{17}C(O)R^{19}$, $-X^2C(O)NR^{17}R^{19}$, $-X^2C(O)R^{19}$, $-X^2NR^17X^2R^{19}$ and $-X^2OX^2R^{19}$; wherein,

X^2 is a bond or C_1-C_4alkylene;

L^3 is a bond, C_1-C_6alkyl or C_1-C_6alkoxy; wherein the C_1-C_6alkyl and C_1-C_6alkoxy groups of L^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, –CN, -C_1-C_6alkyl, C_1-C_6alkoxy, $–OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $–C(O)N(R^{12})_2$, $–N(R^{12})C(O)R^{13}$, C_2-C_{14}heterocycloalkyl, $–S(O)_2R^{13}$, $–S(O)_2N(R^{12})_2$, R^{13}, $-(C(R^{12})_2)_nR^{13}$, $-(C(R^{12})_2)_nR^{14}$, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy;

R^{17} is H or C_1-C_6alkyl; and

R^{19} is R^{20}, C_3-C_{12}cycloalkyl, C_2-C_{14}heterocycloalkyl, C_6-C_{14}aryl or C_3-C_{13}heteroaryl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_{12}cycloalkyl and C_2-C_{14}heterocycloalkyl of R^{19} are optionally substituted with 1 to 3 radicals independently selected from halogen, nitro, cyano, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkylthio, hydroxyl-C_1-C_6alkyl, halo-substituted-C_1-C_6alkyl, and halo-substituted-C_1-C_6alkoxy;

R^2 and R^3 are independently selected from H, $(CH_2)_nR^{11}$, $-C(O)R^{12}$, $-CR^{12}$=NOCR^{12}, $–NR^8R^{10}$, halogen, R^{20}, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_1-C_6alkoxy, C_1-C_6alkylthio, hydroxyl-C_1-C_6alkyl, halo-substituted-C_1-C_6alkyl, and halo-substituted-C_1-C_6alkoxy, C_6-C_{14}aryl, C_3-C_{13}heteroaryl and C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_3-C_{13}heteroaryl, and C_2-C_{14}heterocycloalkyl of R^2 and R^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-NO_2$, $–OR^{12}$, $–OR^{10}$, =O, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $–NR^{12}C(O)N(R^{12})_2$, $-NHS(O)_2R^{13}$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-C(O)N(R^{12}R^{10})$, $–N(R^{12})C(O)R^{13}$, $–C(O)N(R^{11})_2$, $–C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$,$–S(O)_2R^{12}$, $–S(O)_2N(R^{11})_2$, $–S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $–S(O)_2R^{13}$, $–R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy;

R^4 is H, C_1-C_6alkyl or $-(CR^{12}R^{12})_nR^{11}$;

R^5 is H or C_1-C_6alkyl;

R^6 is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_1-C_6alkyl, C_3-C_8cycloalkyl, halo-substituted C_1-C_6alkyl, -$(CH_2)_nR^9$, R^{20}, -L^3R^9 or -Y^1-L^1-R^{14}, wherein,

Y^1 is arylene, heteroarylene or heterocycloalkylene, and

L^1- is a bond, -O-, -C(O)-, -C(O)N(R^{11})-, -$(C(R^{12})_2)_n$- or -$O(CH_2)_n$-;

and wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, halo-substituted C_1-C_6alkyl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^6 and Y^1 are optionally substituted with 1 to 3 substituents independently selected from, halogen, -CN, –OR^{12}, –OR^{10}, -$C(O)R^{12}$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{11})_2$, -$N(R^{12})_2$, -$N(R^{12}R^{10})$, -$N(R^{12}R^{11})$, -$(CR^{12}R^{12})_nR^{11}$, -SR^8, –$NR^{12}C(O)N(R^{12})_2$, -$C(O)N(R^{12}R^{10})$, –$N(R^{12})C(O)R^{13}$, –$C(O)N(R^{11})_2$, –$C(O)N(R^{12})_2$, -$(CR^{12}R^{12})_nR^{11}$, -$(CH_2)_nR^{12}$, -$(CH_2)_nR^{13}$, -$O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, -$O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, –$S(O)_2R^{12}$, –$S(O)_2N(R^{11})_2$, –$S(O)_2N(R^{12})_2$, R^{12}, R^{10}, -OR^{13}, -$C(O)R^{13}$, -$OC(O)R^{13}$, -$C(O)OR^{13}$, –$S(O)_2R^{13}$, –R^{13}, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^7 is H or C_1-C_6 alkyl;

R^8 is H or C_1-C_6 alkyl;

R^9 is R^{20}, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or Y^2-L^2-R^{14}, wherein,

Y^2 is bond, arylene, heteroarylene or heterocycloalkylene, and

L^2- is a bond, -O-, or -$O(CH_2)_n$-;

and wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl of R^9 and Y^2 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, =O, –OR^{12}, –OR^{10}, -$C(O)R^{12}$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{11})_2$, -$N(R^{12})_2$, -$N(R^{12}R^{10})$, -$N(R^{12}R^{11})$, -$(CR^{12}R^{12})_nR^{11}$, -SR^8, –$NR^{12}C(O)N(R^{12})_2$, -$C(O)N(R^{12}R^{10})$, –$N(R^{12})C(O)R^{13}$, –$C(O)N(R^{11})_2$, –$C(O)N(R^{12})_2$, -$(CR^{12}R^{12})_nR^{11}$, -$(CH_2)_nR^{12}$, -$(CH_2)_nR^{13}$, -$O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, -$O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, –$S(O)_2R^{12}$, –$S(O)_2N(R^{11})_2$, –$S(O)_2N(R^{12})_2$, R^{12}, R^{10}, -OR^{13}, -$C(O)R^{13}$, -$OC(O)R^{13}$, -$C(O)OR^{13}$, –$S(O)_2R^{13}$, –R^{13}, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^{10} is halo-substituted C_1-C_6alkyl, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or -$(CH_2)_nR^{11}$, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^{10} are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, hydroxl, –OR^{12}, –OR^{10}, -$C(O)R^{12}$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$N(R^{11})_2$, -$N(R^{12})_2$, -$N(R^{12}R^{10})$, -$N(R^{12}R^{11})$, -$(CR^{12}R^{12})_nR^{11}$, -

SR^8, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^{11} is $-N(R^{12})_2$, $-OR^{13}$, R^{20}, $-C(O)N(R^{12})_2$, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl, or C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl of R^{11} are optionally substituted with 1 to 3 substituents independently selected from halogen, $-CN$, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

each R^{12} is independently selected from H, C_1-C_6alkyl, C_2-C_6alkene, halo-substituted C_1-C_6alkyl and C_3-C_8cycloalkyl, or each R^{12} is independently a C_1-C_6alkyl that together with N they are attached to form a heterocycloalkyl;

R^{13} is H, C_1-C_6 alkyl, C_3-C_8cycloalkyl, halo-substituted C_1-C_6 alkyl or C_2-C_{14}heterocycloalkyl;

R^{14} is H, halogen, OR^{13}, R^{20}, -CN, $-S(O)_2N(R^{12})_2$, $-S(O)_2R^{13}$, $-C(O)N(R^{12})_2$, $N(R^{12})_2$, C_1-C_6alkyl, halo-substituted C_1-C_6alkyl, C_6-C_{14}aryl, heteroaryl or C_2-C_{14}heterocycloalkyl, wherein the C_2-C_{14}heterocycloalkyl, C_6-C_{14}aryl and C_3-C_{13}heteroaryl are optionally substituted with 1-3 substituents independently selected from halogen, $-CN$, C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_8cycloalkyl, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)(C(R^{12})_2)_nR^{16}$, $-C(O)N(R^{12})_2$, heterocycloalkyl, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, $-NHS(O)_2R^{13}$, R^{13}, R^{10}, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $-(C(R^{12})_2)_nR^{16}$, , halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy;

R^{15} is H, C_1-C_6alkyl, C_2-C_6alkenyl, -CN, halogen, R^{10},

R^{16} is H, halogen, OR^{13}, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, -CN, $-S(O)_2N(R^{12})_2$, $-S(O)_2R^{13}$, $C(O)N(R^{12})_2$, $-NR^{12}C(O)(R^{12})$, halo-substituted C_1-C_6alkyl, or C_2-C_{14}heterocycloalkyl;

R^{20} is  ,  or  , and

each n is independently 1, 2, 3, 4, 5 or 6.

[000112] In certain embodiments such compounds, pharmaceutically acceptable salts, isomers and pharmaceutically acceptable solvates thereof have the structure of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id) or Formula (Ie), wherein R^1-R^{21}, m, n, and p are as described herein:



(Ia)



(Ib)



(Ic)



(Id)



(Ie).

[000113] The present invention also includes all suitable isotopic variations of the compounds of the invention, or pharmaceutically acceptable salts thereof. An isotopic variation of a compound of the invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that may be incorporated into the compounds of the invention and pharmaceutically acceptable salts thereof include but are not limited to isotopes of hydrogen, carbon, nitrogen and oxygen such as as ^{2}H, ^{3}H, ^{11}C, ^{13}C, ^{14}C, ^{15}N, ^{17}O, ^{18}O, ^{35}S, ^{18}F, ^{36}Cl and ^{123}I. Certain isotopic variations of the compounds of the invention and pharmaceutically acceptable salts thereof, for example, those in which a radioactive isotope such as ^{3}H or ^{14}C is incorporated, are useful in drug and/or substrate tissue distribution studies. In particular examples, ^{3}H and ^{14}C isotopes may be used for their ease of preparation and detectability. In other examples, substitution with isotopes such as ^{2}H may afford certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements. Isotopic variations of the compounds of the invention or pharmaceutically acceptable salts thereof can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.

[000114] These compounds and pharmaceutical compositions of the present invention are useful for treating or preventing a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, neurological inflammation, chronic arthritis inflammation, hypertension, respiratory diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases, immunologically-mediated diseases, and viral diseases. The compositions are also useful in methods for preventing cell death and hyperplasia and therefore may be used to treat or prevent reperfusion/ischemia in stroke, heart attacks, and organ hypoxia. The compositions are also useful in methods for preventing thrombin-induced platelet aggregation. The compositions are especially useful for disorders such as chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), rheumatoid arthritis, asthma, osteoarthritis, ischemia, cancer (including, but not limited to, prostate cancer, ovarian cancer, breast cancer and endometrial cancer), liver disease including hepatic ischemia, heart disease such as myocardial infarction and congestive heart failure, pathologic immune conditions involving T cell activation, and neurodegenerative disorders.

Pharmacology and Utility

[000115] Protein kinases (PTK) play a central role in the regulation of a wide variety of cellular processes and maintaining control over cellular function. Protein kinases catalyze and regulate the process of phosphorylation, whereby the kinases covalently attach phosphate groups to proteins or lipid targets in response to a variety of extracellular signals. Examples of such stimuli include hormones, neurotransmitters, growth and differentiation factors, cell cycle events, environmental stresses and nutritional stresses. An extracellular stimulus may affect one or more cellular responses related to cell growth, migration, differentiation, secretion of hormones, activation of transcription factors, muscle contraction, glucose metabolism, control of protein synthesis, and regulation of the cell cycle.

[000116] Many diseases are associated with abnormal cellular responses triggered by protein kinase-mediated events. These diseases include, but are not limited to, autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, respiratory diseases, allergies and asthma, Alzheimer's disease, and hormone-related diseases.

[000117] Examples of protein-tyrosine kinases include, but are not limited to,

(a) tyrosine kinases such as Irk, IGFR-1, Zap-70, Bmx, Btk, CHK (Csk homologous kinase), CSK (C-terminal Src Kinase), Itk-1, Src (c-Src, Lyn, Fyn, Lck, Syk, Hck, Yes, Blk, Fgr and Frk), Tec, Txk/Rlk, Abl, EGFR (EGFR-1/ErbB-1, ErbB-2/NEU/HER-2, ErbB-3 and ErbB-4), FAK, FGF1R (also FGFR1 or FGR-1), FGF2R (also FGR-2), MET (also Met-I or c-MET), PDGFR (.alpha. and .beta.), Tie-1, Tie-2 (also Tek-1 or Tek), VEGFR1 (also FLT-1), VEGFR2 (also KDR), FLT-3, FLT-4, c-KIT, JAK1,

JAK2, JAK3, TYK2, LOK, RET, TRKA, PYK2, ALK (Anaplastic Lymphoma Kinase), EPHA (1-8), EPHB (1-6), RON, Fes, Fer or EPHB4 (also EPHB4-1), and

(b) and serine/threonine kinases such as Aurora, c-RAF, SGK, MAP kinases (e.g., MKK4, MKK6, etc.), SAPK2α, SAPK2β, Ark, ATM (1-3), CamK (1-IV), CamKK, Chk1 and 2 (Checkpoint kinases), CKI, CK2, Erk, IKK-I (also IKK-ALPHA or CHUK), IKK-2 (also IKK-BETA), Ilk, Jnk (1-3), LimK (1 and 2), MLK3Raf (A, B, and C), CDK (1-10), PKC (including all PKC subtypes), Plk (1-3), NIK, Pak (1-3), PDK1, PKR, RhoK, RIP, RIP-2, GSK3 (α and β), PKA, P38, Erk (1-3), PKB (including all PKB subtypes) (also AKT-1, AKT-2, AKT-3 or AKT3-1), IRAK1, FRK, SGK, TAK1 and Tp1-2 (also COT).

[000118] Phosphorylation modulates or regulates a variety of cellular processes such as proliferation, growth, differentiation, metabolism, apoptosis, motility, transcription, translation and other signaling processes. Aberrant or excessive PTK activity has been observed in many disease states including, but not limited to, benign and malignant proliferative disorders, diseases resulting from inappropriate activation of the immune system and diseases resulting from inappropriate activation of the nervous systems. Specific diseases and disease conditions include, but are not limited to, autoimmune disorders, allograft rejection, graft vs. host disease, diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, osteoarthritis, rheumatoid arthritis, synovial pannus invasion in arthritis, multiple sclerosis, myasthenia gravis, diabetes mellitus, diabetic angiopathy, retinopathy of prematurity, infantile hemangiomas, non-small cell lung, bladder and head and neck cancers, prostate cancer, breast cancer, ovarian cancer, gastric and pancreatic cancer, psoriasis, fibrosis, rheumatoid arthritis, atherosclerosis, restenosis, auto-immune disease, allergy, respiratory diseases, asthma, transplantation rejection, inflammation, thrombosis, retinal vessel proliferation, inflammatory bowel disease, Crohn's disease, ulcerative colitis, bone diseases, transplant or bone marrow transplant rejection, lupus, chronic pancreatitis, cachexia, septic shock, fibroproliferative and differentiative skin diseases or disorders, central nervous system diseases, neurodegenerative diseases, disorders or conditions related to nerve damage and axon degeneration subsequent to a brain or spinal cord injury, acute or chronic cancer, ocular diseases, viral infections, heart disease, lung or pulmonary diseases or kidney or renal diseases and bronchitis.

[000119] Tyrosine kinases can be broadly classified as receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular) protein tyrosine kinases. Inappropriate or uncontrolled activation of many of these kinase (aberrant protein tyrosine kinase activity), for example by over-expression or mutation, results in uncontrolled cell growth. Many of the protein tyrosine kinases, whether a receptor or non-receptor tyrosine kinase have been found to be involved in cellular signaling pathways involved in numerous pathogenic conditions, including, but not limited to, immunomodulation, inflammation, or proliferative disorders such as cancer.

[000120] Compounds of the invention are screened against the kinase panel (wild type and/or mutation thereof) and modulate the activity of at least one panel kinase panel member. Examples of kinases that are inhibited by the compounds and compositions of the invention and against which the methods described herein are useful, include, but are not limited to Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-1R, Alk, c-FMS kinases, and mutant forms thereof. As such, the compounds and compositions of the invention are useful for treating diseases or disorders in which such kinases contribute to the pathology and/or symptomology of a disease or disorder associated with such kinases. Such diseases or disorders include, but are not limited to, pancreatic cancer, papillary thyroid carcinoma, ovarian carcinoma, human adenoid cystic carcinoma, non small cell lung cancer, secretory breast carcinoma, congenital fibrosarcoma, congenital mesoblastic nephroma, acute myelogenous leukemia, psoriasis, metastasis, cancer-related pain and neuroblastoma.

Receptor Tyrosine Kinases (RTKs).

[000121] The Receptor Tyrosine Kinases (RTKs) comprise a large family of transmembrane receptors with diverse biological activities. A number of distinct RTK subfamilies have been identified including, but not limited to, EGF receptor family, the Insulin receptor family, the PDGF receptor family, the FGF receptor family, the VEGF receptor family, the HGF receptor family, the Trk receptor family), the EPH receptor family, the AXL receptor family, the LTK receptor family, the TIE receptor family), the ROR receptor family, the DDR receptor family, the RET receptor family, the KLG receptor family, the RYK receptor family and the MuSK receptor family.

[000122] Receptor tyrosine kinases have been shown to be not only key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. The receptor tyrosine kinase (RTK) family includes receptors that are crucial for the growth and differentiation of a variety of cell types. The intrinsic function of RTK mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), typically followed by receptor dimerization, stimulation of the intrinsic protein tyrosine kinase activity and receptor trans-phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response such as, by way of example only, cell division, differentiation, metabolic effects, and changes in the extracellular microenvironment.

Tropomyosin-Receptor-Kinase (Trk) Family

[000123] The Trk family receptor tyrosine kinases, TrkA (NTRK1), TrkB (NTRK2), and TrkC (NTRK3), are the signaling receptors that mediate the biological actions of the peptide hormones of the neurotrophin family. Trk receptors are membrane-bound receptor that, through several signal cascades, controls neuronal growth and survival, and differentiation, migration and metastasis of tumor cells. The neurotrophin family of growth factors includes nerve growth factor (NGF), brain-derived neurotrophic

factor (BDNF), and two neurotrophins (NT), NT-3, and NT-4. Neurotrophins are critical to the functioning of the nervous system, and the activation of Trk receptors by neurotrophin binding leads to activation of signal cascades resulting in promoting survival and other functional regulation of cells. Each type of neurotrophin has a different binding affinity toward its corresponding Trk receptor, and upon neurotrophin binding, the Trk receptors phosphorylates themselves and members of the MAPK pathway. The differences in the signaling initiated by these distinct types of receptors are important for generating diverse biological responses.

[000124] The Trk receptors are implicated in the development and progression of cancer, possibly by upregulation of either the receptor, their ligand (NGF), BDNF, NT-3, and NT-4), or both. In many cases high Trk expression is associated with aggressive tumor behavior, poor prognosis and metastasis. Thus, diseases and disorders related to Trk receptors result from 1) expression of a Trk receptor(s) in cells which normally do not express such a receptor(s); 2) expression of a Trk receptor(s) by cells which normally do not express such a receptor(s); 3) increased expression of Trk receptor(s) leading to unwanted cell proliferation; 4) increased expression of Trk receptor(s) leading to adhesion independent cell survival; 5) mutations leading to constitutive activation of Trk receptor(s); 6) over stimulation of Trk receptor(s) due to abnormally high amount of, or mutations in, Trk receptor(s), and/or 7) abnormally high amount of Trk receptor(s) activity due to abnormally high amount of, or mutations in, Trk receptor(s).

[000125] Genetic abnormalities, i.e. point mutations and chromosomal rearrangements involving both the genes expressing TrkB and TrkC have been found in a variety of cancer types. In a kinome-wide approach to identify point mutants in tyrosine kinases, mutations in the genes expressing TrkB and TrkC were found in cell lines and primary samples from patients with colorectal cancer. In addition, chromosomal translocations involving the genes expressing TrkA and TrkB have been found in several different types of tumors. Gene rearrangements involving the genes expressing TrkA and a set of different fusion partners (TPM3, TPR, TFG) are a hallmark of a subset of papillary thyroid cancers. Moreover, secretary breast cancer, infant fibrosarcoma and congenital mesoblastic nephroma have been shown to be associated with a chromosomal rearrangement t(12;15) generating a ETV6-NTRK3 fusion gene that was shown to have constitutive kinase activity and transforming potential in several different cell lines including fibroblasts, hematopoietic cells and breast epithelial cells.

[000126] TrkA has the highest affinity to the binding nerve growth factor (NGF). NGF is important in both local and nuclear actions, regulating growth cones, motility, and expression of genes encoding the biosynthesis enzymes for neurotransmitters. Nocireceptive sensory neurons express mostly trkA and not trkB or trkC.

[000127] TrkB serves as a receptor for both BDNF and NT-4, and is expressed in neuroendocrine-type cells in the small intestine and the colon, in the alpha cells of the pancreas, in the monocytes and macrophages of the lymph nodes and of the spleen, and in the granular layers of the epidermis. TrkB is

also expressed in cancerous prostate cells but not in normal cells.

[000128] The binding of BDNF to TrkB receptor causes activation of intercellular cascades which regulate neuronal development and plasticity, long-term potentiation, and apoptosis. BDNF promotes the proliferation, differentiation and growth and survival of normal neural components such as retinal cells and glial cells. In addition, TrkB activation is a potent and specific suppressor of anchorage independent cell death (anoikis), which is apoptosis induced by loss of attachment of a cell to its matrix. By way of example, activation of the Phosphatidylinositol-3kinase/Protein Kinase B signaling axis by TrkB promotes the survival of non-transformed epithelial cells in 3-dimensional cultures and induces tumor formation and metastasis of those cells in immuno-compromised mice. Anchorage independent cell survival is a metastatic process allowing tumor cells to migrate through the systemic circulation and grow at distant organs. Agonism of TrkB results in the failure of induced cell death by cancer treatments. Thus, TrkB modulation is a target for treatment of benign and malignant proliferative diseases, especially tumor diseases.

[000129] Diseases and disorders related to the TrkB receptor include, but are not limited to, cancers, such as, by way of example only, neuroblastoma progression, Wilm's tumor progression, breast cancer, pancreatic cancer, colon cancer, prostate cancer, and lung cancer. The TrkB receptor has been shown to be associated with Alzheimer's disease.

[000130] TrkC is activated by binding with NT-3 and is expressed by proprioceptive sensory neurons. The axons of these proprioceptive sensory neurons are much thicker than those of nocireceptive sensory neurons, which express TrkA. Signalling through TrkC leads to cell differentiation and development of proprioceptive neurons that sense body position. Mutations in this gene expressing TrkC is associated with medulloblastomas, secretory breast carcinomas and other cancers. In addition, high expression of TrkC is a hallmark of melanoma, especially in cases with brain metastasis.

[000131] Compounds described herein are also used for the treatment of diseases which respond to an inhibition of the Trk receptor tyrosine kinases (TrkA, TrkB, and TrkC). Compounds described herein inhibit Trk receptor tyrosine kinases (TrkA, TrkB, and TrkC) activity and are, therefore, suitable for the treatment of diseases, such as, neuroblastoma, Wilm's tumor, breast cancer, pancreatic cancer, colon cancer, prostate cancer, and lung cancer.

Platelet-derived Growth Factor (PDGF) receptor family

[000132] PDGF (Platelet-derived Growth Factor) is a very commonly occurring growth factor, which plays an important role both in normal growth and also in pathological cell proliferation, such as is seen in carcinogenesis and in diseases of the smooth-muscle cells of blood vessels, for example in atherosclerosis and thrombosis. The PDGF growth factor family consists of PDGF-A, PDGF-B, PDGF-C and PDGF-D, which form either homo- or heterodimers (AA, AB, BB, CC, DD) that bind to the protein tyrosine kinase receptors PDGFR-α and PDGFR-β. Dimerization of the growth factors is a prerequisite for activation of

the kinase, as the monomeric forms are inactive. The two receptor isoforms dimerize upon binding resulting in three possible receptor combinations, PDGFR-αα, PDGFR-ββ and PDGFR−αβ. Growth factor AA binds only to -αα, growth factor BB can bind with -αα, -ββ and -αβ, growth factors CC and AB specifically interact with -αα and -αβ, and growth factor DD binds to -ββ.

[000133] Key downstream mediators of PDGFR signaling are Ras/mitogen-activated protein kinase (MAPK), PI-3 kinase and phospholipase-γ (PLCγ) pathways. MAPK family members regulate various biological functions by phosphorylation of target molecules (transcription factors and other kinases) and thus contribute to regulation of cellular processes such as proliferation, differentiation, apoptosis and immunoresponses. PI-3 kinase activation generated PIP3 which functions as a second messenger to activate downstream tyrosine kinases Btk and Itk, the Ser/Thr kinases PDK1 and Akt (PKB). Akt activation is involved in survival, proliferation and cell growth. After activation PLCγ hydolyses its substrate, PtdIns(4,5)P2, and forms two secondary messengers, diacylglycerol and Ins(1,4,5)P3 which stimulates intracellular processes such as proliferation, angiogenesis and cell motility. The PDGF-receptor plays an important role in the maintenance, growth and development of hematopoietic and non-hematopoietic cells.

[000134] PDGFR is expressed on early stem cells, mast cells, myeloid cells, mesenchymal cells and smooth muscle cells. Only PDGFR-β is implicated in myeloid leukemias-usually as a translocation partner with Tel, Huntingtin interacting protein (HIP1) or Rabaptin5. Activation mutations in PDGFR-α kinase domain are associated with gastrointestinal stromal tumors (GIST).

Vascular Endothelial Growth Factor (VEGF) Receptor family

[000135] VEGF, also known as fms-related tyrosine kinase-1 (FLT1), is an important signaling protein involved in both vasculogenesis (formation of embryonic circulatory system) and angiogenesis (growth of blood vessels from pre-existing vasculature). Structurally VEGF belongs to to the PDGF family of cytokine-knot growth factors. The VEGF sub-family of growth factors includes VEGF-A, VEGF-B, VEGF-C and VEGF-D. VEGF-A binds to receptor VEGFR-1 (Flt-1) and to VEGFR-2 (KDR/Flk-1). VEGF-C and VEGF-D bind to receptor VEGFR-3 and mediate lymphangiogenesis. The VGFR receptors mediate the angiogenic process, and are thus involved in supporting the progression of cancers and other diseases involving inappropriate vascularization (e.g., diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, retinopathy of prematurity, and infantile hemangiomas).

Fms-like tyrosine kinase

[000136] The fms-like tyrosine kinase-3 (FLT3) ligand (FLT3L) is one of the cytokines that affects the development of multiple hematopoietic lineages. These effects occur through the binding of FLT3L to the FLT3 receptor, also referred to as fetal liver tkinase-2 (flk-2) and STK-1, a receptor tyrosine kinase (RTK) expressed on hematopoietic stem and progenitor cells. FLT3 is a member of the type III receptor tyrosine kinase (RTK) family. The ligand for FLT3 is expressed by the marrow stromal cells and other cells and

synergizes with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells. Flt3 plays an important role in the maintenance, growth and development of hematopoietic and non-hematopoietic cells.

[000137] The FLT3 gene encodes a membrane-bound RTK that plays an important role in proliferation, differentiation and apoptosis of cells during normal hematopoiesis. The FLT3 gene is mainly expressed by early meyloid and lymphoid progenitor cells. Hematopoietic disorders are pre-malignant disorders and include, for instance, the myeloproliferative disorders, such as thrombocythemia, essential thrombocytosis (ET), angiogenic myeloid metaplasia, myelofibrosis (MF), myelofibrosis with myeloid metaplasia (MMM), chronic idiopathic myelofibrosis (IMF), and polycythemia vera (PV), the cytopenias, and pre-malignant myelodysplastic syndromes. Hematological malignancies include leukemias, lymphomas (non-Hodgkin's lymphoma), Hodgkin's disease (also called Hodgkin's lymphoma), and myeloma--for instance, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), acute undifferentiated leukemia (AUL), anaplastic large-cell lymphoma (ALCL), prolymphocytic leukemia (PML), juvenile myelomonocyctic leukemia (JMML), adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS), mixed lineage leukemia (MLL), myelodysplastic syndromes (MDSs), myeloproliferative disorders (MPD), multiple myeloma, (MM) and myeloid sarcoma.

[000138] Aberrant expression of the Flt3 gene has been documented in both adult and childhood leukemias including acute myeloid leukemia (AML), AML with trilineage myelodysplasia (AML/TMDS), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS). Activating mutations of the Flt3 receptor have been found in about 35% of patients with acute myeloblastic leukemia (AML), and are associated with a poor prognosis. The most common mutation involves in-frame duplication within the juxtamembrane domain, with an additional 5-10% of patients having a point mutation at asparagine 835. Both of these mutations are associated with constitutive activation of the tyrosine kinase activity of Flt3, and result in proliferation and viability signals in the absence of ligand. Patients expressing the mutant form of the receptor have been shown to have a decreased chance for cure. Thus, there is accumulating evidence for a role for hyper-activated (mutated) Flt3 kinase activity in human leukemias and myelodysplastic syndrome.

[000139] FLT-3 and c-Kit regulate maintenance of stem cell/early progenitor pools as well the development of mature lymphoid and myeloid cells. Both receptors contain an intrinsic kinase domain that is activated upon ligand-mediated dimerization of the receptors. Upon activation, the kinase domain induces autophosphorylation of the receptor as well as the phosphorylation of various cytoplasmic proteins that help propogate the activation signal leading to growth, differentiation and survival. Some of the downstream regulators of FLT-3 and c-Kit receptor signaling include, PLCγ, PI3-kinase, Grb-2, SHIP and Src related kinases. Both receptor tyrosine kinases have been shown to play a role in a variety of hematopoietic and

non-hematopoietic malignancies. Mutations that induce ligand independent activation of FLT-3 and c-Kit have been implicated acute-myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), mastocytosis and gastrointestinal stromal tumor (GIST). These mutations include single amino acid changes in the kinase domain or internal tandem duplications, point mutations or in-frame deletions of the juxtamembrane region of the receptors. In addition to activating mutations, ligand dependent (autocrine or paracrine) stimulation of over-expressed wild-type FLT-3 or c-Kit can contribute to the malignant phenotype.

[000140] c-Fms encodes for macrophage colony stimulating factor receptor (M-CSF-1R) which is expressed predominately in the monocytes/macrophage lineage. MCSF-1R and its ligand regulate macrophage lineage growth and differentiation. Like the other family members, MCSF-1R contains an intrinsic kinase domain that is activated upon ligand-induced dimerization of the receptor. MCSF-1R is also expressed in non-hematopoietic cells including mammary gland epithelial cells and neurons. Mutations in this receptor are potentially linked to myeloid leukemias and its expression is correlated with metastatic breast, ovarian and endometrial carcinomas. Another possible indication for antagonists of MCSF-1R is osteoporosis.

[000141] Compounds described herein are inhibitors of FLT-3 and c-kit and are used for the treatment of diseases which respond to an inhibition of the FLT-3 c-kit receptors.

Insulin-like Growth Factor 1 (IGF-1) Receptor

[000142] The Insulin-like Growth Factor 1 (IGF-1) Receptor is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-2. IGF-1R mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF-1 plays an important role in survival and proliferation in mitosis-competent cells, and growth (hypertrophy) in tissues such as skeletal muscle and cardiac muscle. The IGFR signalling pathway is of critical importance during normal development of mammary gland tissue during pregnancy and lactation. During pregnancy, there is intense proliferation of epithelial cells which form the duct and gland tissue. Following weaning, the cells undergo apoptosis and all the tissue is destroyed. Several growth factors and hormones are involved in this overall process, and IGF-1R is believed to have roles in the differentiation of the cells and a key role in inhibiting apoptosis until weaning is complete.

[000143] The IGF-1R is implicated in several cancers including, but not limited to, breast cancer. In some instances its anti-apoptotic properties allow cancerous cells to resist the cytotoxic properties of chemotheraputic drugs or radiotherapy. It is further implicated in breast cancer by increasing the metastatic potential of the original tumour by inferring the ability to promote vascularisation.

RET receptor family

[000144] The RET proto-oncogene encodes a receptor tyrosine kinase for members of the glial cell line derived neurotrophic factor (GDNF) family of extracellular signalling molecules. RET loss of function

mutations are associated with the development of Hirschsprung's disease, while gain of function mutaions are associated with development of various types of cancer, including medullar thyroid carcinoma and multiple endocrine neoplasias type II and III.

[000145] RET is the receptor for members of the glial cell line derived neurotrophic factor (GDNF) family of extracellular signalling molecules (GFL's). There are three different isoforms, RET51, RET43 and RET9, containing 51, 43 and 9 amino acids in their C-terminal tail, respectively. RET signal transducition is key to the development of normal kidneys and the enteric nervous system.

[000146] In order to activate RET GFLs first need to form a complex with a glycosylphosphatidylinositol (GPI)-anchored co-receptor. The co-receptors themselves are classified as members of the GDNF receptor-α (GFRα) protein family. Different members of the GFRα family (GFRα1-GFRα4) exhibit a specific binding activity for a specific GFLs. Upon GFL-GFRα complex formation, the complex then brings together two molecules of RET, triggering trans-autophosphorylation of specific tyrosine residues within the tyrosine kinase domain of each RET molecule. Tyr900 and Tyr905 within the activation loop (A-loop) of the kinase domain have been shown to be autophosphorylation sites by mass spectrometry. Phosphorylation of Tyr905 stabilizes the active conformation of the kinase which in turn results in the autophosphorylation of other tyrosine residues mainly located in the C-terminal tail region of the molecule.

c–Kit receptor

[000147] The compounds of the present invention also inhibit cellular processes involving stem-cell factor (SCF, also known as the c-kit ligand or steel factor), such as inhibiting SCF receptor (kit) autophosphorylation and SCF-stimulated activation of MAPK kinase (mitogen-activated protein kinase). MO7e cells are a human promegakaryocytic leukemia cell line, which depends on SCF for proliferation.

[000148] c-Kit has a substantial homology to the PDGF receptor and to the CSF-1 receptor (c-Fms). Investigations on various erythroid and myeloid cell lines indicate an expression of the c-Kit gene in early stages of differentiation. Certain tumors such as glioblastoma cells likewise exhibit a pronounced expression of the c-Kit gene.

Anaplastic lymphoma kinase (Ki-1 or ALK)

[000149] ALK is a novel receptor protein-tyrosine kinase having a putative transmembrane domain and an extracellular domain. ALK plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system.

[000150] Anaplastic lymphoma kinase (ALK), a member of the insulin receptor superfamily of receptor tyrosine kinases, has been implicated in oncogenesis in hematopoietic and non-hematopoietic tumors. The aberrant expression of full-length ALK receptor proteins has been reported in neuroblastomas and glioblastomas; and ALK fusion proteins have occurred in anaplastic large cell lymphoma.

Non-Receptor Tyrosine Kinases.

[000151] Non-receptor tyrosine kinases represent a collection of cellular enzymes that lack extracellular

and transmembrane sequences. Over twenty-four individual non-receptor tyrosine kinases, comprising eleven (11) subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack and LIMK) have been identified. The Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs and includes Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The Src subfamily of enzymes has been linked to oncogenesis and immune responses.

[000152] The Src family of kinases is implicated in cancer, immune system dysfunction osteopetrosis, and bone remodeling diseases, and therefore Src kinases are considered as potential therapeutic targets for various human diseases. Src expression is linked to cancers such as colon, breast, hepatic and pancreatic cancer, certain B-cell leukemias and lymphomas. In addition, antisense Src expressed in ovarian and colon tumor cells inhibits tumor growth.

[000153] Csk, or C-terminal Src kinase, phosphorylates and thereby inhibits Src catalytic activity. Suppression of arthritic bone destruction has been achieved by the overexpression of Csk in rheumatoid synoviocytes and osteoclasts. This implies that Src inhibition may prevent joint destruction that is characteristic in patients suffering from rheumatoid arthritis. Src also plays a role in the replication of hepatitis B virus. The virally encoded transcription factor HBx activates Src in a step required for propagation of the virus.

[000154] Other Src family kinases are also potential therapeutic targets. Lck plays a role in T-cell signaling, and mice that lack the Lck gene have a poor ability to develop thymocytes. The function of Lck as a positive activator of T-cell signaling suggests that Lck inhibitors may be useful for treating autoimmune disease such as rheumatoid arthritis. Hck, Fgr and Lyn are important mediators of integrin signaling in myeloid leukocytes. Inhibition of these kinase mediators may therefore be useful for treating inflammation.

Spleen Tyrosine Kinase (Syk)

[000155] Spleen tyrosine kinase (SYK) and Zap-70 are members of the Syk family of tyrosine kinases. These non-receptor cytoplasmic tyrosine kinases share a characteristic by a carboxy terminal kinase domain and a dual SH2 domain separated by a linker domain. Syk is a non-receptor linked protein tyrosine kinase which plays a critical role in mediator of immunoreceptor signalling in a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptors (such as FcεRI) and the B-cell receptor, are important for both allergic diseases and antibody-mediated autoimmune diseases. Syk also plays a role in FcεRI mediated mast cell degranulation and eosiniphil activation. Accordingly, Syk kinase is implicated in various allergic disorders, in particular asthma.

[000156] Inhibition of eosinophil apoptosis has been proposed as key mechanisms for the development of blood and tissue eosinophilia in asthma. IL-5 and GM-CSF are upregulated in asthma and are proposed to cause blood and tissue eosinophilia by inhibition of eosinophil apoptosis. Inhibition of eosinophil

apoptosis has been proposed as a key mechanism for the development of blood and tissue eosinophilia in asthma. Syk kinase is required for the prevention of eosinophil apoptosis by cytokines.

[000157] While Syk and Zap-70 are primarily expressed in hematopoietic tissues, Syk is also expressed in a variety of other tissues. Within B and T cells respectively, Syk and Zap-70 transmit signals from the B-cell receptor and T-cell receptor. Syk plays a similar role in transmitting signals from a variety of cell surface receptors including CD74, Fc Receptor, and integrins.

[000158] Abnormal function of Syk has been implicated in several instances of hematopoeitic malignancies including translocations involving Itk and Tel. Constitutive Syk activity can transform B cells. Several transforming viruses contain "Immunoreceptor Tyrosine Activation Motifs" (ITAMs) which lead to activation of Syk including Epstein Barr virus, bovine leukemia virus, and mouse mammary tumor virus.

[000159] Syk kinase is known to play a critical role in other signaling cascades. For example, Syk kinase is an effector of B-cell receptor (BCR) signaling and is an essential component of integrin beta(1), beta(2) and beta(3) signaling in neutrophils.

[000160] Syk kinase is important in transducing the downstream cellular signals associated with cross-linking Fc epsilon RI (Fcer1) and or Fc epsilon RI (Fcer1) receptors, and is positioned early in the signalling cascade. In mast cells, for example, the early sequence of Fc epsilon RI (Fcer1) signalling following allergen cross-linking of receptor-IgE complexes involves first Lyn (a Src family tyrosine kinase) and then Syk. Inhibitors of Syk activity would therefore be expected to inhibit all downstream signalling cascades thereby alleviating the immediate allergic response and adverse events initiated by the release of pro-inflammatory mediators and spasmogens.

[000161] Allergic rhinitis and asthma are diseases associated with hypersensitivity reactions and inflammatory events involving a multitude of cell types including mast cells, eosinophils, T cells and dendritic cells. Following exposure to allergen, high affinity immunoglobulin receptors for IgE (Fc epsilon RI) and IgG (Fc epsilon.RI) become cross-linked and activate downstream processes in mast cells and other cell types leading to the release of pro-inflammatory mediators and airway spasmogens. In the mast cell, for example, IgE receptor cross-linking by allergen leads to release of mediators including histamine from pre-formed granules, as well as the synthesis and release of newly synthesised lipid mediators including prostaglandins and leukotrienes.

[000162] Rheumatoid Arthritis (RA) is an auto-immune disease affecting approximately 1% of the population. It is characterised by inflammation of articular joints leading to debilitating destruction of bone and cartilage. Targeting B cell function is a therapeutic strategy in auto-immune diseases such as RA, with B cell function and auto-antibody production being central to the ongoing pathology in the disease.

[000163] Studies using cells from mice deficient in the Spleen Tyrosine Kinase (Syk) have demonstrated a non-redundant role of this kinase in B cell function. The deficiency in Syk is characterised by a block in B cell development. These studies, along with studies on mature B cells deficient in Syk, demonstrate that

Syk is required for the differentiation and activation of B cells. Hence, inhibition of Syk in RA patients is likely to block B cell function and thereby reduce Rheumatoid Factor production. In addition to the role of Syk in B cell function, and of further relevance to the treatment of RA, is the requirement for Syk activity in Fc receptor (FcR) signalling. FcR activation by immune complexes in RA has been suggested to contribute to the release of multiple pro-inflammatory mediators.

[000164] Syk also plays a role in FcγR dependent and independent response in bone marrow derived macrophages. Syk deficient macrophages are defective in phagocytosis induced by FcγR, but have normal phagocytosis in response to complement. Aerosolized Syk antisense suppresses Syk expression and mediator release from macrophages.

[000165] Loss of Syk was found in childhood pro-B cell ALL. Syk is an important suppressor of breast cancer cell growth and metastasis. Tel-Syk fusion protein was found in patients with atypical myelodysplastic syndrome and constitutively activates PI3-K/Akt, MAPK and Jak2 independent STAT5 signaling.Overexpression of Tel-Syk fusion protein causes B-cell lymphoma in mice (differentiation defect in pre-B-cells). ITK-Syk fusion protein was found in 17% of patients with unspecified peripheral T-cell lymphomas. Syk overexpression is associated with mantle cell lymphoma and Waldenstroem`s makroglobulinaemia.

[000166] The compounds described herein are inhibitors of Syk kinase activity and have therapeutic benefit in the treatment of disorders associated with inappropriate Syk activity, in particular in the treatment and prevention of disease states mediated by Syk. Such disease states include inflammatory, allergic and autoimmune diseases, by way of example only, asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohns disease, bronchitis, dermatitis, allergic rhinitis, psoriasis, scleroderma, urticaria, rheumatoid arthritis, multiple sclerosis, cancer, breast cancer, HIV and lupus

[000167] Furthermore, the compounds, compositions and methods of the present invention provides methods of regulating, and in particular inhibiting, signal transduction cascades in which Syk plays a role. The method generally involves contacting a Syk-dependent receptor or a cell expressing a Syk-dependent receptor with an amount of a compound described herein, or prodrug a compound described herein, or an acceptable salt, hydrate, solvate, N-oxide and/or composition thereof, effective to regulate or inhibit the signal transduction cascade. The methods are used to regulate, and in particular inhibit, downstream processes or cellular responses elicited by activation of the particular Syk-dependent signal transduction cascade. The methods are practiced to regulate any signal trasduction cascade where Syk is not known or later discovered to play a role. The methods are practiced in *in-vitro* contexts or in *in-vivo* contexts as a therapeutic approach towards the treatment or prevention of diseases characterized by, caused by or associated with activation of the Syk-dependent signal transduction cascade. Non-limited examples of such diseases include those described above.

[000168] The compounds, compositions and methods of the present invention are inhibitors of Syk kinase, and therefore regulate, and in particular inhibit, any signaling cascade where Syk plays a role, such as, fore example, the Fc receptor, BCR and integrin signaling cascades, as well as the cellular responses elicited through these signaling cascades. The particular cellular response regulated or inhibited will depend, in part, on the specific cell type and receptor signaling cascade. Non-limiting examples of cellular responses that may be regulated or inhibited with the compounds described herein include a respiratory burst, cellular adhesion, cellular degranulation, cell spreading, cell migration, phagocytosis (e.g., in macrophages), calcium ion flux (e.g., in mast, basophil, neutrophil, eosinophil and B-cells), platelet aggregation, and cell maturation (e.g., in B-cells).

Zeta-chain-associated protein kinase 70 (ZAP70) Kinase

[000169] ZAP-70 is normally expressed in T cells and natural killer cells and has a critical role in the initiation of T-cell signaling. ZAP-70 in B cells is used as a prognostic marker in identifying different forms of chronic lymphocytic leukemia (CLL).

[000170] T lymphocytes are activated by engagement of the T cell receptor with processed antigen fragments presented by professional antigen presenting cells (e.g. macrophages, dendritic cells and B cells). Upon this activation, the tyrosine kinase Lck becomes activated and phosphorylates the intracellular portions of the CD3 complex (called ITAMs). The most important member of the CD3 family is CD3-zeta to which ZAP-70 binds. The tandem SH2-domains of ZAP-70 are engaged by the doubly phosphorylated ITAMs of CD3-zeta, which positions ZAP-70 to phosphorylate the transmembrane protein LAT (Linker of Activated T cells). Phosphorylated LAT in turn serves as a docking site to which a number of signaling proteins bind. The final outcome of T cell activation is the transcription of several gene products which allow the T cells to differentiate, proliferate and secrete a number of cytokines.

[000171] In accordance with the foregoing, the present invention further provides a method for preventing or treating any of the diseases or disorders described above in a subject in need of such treatment, which method comprises administering to said subject a therapeutically effective amount (*See, "Administration and Pharmaceutical Compositions", infra*) of a compound of Formula I or a pharmaceutically acceptable salt thereof. For any of the above uses, the required dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired.

Administration and Pharmaceutical Compositions

[000172] For the therapeutic uses of compounds provided herein, including compounds of Formula (I), or pharmaceutically acceptable salts, solvates, N-oxides, prodrugs and isomers thereof, such compounds are administered in therapeutically effective amounts either alone or as part of a pharmaceutical composition. Accordingly, provided herein are pharmaceutical compositions, which comprise at least one compound provided herein, including at least one compound of Formulas (I), pharmaceutically acceptable salts and/or solvates thereof, and one or more pharmaceutically acceptable carriers, diluents, adjuvant or excipients. In

addition, such compounds and compositions are administered singly or in combination with one or more additional therapeutic agents. The method of administration of such compounds and compositions include, but are not limited to, oral administration, rectal administration, parenteral, intravenous administration, intravitreal administration, subcutaneous administration, intramuscular administration, inhalation, intranasal administration, dermal administration, topical administration, ophthalmic administration or buccal administration, tracheal administration, bronchial administration, sublingual administration or otic administration.

[000173] The therapeutically effective amount will vary depending on, among others, the disease indicated, the severity of the disease, the age and relative health of the subject, the potency of the compound administered, the mode of administration and the treatment desired. In certain embodiments, the daily dosage of a compound of Formula (I), satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.03 to 2.5mg/kg per body weight. In certain embodiments, the daily dosage of a compound of Formula (I), administered by inhalation, is in the range from 0.05 micrograms per kilogram body weight (μg/kg) to 100 micrograms per kilogram body weight (μg/kg). In other embodiments, the daily dosage of a compound of Formula (I), administered orally, is in the range from 0.01 micrograms per kilogram body weight (μg/kg) to 100 milligrams per kilogram body weight (mg/kg). An indicated daily dosage in the larger mammal, e.g. humans, is in the range from about 0.5mg to about 100mg of a compound of Formula (I), conveniently administered, e.g. in divided doses up to four times a day or in controlled release form. In certain embodiment, unit dosage forms for oral administration comprise from about 1 to 50 mg of a compound of Formula (I).

[000174] In certain embodiments, compounds of the invention, and salts and solvates thereof, are administered as the raw chemical, while in other embodiments the compounds of the invention, and salts and solvates thereof, are administered as a pharmaceutical composition. Accordingly, provided herein are pharmaceutical compositions, which comprise at least one compound of Formulas (I), salts and/or solvates thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients. Futhermore, another aspect provided herein is a process for the preparation of such pharmaceutical composition including admixing a compound of the Formula (I) described herein, and salts and solvates thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients. Pharmaceutical compositions comprising a compound of the present invention in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent can be manufactured in a conventional manner by mixing, granulating or coating methods. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.

[000175] Compounds of the invention, and salts and solvates thereof, can be administered as pharmaceutical compositions by any conventional route including, but not limited to, intravenous

administration (parenteral), oral administration, rectal administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration.

[000176] Compounds provided herein are administered alone, or are administered by way of known pharmaceutical formulations, including tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, lotions, gels, ointments or creams for topical administration, and the like.

[000177] Other aspects provided herein are processes for the preparation of pharmaceutical composition which comprise at least one compound of Formulas (I), or pharmaceutically acceptable salts and/or solvates thereof. In certain embodiments, such processes include admixing a compound of the Formula (I), and pharmaceutically acceptable salts and solvates thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients. In certain embodiments, the pharmaceutical compositions comprising a compound of Formula (I) in free form or in a pharmaceutically acceptable salt or solvate form, in association with at least one pharmaceutically acceptable carrier, diluent or excipient are manufactured by mixing, granulating and/or coating methods. In other embodiments, such compositions optionally contain excipients, such as adjuvants, preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In other embodiments, such compositions are sterilized.

[000178] In certain embodiments, pharmaceutical formulations (pharmaceutical compositions) provided herein include those in which the active ingredient is present in at least 1% by weight. In certain embodiments, pharmaceutical formulations (pharmaceutical compositions) provided herein include those in which the active ingredient is present in at least 5% by weight. In certain embodiments, pharmaceutical formulations (pharmaceutical compositions) provided herein include those in which the active ingredient is present in at least 1o% by weight. In certain embodiments, pharmaceutical formulations (pharmaceutical compositions) provided herein include those in which the active ingredient is present in at least 20% by weight. In certain embodiments, pharmaceutical formulations (pharmaceutical compositions) provided herein include those in which the active ingredient is present in at least 20% by weight. In certain embodiments, pharmaceutical formulations (pharmaceutical compositions) provided herein include those in which the active ingredient is present in at least 40% by weight. In certain embodiments, pharmaceutical formulations (pharmaceutical compositions) provided herein include those in which the active ingredient is present in at least 50% by weight.. That is, the ratio of active ingredient to the other components (by way of example, the addition of adjuvant, diluent and carrier) of the pharmaceutical composition is at least 1:99, 5:95, 10:90, 20:80, 30:70, 40:60 or at least 50:50 by weight.

Oral Dosage Forms

[000179] In certain embodiments, the pharmaceutical compositions containing at least one compound of Formula (I) are administered orally as discrete dosage forms, wherein such dosage forms include, but are

not limited to, capsules, gelatin capsules, caplets, tablets, chewable tablets, powders, granules, syrups, flavored syrups, solutions or suspensions in aqueous or non-aqueous liquids, edible foams or whips, and oil-in-water liquid emulsions or water-in-oil liquid emulsions.

[000180] The capsules, gelatin capsules, caplets, tablets, chewable tablets, powders or granules, used for the oral administration of at least one compound of Formula (I) are prepared by admixing at least one compound of Formula (I) (active ingredient) together with at least one excipient using conventional pharmaceutical compounding techniques. Non-limiting examples of excipients used in oral dosage forms described herein include, but are not limited to, binders, fillers, disintegrants, lubricants, absorbents, colorants, flavors, preservatives and sweeteners.

[000181] Non-limiting examples of such binders include, but are not limited to, corn starch, potato starch, starch paste, pre-gelatinized starch, or other starches, sugars, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, tragacanth, guar gum, cellulose and its derivatives (by way of example only, ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethylcellulose, methyl cellulose, hydroxypropyl methylcellulose and microcrystalline cellulose), magnesium aluminum silicate, polyvinyl pyrrolidone and combinations thereof.

[000182] Non-limiting examples of such fillers include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. In certain embodiments, the binder or filler in pharmaceutical compositions provided herein are present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form.

[000183] Non-limiting examples of such disintegrants include, but are not limited to, agar-agar, alginic acid, sodium alginate, calcium carbonate, sodium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and combinations thereof. In certain embodiments, the amount of disintegrant used in the pharmaceutical compositions provided herein is from about 0.5 to about 15 weight percent of disintegrant, while in other embodiments the amount is from about 1 to about 5 weight percent of disintegrant.

[000184] Non-limiting examples of such lubricants include, but are not limited to, sodium stearate, calcium stearate, magnesium stearate, stearic acid, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, sodium lauryl sulfate, talc, hydrogenated vegetable oil (by way of example only, peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, sodium oleate, ethyl oleate, ethyl laureate, agar, silica, a syloid silica gel (AEROSIL 200, manufactured by W.R. Grace Co. of Baltimore, Md.), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Plano, Tex.), CAB-O-SIL (a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, Mass.) and combinations thereof. In certain embodiments, the amount of lubricants used in

the pharmaceutical compositions provided herein is in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms.

[000185] Non-limiting examples of such diluents include, but are not limited to, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine or combinations thereof.

[000186] In certain embodiments, tablets and capsules are prepared by uniformly admixing at least one compound of Formula (I) (active ingredients) with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary. In certain embodiments, tablets are prepared by compression. In other embodiments, tablets are prepared by molding.

[000187] In certain embodiments, at least one compound of Formula (I) is orally administered as a controlled release dosage form. Such dosage forms are used to provide slow or controlled-release of one or more compounds of Formula (I). Controlled release is obtained using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof. In certain embodiments, controlled-release dosage forms are used to extend activity of the compound of Formula (I), reduce dosage frequency, and increase patient compliance.

[000188] Administration of compounds of Formula (I) as oral fluids such as solution, syrups and elixirs are prepared in unit dosage forms such that a given quantity of solution, syrups or elixirs contains a predetermined amount of a compound of Formula (I). Syrups are prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions are formulated by dispersing the compound in a non-toxic vehicle. Non-limiting examples of excipients used in as oral fluids for oral administration include, but are not limited to, solubilizers, emulsifiers, flavoring agents, preservatives, and coloring agents. Non-limiting examples of solubilizers and emulsifiers include, but are not limited to, water, glycols, oils, alcohols, ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers. Non-limiting examples of preservatives include, but are not limited to, sodium benzoate. Non-limiting examples of flavoring agents include, but are not limited to, peppermint oil or natural sweeteners or saccharin or other artificial sweeteners.

Parenteral Dosage Forms

[000189] In certain embodiments pharmaceutical compositions containing at least one compound of Formula (I) are administered parenterally by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial.

[000190] Such parenteral dosage forms are administered in the form of sterile or sterilizable injectable solutions, suspensions, dry and/or lyophylized products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection (reconstitutable powders) and emulsions. Vehicles used in such dosage forms include, but are not limited to, Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium

Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

Transdermal Dosage Forms

[000191] In certain embodiments pharmaceutical compositions containing at least one compound of Formula (I) are administered transdemally. Such transdermal dosage forms include "reservoir type" or "matrix type" patches, which are applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of a compound of Formula (I). By way of example only, such transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin. In other embodiments, matrix transdermal formulations are used.

[000192] Formulations for transdermal delivery of a compound of Formula (I) include an effective amount of a compound of Formula (I), a carrier and an optional diluent. A carrier includes, but is not limited to, absorbable pharmacologically acceptable solvents to assist passage through the skin of the host, such as water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and combinations thereof.

[000193] In certain embodiments, such transdermal delivery systems include penetration enhancers to assist in delivering one or more compounds of Formula (I) to the tissue. Such penetration enhancers include, but are not limited to, acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).

[000194] In other embodiments, the pH of such a transdermal pharmaceutical composition or dosage form, or of the tissue to which the pharmaceutical composition or dosage form is applied, is adjusted to improve delivery of one or more compounds of Formula (I). In other embodiments, the polarity of a solvent carrier, its ionic strength, or tonicity are adjusted to improve delivery. In other embodiments, compounds such as stearates are added to advantageously alter the hydrophilicity or lipophilicity of one or more compounds of Formula (I) so as to improve delivery. In certain embodiments, such stearates serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent. In other embodiments, different salts, hydrates or solvates of the compounds of Formula (I) are used to further adjust the properties of the resulting composition.

Topical Dosage Forms

[000195] In certain embodiments at least one compound of Formula (I) is administered by topical application of pharmaceutical composition containing at least one compound of Formula (I) in the form of lotions, gels, ointments solutions, emulsions, suspensions or creams. Suitable formulations for topical application to the skin are aqueous solutions, ointments, creams or gels, while formulations for ophthalmic administration are aqueous solutions. Such formulations optionally contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

[000196] Such topical formulations include at least one carrier, and optionally at least one diluent. Such carriers and diluents include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and combinations thereof.

[000197] In certain embodiments, such topical formulations include penetration enhancers to assist in delivering one or more compounds of Formula (I) to the tissue. Such penetration enhancers include, but are not limited to, acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).

[000198] In certain embodiments pharmaceutical compositions containing at least one compound of Formula (I) are administered by inhalation. Dosage forms for inhaled administration are formulated as aerosols or dry powders. Aerosol formulations for inhalation administration comprise a solution or fine suspension of at least one compound of Formula (I) in a pharmaceutically acceptable aqueous or non-aqueous solvent. In addition, such pharmaceutical compositions optionally comprise a powder base such as lactose, glucose, trehalose, mannitol or starch, and optionally a performance modifier such as L-leucine or another amino acid, and/or metals salts of stearic acid such as magnesium or calcium stearate.

[000199] In certain embodiments, compounds of Formula (I) are be administered directly to the lung by inhalation using a Metered Dose Inhaler ("MDI"), which utilizes canisters that contain a suitable low boiling propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas, or a Dry Powder Inhaler (DPI) device which uses a burst of gas to create a cloud of dry powder inside a container, which is then be inhaled by the patient. In certain embodiments, capsules and cartridges of gelatin for use in an inhaler or insufflator are formulated containing a powder mixture of a compound of Formula (I) and a powder base such as lactose or starch. In certain embodiments, compounds of Formula (I) are delivered to the lung using a liquid spray device, wherein such devices use extremely small nozzle holes to aerosolize liquid drug formulations that can then be directly inhaled into the lung. In other embodiments, compounds of Formula (I) are delivered to the lung using a nebulizer device, wherein a nebulizers creates an aerosols of liquid drug formulations by using ultrasonic energy to form fine particles that can be readily inhaled. In other embodiments, compounds of Formula (I) are delivered to the lung using an electrohydrodynamic ("EHD") aerosol device wherein such EHD aerosol

devices use electrical energy to aerosolize liquid drug solutions or suspensions.

[000200] In certain embodiments, the pharmaceutical composition containing at least one compound of Formula (I), or pharmaceutically acceptable salts and solvates thereof, described herein, also contain one or more absorption enhancers. In certain embodiments, such absorption enhancers include, but are not limited to, sodium glycocholate, sodium caprate, N-lauryl-β-D-maltopyranoside, EDTA, and mixed micelles.

[000201] In certain embodiments pharmaceutical compositions containing at least one compound of Formula (I) are administered nasally. The dosage forms for nasal administration are formulated as aerosols, solutions, drops, gels or dry powders.

[000202] In certain embodiments pharmaceutical compositions containing at least one compound of Formula (I) are administered rectally in the form of suppositories, enemas, ointment, creams rectal foams or rectal gels. In certain embodiments such suppositories are prepared from fatty emulsions or suspensions, cocoa butter or other glycerides.

[000203] In certain embodiments pharmaceutical compositions containing at least one compound of Formula (I) are administered opthamically as eye drops. Such formulations are aqueous solutions that optionally contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

[000204] In certain embodiments pharmaceutical compositions containing at least one compound of Formula (I) are administered otically as ear drops. Such formulations are aqueous solutions that optionally contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

[000205] In certain embodiments pharmaceutical compositions containing at least one compound of Formula (I) are formulated as a depot preparation. Such long acting formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. In certain embodiments, such formulations include polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[000206] In other embodiments, a compound of Formula (I) described herein, or a pharmaceutically acceptable salt, N-oxide, isomer or solvate thereof, or a pharmaceutical composition containing such compounds of Formula (I), is administered to a patient who has not previously undergone or is not currently undergoing treatment with another therapeutic agent.

[000207] In certain embodiments pharmaceutical compositions containing at least one compound of Formula (I) are administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes are formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

[000208] The invention provides compounds of Formula (I) and salts, solvates and pharmaceutical compositions thereof for use in modulating Syk activity, including inhibiting Syk activity. The invention provides compounds of Formula (I) and salts, solvates and pharmaceutical compositions thereof for use in

the treatment of diseases and conditions mediated by inappropriate Syk activity. By way of example only, this inappropriate Syk activity is any Syk activity that deviates from the normal Syk activity expected in a particular mammalian subject. Inappropriate Syk activity may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and or control of Syk activity. Such inappropriate activity may result then, for example, from overexpression or mutation of the protein kinase leading to inappropriate or uncontrolled activation.

[000209] In a further embodiment, the present invention is directed to methods of regulating, modulating, or inhibiting Syk, using compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, for the prevention and/or treatment of disorders related to unregulated Syk activity.

[000210] In a further embodiment, the present invention provides a method of treatment of a mammal suffering from a disorder mediated by Syk activity, which includes administering to said subject an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, or a physiologically functional derivative thereof.

[000211] In a further embodiment, the present invention provides for the use of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of a disease or condition/disorder mediated by Syk activity.

[000212] In a further embodiment, the disease or condition mediated by inappropriate Syk activity is rheumatoid arthritis. In a further embodiment, the disease or condition mediated by inappropriate Syk activity is allergic rhinitis. In a further embodiment, the disease or condition mediated by inappropriate Syk activity is chronic obstructive pulmonary disease (COPD). In a further embodiment, the disease or condition mediated by inappropriate Syk activity is adult respiratory distress syndrome (ARDs).

[000213] In a further embodiment, the present invention provides a pharmaceutical composition comprising at least one compound of Formula (I) adapted for administration by the oral route, for treating, for example, rheumatoid arthritis. In a further embodiment, the present invention provides a pharmaceutical composition comprising at least one compound of Formula (I) adapted for administration by the nasal route, for treating, for example, allergic rhinitis. In a further embodiment, the present invention provides a pharmaceutical composition comprising at least one compound of Formula (I) adapted for administration by the inhaled route, for treating, for example, COPD or ARDS.

Combination therapies

[000214] In certain embodiments, a compound of Formula (I) is used in combination with a second therapeutic agent, for ameliorating a condition mediated by a protein kinase, such as a Syk-mediated condition. In certain embodiments, the compounds of the invention are used in combination with a chemotherapeutic agent to treat a cell proliferative disorder, including but not limited to, lymphoma, osteosarcoma, melanoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor. In certain embodiments, the compounds of the invention

are used in combination with an agent to treat respiratory diseases.

[000215] In certain embodiments, compounds of the present invention, and their salts and solvates thereof, are administered alone or in combination with other therapeutic agents (pharmaceutical combinations) for the treatment of diseases and conditions associated with inappropriate Syk activity. In certain embodiment, the compounds and pharmaceutically acceptable compositions of the invention are administered concurrently with one or more other desired therapeutics or medical procedures. In other embodiment, the compounds and pharmaceutically acceptable compositions of the invention are administered prior to one or more other desired therapeutics or medical procedures. In certain embodiment, the compounds and pharmaceutically acceptable compositions of the invention are administered subsequent to one or more other desired therapeutics or medical procedures.

[000216] Chemotherapeutic agents or other anti-proliferative agents used in combination with the compounds of the invention to treat proliferative diseases and cancer include, but are not limited to, surgery, radiotherapy (gamma.-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes), endocrine therapy, biologic response modifiers (interferons, interleukins, and tumor necrosis factor (TNF)), hyperthermia and cryotherapy, agents to attenuate any adverse effects (e.g., antiemetics), and other approved chemotherapeutic drugs, including, but not limited to, alkylating drugs (mechlorethamine, chlorambucil, Cyclophosphamide, Melphalan, Ifosfamide), antimetabolites (Methotrexate), purine antagonists and pyrimidine antagonists (6-Mercaptopurine, 5-Fluorouracil, Cytarabile, Gemcitabine), spindle poisons (Vinblastine, Vincristine, Vinorelbine, Paclitaxel), podophyllotoxins (Etoposide, Irinotecan, Topotecan), antibiotics (Doxorubicin, Bleomycin, Mitomycin), nitrosoureas (Carmustine, Lomustine), inorganic ions (Cisplatin, Carboplatin), enzymes (Asparaginase), and hormones (Tamoxifen, Leuprolide, Flutamide, and Megestrol), GLEEVEC™, adriamycin, dexamethasone, and cyclophosphamide.

[000217] Other chemotherapeutic agents which are used in the compositions and methods of the invention include but are not limited to anthracyclines, alkylating agents (e.g., mitomycin C), alkyl sulfonates, aziridines, ethylenimines, methylmelamines, nitrogen mustards, nitrosoureas, antibiotics, antimetabolites, folic acid analogs (e.g., dihydrofolate reductase inhibitors such as methotrexate), purine analogs, pyrimidine analogs, enzymes, podophyllotoxins, platinum-containing agents, interferons, and interleukins. Particular examples of known chemotherapeutic agents which may be used in the compositions and methods of the invention include, but are not limited to, busulfan, improsulfan, piposulfan, benzodepa, carboquone, meturedepa, uredepa, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolomelamine, chlorambucil, chlornaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, dacarbazine, mannomustine,

mitobronitol, mitolactol, pipobroman, aclacinomycins, actinomycin F(1), anthramycin, azaserine, bleomycin, cactinomycin, carubicin, carzinophilin, chromomycin, dactinomycin, daunorubicin, daunomycin, 6-diazo-5-oxo-1-norleucine, doxorubicin, epirubicin, mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, plicamycin, porfiromycin, puromycin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, methotrexate, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, fluorouracil, tegafur, L-asparaginase, pulmozyme, aceglatone, aldophosphamide glycoside, aminolevulinic acid, amsacrine, bestrabucil, bisantrene, carboplatin, cisplatin, defofamide, demecolcine, diaziquone, elfornithine, elliptinium acetate, etoglucid, etoposide, flutamide, gallium nitrate, hydroxyurea, interferon-alpha, interferon-beta, interferon-gamma, interleukin-2, lentinan, lonidamine, mitoguazone, mitoxantrone, mopidamol, nitracrine, pentostatin, phenamet, pirarubicin, podophyllinic acid, 2-ethylhydrazide, procarbazine, razoxane, sizofiran, spirogermanium, paclitaxel, tamoxifen, teniposide, tenuazonic acid, triaziquone, 2,2',2"-trichlorotriethylamine, urethane, vinblastine, vincristine, and vindesine.

[000218] Other agents used in combination with the compounds of the invention include, but are not limited to: treatments for Alzheimer's Disease such as ARRICEPT™ and EXCELON™; treatments for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., AVONEX™ and REBIF™), COPAXONE™, and mitoxantrone; treatments for asthma such as albuterol and SINGULAIR™; agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophosphamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth factors; and agents for treating immunodeficiency disorders such as gamma globulin.

[000219] Other agents having synergic effects when used in combination with the compounds include, but are not limited to, immunomodulatory or anti-inflammatory substances, for example cyclosporin, rapamycin, or ascomycin, or immunosuppressant analogues thereof, for example cyclosporin A (CsA), cyclosporin G, FK-506, rapamycin, or comparable compounds, corticosteroids, cyclophosphamide, azathioprine, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil,

15deoxyspergualin, immunosuppressant antibodies, especially monoclonal antibodies for leukocyte receptors, for example MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58 or their ligands, or other immunomodulatory compounds, such as CTLA41g. Where the compounds of the invention are administered in conjunction with other therapies, dosages of the co-administered compounds will of course vary depending on the type of co-drug employed, on the specific drug employed, on the condition being treated and so forth.

[000220] The invention also provides for a pharmaceutical combinations, e.g. a kit, comprising a) a first agent which is a compound of the invention as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent. The kit can comprise instructions for its administration.

Processes for Making Compounds of the Invention

[000221] General procedures for preparing compounds of the invention are described in the Examples, *infra*. In the reactions described, reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, may be protected to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice (see e.g., T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1991).

[000222] In certain embodiments compounds of the invention are prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid. In other embodiments, a pharmaceutically acceptable base addition salt of a compound of the invention is prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Alternatively, the salt forms of the compounds of the invention are prepared using salts of the starting materials or intermediates. In certain embodiments, the compounds of the invention are in the form of other salts including, but not limited to, oxalates or trifluoroacetates.

[000223] A pharmaceutically acceptable acid addition salt is formed by reaction of the free base form a compound of Formula (I) with a suitable inorganic or organic acid including, but not limitd to, hydrobromic, hydrochloric, sulfuric, nitric, phosphoric, succinic, maleic, formic, acetic, propionic, fumaric, citric, tartaric, lactic, benzoic, salicylic, glutamic, aspartic, p-toluenesulfonic, benzenesulfonic, methanesulfonic, ethanesulfonic, naphthalenesulfonic such as 2-naphthalenesulfonic, or hexanoic acid. A pharmaceutically acceptable acid addition salt of a compound of formula (I) can comprise or be, for example, a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, formarate, acetate, propionate, fumarate, citrate, tartrate, lactate, benzoate, salicylate, glutamate, aspartate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, ethanesulfonate, naphthalenesulfonate (e.g. 2-naphthalenesulfonate) or hexanoate salt.

[000224] The free acid or free base forms of the compounds of the invention may be prepared from the

corresponding base addition salt or acid addition salt from, respectively. For example a compound of the invention in an acid addition salt form may be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound of the invention in a base addition salt form may be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc.).

[000225] Compounds of the invention in unoxidized form may be prepared from N-oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80°C.

[000226] Prodrug derivatives of the compounds of the invention may be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropriate prodrugs may be prepared by reacting a non-derivatized compound of the invention with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate, or the like).

[000227] Protected derivatives of the compounds of the invention may be made by means known to those of ordinary skill in the art. A detailed description of techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, "Protecting Groups in Organic Chemistry", 3rd edition, John Wiley and Sons, Inc., 1999.

[000228] Compounds of the present invention may be conveniently prepared or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.

[000229] Compounds of the invention may be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. Resolution of enantiomers may be carried out using covalent diastereomeric derivatives of the compounds of the invention, or by using dissociable complexes (e.g., crystalline diastereomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubility, reactivity, etc.) and may be readily separated by taking advantage of these dissimilarities. The diastereomers may be separated by chromatography, or by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.

[000230] Compounds of Formula (I) are made by processes described herein and in the Examples. In

certain embodiments, compounds of Formula (I) are made by:

(a) optionally converting a compound of the invention into a pharmaceutically acceptable salt;

(c) optionally converting a salt form of a compound of the invention to a non-salt form;

(d) optionally converting an unoxidized form of a compound of the invention into a pharmaceutically acceptable N-oxide;

(e) optionally converting an N-oxide form of a compound of the invention to its unoxidized form;

(f) optionally resolving an individual isomer of a compound of the invention from a mixture of isomers;

(g) optionally converting a non-derivatized compound of the invention into a pharmaceutically acceptable prodrug derivative; and

(h) optionally converting a prodrug derivative of a compound of the invention to its non-derivatized form.

[000231] One of skill in the art will appreciate that the above transformations are only representative of methods for preparation of the compounds of the present invention, and that other well known methods can similarly be used.

[000232] The synthesis of certain compounds of Formula (I) is illustrated in scheme (I), scheme (II), scheme (III) and scheme (IV).

Scheme (I)



Scheme (II)



Scheme (III)



Scheme (IV)



[000233] In certain compounds of Formula (I), the R^1 and R^2 of schemes (I) and scheme (IV) are

optionally selected from halogen, –CN, C_1-C_6 alkyl, C_1-C_6 alkoxy, $–OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $–C(O)N(R^{12})_2$, C_2-C_{14}heterocycloalkyl, $–S(O)_2R^{13}$, $–S(O)_2 N(R^{12})_2$, R^{13}, $-(CH_2)_nR^{13}$, $-(CH_2)_nR^{14}$ halo-substituted C_1-C_6 alkyl and halo-substituted C_1-C_6 alkoxy, and each n is independently 1, 2, 3, 4, 5 or 6. R^{12} and R^{13} are as described herein.

[000234] In certain compounds of Formula (I), the R groups of schemes (II) and scheme (III) are optionally selected from halogen, –CN, C_1-C_6 alkyl, C_1-C_6 alkoxy, $–OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $–C(O)N(R^{12})_2$, C_2-C_{14}heterocycloalkyl, $–S(O)_2R^{13}$, $–S(O)_2 N(R^{12})_2$, R^{13}, $-(CH_2)_nR^{13}$, $-(CH_2)_nR^{14}$ halo-substituted C_1-C_6 alkyl and halo-substituted C_1-C_6 alkoxy, and each n is independently 1, 2, 3, 4, 5 or 6. R^{12} and R^{13} are as described herein.

[000235] The synthesis of certain intermediates used in the synthesis of compounds of Formula (I) is illustrated in scheme (V) and scheme (VI).

Scheme (V)



Scheme (VI)



[000236] The synthesis of certain compounds of Formula (I) using the 6,8-dichloro-2,7-naphthyridin-1(2H)-one (24) intermediate compound is illustrated in scheme (VII) and scheme (VIII).

Scheme (VII)



24 26 26 26 26

Scheme (VIII)



24 27 28 28 28 28

[000237] In certain compounds of Formula (I), the R^1 of scheme (VII) and scheme (VIII) is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_1-C_6alkyl, C_3-C_8cycloalkyl, halo-substituted C_1-C_6alkyl, -

$(CH_2)_nR^9$, $-L^3R^9$ or $-Y^1-L^1-R^{14}$, wherein, Y^1 is arylene, heteroarylene or heterocycloalkylene, and L^1- is a bond, -O-, -C(O)-, $-C(O)N(R^{11})-$, $-(C(R^{12})_2)_n-$ or $-O(CH_2)_n-$ and wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, halo-substituted C_1-C_6alkyl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl and Y^1 are optionally substituted with 1 to 3 substituents independently selected from halogen, –CN, $-C_1$-C_6 alkyl, C_1-C_6alkoxy, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)N(R^{12})_2$, C_2-C_{14}heterocycloalkyl, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, R^{13}, $-(CH_2)_nR^{13}$, $-(CH_2)_nR^{14}$, halo-substituted C_1-C_6 alkyl and halo-substituted C_1-C_6alkoxy, and each n is independently 1, 2, 3, 4, 5 or 6.

[000238] In certain compounds of Formula (I), the R^1 of scheme (VII) and scheme (VIII) is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or Y^2-L^2-R^{14}, wherein, Y^2 is bond, arylene, heteroarylene or heterocycloalkylene, and L^2- is a bond, -O-, or $-O(CH_2)_n-$, and wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl and Y^2 are optionally substituted with 1 to 3 substituents independently selected from halogen, –CN, =O, C_1-C_6alkyl, C_1-C_6alkoxy, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)N(R^{12})_2$, C_2-C_{14}heterocycloalkyl, $-S(O)_2R^{13}$, $-NR^{12}S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, R^{13}, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{14}$, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy.

[000239] In certain compounds of Formula (I), the R^2 of scheme (VII) and scheme (VIII) is H or C_1-C_6 alkyl, and the R^3 is halo-substituted C_1-C_6alkyl, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or $-(CH_2)_nR^{11}$, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl or C_3-C_8cycloalkyl are optionally substituted with 1 to 3 substituents independently selected from halogen, –CN, C_1-C_6alkyl, hydroxyl- C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_8cycloalkyl, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)N(R^{12})_2$, C_2-C_{14}heterocycloalkyl, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, $-NHS(O)_2R^{13}$, R^{13}, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{14}$, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy.

[000240] In certain compounds of Formula (I), the R^4 of scheme (VII) and scheme (VIII) is halogen, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkylthio, hydroxyl-C_1-C_6alkyl, halo-substituted-C_1-C_6alkyl, and halo-substituted-C_1-C_6alkoxy, C_6-C_{14}aryl, C_3-C_{13}heteroaryl and C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, and C_2-C_{14}heterocycloalkyl of R^2 and R^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-NO_2$, $-OR^{12}$, $-OR^{10}$, =O, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, C_2-C_{14}heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy.

[000241] In certain embodiments of the R^1, R^2, R^3 and R^4 groups of scheme (VII) and scheme (VIII) presented above, R^{11} is $-N(R^{12})_2$, $-OR^{13}$, $-C(O)N(R^{12})_2$, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl, or C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl of R^{11} are optionally substituted with 1 to 3 substituents independently selected from halogen, –CN, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_3-

C_8cycloalkyl, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)N(R^{12})_2$, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, $-NHS(O)_2R^{13}$, R^{13}, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{14}$, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy, and each n is independently 1, 2, 3, 4, 5 or 6.

[000242] In certain embodiments of the R^1, R^2, R^3 and R^4 groups of scheme (VII) and scheme (VIII) presented above, each R^{12} is independently selected from H, C_1-C_6alkyl, C_2-C_6alkene, halo-substituted C_1-C_6alkyl and C_3-C_8cycloalkyl, or each R^{12} is independently a C_1-C_6alkyl that together with N they are attached to form a heterocycloalkyl group.

[000243] In certain embodiments of the R^1, R^2, R^3 and R^4 groups of scheme (XIV) and scheme (VIII) presented above, R^{13} is H, C_1-C_6 alkyl, C_3-C_8cycloalkyl, halo-substituted C_1-C_6 alkyl or C_2-C_{14}heterocycloalkyl.

[000244] In certain embodiments of the R^1, R^2, R^3 and R^4 groups of scheme (XIV) and scheme (VIII) presented above, R^{14} is H, halogen, OR^{13}, -CN, $-S(O)_2N(R^{12})_2$, $-S(O)_2R^{13}$, $-C(O)N(R^{12})_2$, $N(R^{12})_2$, C_1-C_6alkyl, halo-substituted C_1-C_6alkyl, C_6-C_{14}aryl, heteroaryl or C_2-C_{14}heterocycloalkyl, wherein the C_2-C_{14}heterocycloalkyl, C_6-C_{14}aryl and C_3-C_{13}heteroaryl are optionally substituted with 1-3 substituents independently selected from halogen, –CN, C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_8cycloalkyl, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)(C(R^{12})_2)_nR^{16}$, $-C(O)N(R^{12})_2$, heterocycloalkyl, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, $-NHS(O)_2R^{13}$, R^{13}, R^{10}, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-(C(R^{12})_2)_nR^{16}$, , halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy and each n is independently 1, 2, 3, 4, 5 or 6.

[000245] In certain embodiments of scheme (VII) the NH moiety of 6,8-dichloro-2,7-naphthyridin-1(2H)-one (24) is protected with apprtopriated amine protecting groups prior to subsequent reactions and then deprotected to give the final product.

Examples

[000246] The present invention is further exemplified, but not limited, by the following examples that illustrate the preparation of compounds of Formula (I) according to the invention.

Example 1

Synthesis of 6-phenyl-8-(3-(trifluoromethyl)phenylamino)-2,7-naphthyridin-1(2H)-one



Example 1a: 4-Iodo-2-methoxynicotinic acid



[000247] To a solution of 4-iodo-2-methoxynicotinaldehyde (1 g, 3.58 mmol) in *t*-BuOH (6 mL), cooled at 25 °C, is added 2-methyl-2-butene (6 mL, 2 M solution), Na_2HPO_4 (1.2 g) and water (3 mL). The reaction mixture is stirred for 5 minutes and sodium chlorite (800 mg, 8.9 mmol) is added slowly. Stirring of the mixture is continued until the aldehyde is completely consumed (3 hours, monitored by LCMS). The reaction is quenched with aq. formic acid. The mixture is partitioned between ethyl acetate (100 mL) and the organic extracts are washed with brine, dried over Na_2SO_4, filtered and concentrated. The white powder was used for the next reaction without any further purification. ^{1}H NMR 400 MHz (DMSO-d_6) δ 10.06 (s, 1H), 7.89 (*d*, 1H, *J* = 5.6 Hz), 7.48 (*d*, 1H, *J* = 5.6 Hz), 3.87 (*s*, 1H); MS *m/z* 294.1 (M + 1). MS *m/z* 280.01 (M + 1).

Example 1b: Methyl 4-iodo-2-methoxynicotinate



[000248] 4-Iodo-2-methoxynicotinic acid (800 mg, 2.87 mmol) is dissolved in MeOH (7 mL) and cooled at 0 °C. Trimethylsilyldiazomethane (9 mL, 2M in hexane, 4.5 mmol) is added slowly over 20 minutes. The reaction mixture is brought to room temperature and stirred for 16 hours. The reaction mixture is concentrated and purified by silica gel column chromatography using hexane:ethyl acetate as eluent to afford the desired compound. ^{1}H NMR 400 MHz (DMSO-d_6) δ 7.88 (d, 1H, J = 5.6 Hz), 7.34 (*d*, 1H, J = 5.6 Hz), 4.12 (*s*, 3H), 3.84 (*s*, 1H); MS *m/z* 294.1 (M + 1).

Example 1c: Methyl 2-methoxy-4-(phenylethynyl)nicotinate



[000249] A mixture of methyl 4-iodo-2-methoxynicotinate (400 mg, 1.36 mmol), ethynylbenzene (167 mg, 1.63 mmol), $Pd(PPh_3)_2Cl_2$ (47 mg, 0.068 mmol), CuI (7.7 mg, 0.04 mmol) and triethylamine (400 uL) is stirred at room temperature for 20 hours. The mixture is diluted with water, made alkaline with K_2CO_3 and extracted with $CHCl_3$. The organic layer is washed with brine, water and concentrated under vacuum.

The title compound is purified by silica gel column chromatography using hexane/ethyl acetate as eluent. MS *m/z* 268.1 (M + 1).

Example 1d: 8-methoxy-3-phenyl-2,7-naphthyridin-1(2H)-one



[000250] Methyl 2-methoxy-4-(phenylethynyl)nicotinate (100 mg, 0.37 mmol) is dissolved in 7% NH_3 in MeOH (3 mL) and heated at 115 °C in a sealed tube for 24 hours. The reaction mixture is cooled to 0 °C and the cyclized product is crystallized out. The compound is collected by filtration and dried after washing with hexanes. MS *m/z* 253.1 (M + 1).

Example 1e: 1-Chloro-8-methoxy-3-phenyl-2,7-naphthyridine



[000251] 8-Methoxy-3-phenyl-2,7-naphthyridin-1(2H)-one (80 mg, 0.32 mmol) is dissolved in CH_3CN (2 mL) and $POCl_3$ (59 uL, 0.64 mmol). The mixture is stirred at 80 °C for 3 hours. POCl3 is removed and neutralized with sat. $NaHCO_3$. The compound is extracted with $CHCl_3$ and the organic layer is dried (Na_2SO_4) and evaporated to yield the crude compound and used for the next step without any further purification. MS *m/z* 271.1 (M + 1).

Example 1f: 6-Phenyl-8-(3-(trifluoromethyl)phenylamino)-2,7-naphthyridin-1(2H)-one



[000252] A mixture of 1-chloro-8-methoxy-3-phenyl-2,7-naphthyridine (30 mg, 0.11 mmol) and 3-(trifluoromethyl)aniline in sec-BuOH (200 uL) is irradiated in a microwave at 120 °C for 30 minutes. HCl

(50 uL, 6N in dioxane) is added and stirred at room temperature for 2 hours. The reaction mixture is directly subjected to prep-HPLC to afford the title compound as a TFA salt. ^{1}H NMR 400 MHz (DMSO-d_6) δ 12.09 (s, 1H), 10.70, (s, 1H), 10.55 (s, 1H), 8.84 (s, 1H), 8.29 (s, 1H), 8.19 (s, 1H), 8.03-7.97 9 (m, 2H), 7.69 (*d*, 1H, *J* = 7.6 Hz), 7.57-7.49 (m, 3H), 7.40 (*d*, 1H, *J* = 7.6 Hz), 6.72 (*dd*, 1H, *J* = 3.2, 1.6 Hz); MS *m/z* 382.1 (M + 1).

Example 2

Synthesis of 6-(3-aminopropyl)-8-(3-(trifluoromethyl)phenylamino)-2,7-naphthyridin-1(2H)-one



Example 2a: Methyl 4-(5-(1,3-dioxoisoindolin-2-yl)pent-1-ynyl)-2-methoxynicotinate



[000253] A mixture of methyl 4-iodo-2-methoxynicotinate (400 mg, 1.36 mmol), 2-(pent-4-ynyl)isoindoline-1,3-dione (318 mg, 1.5 mmol), $Pd(PPh_3)_2Cl_2$ (47 mg, 0.068 mmol), CuI (7.7 mg, 0.04 mmol) and triethylamine (400 uL) is stirred at room temperature for 20 hours. The mixture is diluted with water, made alkaline with K_2CO_3 and extracted with $CHCl_3$. The organic layer is washed with brine, water and concentrated under vacuum. The title compound is purified by silica gel column chromatography using hexane/ethyl acetate as eluent. MS *m/z* 379.1 (M + 1).

Example 2b: 2-(3-(8-Methoxy-1-oxo-1,2-dihydro-2,7-naphthyridin-3-yl)propyl)isoindoline-1,3-dione



[000254] Methyl 4-(5-(1,3-dioxoisoindolin-2-yl)pent-1-ynyl)-2-methoxynicotinate (100 mg, 0.26 mmol) is dissolved in 7% NH_3 in MeOH (3 mL) and heated at 115 °C in a sealed tube for 24 hours. The reaction mixture is cooled and the solvents are removed by evaporation. The cyclized product is separated using silica gel column chromatography using hexan:ethyl acetate as solvent. MS *m/z* 364.1 (M + 1).

Example 2c: 2-(3-(1-chloro-8-methoxy-2,7-naphthyridin-3-yl)propyl)isoindoline-1,3-dione



[000255] 2-(3-(8-Methoxy-1-oxo-1,2-dihydro-2,7-naphthyridin-3-yl)propyl)isoindoline-1,3-dione (200 mg, 0.55 mmol) is dissolved in CH_3CN (2 mL) and $POCl_3$ (59 uL, 0.64 mmol). The mixture is stirred at 80 °C for 3 hours. $POCl_3$ is removed and neutralized with sat. $NaHCO_3$. The compound is extracted with $CHCl_3$ and the organic layer is dried (Na_2SO_4) and evaporated to yield the crude compound, which is used in the next step without any further purification. MS *m/z* 382.1 (M + 1).

Example 2d: 6-(3-aminopropyl)-8-(3-(trifluoromethyl)phenylamino)-2,7-naphthyridin-1(2H)-one



[000256] A mixture of 2-(3-(1-chloro-8-methoxy-2,7-naphthyridin-3-yl)propyl)isoindoline-1,3-dione (60 mg, 0.14 mmol) and 3-(trifluoromethyl)aniline (24.8 mg, 0.15 mmol) in sec-BuOH (200 uL) is irradiated in a microwave at 120 °C for 30 minutes. HCl (50 uL, 6N in dioxane) is added and stirred at room temperature for 2 hours. The solvent is completely removed and the mixture is dried. The mixture is then

dissolved in EtOH (1 mL) and hydrazine (6.4 mg, 0.2 mmol) is added. The mixture is stirred at 60 °C for 2 hours. The reaction mixture is directly subjected to prep-HPLC to afford the title compound as a TFA salt. ^{1}H NMR (400 MHz, MeOD-d_4) δ 8.42 (s, 1H), 7.74 (d, 1H), 7.29 (t, 1H), 7.12 (d, 1H), 6.43 (d, 1H), 6.00 (d, 1H), 5.42 (s, 1H), 3.99(t, 2H), 3.60 (m, 3H), 2.93 (t, 2H); MS *m/z* 363.20 (M + 1).

Example 3

Synthesis of 6-(2-aminoethylamino)-8-(3-(trifluoromethyl)phenylamino)-2,7-naphthyridin-1(2H)-one



Example 3a: (*E*)-2,6-dichloro-4-(2-(pyrrolidin-1-yl)vinyl)nicotinonitrile



[000257] A mixture of dimethylformamide dimethylacetal (20 mL, 0.149 mol) and pyrrolidine (18.7 mL, 0.224 mol) is stirred at 95 °C for 2 hours under N_2 and then the reaction mixture is distilled at atmospheric pressure under N_2 to remove volatiles. Then the reaction mixture is distilled under reduced pressure. The fraction is distilled at approximately 100°C (bp) at 100 mbar while the heating bath temperature is gradually raised to 150 °C. 12 g of the condensation product is collected as a colorless oil. A suspension of the above condensation product (6 g, 0.032 mol) in 10 mL of isopropanol is treated with 3-cyano-4-methylpyridine (10.1g, 0.016 mol) and is stirred at 90 °C for 2 hours and the precipitate is filtered to give 2,6-dichloro-4-(2-(pyrrolidin-1-yl)vinyl)nicotinonitrile as a brick red solid.

Example 3b: 6,8-dichloro-2,7-naphthyridin-1(2H)-one



[000258] A suspension 2,6-dichloro-4-(2-(pyrrolidin-1-yl)vinyl)nicotinonitrile (2 g, 7.457 mmol) in 6 mL of conc-HCl is stirred at 60 °C for 6 hours and stirred at room temperature for 1 hour. The reaction mixture is added to 50 mL of water and the precipitate is collected by filtration and washed with water and ether to give 1.4 g of 6,8-dichloro-2,7-naphthyridin-1(2H)-one as a crude product (pale yellow solid). The

dichloro compound was used for the reaction transformations without any further purification.

Example 3c: 6-(2-aminoethylamino)-8-(3-(trifluoromethyl)phenylamino)-2,7-naphthyridin-1(2H)-one



[000259] A suspension of 6,8-dichloro-2,7-naphthyridin-1(2H)-one (50 mg, 0.23 mmol) and 3-trifluoromethylaniline (37.6 mg, 0.23 mmol) in 0.1 mL NMP is irradiated by microwave at 130 °C for 45 minutes. LCMS shows the quantitative conversion and the crude product is used for the next amination reaction step without any further purification.

[000260] Ethane-1,2-diamine (15 mg, 0.25 mmol) is added to the above reaction mixture and is then irradiated by microwave at 155 °C for 45 minutes. The mixture is directly subjected to prep-HPLC to afford the title compound. ^{1}H NMR (400 MHz, MeOD-d_4) δ 8.40 (s, 1H), 7.63 (d, 1H), 7.39 (t, 1H), 7.17 (d, 1H), 7.11 (d, 1H), 6.12 (d, 1H), 5.80 (s, 1H), 3.56(t, 2H), 3.37 (s, 3H), 3.03 (t, 2H); MS *m/z* 376.15 (M + 1).

Example 4

Synthesis of 6-(2-aminoethylamino)-8-(3-(trifluoromethyl)phenylamino)-2,7-naphthyridin-1(2H)-one



Example 4a: (*E*)-2,6-Dichloro-4-(2-(dimethylamino)vinyl)nicotinonitrile



[000261] To 2,6-dichloro-4-methylnicotinonitrile (20.3g, 0.108 mol) in 200 mL of isopropyl alchohol is added *N,N*- dimethylformamide dimethlacetal (14.4 mL, 0.108 mol) and the reaction is stirred at 65 °C for 18 hrs. After the reaction is cooled to ambient temperature, the precipitate is collected by filtration, washed with 50 mL of isopropyl alcohol, and air dried giving (*E*)-2,6-Dichloro-4-(2-(dimethylamino)vinyl)nicotinonitrile as a yellow solid. MS (ES+) calcd. 242.02; found 242.10 (MH+). H-

NMR (600MHz, DMSO-*d*6) 2.90 (br.s, 3H), 3.17 (br.s, 3H), 5.05 (d, J= 12.6Hz, 1H), 7.61 (s, 1H), 8.09 (d, J= 12.6Hz, 1H).

Example 4b: 6,8-dichloro-2,7-naphthyridin-1(2*H*)-one



[000262] To (*E*)-2,6-dichloro-4-(2-(dimethylamino)vinyl)nicotinonitrile (2.00 g, 8.26 mmol) in a 40 ml glass vial is added 8 mL of conc. HCl and the vial is sealed. The reaction is stirred at a temperature of 43 °C to 45 °C for 18 hrs. After cooling to ambient temperature 10 g of ice water is added to the resulting heavy yellow slurry. The precipitate is collected by filtration, washed successively with cold water (10 mL), ether (10 mL), and ethyl acetate (20 mL), and dried under vacuum, giving 6,8-dichloro-2,7-naphthyridin-1(2*H*)-one as a slightly yellow solid. MS (ES+) calcd. 214.97; found 215.00 (MH+). H-NMR (600MHz, DMSO-*d*6) 6.53 (d, J= 6.6Hz, 1H), 7.51 (t, J= 6.6Hz, 1H), 7.78 (s, 1H), 11.77 (br.s, 1H).

Example 4c: 6-(2-aminoethylamino)-8-(3-(trifluoromethyl)phenylamino)-2,7-naphthyridin-1(2H)-one



[000263] A suspension of 6,8-dichloro-2,7-naphthyridin-1(2H)-one (50 mg, 0.23 mmol) and 3-trifluoromethylaniline (37.6 mg, 0.23 mmol) in 0.1 mL NMP is irradiated by microwave at 130 °C for 45 minutes. LC/MS shows quantitative conversion and the crude product is used for the next amination reaction step without further purification.

[000264] Ethane-1,2-diamine (15 mg, 0.25 mmol) is added to the above reaction mixture and is then irradiated by microwave at 155 °C for 45 minutes. The mixture is directly subjected to prep-HPLC to give 6-(2-aminoethylamino)-8-(3-(trifluoromethyl)phenylamino)-2,7-naphthyridin-1(2H)-one. ^{1}H NMR (400 MHz, MeOD-d_4) δ 8.40 (s, 1H), 7.63 (d, 1H), 7.39 (t, 1H), 7.17 (d, 1H), 7.11 (d, 1H), 6.12 (d, 1H), 5.80 (s, 1H), 3.56(t, 2H), 3.37 (s, 3H), 3.03 (t, 2H); MS *m/z* 376.15 (M + 1).

Example 5

Synthesis of 8-(3-methyl-4-((R)-2-methylmorpholino)phenylamino)-6-(pyrimidin-5-yl)-2,7-naphthyridin-1(2H)-one



Example 5a: (R)-2-methylmorpholine hydrochloride



[000265] *N*-Benzylethanolamine (39.8 g, 250 mmol) was stirred with (*R*)-(+)-propylene oxide (17.6 g, 99%, 300 mmol) in a sealed tube at 45 °C overnight (17h). Evaporation of the excess of propylene oxide in vacuo gave the diol residue which was used directly for the next step. The diol (270 mmol) was dissolved in dioxane (250 mL, anhydrous). KOH (52 g, 810 mmole, powder) and tris(3,6-dioxaheptyl)amine (0.91 mL, 2.7 mmole) were added and the mixture was cooled to 0 °C after which tosyl chloride (51.5 g, 270 mmol, in 250 mL anhydrous dioxane) was added dropwise. The reaction mixture was allowed to stir at 0 °C for 45 minutes after which it was warmed to room temperature and stirred overnight. The reaction mixture was filtered (to remove insolubles, KCl, KOH) and the filtrate was evaporated in vacuo. HCl (2 N, 400 mL) was added to the product and the resulting acidic aqueous solution was washed with ethyl acetate (200 mLx2), the solution cooled to 0 °C and neutralized by adding NaOH (pH monitored with pH paper). The mixture was then extracted with ethyl acetate. The organic phase was washed with brine, then dried over Na_2SO_4. The crude was purified by chromatography on silica gel (5~20% ethyl acetate in DCM) to give the cyclized product.

[000266] The free base is converted to the HCl salt and recrystallized as follows: The free base obtained above was treated with HCl (2 M in ether, 50 mL) and subject to evaporation to yield the HCl salt. The salt was mixed with ethyl acetate (120 mL) and heated to reflux. EtOH was added dropwise cautiously until the entire solid just dissolved. Then it was cooled to room temperature

and kept in the refrigerator overnight. The precipitate obtained was filtered to give pure product.

[000267] A solution of the recrystalized salt (6.28 g, 27.6 mmole) in ethanol (30 mL) was hydrogenated over 10% Pd/C (0.63 g) under pressure (55 psi) at room temperature overnight. The mixture was filtered through celite (washed with EtOH) and the filtrate was evaporated to give an oil. Addition of ether and subsequent evaporation gave R-2-methylmorpholine hydrochloride (> 99% ee) as a hygroscopic solid.

Example 5b: (R)-3-methyl-4-(2-methylmorpholino)aniline



[000268] Under N_2 atmosphere, to a mixture of (*R*)-2-methylmorpholine HCl salt (1.1g, 8 mmol), *N*-(4-bromo-3-methylphenyl)acetamide (1.7 g, 7.45 mmol), Pd2dba3 (92 mg, 0.1 mmol) and 2-(di-*t*-butylphosphino)biphenyl (72 mg, 0.24 mmnol) was added LiHMDS (28 mmol, 28 mL, 1 M in THF). The resulting mixture was stirred at 65 °C overnight. THF was removed under reduced pressure. The residue was treated with HCl (1N), basified with NaHCO3, and then extracted with EtOAc. The combined organics was washed with brine and dried over Na_2SO_4. The crude was purified by flash chromatography on silica gel (40-100% EtOAc in hexanes) to afford the product as a yellow solid.

[000269] A solution of the product obtained above (693 mg) in EtOH-HCl (2N) (1:1, 14 mL) was heated for 30 minutes in a microwave. The mixture was cooled to room temperature, and EtOH was removed by rotavapor. The residue was dissolved in EtOAc, washed with NaHCO3, brine, then dried over Na_2SO_4. Upon removal of solvent, the product was obtained as a brown oil which was used in next step without further purification.

Example 5c: 8-(3-methyl-4-((R)-2-methylmorpholino)phenylamino)-6-(pyrimidin-5-yl)-2,7-naphthyridin-1(2H)-one



[000270] A mixture of dichloro compound (691 mg, 2.75 mmol) and aniline compound (567 mg, 2.75 mmol) in i-PrOH (10 mL) was heated at 130 °C for 2 days in a sealed tube. The solid was collected by filtration (960 mg). To a mixture of the monocholoro compound (211 mg, 0.5 mmol), pyrimidin-5-ylboronic acid (124 mg, 1 mmol) and $Pd(PPh_3)_4$ (29 mg, 0.025 mmol) in dioxane (10 mL) was added Na_2CO_3 (1M, 2 mL) and water (2 mL). The reaction mixture was heated at 120 °C for 30 minutes in a microwave. The mixture was extracted with DCM (30 mLX3), the combined organics was washed with brine, then dried over Na_2SO_4. The solvent was removed, and the residue was subjected to flash chromatography on silica gel (0-10% MeOH in DCM) to afford the product 8-(3-methyl-4-((R)-2-methylmorpholino)phenylamino)-6-(pyrimidin-5-yl)-2,7-naphthyridin-1(2H)-one as a yellow solid. ^1H NMR (400 MHz, CDCl3) δ 11.44 (s, 1H), 9.80 (s, 1H), 9.40 (s, 2H), 9.27 (s, 1H, br), 7.76 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.58 (d, *J* = 2.4 Hz, 1H), 7.24 (d, *J* = 6.4 Hz, 1H), 7.12 (s, 1H), 7.07 (d, *J* = 8.4 Hz, 1H), 6.49 (d, *J* = 6.4 Hz, 1H), 4.03-3.95 (m, 1H), 3.90-3.77 (m, 2H), 3.03-2.81 (m, 3H), 2.55 (dd, *J* = 11.2, 9.6 Hz, 1H), 2.37 (s, 3H), 1.23 (d, *J* = 6.4 Hz, 3H).

Example 6

Synthesis of (R)-8-(3-methyl-4-(2-methylmorpholino)phenylamino)-6-(6-methylpyridin-3-yl)-2,7-naphthyridin-1(2H)-one



[000271] A mixture of (R)-6-chloro-8-(3-methyl-4-(2-methylmorpholino)phenylamino)-2,7-naphthyridin-1(2H)-one (770 mg, 2.0 mmol), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (0.8 g, 3.65 mmol), $Pd(PPh_3)_4$ (200.0 mg, 0.173 mmol) and Na_2CO_3 (1.0 g, 9.45 mmol) in a mixed solvent of dioxane (16.0 mL) and H_2O (4.0 mL) was purged with N_2, heated at 90 °C for 16 hours, evaporated to result in a residue which was subjected to chromatography with gradient mixed solvents from DCM/MeOH/28% aqueous NH_4OH (49:10:1) to (19:10:1) afforded a product which was then recrystallized in toluene to afford the title compound. ^{1}H NMR (DMSO-d_6) δ 1.12 (d, J = 6.4 Hz, 3H, CH_3), 2.31 (s, 3H, CH_3), 2.42 (m, 1H), 2.55 (s, 3H, CH_3), 2.70 (m, 1H), 2.85-2.95 (2H), 3.65-3.73 (2H), 3.85 (m, 1H), 6.53 (d, J = 7.2 Hz, 1H), 7.07 (d, J = 8.4 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 7.2 Hz, 1H), 7.48 (s, 1H), 7.66 (d, J = 2.4 Hz, 1H), 7.74 (dd, J = 8.0, 2.4 Hz, 1H), 8.35 (dd, J = 8.8, 2.4 Hz, 1H), 9.20 (s, 1H), 11.77 (br s, 1H, NH), 11.92 (br s, 1H, NH); ESI-MS m/z 442.2 (MH^+); Anal. Calcd for $C_{26}H_{27}N_5O_2$: C, 70.73; H, 6.16; N, 15.86. Found: C, 70.73; H, 6.13; N, 15.83.

Example 7

Synthesis of 6-(6-methoxypyrazin-2-yl)-8-(4-morpholinophenylamino)-2,7-naphthyridin-1(2H)-one



[000272] 6-chloro-8-(4-morpholinophenylamino)-2,7-naphthyridin-1(2H)-one (30 mg, 0.084 mmol) was dissolved in DMF (1 mL) in a microwave vial and 2-methoxy-6-(tributylstannyl)pyrazine (40 mg, 0.1 mmol) was added followed by $PdCl_2$dppf (6.1 mg, 0.0084 mmol) at room temperature. The vial was flushed with nitrogen and closed the cap and subjected to microwave irradiation at 135 C for 60 minutes. The reaction mixture was diluted with DMSO and purified by prep HPLC. The compound was isolated as a TFA salt. ^{1}H NMR (400 MHz, DMSO-*d6*) δ 11.14 (s, 1H), 8.96 (s, 1H), 8.33 (s, 1H), 7.68 (s, 1H), 7.67 (*d*, 2H, J = 8.8 Hz), 7.38 (m, 1H), 6.95 (d,

2H, *J* = 8.8 Hz), 6.57 (*d*, 1H, *J* = 7.2 Hz), 4.0 (s, 3H), 3.69 (t, 4H, J = 4.8 Hz), 3.04 (t, 4H, J = 4.8 Hz); MS *m/z* 431.2 (M + 1).

Example 8

Synthesis of 8-(Alkylamino)-6-aryl-2-methyl-2,7-naphthyridin-1(2H)-ones



Example 8a: *6,8-Dichloro-2-methyl-2,7-naphthyridin-1(2H)-one*



[000273] To a solution of 6,8-dichloro-2,7-naphthyridin-1(2H)-one (215.0 mg, 1.0 mmol) in dry DMF (10 mL) was added NaH (100 mg, 60% in mineral oil, 2.5 mmol) at 0 °C under N_2. After the reaction mixture was allowed to be warmed to room temperature and stirred for 20 minutes, CH_3I (0.25 mL, 568.08 mg, 4.0 mmol) was added via syringe. The reaction mixture was stirred at room temperature for 18 hours and concentrated under reduced pressure. The residue was diluted with EtOAc (100 mL), washed with saturated NH_4Cl solution (2 × 50 mL), water (30 mL) and brine (20 mL), and concentrated to afford the crude title compound. ESI-MS *m/z* 229.0 (MH^+).

Example 8b: *6-Chloro-2-methyl-8-(methylamino)-2,7-naphthyridin-1(2H)-one*



[000274] A mixture of 6,8-dichloro-2-methyl-2,7-naphthyridin-1(2H)-one (46 mg, 0.2 mmol) and CH_3NH_2 solution in THF (2.0 M, 2.5 mL) was heated at 95 °C for 5 hours and evaporated to afford the crude title compound. ESI-MS *m/z* 224.0 (MH^+).

Example 8c: *2-Methyl-8-(methylamino)-6-(pyrimidin-5-yl)-2,7-naphthyridin-1(2H)-one*



[000275] A mixture of crude 6-chloro-2-methyl-8-(methylamino)-2,7-naphthyridin-1(2H)-one (6 mg, ~0.025 mmol), pyrimidin-5-ylboronic acid (6.2 mg, 0.05 mmol), $Pd(PPh_3)_4$ (2.5 mg, 0.002 mmol) and Na_2CO_3 (10.6 mg, 0.1 mol) in a mixed solvent of dioxane (1.5 mL) and H_2O (0.5 mL) was purged with N_2, heated at 90 °C for 16 hours and evaporated to result in a residue that was subjected to HPLC purification to afford TFA salt of the title compound. ESI-MS *m/z* 268.1 (MH^+).

[000276] By repeating the procedures described in the above examples, using appropriate starting materials, the following compounds of Formula I, as identified in Table 1, are obtained.

Table 1

No.	Structure	Physical Data ^{1}H NMR 400 MHz (DMSO-d_6) and/or MS (m/z)	No.	Structure	Physical Data ^{1}H NMR 400 MHz (DMSO-d_6) and/or MS (m/z)
1		MS *m/z* 398.1 (M + 1).	569		MS *m/z* 322.1 (M + 1).
2		MS *m/z* 399.1 (M + 1).	570		MS *m/z* 352.1 (M + 1).

3		MS *m/z* 351.1 (M + 1).	571		MS *m/z* 446.2 (M + 1).
4		MS *m/z* 380.2 (M + 1).	572		MS *m/z* 416.2 (M + 1).
5		MS *m/z* 363.1 (M + 1).	573		MS *m/z* 429.2 (M + 1).
6		MS *m/z* 427.1 (M + 1).	574		MS *m/z* 459.2 (M + 1).
7		MS *m/z* 410.1 (M + 1).	575		MS *m/z* 473.2 (M + 1).

8		MS *m/z* 363.14 (M + 1).	576		MS *m/z* 473.2 (M + 1).
9		MS *m/z* 349.1 (M + 1).	578		MS *m/z* 460.2 (M + 1).
10		MS *m/z* 450.1 (M + 1).	579		MS *m/z* 460.2 (M + 1).
11		MS *m/z* 399.1 (M + 1).	580		MS *m/z* 443.2 (M + 1).
12		MS *m/z* 382.1 (M + 1).	581		MS *m/z* 484.2 (M + 1).

13		MS *m/z* 344.2 (M + 1).	582		MS *m/z* 417.2 (M + 1).
14		MS *m/z* 398.1 (M + 1).	583		MS *m/z* 541.2 (M + 1).
15		MS *m/z* 380.1 (M + 1).	584		MS *m/z* 473.2 (M + 1).
16		MS *m/z* 412.2 (M + 1).	585		MS *m/z* 459.2 (M + 1).
17		MS *m/z* 380.2 (M + 1).	586		MS *m/z* 439.2 (M + 1).

18		MS *m/z* 408.2 (M + 1).	587		MS *m/z* 443.2 (M + 1).
19		MS *m/z* 465.1 (M + 1).	588		MS *m/z* 473.2 (M + 1).
20		MS *m/z* 427.1 (M + 1).	589		MS *m/z* 453.2 (M + 1).
21		MS *m/z* 385.2 (M + 1).	590		MS *m/z* 483.2 (M + 1).
22		MS *m/z* 377.1 (M + 1).	591		MS *m/z* 466.2 (M + 1).

23		MS *m/z* 379.2 (M + 1).	592		MS *m/z* 429.2 (M + 1).
24		MS *m/z* 400.1 (M + 1).	593		MS *m/z* 456.2 (M + 1).
25		MS *m/z* 391.17 (M + 1).	594		MS *m/z* 519.2 (M + 1).
26		MS *m/z* 377.2 (M + 1).	595		MS *m/z* 532.2 (M + 1).
27		MS *m/z* 379.21 (M + 1).	596		MS *m/z* 549.2 (M + 1).

28		MS *m/z* 355.1 (M + 1).	597		MS *m/z* 508.3 (M + 1).
29		MS *m/z* 325.1 (M + 1).	598		MS *m/z* 522.3 (M + 1).
30		MS *m/z* 355.1 (M + 1).	599		MS *m/z* 444.2 (M + 1).
31		MS *m/z* 393.1 (M + 1).	600		MS *m/z* 445.2 (M + 1).
32		MS *m/z* 411.22 (M + 1).	601		MS *m/z* 414.2 (M + 1).

33		MS *m/z* 392.2 (M + 1).	602		MS *m/z* 491.3 (M + 1).
34		MS *m/z* 388.1 (M + 1).	603		MS *m/z* 456.2 (M + 1).
35		MS *m/z* 418.25 (M + 1).	604		MS *m/z* 431.2 (M + 1).
36		MS *m/z* 467.16 (M + 1).	605		MS *m/z* 503.3 (M + 1).
37		MS *m/z* 421.26 (M + 1).	606		MS *m/z* 469.2 (M + 1).

38		MS *m/z* 427.21 (M + 1).	607		MS *m/z* 492.3 (M + 1).
39		MS *m/z* 238.1 (M + 1).	608		MS *m/z* 511.3 (M + 1).
40		MS *m/z* 394.23 (M + 1).	609		MS *m/z* 499.3 (M + 1).
41		MS *m/z* 394.23 (M + 1).	610		MS *m/z* 480.2 (M + 1).
42		MS *m/z* 379.22 (M + 1).	611		MS *m/z* 480.2 (M + 1).

43		MS *m/z* 449.14 (M + 1).	612		MS *m/z* 438.2 (M + 1).
44		MS *m/z* 497.21 (M + 1).	613		MS *m/z* 492.2 (M + 1).
45		MS *m/z* 424.24 (M + 1).	614		MS *m/z* 513.3 (M + 1).
46		MS *m/z* 475.19 (M + 1).	615		MS *m/z* 498.2 (M + 1).
47		MS *m/z* 485.2 (M + 1).	616		MS *m/z* 485.2 (M + 1).

48		MS *m/z* 398.19 (M + 1).	617		MS *m/z* 469.2 (M + 1).
49		MS *m/z* 397.2 (M + 1).	618		MS *m/z* 400.2 (M + 1).
50		MS *m/z* 429.16 (M + 1).	619		MS *m/z* 400.2 (M + 1).
51		MS *m/z* 402.2 (M + 1).	620		MS *m/z* 383.2 (M + 1).
52		MS *m/z* 413.33 (M + 1).	621		MS *m/z* 370.2 (M + 1).

53		MS *m/z* 416.2 (M + 1).	622		MS *m/z* 508.3 (M + 1).
54		MS *m/z* 437.21 (M + 1).	623		MS *m/z* 513.3 (M + 1).
55		MS *m/z* 414.2 (M + 1).	624		MS *m/z* 471.2 (M + 1).
56		MS *m/z* 428.21 (M + 1).	625		MS *m/z* 427.2 (M + 1).
57		MS *m/z* 403.21 (M + 1).	626		MS *m/z* 457.2 (M + 1).

58		MS *m/z* 443.21 (M + 1).	627		MS *m/z* 541.3 (M + 1).
59		MS *m/z* 417.1 (M + 1).	628		MS *m/z* 468.2 (M + 1).
60		MS *m/z* 455.2 (M + 1).	629		MS *m/z* 482.3 (M + 1).
61		MS *m/z* 434.1 (M + 1).	630		MS *m/z* 449.2 (M + 1).
62		MS *m/z* 402.2 (M + 1).	631		MS *m/z* 507.2 (M + 1).

63		MS *m/z* 479.21 (M + 1).	632		MS *m/z* 493.2 (M + 1).
64		MS *m/z* 422.26 (M + 1).	633		MS *m/z* 462.2 (M + 1).
65		MS *m/z* 455.21 (M + 1).	634		MS *m/z* 479.2 (M + 1).
66		MS *m/z* 441.23 (M + 1).	635		MS *m/z* 413.2 (M + 1).
67		MS *m/z* 413.2 (M + 1).	636		MS *m/z* 429.2 (M + 1).

68		MS *m/z* 448.1 (M + 1).	637		^{1}H NMR (400 MHz, DMSO-*d6*) δ 12.03 (s, 1H), 9.06 (s, 1H), 7.84 (d, 2H, J = 8.8 Hz), 7.85 (s, 1H), 7.49 (t, 1H, J = 6.4 Hz), 7.36 (d, 2H, *J* = 8.8 Hz), 6.69 (*d*, 1H, *J* = 6.8 Hz), 4.08 (s, 3H), 3.43-3.40 (m, 2H), 3.32-3.31 (m, 2H), 3.09 (q, 2H, J = 7.2 Hz), 2.50 (brs, 8H), 1.28 (t, 3H, J = 7.2 Hz); MS *m/z* 486.2 (M + 1).
69		MS *m/z* 533.2 (M + 1).	638		^{1}H NMR (400 MHz, DMSO-*d6*) δ 12.12 (s, 1H), 9.42 (s, 1H), 9.26 (s, 1H), 7.86 (*d*, 2H, *J* = 8.8 Hz), 7.15 (s, 1H), 6.96 (d, 2H, *J* = 8.8 Hz), 6.90 (*d*, 1H, *J* = 5.2 Hz), 6.31 (d, 1H, *J* = 6.8 Hz) ;MS *m/z* 414.03 (M + 1).
70		MS *m/z* 430.1 (M + 1).	639		^{1}H NMR (400 MHz, DMSO-*d6*) δ 12.16 (s, 1H), 8.99 (s, 1H), 8.97 (s, 1H), 7.84 (*d*, 2H, *J* = 8.4 Hz), 7.66 (s, 1H), 7.46 (s, 1H), 7.43 (d, 2H, *J* = 8.4 Hz), 7.41 (m, 1H), 6.52 (d, 1H, *J* = 7.2 Hz), 3.71 (t, 4H, J = 4.8 Hz), 3.05 (t, 4H, J = 4.8 Hz); MS *m/z* 401.2 (M + 1).

71		MS *m/z* 478.2 (M + 1).	640		^{1}H NMR (400 MHz, DMSO-*d6*) δ 12.02 (s, 1H), 9.01 (s, 1H), 8.40 (s, 1H), 7.81 (s, 1H), 7.72 (*dd*, 1H, *J* = 3.8, 2 Hz), 7.65 (d, 1H, J = 2Hz), 7.48 (t, 1H, J = 6.4 Hz), 7.24 (d, 1H, *J* = 8.8 Hz), 6.63 (*d*, 1H, *J* = 6.8 Hz), 3.92 (s, 3H), 3.72-3.30 (m, 2H), 3.59-3.58 (m, 2H), 3.35 (s, 3H), 3.30-3.27 (m, 2H), 3.14-3.06 (m, 2H), 2.82-2.76 (m, 1H), 2.72 (s, 3H), 2.14 (m, 2H), 1.97 (m, 2H);MS *m/z* 501.2 (M + 1).
72		MS *m/z* 442.1 (M + 1).	641		MS *m/z* 507.2 (M + 1).
73		MS *m/z* 318.1 (M + 1).	642		^{1}H NMR (400 MHz, DMSO-*d6*) δ 12.17 (s, 1H), 8.98 (s, 1H), 8.96 (s, 1H), 7.80 (*d*, 2H, *J* = 8.4 Hz), 7.66 (s, 1H), 7.46 (s, 1H), 7.39 (d, 2H, *J* = 8.4 Hz), 7.32 (m, 1H), 6.52 (d, 1H, *J* = 7.2 Hz), 3.48 (s, 3H), 2.93 (m, 4H), 2.72 (m, 1H), 2.04 (m, 2H), 1.94 (m, 2H); MS *m/z* 413.2 (M + 1).

74		MS *m/z* 399.0 (M + 1).	643		^{1}H NMR (400 MHz, DMSO-*d6*) δ 11.95 (s, 1H), 9.08 (s, 1H), 8.42 (s, 1H), 7.82 (s, 1H), 7.77 (*dd*, 1H, *J* = 3.8, 2 Hz), 7.64 (d, 1H, J = 2Hz), 7.47 (t, 1H, J = 6.4 Hz), 7.27 (d, 1H, *J* = 8.8 Hz), 6.68 (*d*, 1H, *J* = 6.8 Hz), 4.08 (s, 3H), 3.98-3.95 (m, 2H), 3.51-3.45 (m, 2H), 2.98-2.93 (m, 1H), 2.38 (s, 3H), 1.72-1.62 (m, 4H); MS *m/z* 444.1 (M + 1).
75		MS *m/z* 486.2 (M + 1).	644		^{1}H NMR (400 MHz, DMSO-*d6*) δ 11.97 (s, 1H), 9.34 (s, 2H), 7.79 (*d*, 2H, *J* = 8.8 Hz), 7.58 (s, 1H), 7.47-7.44 (m, 1H), 7.26 (d, 2H, *J* = 8.8 Hz), 6.53 (*d*, 1H, *J* = 7.2 Hz), 3.58-3.55 (m, 2H), 3.32 (s, 3H), 3.30-3.28 (m, 3H), 3.14-3.06 (m, 2H), (m, 3H), 2.82-2.76 (m, 4H), 2.71 (s, 3H), 2.14 (m, 2H), 1.98 (m, 2H); MS *m/z* 431.2 (M + 1).

76		MS *m/z* 381.1 (M + 1).	645		^{1}H NMR (400 MHz, DMSO-*d6*) δ 11.97 (s, 1H), 8.95 (d, 1H, J = 2.0 Hz), 8.41 (*d*, 1H, *J* = 2.8 Hz), 8.0 (brs, 1H), 7.77-7.75 (m, 1H), 7.71 (d, 1H, *J* = 2.4 Hz), 7.64 (s, 1H), 7.46 (*t*, 1H, *J* = 6.8 Hz), 7.17 (d, 1H, J = 8.4 Hz), 6.58 (*dd*, 1H, J = 7.2, 1.2 Hz), 3.97 (s, 3H), 3.72-3.30 (m, 2H), 3.59-3.58 (m, 2H), 3.35 (s, 3H), 3.30-3.28 (m, 2H), 3.14-3.06 (m, 2H), 2.82-2.76 (m, 1H), 2.71 (s, 3H), 2.14 (m, 2H), 1.98 (m, 2H); MS *m/z* 500.1 (M + 1).
77		MS *m/z* 430.1 (M + 1).	646		MS *m/z* 504.1 (M +1)
78		MS *m/z* 441.0 (M + 1).	647		MS *m/z* 521.14 (M + 1).

79		MS *m/z* 413.1 (M + 1).	648		MS *m/z* 492.18 (M + 1).
80		MS *m/z* 470.1 (M + 1).	649		MS *m/z* 505.2 (M + 1).
81		MS *m/z* 404.16 (M + 1).	650		MS *m/z* 460.1 (M + 1).
82		MS *m/z* 421.23 (M + 1).	651		MS *m/z* 507.13 (M + 1).
83		MS *m/z* 435.25 (M + 1).	652		MS *m/z* 522.1 (M + 1).

84		MS *m/z* 421.2 (M + 1).	653		MS *m/z* 430.16 (M + 1).
85		MS *m/z* 407.21 (M + 1).	654		MS *m/z* 445.1 (M + 1).
86		MS *m/z* 435.24 (M + 1).	655		MS *m/z* 507.1 (M + 1).
87		MS *m/z* 407.12 (M + 1).	656		MS *m/z* 521.2 (M + 1).
88		MS *m/z* 435.32 (M + 1).	657		MS *m/z* 496.12 (M + 1).

89		MS *m/z* 422.21 (M + 1).	658		MS *m/z* 507.1 (M + 1).
90		MS *m/z* 421.23 (M + 1).	659		MS *m/z* 424.2 (M + 1).
91		MS *m/z* 407.21 (M + 1).	660		MS *m/z* 510.2 (M + 1).
92		^{1}H NMR (400 MHz, MeOD-d_4) δ 8.40 (s, 1H), 7.63 (d, 1H), 7.39 (t, 1H), 7.17 (d, 1H), 7.11 (d, 1H), 6.12 (d, 1H), 5.80 (s, 1H), 3.56(t, 2H), 3.37 (s, 3H), 3.03 (t, 2H); MS *m/z* 376.15 (M + 1).	661		MS *m/z* 501.2 (M + 1).
93		MS *m/z* 397.12 (M + 1).	662		MS *m/z* 489.12 (M + 1).

94		MS *m/z* 416.2 (M + 1).	663		MS *m/z* 477.1 (M + 1).
95		MS *m/z* 415.17 (M + 1).	664		MS *m/z* 416.2 (M + 1).
96		MS *m/z* 429.16 (M + 1).	665		MS *m/z* 474.2 (M + 1).
97		MS *m/z* 413.19 (M + 1).	666		MS *m/z* 474.2 (M + 1).
98		MS *m/z* 430.4 (M + 1).	667		MS *m/z* 361.1 (M + 1).
99		MS *m/z* 389.14 (M + 1).	668		MS *m/z* 460.1 (M + 1).

100		^{1}H NMR (400 MHz, MeOD-d_4) δ 8.40 (s, 1H), 7.65 (d, 1H), 7.38 (t, 1H), 7.15 (d, 1H), 6.90 (d, 1H), 6.10 (d, 1H), 5.79 (s, 1H), 3.49(t, 2H), 2.90 (t, 2H); MS *m/z* 364.22 (M + 1).	669		MS *m/z* 388.12 (M + 1).
101		MS *m/z* 433.11 (M + 1).	670		MS *m/z* 459.2 (M + 1).
102		MS *m/z* 433.02 (M + 1).	671		MS *m/z* 473.2 (M + 1).
103		MS *m/z* 467.12 (M + 1).	672		MS *m/z* 458.2 (M + 1).
104		MS *m/z* 417.16 (M + 1).	673		MS *m/z* 472.2 (M + 1).

105		MS *m/z* 459.23 (M + 1).	674		MS *m/z* 429.2 (M + 1).
106		MS *m/z* 483.23 (M + 1).	675		MS *m/z* 430.2 (M + 1).
107		^{1}H NMR (400 MHz, MeOD-d_4) δ 8.07 (m, 2H), 7.71 (d, 2H), 7.45 (m, 2H), 7.21 (d, 2H), 6.93 (dd, 2H), 6.47 (d, 1H), 4.04 (s, 2H), 3.76 (t, 4H), 3.03 (dd, 4H); MS *m/z* 428.21 (M + 1).	676		MS *m/z* 535.2 (M + 1).
108		MS *m/z* 428.31 (M + 1).	678		MS *m/z* 446.2 (M + 1).

109		MS *m/z* 413.20 (M + 1).	679		MS *m/z* 444.2 (M + 1).
110		MS *m/z* 413.20 (M + 1).	680		MS *m/z* 464.2 (M + 1).
111		^{1}H NMR (400 MHz, MeOD-d_4) δ 7.82 (m, 2H), 7.49 (m, 2H), 7.19 (m, 5H), 6.77 (m, 1H), 6.48 (d, 1H), 3.29(m, 2H), 2.93 (m, 2H), 2.72 (m, 1H), 1.94 (m, 2H), 1.77 (m, 2H); MS *m/z* 413.13 (M + 1).	681		MS *m/z* 535.2 (M + 1).
112		MS *m/z* 397.2 (M + 1).	682		MS *m/z* 490.2 (M + 1).
113		MS *m/z* 401.1 (M + 1).	683		MS *m/z* 374.2 (M + 1).

114		^{1}H NMR (400 MHz, MeOD-d_4) δ 8.07 (s, 1H), 7.94 (s, 1H), 7.75 (dd, 1H), 7.16 (dd, 1H), 6.93 (s, 1H), 6.39 (d, 1H), 6.12 (d, 1H), 3.88(s, 3H), 3.22 (m, 2H), 2.88 (m, 2H), 2.71 (m, 1H), 1.90 (m, 2H), 1.73 (m, 2H); MS *m/z* 387.21 (M + 1).	684		MS *m/z* 459.2 (M + 1).
115		MS *m/z* 401.1 (M + 1).	685		MS *m/z* 429.2 (M + 1).
116		MS *m/z* 389.1 (M + 1).	686		MS *m/z* 429.2 (M + 1).
117		MS *m/z* 401.2 (M + 1).	687		MS *m/z* 448.2 (M + 1).

118		MS *m/z* 404.1 (M + 1).	688		MS *m/z* 416.2 (M + 1).
119		MS *m/z* 258.1 (M + 1).	689		MS *m/z* 431.2 (M + 1).
120		MS *m/z* 403.1 (M + 1).	690		MS *m/z* 441.2 (M + 1).
121		MS *m/z* 322.1 (M + 1).	691		MS *m/z* 458.2 (M + 1).
122		MS *m/z* 360.1 (M + 1).	692		MS *m/z* 425.2 (M + 1).

123		MS *m/z* 415.2 (M + 1).	693		MS *m/z* 437.2 (M + 1).
124		MS *m/z* 434.0 (M + 1).	694		MS *m/z* 430.2 (M + 1).
125		MS *m/z* 428.1 (M + 1).	695		MS *m/z* 429.2 (M + 1).
126		MS *m/z* 442.1 (M + 1).	696		MS *m/z* 471.2 (M + 1).
127		MS *m/z* 394.0 (M + 1).	697		MS *m/z* 471.2 (M + 1).

128		MS *m/z* 382.2 (M + 1).	698		MS *m/z* 470.2 (M + 1).
129		MS *m/z* 499.2 (M + 1).	699		MS *m/z* 443.2 (M + 1).
130		MS *m/z* 485.0 (M + 1).	700		MS *m/z* 458.2 (M + 1).
131		MS *m/z* 541.1 (M + 1).	701		MS *m/z* 461.2 (M + 1).

132		MS *m/z* 457.1 (M + 1).	702		MS *m/z* 423.2 (M + 1).
133		MS *m/z* 429.3 (M + 1).	703		MS *m/z* 441.2 (M + 1).
134		MS *m/z* 473.1 (M + 1).	704		MS *m/z* 429.2 (M + 1).
135		MS *m/z* 486.1 (M + 1).	705		MS *m/z* 430.2 (M + 1).
136		MS *m/z* 405.2 (M + 1).	706		MS *m/z* 430.2 (M + 1).

137		MS *m/z* 419.2 (M + 1).	707		MS *m/z* 457.2 (M + 1).
138		MS *m/z* 419.1 (M + 1).	708		MS *m/z* 430.2 (M + 1).
139		MS *m/z* 449.1 (M + 1).	709		MS *m/z* 444.2 (M + 1).
140		MS *m/z* 415.1 (M + 1).	710		MS *m/z* 473.2 (M + 1).
141		MS *m/z* 379.1 (M + 1).	711		MS *m/z* 325.2 (M + 1).

142		MS *m/z* 433.1 (M + 1).	712		MS *m/z* 352.2 (M + 1).
143		MS *m/z* 479.2 (M + 1).	713		MS *m/z* 456.2 (M + 1).
144		MS *m/z* 509.1 (M + 1).	714		MS *m/z* 430.2 (M + 1).
145		MS *m/z* 431.1 (M + 1).	715		MS *m/z* 416.2 (M + 1).
146		MS *m/z* 479.1 (M + 1).	716		MS *m/z* 431.2 (M + 1).

147		MS *m/z* 432.1 (M + 1).	717		MS *m/z* 420.2 (M + 1).
148		^{1}H NMR (400 MHz, DMSO-d6) δ 12.29 (s, 1H), 11.29 (s, 1H), 9.5 (s, 1H), 9.30 (s, 1H), 7.95 (*d*, 2H, *J* = 8.4 Hz), 7.90 (d, 2H, *J* = 8.4 Hz), 7.76 (s, 1H), 7.52 (d, 1H, J = 7.2 Hz), 6.59 (d, 1H, *J* = 6.8 Hz), 2.79 (d, 1H, J = 4.8 Hz); MS *m/z* 373.2 (M + 1).	718		MS *m/z* 459.2 (M + 1).
149		MS *m/z* 432.14 (M + 1).	719		MS *m/z* 458.2 (M + 1).
150		MS *m/z* 427.21 (M + 1).	720		MS *m/z* 475.2 (M + 1).

151		^{1}H NMR (400 MHz, DMSO-*d6*) δ 12.17 (s, 1H), 9.41 (s, 1H), 9.23 (s, 1H), 7.84 (*d*, 2H, *J* = 8.4 Hz), 7.66 (s, 1H), 7.46 (s, 1H), 7.43 (d, 2H, *J* = 8.4 Hz), 7.41 (m, 1H), 6.52 (d, 1H, *J* = 7.2 Hz), 3.2 (s, 3H), 2.9 (s, 3H) MS *m/z* 387.11 (M + 1).	721		MS *m/z* 422.2 (M + 1).
152		^{1}H NMR (400 MHz, DMSO-*d6*) δ δ 12.14 (s, 1H), 9.43 (s, 1H), 9.25 (s, 1H), 7.85 (*d*, 2H, *J* = 8.8 Hz), 7.15 (s, 1H), 6.94 (d, 2H, *J* = 8.8 Hz), 6.90 (*d*, 1H, *J* = 5.2 Hz), 6.31 (d, 1H, *J* = 6.8 Hz), 3.81 (m, 4H), 3.25 (m, 4H) ; MS *m/z* 416.18 (M + 1).	722		MS *m/z* 475.2 (M + 1).
153		MS *m/z* 426.13 (M + 1).	723		MS *m/z* 483.2 (M + 1).

154		^{1}H NMR (400 MHz, DMSO-d6) δ 12.35 (s, 1H), 8.33 (d, 1H, J = 4.4 Hz), 7.95 (*d*, 2H, *J* = 8.8 Hz), 7.87 (d, 2H, *J* = 8.8 Hz), 7.54 (d, 1H, *J* = 6.8 Hz), 7.29 (d, 1H, *J* = 6.8 Hz), 7.19 (s, 1H), 6.66 (d, 2H, *J* = 6.8 Hz), 3.4 (s, 3H), 2.6 (s, 3H), 2.53 (s, 3H); MS *m/z* 400.1 (M + 1).	724		MS *m/z* 437.2 (M + 1).
155		MS *m/z* 492.26 (M + 1).	725		MS *m/z* 444.2 (M + 1).
156		^{1}H NMR (400 MHz, DMSO-d6) δ 11.73 (s, 1H), 8.57 (s, 1H), 8.25 (m, 1H), 7.84 (*m*, 2H)), 7.70 (*d*, 2H, *J* = 8.8 Hz), 7.75 (d, 2H, *J* = 8.8 Hz), 7.44 (*t*, 1H, *J* = 6.8 Hz), 7.36 (*d*, 1H, *J* = 6.8 Hz), 6.92 (d, 2H, J = 8.8 Hz), 6.52 (d, 1H, *J* = 6.8 Hz), 3.69 (m, 4H), 3.09 (m, 4H); MS *m/z* 478.31 (M + 1).	726		MS *m/z* 386.2 (M + 1).

157		MS *m/z* 452.2 (M + 1).	727		MS *m/z* 475.2 (M + 1).
158		^{1}H NMR (400 MHz, DMSO-d6) δ 11.87 (s, 1H), 8.68 (s, 1H), 8.46 (d, 1H, *J* = 4.8 Hz), 8.03 (*d*, 1H, *J* = 4.8 Hz), 7.83 (*d*, 2H, *J* = 8.8 Hz), 7.75 (d, 2H, *J* = 8.8 Hz), 7.46 (*t*, 1H, *J* = 6.8 Hz), 7.35 (*d*, 1H, *J* = 5.2 Hz), 6.61 (d, 1H, *J* = 6.8 Hz), 3.80 (m, 4H), 3.3 (s, 3H), 3.23 (m, 4H) ; MS *m/z* 477.2 (M + 1).	728		MS *m/z* 494.2 (M + 1).
159		MS *m/z* 501.12 (M + 1).	729		MS *m/z* 516.2 (M + 1).

160		^{1}H NMR (400 MHz, DMSO-d6) δ 12.24 (s, 1H), 11.86 (*d*, 1H, *J* = 6 Hz), 8.63 (s, 1H), 8.46 (d, 1H, *J* = 4.8 Hz), 8.22 (*d*, 1H, *J* = 4.8 Hz), 7.82 (*d*, 2H, *J* = 8.8 Hz), 7.66 (t, 1H, J = 7.6), 7.41 (s, 1H), (d, 2H, *J* = 8.8 Hz), 7.44 (*t*, 1H, *J* = 6.8 Hz), 7.35 (*d*, 1H, *J* = 5.2 Hz), 7.13 (s, 1H), 6.55 (d, 1H, *J* = 6.8 Hz), 2.70 (d, 3H, *J* = 4.8 Hz), 2.40 (s, 3H); MS *m/z* 386.17 (M + 1).	730		MS *m/z* 443.2 (M + 1).
161		MS *m/z* 441.1 (M + 1).	731		MS *m/z* 486.2 (M + 1).
162		MS *m/z* 455.1 (M + 1).	732		MS *m/z* 376.2 (M + 1).

163		^{1}H NMR (400 MHz, DMSO-d6) δ 12.23 (s, 1H), 9.57 (d, 1H, J = 2.0 Hz), 9.12 (d, 1H, J = 2 Hz), 8.31 (m, 1H), 7.90 (d, 2H, J = 8.8 Hz), 7.82 (d, 2H, J = 8.8 Hz), 7.78 (s, 1H), 7.46 (d, 1H, J = 6.8 Hz), 6.58 (d, 1H, J = 6.8 Hz), 3.37 (s, 3H), 2.72 (d, 3H, J = 4.4 Hz); MS *m/z* 450.03 (M + 1).	733		MS *m/z* 444.2 (M + 1).
164		^{1}H NMR (400 MHz, DMSO-d6) δ 12.02 (s, 1H), 11.92 (s, 1H), 9.90 (brs, 1H), 9.47 (s, 1H), 9.29 (s, 1H), 7.82 (*d*, 2H, *J* = 8.4 Hz), 7.67 (s, 1H), 7.49 (m, 1H), 7.28 (d, 2H, *J* = 8.4 Hz), 6.56 (d, 1H, *J* = 6.8 Hz), 3.48 (m, 3H), 2.93 (m, 4H), 2.72 (m, 1H), 2.04 (m, 2H), 1.94 (m, 2H); MS *m/z* 413.2 (M + 1).	734		MS *m/z* 442.2 (M + 1).
165		MS *m/z* 469.2 (M + 1).	735		MS *m/z* 460.2 (M + 1).

166		MS *m/z* 459.31 (M + 1).	736		MS *m/z* 459.2 (M + 1).
167		^{1}H NMR (400 MHz, DMSO-d6) δ δ 12.08 (s, 1H), 9.06 (s, 1H), 8.89 (m, 1H), 8.08 (m, 1H), 7.78 (*d*, 2H, *J* = 8.8 Hz), 7.59 (m, 1H), 7.26 (d, 2H, *J* = 8.8 Hz), 6.65 (d, 1H, *J* = 6.8 Hz), 3.91 (s, 4H), 3.30 (m, 4H), 2.72 (s, 3H); MS *m/z* 414.2 (M + 1).	737		MS *m/z* 430.2 (M + 1).
168		MS *m/z* 443.1 (M + 1).	738		MS *m/z* 452.2 (M + 1).

169		^{1}H NMR (400 MHz, DMSO-d6) δ 12.21 (s, 1H), 11.94 (s, 1H), 9.43 (s, 1H), 9.24 (s, 1H), 7.87 (*d*, 2H, *J* = 8.4 Hz), 7.90 (d, 2H, *J* = 8.4 Hz), 7.76 (s, 1H), 7.52 (d, 1H, *J* = 7.2 Hz), 6.59 (d, 1H, *J* = 6.8 Hz), 3.16 (m, 2H), 1.47 (m, 2H), 0.84 (t, 3H, *J* = 7.2 Hz); MS *m/z* 401.2 (M + 1).	739		MS *m/z* 437.2 (M + 1).
170		MS *m/z* 474.2 (M + 1).	740		MS *m/z* 445.2 (M + 1).
171		MS *m/z* 430.21 (M + 1).	741		MS *m/z* 484.1 (M + 1).

172		^{1}H NMR (400 MHz, DMSO-d6) δ 11.82 (s, 1H), 8.92 (s, 1H), 7.65 (*d*, 2H, *J* = 8.4 Hz), 7.35 (s, 1H), 7.12 (d, 2H, *J* = 8.4 Hz), 6.47 (d, 1H, *J* = 6.8 Hz), 4.01 (s, 3H), 3.92 (s, 3H), 3.27 (s, 3H), 2.88 (m, 4H), 2.22 (m, 1H), 1.72-1.58 (m, 4H); MS *m/z* 473.1 (M + 1).	742		MS *m/z* 435.12 (M + 1).
173		MS *m/z* 414.1 (M + 1).	743		MS *m/z* 443.22 (M + 1).
174		MS *m/z* 402.12 (M + 1).	744		MS *m/z* 443.1 (M + 1).
175		MS *m/z* 432.2 (M + 1).	745		MS *m/z* 470.1 (M + 1).

176		MS *m/z* 378.2 (M + 1).	746		MS *m/z* 472.1 (M + 1).
177		MS *m/z* 430.32 (M + 1).	747		MS *m/z* 497.1 (M + 1).
178		MS *m/z* 379.12 (M + 1).	748		MS *m/z* 457.2 (M + 1).
179		MS *m/z* 426.3 (M + 1).	749		MS *m/z* 413.2 (M + 1).
180		MS *m/z* 441.2 (M + 1).	750		MS *m/z* 472.1 (M + 1).

181		MS *m/z* 495.2 (M + 1).	751		MS *m/z* 444.2 (M + 1).
182		MS *m/z* 498.06 (M + 1).	752		MS *m/z* 474.2 (M + 1).
183		MS *m/z* 420.1 (M + 1).	753		MS *m/z* 474.1 (M + 1).
184		MS *m/z* 428.16 (M + 1).	754		MS *m/z* 491.2 (M + 1).

185		MS *m/z* 428.11 (M + 1).	755		MS *m/z* 503.3 (M + 1).
186		MS *m/z* 455.12 (M + 1).	756		MS *m/z* 489.2 (M + 1).
187		MS *m/z* 490.1 (M + 1).	757		MS *m/z* 504.1 (M + 1).
188		MS *m/z* 484.22 (M + 1).	758		MS *m/z* 484.2 (M + 1).

189		MS *m/z* 498.2 (M + 1).	759		MS *m/z* 516.11 (M + 1).
190		MS *m/z* 415.16 (M + 1).	760		MS *m/z* 459.3 (M + 1).
191		MS *m/z* 427.1 (M + 1).	761		MS *m/z* 457.2 (M + 1).
192		MS *m/z* 470.1 (M + 1).	762		MS *m/z* 499.1 (M + 1).
193		MS *m/z* 420.1 (M + 1).	763		MS *m/z* 399.1 (M + 1).

194		MS *m/z* 434.01 (M + 1).	764		MS *m/z* 412.2 (M + 1).
195		MS *m/z* 446.23 (M + 1).	765		MS *m/z* 413.1 (M + 1).
196		MS *m/z* 415.14 (M + 1).	766		MS *m/z* 458.2 (M + 1).
197		MS *m/z* 444.1 (M + 1).	767		MS *m/z* 414.3 (M + 1).
198		MS *m/z* 425.1 (M + 1).	768		MS *m/z* 400.2 (M + 1).

199		MS *m/z* 416.08 (M + 1).	769		MS *m/z* 541.13 (M + 1).
200		MS *m/z* 487.1 (M + 1).	770		MS *m/z* 431.23 (M + 1).
201		MS *m/z* 492.23 (M + 1).	771		MS *m/z* 414.12 (M + 1).
202		MS *m/z* 519.21 (M + 1).	772		MS *m/z* 444.2 (M + 1).
203		MS *m/z* 442.01 (M + 1).	773		MS *m/z* 489.21 (M + 1).

204		MS *m/z* 392.4 (M + 1).	774		MS *m/z* 413.2 (M + 1).
205		MS *m/z* 499.13 (M + 1).	775		MS *m/z* 458.2 (M + 1).
206		MS *m/z* 493.11 (M + 1).	776		MS *m/z* 489.1 (M + 1).
207		MS *m/z* 526.1 (M + 1).	778		MS *m/z* 503.1 (M + 1).
208		MS *m/z* 451.13 (M + 1).	779		MS *m/z* 473.2 (M + 1).

209		MS *m/z* 447.2 (M + 1).	780		MS *m/z* 502.11 (M + 1).
210		MS *m/z* 416.12 (M + 1).	781		MS *m/z* 509.2 (M + 1).
211		MS *m/z* 504.1 (M + 1).	782		MS *m/z* 442.21 (M + 1).
212		MS *m/z* 476.3 (M + 1).	783		MS *m/z* 488.32 (M + 1).
213		MS *m/z* 474.3 (M + 1).	784		MS *m/z* 474.1 (M + 1).

214		MS *m/z* 468.2 (M + 1).	785		MS *m/z* 417.1 (M + 1).
215		MS *m/z* 501.3 (M + 1).	786		MS *m/z* 516.1 (M + 1).
216		MS *m/z* 461.3 (M + 1).	787		MS *m/z* 525.2 (M + 1).
217		MS *m/z* 434.2 (M + 1).	788		MS *m/z* 474.2 (M + 1).
218		MS *m/z* 503.3 (M + 1).	789		MS *m/z* 457.3 (M + 1).

219		MS *m/z* 452.2 (M + 1).	790		MS *m/z* 522.2 (M + 1).
220		MS *m/z* 434.2 (M + 1).	791		MS *m/z* 446.1 (M + 1).
221		MS *m/z* 454.2 (M + 1).	792		MS *m/z* 446.11 (M + 1).
222		MS *m/z* 486.2 (M + 1).	793		MS *m/z* 463.12 (M + 1).

223		MS *m/z* 448.3 (M + 1).	794		MS *m/z* 431.24 (M + 1).
224		MS *m/z* 454.2 (M + 1).	795		MS *m/z* 487.23 (M + 1).
225		MS *m/z* 472.2 (M + 1).	796		MS *m/z* 539.1 (M + 1).
226		MS *m/z* 486.2 (M + 1).	797		MS *m/z* 415.1 (M + 1).
227		MS *m/z* 472.2 (M + 1).	798		MS *m/z* 503.2 (M + 1).

228		MS *m/z* 440.2 (M + 1).	799		MS *m/z* 473.2 (M + 1).
229		MS *m/z* 436.2 (M + 1).	800		MS *m/z* 457.1 (M + 1).
230		MS *m/z* 422.2 (M + 1).	801		MS *m/z* 456.12 (M + 1).
231		MS *m/z* 466.2 (M + 1).	802		MS *m/z* 439.2 (M + 1).
232		MS *m/z* 502.3 (M + 1).	803		MS *m/z* 429.1 (M + 1).

233		MS *m/z* 436.2 (M + 1).	804		MS *m/z* 443.1 (M + 1).
234		ESI-MS m/z 480.2 (MH^+).	805		MS *m/z* 457.1 (M + 1).
235		ESI-MS m/z 478.2 (MH^+).	806		MS *m/z* 485.1 (M + 1).
236		ESI-MS m/z 452.2 (MH^+).	807		MS *m/z* 446.2 (M + 1).

237		^{1}H NMR (MeOD-d_4) δ 1.79 (m, 4H), 2.79 (m, 1H), 3.58 (m, 2H), 4.06 (d, J = 10.8 Hz, 2H), 5.55(s, 2H), 6.49 (d, J = 6.8 Hz, 1H), 7.06 (s, 1H), 7.24 (dd, J = 7.2, 11.2 Hz, 4H), 7.37 (dd, J =5.2, 6.8 Hz, 1H), 7.82 (d, J = 8.8 Hz, 2H), 7.84 (dd, J = 1.6, 7.6 Hz, 1H), 1H), 8.13 (s, 1H), 8.37 (s, 1H), 8.55 (d, J =4.8 Hz, 1H), 11.72 (s, 1H); ESI-MS m/z 479.2 (MH^+).	808		MS *m/z* 429.3 (M + 1).
238		ESI-MS m/z 522.2 (MH^+).	809		MS *m/z* 458.1 (M + 1).
239		ESI-MS m/z 528.2 (MH^+).	810		MS *m/z* 488.1 (M + 1).

240		ESI-MS m/z 529.2 (MH^+).	811		MS *m/z* 484.1 (M + 1).
241		ESI-MS m/z 549.2 (MH^+).	812		MS *m/z* 514.2 (M + 1).
242		ESI-MS m/z 563.2 (MH^+).	813		MS *m/z* 484.1 (M + 1).
243		ESI-MS m/z 458.2 (MH^+).	814		MS *m/z* 514.12 (M + 1).
244		ESI-MS m/z 506.2 (MH^+).	815		MS *m/z* 377.11 (M + 1).

245		ESI-MS m/z 504.2 (MH^+).	816		MS *m/z* 392.2 (M + 1).
246		^{1}H NMR (DMSO-d_6) δ 1.19 (t, J = 7.2 Hz, 3H), 3.09 (t, J = 4.8 Hz, 4H), 3.50 (dd, J = 7.2, 14.8 Hz, 2H), 3.76 (t, J = 4.4 Hz, 4H), 6.57 (d, J =7.2 Hz, 1H), 6.98 (d, J = 9.2 Hz, 2H), 7.48 (t, J = 6.8 Hz, 1H), 1H), 7.68 (s, 1H), 7.72 (d, J =8.8 Hz, 2H), 8.88 (t, J = 2.4 Hz, 1H), 9.09 (d, J = 2.0 Hz, 1H), 9.60 (d, J = 2.0 Hz, 1H), 11.82 (s, 1H), 11.87 (bs, 1H); ESI-MS m/z 492.2 (MH^+).	817		MS *m/z* 486.2 (M + 1).
247		ESI-MS m/z 490.2 (MH^+).	818		MS *m/z* 460.3 (M + 1).

248		ESI-MS m/z 568.2 (MH^+).	819		MS *m/z* 438.1 (M + 1).
249		^{1}H NMR (DMSO-d_6) δ 1.21 (t, J = 7.2 Hz, 3H), 2.79 (d, J = 4.8 Hz, 3H), 3.52 (dd, J = 7.2, 14.8 Hz, 2H), 6.64 (d, J =6.8 Hz, 1H), 7.54 (d, J = 6.8 Hz, 1H), 7.85 (s, 1H), 7.92 (dd, J =8.8, 34.0 Hz, 4H), 8.38 (d, J = 4.4 Hz, 1H), 8.92 (t, J = 2.0 Hz, 1H), 9.13 (d, J = 2.0 Hz, 1H), 9.65(d, J = 2.0 Hz, 1H), 12.01 (s, 1H), 12.36 (s, 1H); ESI-MS m/z 464.2 (MH^+).	820		MS *m/z* 500.2 (M + 1).
250		ESI-MS m/z 518.2 (MH^+).	821		MS *m/z* 459.2 (M + 1).

251		ESI-MS m/z 504.2 (MH^+).	822		MS *m/z* 513.1 (M + 1).
252		^{1}H NMR ($CDCl_3$+MeOD-d_4) δ 0.96 (d, J = 6.8 Hz, 6H), 1.90 (m, 4H), 2.24 (m,1H), 2.54 (t, J = 10.4 Hz, H) 2.67 (m, 1H), 3.24 (d, 12.0 Hz, 2H), 4.01 (d, J = 7.2 Hz, 2H), 6.45 (d, J =6.8 Hz, 1H), 6.98 (s, 1H), 7.21 (d, J = 6.8 Hz, 1H), 7.24 (d, J =8.4 Hz, 2H), 7.84 (dd, J = 1.6, 8.4 Hz, 2H), 8.04 (s, 1H), 8.11 (s, 1H), 11.70 (s, 1H); ESI-MS m/z 457.2 (MH^+).	823		MS *m/z* 489.2 (M + 1).
253		ESI-MS m/z 415.2 (MH^+).	824		MS *m/z* 500.1 (M + 1).

254		ESI-MS m/z 429.2 (MH^+).	825		MS *m/z* 500.1 (M + 1).
255		ESI-MS m/z 443.2 (MH^+).	826		MS *m/z* 431.4 (M + 1).
256		ESI-MS m/z 429.2 (MH^+).	827		MS *m/z* 515.1 (M + 1).
257		^{1}H NMR (MeOD-d_4) □ 0.85 (d, J = 6.8 Hz, 6H), 1.68 (m, 2H), 1.72 (d, J = 12.8 Hz, 2H), 2.13 (m, 1H) 2.64 (m, 1H), 2.78 (m, 2H), 3.93 (d, J = 7.2 Hz, 2H), 6.39 (d, J = 6.8 Hz, 1H), 6.94 (s, 1H), 7.16 (dd, J = 4.8, 8.4 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.97 (s, 1H), 8.09 (s, 1H);ESI-MS m/z 443.2 (MH^+).	828		MS *m/z* 517.2 (M + 1).

258		ESI-MS m/z 457.2 (MH^+).	829		MS *m/z* 454.1 (M + 1).
259		ESI-MS m/z 473.2 (MH^+).	830		MS *m/z* 454.1 (M + 1).
260		ESI-MS m/z 500.2 (MH^+).	831		MS *m/z* 440.2 (M + 1).
261		^{1}H NMR (MeOD-d_4) □ 1.87 (m, 2H), 2.01 (d, J = 14.0 Hz, 2H), 2.47 (s, 3H), 2.81 (m, 1H), 3.04 (m,2H), 3.39 (m, 2H), 6.45 (d, J = 6.8 Hz, 1H), 6.90 (s, 1H), 7.19 (dd, J = 4.8, 7.2 Hz, 1H), 7.70 (dd, J = 2.0, 6.4 Hz, 1H), 7.95 (s, 1H);ESI-MS m/z 401.2 (MH^+).	832		MS *m/z* 453.1 (M + 1).

262		^{1}H NMR (MeOD-d_4) □ 1.92 (m, 2H), 2.12 (d, J = 14.0 Hz, 2H), 2.91 (m, 1H), 3.14 (m,2H), 3.50 (m, 2H), 5.07 (s, 2H), 6.51 (d, J = 6.8 Hz, 1H), 7.06 (s, 1H), 7.28 (t, J = 8.4 Hz, 1H), 7.88 (d, J = 8.4 Hz, 1H), 8.14 (s, 1H), 8.27 (s, 1H);ESI-MS m/z 445.2 (MH^+).	833		MS *m/z* 604.1 (M + 1).
263		ESI-MS m/z 415.2 (MH^+).	834		MS *m/z* 577.1 (M + 1).
264		ESI-MS m/z 445.2 (MH^+).	835		MS *m/z* 498.2 (M + 1).
265		ESI-MS m/z 457.2 (MH^+).	836		MS *m/z* 528.1 (M + 1).

266		ESI-MS m/z 472.2 (MH^+).	837		MS *m/z* 498.2 (M + 1).
267		ESI-MS m/z 415.2 (MH^+).	838		MS *m/z* 528.2 (M + 1).
268		ESI-MS m/z 429.2 (MH^+).	839		MS *m/z* 489.2 (M + 1).
269		ESI-MS m/z 479.2 (MH^+).	840		MS *m/z* 472.12 (M + 1).

270		ESI-MS m/z 550.2 (MH^+).	841		MS *m/z* 353.1 (M + 1).
271		ESI-MS m/z 514.2 (MH^+).	842		MS *m/z* 311.2 (M + 1).
272		ESI-MS m/z 380.2 (MH^+).	843		ESI-MS *m/z* 385.1 (MH^+)
273		ESI-MS m/z 434.2 (MH^+).	844		^{1}H NMR (DMSO-d_6) δ 3.09 (t, *J* = 4.8 Hz, 4H), 3.75 (t, *J* = 4.8 Hz, 4H), 4.01 (s, 3H, CH_3), 6.63 (d, *J* = 7.4 Hz, 1H), 6.92 (d, *J* = 7.4 Hz, 1H), 7.01 (d, *J* = 9.0 Hz, 2H), 7.41 (br m, 1H), 7.76 (d, *J* = 9.0 Hz, 2H), 7.79 (s, 1H), 7.88 (dd, *J* = 8.0, 7.2 Hz, 1H), 7.95 (d, *J* = 7.2 Hz, 1H); ESI-MS *m/z* 430.2 (MH^+); Anal. Calcd for $C_{24}H_{23}N_5O_3$: C, 67.12; H, 5.40; N, 16.31. Found: C, 66.85; H, 5.32; N, 16.30.

274		ESI-MS m/z 420.2 (MH^+).	845		ESI-MS *m/z* 473.2 (MH^+)
275		ESI-MS m/z 432.2 (MH^+).	846		ESI-MS *m/z* 458.2 (MH^+)
276		ESI-MS m/z 429.2 (MH^+).	847		ESI-MS *m/z* 471.2 (MH^+)
277		^{1}H NMR (MeOD-d_4) □ 0.96 (d, J = 6.8 Hz, 6H), 1.82 (dd, J = 3.6, 8.4 Hz, 4H), 2.25 (m,1H), 2.81 (m, 1H), 3.60 (m, 2H), 4.02 (d, 7.2 Hz, 2H), 4.09 (dd, J = 3.2, 11.2 Hz, 2H), 6.47 (d, J =7.2 Hz, 1H), 7.00 (s, 1H), 7.22 (d, J = 7.2 Hz, 1H), 7.26 (d, J =8.4 Hz, 2H), 7.84 (dd, J = 1.6, 8.4 Hz, 2H), 8.06 (s, 1H), 8.13 (s, 1H); (ESI-MS m/z 444.2 (MH^+).	848		ESI-MS *m/z* 401.2 (MH^+)

278		ESI-MS m/z 433.2 (MH^+).	849		ESI-MS *m/z* 467.2 (MH^+)
279		ESI-MS m/z 403.2 (MH^+).	850		ESI-MS *m/z* 482.2 (MH^+)
280		ESI-MS m/z 445.2 (MH^+).	851		ESI-MS *m/z* 482.2 (MH^+)
281		^{1}H NMR (MeOD-d_4) □ 1.00 (t, J = 7.6 Hz, 3H), 1.66 (m, 2H), 2.53 (t, J = 4.8 Hz, 4H), 2.86 (t, J = 6.4 Hz, 2H), 3.36 (t, J = 6.8 Hz, 2H), 3.68 (t, J = 4.8 Hz, 4H), 4.37 (t, J =6.4 Hz, 2H), 6.50 (d, J = 7.2 Hz, 1H), 7.10 (s, 1H), 7.25 (d, J = 7.2 Hz, 1H), 7.85 (d, J = 8.8 Hz, 2H), 8.00 (d, J = 8.8 Hz, 2H), 8.07 (s, 1H), 8.27 (s, 1H); ESI-MS m/z 502.2 (MH^+).	852		ESI-MS *m/z* 442.2 (MH^+)

282		ESI-MS m/z 472.2 (MH^+).	853		ESI-MS *m/z* 511.3 (MH^+)
283		ESI-MS m/z 403.2 (MH^+).	854		ESI-MS *m/z* 443.2 (MH^+)
284		ESI-MS m/z 375.2 (MH^+).	855		ESI-MS *m/z* 458.2 (MH^+)
285		^{1}H NMR (MeOD-d_4) □ 0.97 (d, J = 6.8 Hz, 6H), 2.26 (m, 1H(, 4.04 (d, J = 7.2 Hz, 2H), 6.51 (d, J = 7.2 Hz, 1H), 7.12 (s, 1H), 7.29 (d, J = 6.8 Hz, 1H), 7.86 (dd, J = 2.0, 9.2 Hz, 2H), 8.02 (dd, J = 2.0, 6.8 Hz, 2H), 8.09 (s, 1H), 8.22 (s, 1H); ESI-MS m/z 417.2 (MH^+).	856		ESI-MS *m/z* 458.2 (MH^+)

286		^{1}H NMR (MeOD-d_4) □ 2.54 (t, J = 4.4 Hz, 4H), 2.87 (t, J = 6.4 Hz, 2H), 2.94 (s,3H), 3.68 (t, J = 4.4 Hz, 4H), 4.37 (t, J = 6.4 Hz, 2H), 6.49 (d, J = 7.2 Hz, 1H), 7.09 (s, 1H),7.28 (d, J =7.2 Hz, 1H), 7.85 (dd, J = 2.0, 7.2 Hz, 2H), 8.01 (d, J =8.8 Hz, 2H), 8.07 (s, 1H), 8.27 (s, 1H); ESI-MS m/z 474.2 (MH^+).	857		ESI-MS *m/z* 453.2 (MH^+)
287		ESI-MS m/z 444.2 (MH^+).	858		ESI-MS *m/z* 458.2 (MH^+)
288		ESI-MS m/z 486.2 (MH^+).	859		ESI-MS *m/z* 459.2 (MH^+)
289		ESI-MS m/z 500.2 (MH^+).	860		ESI-MS *m/z* 457.2 (MH^+)

290		ESI-MS m/z 500.2 (MH^+).	861		ESI-MS *m/z* 457.2 (MH^+)
291		ESI-MS m/z 526.2 (MH^+).	862		ESI-MS *m/z* 458.2 (MH^+)
292		ESI-MS *m/z* 428.2 (MH^+)	863		ESI-MS *m/z* 443.2 (MH^+)
293		^{1}H NMR (DMSO-d_6) δ 1.60-1.99 (6H), 2.81 (d, *J* = 4.4 Hz, 3 H), 2.93-2.99 (2H), 3.11 (m, 1H), 3.96(s, 3 H), 6.58 (d, *J* = 6.8 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.48 (dd, *J* = 6.8 and 6.0 Hz, 1H), 7.65 (s, 1H), 7.88 (d, *J* = 8.8 Hz, 2H), 8.04 (br, 1H), 8.41 (br, 1H), 8.95 (s, 1H); ESI-MS *m/z* 441.2 (MH^+)	864		ESI-MS *m/z* 430.2 (MH^+)

294		ESI-MS *m/z* 433.1 (MH^+)	865		ESI-MS *m/z* 522.2 (MH^+)
295		ESI-MS *m/z* 506.2 (MH^+)	866		ESI-MS *m/z* 499.2 (MH^+)
296		ESI-MS *m/z* 355.1 (MH^+)	867		ESI-MS *m/z* 483.2 (MH^+)
297		ESI-MS *m/z* 428.2 (MH^+)	868		ESI-MS *m/z* 458.2 (MH^+)
298		ESI-MS *m/z* 419.1 (MH^+)	869		ESI-MS *m/z* 576.2 (MH^+)

299		ESI-MS *m/z* 492.2 (MH^+)	870		ESI-MS *m/z* 560.2 (MH^+)
300		ESI-MS *m/z* 465.2 (MH^+)	871		ESI-MS *m/z* 522.2 (MH^+)
301		ESI-MS *m/z* 463.2 (MH^+)	872		ESI-MS *m/z* 479.1 (MH^+)
302		ESI-MS *m/z* 428.2 (MH^+)	873		ESI-MS *m/z* 493.2 (MH^+)
303		ESI-MS *m/z* 534.2 (MH^+)	874		ESI-MS *m/z* 432.2 (MH^+)

304		^{1}H NMR (DMSO-d_6) δ 1.81-2.04 (4H), 2.19 (s, 3H), 2.81 (m, 1H), 2.96-3.12 (4H), 3.27-3.32 (2H), 3.54-3.60 (2H), 3.96(s, 3 H), 6.56 (d, J = 6.8 Hz, 1H), 7.26 (d, J = 8.8 Hz, 2H), 7.48 (dd, J = 6.8 and 6.4 Hz, 1H), 7.84 (d, J = 8.8 Hz, 2H), 8.05 (br, 1H), 8.41 (br, 1H), 8.94 (br, 1H); ESI-MS m/z 498.2 (MH^+)	875		ESI-MS m/z 432.2 (MH^+)
305		ESI-MS m/z 480.2 (MH^+)	876		ESI-MS m/z 457.2 (MH^+)
306		ESI-MS m/z 528.2 (MH^+)	878		ESI-MS m/z 432.2 (MH^+)
307		ESI-MS m/z 470.3 (MH^+)	879		ESI-MS m/z 433.2 (MH^+)

308		ESI-MS *m/z* 496.3 (MH^+)	880		ESI-MS *m/z* 448.2 (MH^+)
309		ESI-MS *m/z* 499.2 (MH^+)	881		ESI-MS *m/z* 450.2 (MH^+)
310		ESI-MS *m/z* 397.1 (MH^+)	882		ESI-MS *m/z* 540.2 (MH^+)
311		ESI-MS *m/z* 485.3 (MH^+)	883		ESI-MS *m/z* 540.2 (MH^+)
312		ESI-MS *m/z* 454.2 (MH^+)	884		ESI-MS *m/z* 448.2 (MH^+)

313		ESI-MS *m/z* 470.2 (MH^+)	885		ESI-MS *m/z* 449.2 (MH^+)
314		ESI-MS *m/z* 470.2 (MH^+)	886		ESI-MS *m/z* 462.2 (MH^+)
315		ESI-MS *m/z* 470.2 (MH^+)	887		ESI-MS *m/z* 463.2 (MH^+)
316		ESI-MS *m/z* 458.2 (MH^+)	888		ESI-MS *m/z* 446.2 (MH^+)
317		ESI-MS *m/z* 458.2 (MH^+)	889		ESI-MS *m/z* 399.2 (MH^+)

318		^{1}H NMR (DMSO-d_6) δ 1.44 (m, 1H), 1.61 (m, 1H), 1.77-1.85 (2H), 2.04 (s, 3H), 2.59 (m, 1H), 2.77 (m, 1H), 3.14 (m, 1H), 3.92 (m, 1H), 4.53 (m, 1H), 6.56 (d, *J* = 7.2 Hz, 1H), 7.29 (d, *J* = 8.8 Hz, 2H), 7.47 (dd, *J* = 6.8 and 6.0 Hz, 1H), 7.64 (s, 1H), 7.77 (d, *J* = 8.8 Hz, 2H), 8.32 (m, 1H), 8.69 (d, *J* = 2.8 Hz, 1H), 9.20 (m, 1H); ESI-MS *m/z* 458.2 (MH^+)	890		ESI-MS *m/z* 487.2 (MH^+)
319		ESI-MS *m/z* 472.2 (MH^+)	891		ESI-MS *m/z* 458.2 (MH^+)
320		ESI-MS *m/z* 476.2 (MH^+)	892		ESI-MS *m/z* 443.2 (MH^+)
321		ESI-MS *m/z* 472.2 (MH^+)	893		ESI-MS *m/z* 500.3 (MH^+)

322		ESI-MS *m/z* 523.3 (MH^+)	894		ESI-MS *m/z* 485.3 (MH^+)
323		ESI-MS *m/z* 465.2 (MH^+)	895		ESI-MS *m/z* 431.2 (MH^+)
324		ESI-MS *m/z* 465.2 (MH^+)	896		ESI-MS *m/z* 399.2 (MH^+)

325		^{1}H NMR (DMSO-d_6) δ 1.50 (m, 1H), 1.66 (m, 1H), 1.83-1.92 (2H), 2.10 (s, 3H), 2.65 (m, 1H), 2.83 (m, 1H), 2.92 (d, J = 4.8 Hz, 3H), 3.19 (m, 1H), 3.99 (m, 1H), 4.60 (m, 1H), 6.65 (d, J = 7.2 Hz, 1H), 7.33 (d, J = 8.8 Hz, 2H), 7.53 (dd, J = 6.8 and 6.0 Hz, 1H), 7.71 (s, 1H), 7.86 (d, J = 8.8 Hz, 2H), 8.23 (d, J = 8.4 Hz, 1H), 8.70 (d, J = 8.4 Hz, 1H), 8.95 (br, 1H); ESI-MS m/z 497.2 (MH^+)	897		ESI-MS m/z 471.2 (MH^+)
326		ESI-MS m/z 479.2 (MH^+)	898		ESI-MS m/z 472.2 (MH^+)
327		ESI-MS m/z 478.2 (MH^+)	899		ESI-MS m/z 457.2 (MH^+)
328		ESI-MS m/z 478.2 (MH^+)	900		ESI-MS m/z 473.2 (MH^+)

329		ESI-MS *m/z* 479.2 (MH^+)	901		ESI-MS *m/z* 458.2 (MH^+)
330		ESI-MS *m/z* 479.2 (MH^+)	902		ESI-MS *m/z* 443.2 (MH^+)
331		ESI-MS *m/z* 506.2 (MH^+)	903		ESI-MS *m/z* 474.2 (MH^+)
332		ESI-MS *m/z* 520.2 (MH^+)	904		ESI-MS *m/z* 477.2 (MH^+)
333		ESI-MS *m/z* 475.2 (MH^+)	905		ESI-MS *m/z* 447.2 (MH^+)

334		ESI-MS *m/z* 521.2 (MH^+)	906		ESI-MS *m/z* 456.2 (MH^+)
335		ESI-MS *m/z* 505.2 (MH^+)	907		ESI-MS *m/z* 441.2 (MH^+)
336		ESI-MS *m/z* 493.2 (MH^+)	908		ESI-MS *m/z* 470.2 (MH^+)
337		^{1}H NMR (DMSO-d_6) δ 1.60-1.69 (2H), 1.82-1.88 (2H), 2.59 (m, 1H), 2.66 (s, 3H), 2.69 (s, 3H), 2.76-2.83 (2H), 2.89 (s, 3H), 3.60-3.67 (2H), 6.57 (d, *J* = 7.2 Hz, 1H), 7.10 (s, 1H), 7.21 (d, *J* = 8.8 Hz, 2H), 7.48 (dd, *J* = 6.6 and 6.2 Hz, 1H), 7.61 (br, 1H), 7.70 (d, *J* = 8.8 Hz, 2H), 8.25 (br, 1H); ESI-MS *m/z* 504.2 (MH^+)	909		ESI-MS *m/z* 484.2MH^+)

338		ESI-MS *m/z* 508.2 (MH^+)	910		ESI-MS *m/z* 485.2MH^+)
339		^{1}H NMR (DMSO-d_6) δ 1.56-1.65 (2H), 1.79-1.85 (2H), 2.55 (m, 1H), 2.72-2.78 (2H), 2.83 (s, 3H), 3.58-3.63 (2H), 6.56 (d, *J* = 6.8 Hz, 1H), 7.20 (d, *J* = 8.4 Hz, 2H), 7.28 (s, 1H), 7.33 (m, 1H), 7.40 (d, *J* = 6.8 Hz, 1H), 7.69 (d, *J* = 8.4 Hz, 2H), 8.67 (m, 1H); ESI-MS *m/z* 512.1 (MH^+)	911		ESI-MS *m/z* 411.2 (MH^+)
340		ESI-MS *m/z* 477.2 (MH^+)	912		ESI-MS *m/z* 468 (MH^+)
341		ESI-MS *m/z* 507.2 (MH^+)	913		ESI-MS *m/z* 455.2MH^+)

342		^{1}H NMR (DMSO-d_6) δ 1.60-1.70 (2H), 1.83-1.88 (2H), 2.54 (s, 3H), 2.58 (m, 1H), 2.76-2.83 (2H), 2.89 (s, 3H), 3.63-3.67 (2H), 6.58 (d, J = 6.8 Hz, 1H), 7.12 (s, 1H), 7.22 (d, J = 8.8 Hz, 2H), 7.48 (dd, J = 6.8 and 6.0 Hz, 1H), 7.67 (d, J = 5.4 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 8.64 (d, J = 5.4 Hz, 1H), 8.80 (s, 1H); ESI-MS m/z 490.2 (MH^+)	914		ESI-MS m/z 485.2 (MH^+)
343		ESI-MS m/z 575.2 (MH^+)	915		ESI-MS m/z 511.3 (MH^+)
344		ESI-MS m/z 349.1 (MH^+)	916		ESI-MS m/z 588.3 (MH^+)
345		ESI-MS m/z 470.1 (MH^+)	917		ESI-MS m/z 495.3 (MH^+)

346		ESI-MS *m/z* 396.1 (MH^+)	918		ESI-MS *m/z* 572.3 (MH^+)
347		ESI-MS *m/z* 517.1 (MH^+)	919		ESI-MS *m/z* 470.2 (MH^+)
348		ESI-MS *m/z* 338.1 (MH^+)	920		ESI-MS *m/z* 534.2 (MH^+)
349		^{1}H NMR (DMSO-d_6) δ 2.54 (s, 3 H), 6.65 (d, *J* = 6.8 Hz, 1H), 7.53 (dd, *J* = 6.8 and 6.4 Hz, 1H), 7.83 (s, 1H), 7.84 (d, *J* = 8.6 Hz, 2H), 8.03 (d, *J* = 8.6 Hz, 2H), 8.04 (s, 1H), 8.86 (s, 1H), 8.99 (s, 1H), 9.18 (s, 1H), 9.64 (s, 1H); ESI-MS *m/z* 459.1 (MH^+)	921		ESI-MS *m/z* 470.2 (MH^+)

350		ESI-MS *m/z* 339.1 (MH^+)	922		ESI-MS *m/z* 455.2 (MH^+)
351		^{1}H NMR (DMSO-d_6) δ 3.97 (s, 3 H), 6.59 (d, *J* = 6.8 Hz, 1H), 7.49 (dd, *J* = 6.8 and 6.4 Hz, 1H), 7.63 (s, 1H), 7.69 (s, 1H), 7.76 (d, *J* = 8.8 Hz, 2H), 8.02 (d, *J* = 8.8 Hz, 2H), 8.07 (br, 1H), 8.41 (s, 1H), 8.42 (s, 1H), 8.96 (s,1H); ESI-MS *m/z* 412.1 (MH^+)	923		ESI-MS *m/z* 451.2 (MH^+)
352		ESI-MS *m/z* 329.1 (MH^+)	924		ESI-MS *m/z* 451.2 (MH^+)
353		ESI-MS *m/z* 402.2 (MH^+)	925		ESI-MS *m/z* 451.2 (MH^+)
354		ESI-MS *m/z* 438.1 (MH^+)	926		ESI-MS *m/z* 426.2 (MH^+)

355		ESI-MS *m/z* 341.1 (MH^+)	927		ESI-MS *m/z* 444.2 (MH^+)
356		ESI-MS *m/z* 414.2 (MH^+)	928		ESI-MS *m/z* 427.2 (MH^+)
357		ESI-MS *m/z* 341.1 (MH^+)	929		ESI-MS *m/z* 442.2 (MH^+)
358		ESI-MS *m/z* 414.2 (MH^+)	930		ESI-MS *m/z* 383.2 (MH^+)
359		ESI-MS m/z 357.1 (MH^+).	931		ESI-MS *m/z* 442.2 (MH^+)
360		ESI-MS m/z 497.3 (MH^+).	932		ESI-MS *m/z* 440.2 (MH^+)

361		ESI-MS m/z 390.2 (MH^+).	933		ESI-MS *m/z* 456.2 (MH^+)
362		ESI-MS m/z 277.1 (MH^+).	934		ESI-MS *m/z* 427.2 (MH^+)
363		ESI-MS m/z 370.1 (MH^+).	935		ESI-MS *m/z* 413.2 (MH^+)
364		ESI-MS m/z 374.2 (MH^+).	936		ESI-MS *m/z* 443.2 (MH^+)
365		ESI-MS m/z 374.1 (MH^+).	937		ESI-MS *m/z* 457.2 (MH^+)

366		ESI-MS m/z 431.2 (MH^+).	938		ESI-MS *m/z* 443.2 (MH^+)
367		ESI-MS m/z 437.2 (MH^+).	939		ESI-MS *m/z* 457.2 (MH^+)
368		ESI-MS m/z 336.1 (MH^+).	940		ESI-MS *m/z* 509.3 (MH^+)
369		ESI-MS m/z 403.2 (MH^+).	941		ESI-MS *m/z* 411.2 (MH^+)
370		ESI-MS m/z 472.2 (MH^+).	942		ESI-MS *m/z* 455.2 (MH^+)
373		ESI-MS m/z 502.2 (MH^+).	943		ESI-MS *m/z* 387.1 (MH^+)

372		ESI-MS m/z 387.3 (MH^+).	944		ESI-MS *m/z* 431.2 (MH^+)
373		ESI-MS m/z 450.3 (MH^+).	945		ESI-MS *m/z* 461.2 (MH^+)
374		ESI-MS m/z 463.3 (MH^+).	946		ESI-MS *m/z* 475.2 (MH^+)
375		ESI-MS m/z 340.2 (MH^+).	947		ESI-MS *m/z* 370.1 (MH^+)
376		ESI-MS m/z 417.2 (MH^+).	948		ESI-MS *m/z* 444.2 (MH^+)

377		ESI-MS m/z 431.2 (MH^+).	949		ESI-MS *m/z* 414.2 (MH^+)
378		ESI-MS m/z 345.2 (MH^+).	950		ESI-MS *m/z* 401.1 (MH^+)
379		ESI-MS m/z 269.1 (MH^+).	951		ESI-MS *m/z* 445.2 (MH^+)
380		ESI-MS m/z 271.20 (MH^+).	952		ESI-MS *m/z* 475.2 (MH^+)
383		ESI-MS m/z 293.2 (MH^+).	953		ESI-MS *m/z* 480.2 (MH^+)
382		ESI-MS m/z 274.1 (MH^+).	954		ESI-MS *m/z* 497.2 (MH^+)

383		ESI-MS m/z 282.20 (MH^+).	955		ESI-MS *m/z* 494.2 (MH^+)
384		ESI-MS m/z 269.1 (MH^+).	956		ESI-MS *m/z* 494.2 (MH^+)
385		ESI-MS m/z 282.20 (MH^+).	957		ESI-MS *m/z* 481.2 (MH^+)
386		ESI-MS m/z 269.2 (MH^+).	958		ESI-MS *m/z* 478.2 (MH^+)
387		ESI-MS m/z 311.1 (MH^+).	959		ESI-MS *m/z* 409.1 (MH^+)
388		ESI-MS m/z 268.20 (MH+).	960		ESI-MS *m/z* 360.1 (MH^+)

389		ESI-MS m/z 269.1 (MH+).	961		ESI-MS *m/z* 361.1 (MH^+)
390		ESI-MS m/z 435.2 (MH^+).	962		ESI-MS *m/z* 375.1 (MH^+)
393		ESI-MS m/z 527.1 (MH^+).	963		ESI-MS *m/z* 438.2 (MH^+)
392		ESI-MS m/z 427.2 (MH^+).	964		ESI-MS *m/z* 454.2 (MH^+)
393		ESI-MS m/z 461.2 (MH^+).	965		ESI-MS *m/z* 531.2 (MH^+)
394		ESI-MS m/z 435.2 (MH^+).	966		ESI-MS *m/z* 515.2 (MH^+)

395		ESI-MS m/z 462.2 (MH^+).	967		ESI-MS *m/z* 413.2 (MH^+)
396		ESI-MS m/z 469.2 (MH^+).	968		ESI-MS *m/z* 413.2 (MH^+)
397		ESI-MS m/z 561.1 (MH^+).	969		ESI-MS *m/z* 412.2 (MH^+)
398		ESI-MS m/z 513.1 (MH^+).	970		ESI-MS *m/z* 412.2 (MH^+)
399		ESI-MS m/z 449.3 (MH^+).	971		ESI-MS *m/z* 438.2 (MH^+)

400		ESI-MS m/z 460.2 (MH^+).	972		ESI-MS *m/z* 534.2 (MH^+)
401		ESI-MS m/z 514.3 (MH^+).	973		ESI-MS *m/z* 531.2 (MH^+)
402		ESI-MS m/z 541.3 (MH^+).	974		ESI-MS *m/z* 515.2 (MH^+)
403		ESI-MS m/z 554.3 (MH^+).	975		ESI-MS *m/z* 413.2 (MH^+)
404		ESI-MS m/z 592.3 (MH+).	976		ESI-MS *m/z* 412.2 (MH^+)
405		ESI-MS m/z 579.3 (MH+).	978		ESI-MS *m/z* 240.1 (MH^+)

406		ESI-MS m/z 554.3 (MH+).	979		ESI-MS *m/z* 255.1 (MH^+)
407		ESI-MS m/z 545.3 (MH+).	980		ESI-MS *m/z* 441.2 (MH^+)
408		ESI-MS m/z 579.3 (MH+).	981		ESI-MS m/z 445.2 (MH^+).
409		ESI-MS m/z 568.3 (MH+).	982		ESI-MS m/z 526.2 (MH^+).
410		ESI-MS m/z 541.30 (MH+).	983		

411		ESI-MS m/z 511.30 (MH+).	984		ESI-MS m/z 477.2 (MH^+).
412		ESI-MS m/z 498.3 (MH+).	985		ESI-MS m/z 479.2 (MH^+).
413		ESI-MS m/z 525.3 (MH+).	986		ESI-MS m/z 491.2 (MH^+).
414		ESI-MS m/z 538.3 (MH+).	987		ESI-MS m/z 505.2 (MH^+).

415		ESI-MS m/z 576.3 (MH+).	988		ESI-MS m/z 521.2 (MH^+).
416		ESI-MS m/z 562.3 (MH+).	989		ESI-MS m/z 519.2 (MH^+).
417		ESI-MS m/z 537.3 (MH+).	990		ESI-MS m/z 451.2 (MH^+).
418		ESI-MS m/z 528.3 (MH+).	991		ESI-MS m/z 428.2 (MH^+).

419		ESI-MS m/z 524.3 (MH+).	992		ESI-MS m/z 447.2 (MH^+).
420		ESI-MS m/z 562.3 (MH+).	993		ESI-MS m/z 442.2 (MH^+).
421		ESI-MS m/z 494.3 (MH+).	994		^{1}H NMR (MeOD-d_4) δ 2.70 (s, 3H), 3.04 (t, J = 4.8 Hz, 4H),3.41 (s, 3H), 3.72 (t, J = 4.8 Hz, 4H), 6.52 (d, J = 7.2 Hz, 1H), 6.91 (d, J = 8.8 Hz, 2H), 7.01 (s, 1H), 7.47 (d, J = 6.8 Hz, 1H), 7.60 (d, J= 8.8 Hz, 1H), 8.87 (s, 1H), 9.04 (s, 1H), 11.86 (bs, 1H), 11.90 (s, 1H); ESI-MS m/z 492.2 (MH^+).
424		ESI-MS m/z 433.1 (MH+).	995		ESI-MS m/z 490.2 (MH^+).

423		ESI-MS m/z 467.2 (MH+).	996		ESI-MS m/z 504.2 (MH^+).
424		ESI-MS m/z 456.2 (MH+).	997		ESI-MS m/z 479.2 (MH^+).
425		ESI-MS m/z 467.2 (MH+).	998		ESI-MS m/z 491.2 (MH^+).
426		ESI-MS m/z 442.2 (MH+).	999		ESI-MS m/z 468.2 (MH^+).
427		ESI-MS m/z 446.2 (MH+).	1000		ESI-MS m/z 466.2 (MH^+).

428		ESI-MS m/z 443.2 (MH+).	1001		ESI-MS m/z 480.2 (MH^+).
429		ESI-MS m/z 403.2 (MH+).	1002		ESI-MS m/z 430.2 (MH^+).
430		ESI-MS m/z 430.2 (MH+).	1003		^{1}H NMR (MeOD-d_4) δ 3.28 (bs, 4H), 3.86 (s, 4H), 6.55 (dd, J = 1.2, 7.2 Hz, 1H), 7.23 (bs, 2H), 7.36 (dd, J = 2.8, 8.4 Hz, 1H), 7.45 (dd, J= 6.0, 6.8 Hz, 1H), 7.54 (s, 1H), 7.81 (d, J = 8.8 Hz, 2H), 8.64 (dt, J = 2.4, 8.4 Hz, 1H), 8.96 (d, J = 2.8 Hz, 1H), 11.85 (d, J = 5.6 Hz, 1H), 11.94 (s, 1H); ESI-MS m/z 418.2 (MH^+).
431		ESI-MS m/z 467.1 (MH+).	1004		ESI-MS m/z 416.2 (MH^+).

432		ESI-MS m/z 481.2 (MH+).	1005		ESI-MS m/z 430.2 (MH^+).
433		ESI-MS m/z 427.2 (MH+).	1006		ESI-MS m/z 390.2 (MH^+).
434		ESI-MS m/z 433.2 (MH+).	1007		ESI-MS m/z 429.2 (MH^+).
435		ESI-MS m/z 399.2 (MH+).	1008		ESI-MS m/z 427.2 (MH^+).

436		ESI-MS m/z 482.2 (MH+).	1009		^{1}H NMR (MeOD-d_4) δ 1.40 (t, 3H), 3.50 (q, 2H), 3.69 (bs, 4H), 4.12 (bs, 4H), 6.60 (d, J = 6.4 Hz, 1H), 7.16 (d, J= 8.8 Hz, 1H), 7.38 (d, J = 6.4 Hz, 2H), 7.70 (bs, 1H), 8.03 (bs, 2H), 8.57 (d, J = 9.6 Hz, 1H), 8.60 (s, 1H); ESI-MS m/z 443.2 (MH^+).
437		ESI-MS m/z 442.1 (MH+).	1010		ESI-MS m/z 507.2 (MH^+).
438		ESI-MS m/z 483.2 (MH+).	1011		ESI-MS m/z 430.2 (MH^+).
439		ESI-MS m/z 476.1 (MH+).	1012		ESI-MS m/z 415.2 (MH^+).

440		ESI-MS m/z 399.2 (MH+).	1013		ESI-MS m/z 440.2 (MH^+).
441		ESI-MS m/z 445.2 (MH+).	1014		ESI-MS m/z 427.2 (MH^+).
442		ESI-MS m/z 420.1 (MH+).	1015		ESI-MS m/z 452.2 (MH^+).
443		ESI-MS m/z 447.2 (MH+).	1016		ESI-MS m/z 434.2 (MH^+).
444		ESI-MS m/z 530.2 (MH+).	1017		ESI-MS m/z 446.2 (MH^+).

445		ESI-MS m/z 462.2 (MH+).	1018		ESI-MS m/z 457.2 (MH^+).
446		ESI-MS m/z 420.1 (MH+).	1019		ESI-MS m/z 403.2 (MH^+).
447		ESI-MS m/z 406.2 (MH+).	1020		ESI-MS m/z 429.2 (MH^+).
448		ESI-MS m/z 449.2 (MH+).	1021		^{1}H NMR (MeOD-d_4) δ 3.64 (bs, 4H), 4.09 (t, J = 4.4 Hz, 4H), 4.16 (s, 3H), 6.69 (d, J = 7.2 Hz, 1H), 7.51 (d, J = 6.8 Hz, 2H), 7.70 (s, 1H), 7.94 (d, J = 8.0 Hz, 2H), 8.28 (s, 1H); ESI-MS m/z 446.2 (MH^+).

449		ESI-MS m/z 549.2 (MH+).	1022		ESI-MS m/z 415.2 (MH^+).
450		ESI-MS m/z 478.1 (MH+).	1023		ESI-MS m/z 433.2 (MH^+).
451		ESI-MS m/z 498.1 (MH+).	1024		ESI-MS m/z 444.2 (MH^+).
452		ESI-MS m/z 434.2 (MH+).	1025		ESI-MS m/z 430.2 (MH^+).
453		ESI-MS m/z 421.1 (MH+).	1026		ESI-MS m/z 468.2 (MH^+).

454		ESI-MS m/z 482.2 (MH+).	1027		ESI-MS m/z 444.2 (MH^+).
455		ESI-MS m/z 448.2 (MH+).	1028		ESI-MS m/z 440.2 (MH^+).
456		ESI-MS m/z 478.2 (MH+).	1029		^{1}H NMR (DMSO-d_6) δ 1.13 (d, J = 6.4 Hz, 3H), 2.43 (t, J = 10.8 Hz, 1H), 2.74 (t, J = 9.6 Hz, 1H), 3.19 (dd, J = 11.2, 24.0 Hz, 2H), 3.70 (m, 2H), 3.87 (d, J= 10.4 Hz, 1H), 6.53 (d, J = 6.8 Hz, 1H), 7.06 (t, J = 9.2 Hz, 1H), 7.38 (t, J = 7.6 Hz, 2H), 7.45 (d, J = 6.4 Hz, 1H), 7.53 (s, 1H), 8.61 (t, J = 7.2 Hz, 1H), 8.94 (s, 1H), 11.85 (bs, 1H), 12.02 (s, 1H); ESI-MS m/z 450.2 (MH^+).
457		ESI-MS m/z 389.1 (MH+).	1030		ESI-MS m/z 461.2 (MH^+).

458		ESI-MS m/z 435.1 (MH+).	1031		ESI-MS m/z 475.2 (MH^+).
459		ESI-MS m/z 530.2 (MH+).	1032		ESI-MS m/z 373.2 (MH^+).
460		ESI-MS m/z 462.2 (MH+).	1033		ESI-MS m/z 384.2 (MH^+).
461		ESI-MS m/z 531.3 (MH+).	1034		ESI-MS m/z 398.2 (MH^+).

462		ESI-MS m/z 448.2 (MH+).	1035		^{1}H NMR (MeOD-d_4) δ 3.08 (s, 6H), 3.64 (t, J = 6.4 Hz, 2H), 3.74 (t, J = 5.2 Hz, 4H), 4.16 (t, J = 4.8 Hz, 4H), 4.49 (t, J = 6.0 Hz, 2H), 6.74 (d, J= 7.2 Hz, 1H), 7.50 (s, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 9.2 Hz, 2H), 8.08 (d, J = 8.8 Hz, 2H), 9.26 (s, 2H); ESI-MS m/z 487.2 (MH^+).
463		ESI-MS m/z 515.3 (MH+).	1036		ESI-MS m/z 432.2 (MH^+).
464		ESI-MS m/z 489.2 (MH+).	1037		ESI-MS m/z 429.2 (MH^+).
465		ESI-MS m/z 505.2 (MH+).	1038		ESI-MS m/z 444.2 (MH^+).

466		ESI-MS m/z 434.2 (MH+).	1039		^{1}H NMR (DMSO-d_6) δ 3.09 (t, J = 4.8 Hz, 4H), 3.27 (s, 3H), 3.65 (t, J = 5.2 Hz, 2H), 3.75 (t, J = 4.8 Hz, 4H), 4.15 (t, J = 5.2 Hz, 2H), 6.49 (d, J= 7.2 Hz, 1H), 7.00 (d, J = 9.2 Hz, 2H), 7.08 (s, 1H), 7.29 (s, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.69 (d, J = 9.2 Hz, 1H), 8.95 (s, 2H), 11.76 (s, 1H); ESI-MS m/z 474.2 (MH^+).
467		ESI-MS m/z 462.2 (MH+).	1040		ESI-MS m/z 501.2 (MH^+).
468		ESI-MS m/z 435.2 (MH+).	1041		ESI-MS m/z 458.2 (MH^+).

469		ESI-MS m/z 448.2 (MH+).	1042		ESI-MS m/z 486.2 (MH^+).
470		ESI-MS m/z 432.2 (MH+).	1043		ESI-MS m/z 443.2 (MH^+).
471		ESI-MS m/z 420.2 (MH+).	1044		ESI-MS m/z 470.2 (MH^+).
472		ESI-MS m/z 392.1 (MH+).	1045		ESI-MS m/z 526.2 (MH^+).

473		ESI-MS m/z 419.1 (MH+).	1046		ESI-MS m/z 500.2 (MH^+).
474		ESI-MS m/z 419.1 (MH+).	1047		ESI-MS m/z 429.2 (MH^+).
475		ESI-MS m/z 462.2 (MH+).	1048		ESI-MS m/z 457.2 (MH^+).
476		ESI-MS m/z 448.2 (MH+).	1049		ESI-MS m/z 443.2 (MH^+).

478		ESI-MS m/z 462.2 (MH+).	1050		ESI-MS m/z 419.2 (MH^+).
479		ESI-MS m/z 435.2 (MH+).	1051		ESI-MS m/z 457.2 (MH^+).
480		ESI-MS m/z 420.1 (MH+).	1052		ESI-MS m/z 430.2 (MH^+).
481		ESI-MS m/z 389.2 (MH+).	1053		ESI-MS m/z 458.2 (MH^+).

482		ESI-MS m/z 403.2 (MH+).	1054		ESI-MS m/z 541.2 (MH^+).
483		ESI-MS m/z 402.2 (MH+).	1055		^{1}H NMR (DMSO-d_6) δ 1.59 (m, 2H), 1.98 (m, 2H), 2.88 (d, J = 4.8 Hz, 3H), 3.49 (m, 2H), 3.87 (m, 2H), 4.55 (m, 1H), 6.45 (d, J = 7.2 Hz, 1H), 7.03 (d, J = 8.8 Hz, 2H), 7.31 (s, 1H), 7.37 (d, J = 6.8 Hz, 1H), 7.55 (d, J = 4.9 Hz, 1H), 7.71 (d, J = 8.8 Hz, 2H), 9.00 (bs, 2H), 11.66 (bs, 1H), 11.81 (s, 1H); ESI-MS m/z 458.2 (MH^+).
484		ESI-MS m/z 403.2 (MH+).	1056		ESI-MS m/z 472.2 (MH^+).
485		ESI-MS m/z 433.2 (MH+).	1057		ESI-MS m/z 445.2 (MH^+).

486		ESI-MS m/z 445.2 (MH+).	1058		ESI-MS m/z 540.2 (MH^+).
487		ESI-MS m/z 475.2 (MH+).	1059		ESI-MS m/z 460.2 (MH^+).
488		ESI-MS m/z 402.2 (MH+).	1060		ESI-MS m/z 488.2 (MH^+).
489		ESI-MS m/z 415.2 (MH+).	1061		ESI-MS m/z 474.2 (MH^+).

490		ESI-MS m/z 431.2 (MH+).	1062		^{1}H NMR (DMSO-d_6) δ 1.35 (m, 2H), 1.71 (d, J = 12.0 Hz, 2H), 1.92 (t, J = 12.0 Hz, 2H), 2.00 (m, 1H), 2.15 (s, 6H), 2.49 (m, 2H), 2.71 (t, J= 7.2 Hz, 2H), 2.96 (d, J = 11.6 Hz, 2H), 6.49 (d, J = 6,4 Hz, 1H), 7.23 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 6.8 Hz, 1H), 7.58 (s, 1H), 7.75 (d, J = 8.4 Hz, 2H), 9.27 (s, 1H), 9.45 (s, 2H), 12.44 (s, 1H); ESI-MS m/z 470.2 (MH^+).
491		ESI-MS m/z 493.2 (MH+).	1063		ESI-MS m/z 443.2 (MH^+).
492		ESI-MS m/z 445.2 (MH+).	1064		ESI-MS m/z 486.2 (MH^+).

493		ESI-MS m/z 479.2 (MH+).	1065		ESI-MS m/z 429.2 (MH^+).
494		ESI-MS m/z 431.2 (MH+).	1066		ESI-MS m/z 416.2 (MH^+).
495		ESI-MS m/z 457.3 (MH+).	1067		ESI-MS m/z 461.2 (MH^+).
496		ESI-MS m/z 415.2 (MH+).	1068		ESI-MS m/z 411.2 (MH^+).
497		ESI-MS m/z 398.2 (MH+).	1069		ESI-MS m/z 491.2 (MH^+).

498		ESI-MS m/z 400.2 (MH+).	1070		ESI-MS m/z 465.2 (MH^+).
499		ESI-MS m/z 412.2 (MH+).	1071		ESI-MS m/z 479.2 (MH^+).
500		ESI-MS m/z 412.2 (MH+).	1072		ESI-MS m/z 429.2 (MH^+).
501		ESI-MS m/z 412.2 (MH+).	1073		ESI-MS m/z 512.2 (MH^+).

502		ESI-MS m/z 429.2 (MH+).	1074		ESI-MS m/z 443.2 (MH^+).
503		ESI-MS m/z 442.2 (MH+).	1075		ESI-MS m/z 443.2 (MH^+).
504		ESI-MS m/z 429.2 (MH+).	1076		ESI-MS m/z 495.2 (MH^+).
505		ESI-MS m/z 415.2 (MH+).	1077		ESI-MS m/z 509.2 (MH^+).

506		ESI-MS m/z 412.2 (MH+).	1078		ESI-MS m/z 472.2 (MH^+).
507		ESI-MS m/z 426.2 (MH+).	1079		ESI-MS m/z 499.2 (MH^+).
508		ESI-MS m/z 454.2 (MH+).	1080		ESI-MS m/z 472.2 (MH^+).
509		ESI-MS m/z 472.2 (MH+).	1081		ESI-MS m/z 415.2 (MH^+).

510		ESI-MS m/z 522.3 (MH+).	1082		ESI-MS m/z 525.2 (MH^+).
511		ESI-MS m/z 486.2 (MH+).	1083		ESI-MS m/z 488.2 (MH^+).
512		ESI-MS m/z 400.2 (MH+).	1084		ESI-MS m/z 474.2 (MH^+).
513		ESI-MS m/z 508.2 (MH+).	1085		ESI-MS m/z 524.2 (MH^+).

514		ESI-MS m/z 525.6 (MH+).	1086		ESI-MS m/z 538.2 (MH^+).
515		ESI-MS m/z 456.2 (MH+).	1087		ESI-MS m/z 474.2 (MH^+).
516		ESI-MS m/z 524.2 (MH+).	1088		ESI-MS m/z 415.2 (MH^+).
517		ESI-MS m/z 442.2 (MH+).	1089		ESI-MS m/z 488.2 (MH^+).

518		ESI-MS m/z 456.2 (MH+).	1090		ESI-MS m/z 524.2 (MH^+).
519		ESI-MS m/z 499.3 (MH+).	1091		ESI-MS m/z 554.2 (MH^+).
520		ESI-MS m/z 509.3 (MH+).	1092		ESI-MS m/z 423.2 (MH^+).
521		ESI-MS m/z 490.2 (MH+).	1093		ESI-MS m/z 403.2 (MH^+).
522		ESI-MS m/z 456.2 (MH+).	1094		ESI-MS m/z 503.2 (MH^+).

523		ESI-MS m/z 454.3 (MH+).	1095		ESI-MS m/z 474.2 (MH^+).
524		ESI-MS m/z 494.2 (MH+).	1096		ESI-MS m/z 458.2 (MH^+).
525		ESI-MS m/z 414.2 (MH+).	1097		ESI-MS m/z 478.2 (MH^+).
526		ESI-MS m/z 504.2 (MH+).	1098		ESI-MS m/z 320.2 (MH^+).
527		ESI-MS m/z 443.2 (MH+).	1099		ESI-MS m/z 335.2 (MH^+).

528		ESI-MS m/z 443.2 (MH+).	1100		^{1}H NMR (DMSO-d_6) δ 3.87 (s, 3H), 4.02 (s, 3H), 6.44 (d, J = 6.8 Hz, 1H), 7.36 (s, 1H), 7.45 (d, J = 6.8 Hz, 2H), 7.68 (s, 1H), 8.14 (s, 1H), 9.26 (s, 2H), 11.85 (s, 1H); ESI-MS m/z 350.2 (MH^+).
529		ESI-MS m/z 487.2 (MH+).	1101		ESI-MS m/z 524.2 (MH^+).
530		ESI-MS m/z 457.2 (MH+).	1102		ESI-MS m/z 539.2 (MH^+).
531		ESI-MS m/z 457.2 (MH+).	1103		ESI-MS m/z 538.2 (MH^+).

532		ESI-MS m/z 429.2 (MH+).	1104		ESI-MS m/z 537.2 (MH^+).
533		ESI-MS m/z 312.0 (MH+).	1105		ESI-MS m/z 471.2 (MH^+).
534		ESI-MS m/z 346.0 (MH+).	1106		ESI-MS m/z 389.2 (MH^+).
535		ESI-MS m/z 490.2 (MH+).	1107		ESI-MS m/z 335.2 (MH^+).

536		ESI-MS m/z 519.2 (MH+).	1108		ESI-MS m/z 524.2 (MH^+).
537		ESI-MS m/z 519.2 (MH+).	1109		ESI-MS m/z 471.2 (MH^+).
538		ESI-MS m/z 519.2 (MH+).	11110		ESI-MS m/z 471.2 (MH^+).
539		ESI-MS m/z 519.2 (MH+).	1111		ESI-MS m/z 501.2 (MH^+).

540		ESI-MS m/z 365.2 (MH+).	1112		ESI-MS m/z 419.2 (MH^+).
541		ESI-MS m/z 394.2 (MH+).	1113		ESI-MS m/z 405.2 (MH^+).
542		MS *m/z* 545.2 (M + 1).	1114		ESI-MS m/z 538.2 (MH^+).
543		MS *m/z* 531.2 (M + 1).	1115		^{1}H NMR (DMSO-d_6) δ 2.45 (bs, 4H), 2.62 (t, J = 6.0 Hz, 2H), 3.55(t, J = 4.4 Hz, 4H), 3.86 (s, 3H), 4.08 (t, J = 6.4 Hz, 2H), 6.50 (d, J = 7.2 Hz, 1H), 7.09 (s, 2H), 7.24 (s, 1H), 7.64 (d, J = 7.2 Hz, 1H), 7.72 (s, 1H), 8.14 (s, 1H), 8.96 (s, 2H), 11.57 (s, 1H); ESI-MS m/z 448.2 (MH^+).

544		MS *m/z* 341.1 (M + 1).	1116		^{1}H NMR (DMSO-d_6) δ 0.88 (d, J = 6.4 Hz, 4H), 2.17 (m, 1H), 2.44 (s, 3H), 2.51 (m, 3H), 3.12 (bs, 2H), 3.36 (d, J= 11.6 Hz, 2H), 3.65 (t, J = 6.4 Hz, 2H), 3.88 (m, 4H), 4.01 (d, J = 7.2 Hz, 2H), 4.72 (t, J = 6.8 Hz, 2H), 6.44 (d, J = 7.2 Hz, 1H), 7.15 (s, 1H), 7.37 (m, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.81 (m, 3H), 8.06 (s, 1H), 8.12 (s, 1H), 8.31 (s, 1H), 11.70 (d, J = 5.6 Hz, 1H), 11.82 (bs, 1H), 12.02 (s, 1H); ESI-MS m/z 553.2 (MH^+).
545		MS *m/z* 391.1 (M + 1).	1117		ESI-MS m/z 466.2 (MH^+).

546		MS *m/z* 337.2 (M + 1).	1118		^{1}H NMR (DMSO-d_6) δ 3.53 (s, 3H), 3.81 (s, 3H), 6.53 (d, J = 7.2 Hz, 1H), 6.61 (dd, J = 1.6, 8.0 Hz, 1H), 7.14 (s, 2H), 7.15 (s, 1H), 7.27 (t, J = 8.0 Hz, 1H), 7.37 (s, 1H), 7.70 (d, J = 7.2 Hz, 1H), 7.84 (t, J = 2.0 Hz, 1H), 8.99 (s, 2H), 12.12 (s, 1H); ESI-MS m/z 375.2 (MH^+).
547		MS *m/z* 355.2 (M + 1).	1119		ESI-MS m/z 448.2 (MH^+).
548		MS *m/z* 460.2 (M + 1).	1120		ESI-MS m/z 449.2 (MH^+).
549		MS *m/z* 443.2 (M + 1).	1121		ESI-MS m/z 462.2 (MH^+).

550		MS *m/z* 553.2 (M + 1).	1122		ESI-MS m/z 447.2 (MH^+).
551		MS *m/z* 488.2 (M + 1).	1123		ESI-MS m/z 494.2 (MH^+).
552		MS *m/z* 507.2 (M + 1).	1124		ESI-MS m/z 349.2 (MH^+).
553		MS *m/z* 443.2 (M + 1).	1125		ESI-MS m/z 405.2 (MH^+).
554		MS *m/z* 442.2 (M + 1).	1126		ESI-MS m/z 435.2 (MH^+).

555		MS *m/z* 459.2 (M + 1).	1127		ESI-MS m/z 428.2 (MH^+).
556		MS *m/z* 367.2 (M + 1).	1128		ESI-MS m/z 473.2 (MH^+).
557		MS *m/z* 433.2 (M + 1).	1129		ESI-MS m/z 503.2 (MH^+).
558		MS *m/z* 416.2 (M + 1).	1130		ESI-MS m/z 440.2 (MH^+).

559		MS *m/z* 430.2 (M + 1).	1131		ESI-MS m/z 470.2 (MH^+).
560		MS *m/z* 443.2 (M + 1).	1132		ESI-MS m/z 419.2 (MH^+).
561		MS *m/z* 431.2 (M + 1).	1133		ESI-MS m/z 449.2 (MH^+).
562		MS *m/z* 442.2 (M + 1).	1134		ESI-MS m/z 449.2 (MH^+).
563		MS *m/z* 429.2 (M + 1).	1135		ESI-MS m/z 430.2 (MH^+).

564		MS *m/z* 390.2 (M + 1).	1136		ESI-MS m/z 396.2 (MH^+).
565		MS *m/z* 369.1 (M + 1).	1137		ESI-MS m/z 426.2 (MH^+).
566		MS *m/z* 474.2 (M + 1).	1138		ESI-MS m/z 455.2 (MH^+).
567		MS *m/z* 489.2 (M + 1).	1139		ESI-MS m/z 462.2 (MH^+).
568		MS *m/z* 386.1 (M + 1).			

Assays

[000277] Compounds of the present invention are assayed to measure their capacity to inhibit a kinase panel, including but not limited to Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-1R, Alk and c-FMS kinases.

Inhibition of cellular Syk, Zap70 and KDR dependent proliferation

[000278] Compounds of the present invention are assayed to measure their capacity to selectively inhibit cell proliferation of Ba/F3 cells expressing activated Syk, Zap70 and KDR through fusion to the dimerization domain of Tel (ETV6) transcription factor compared with parental BaF3 cells.

Luciferase expressing Ba/F3 murine pro-B cells are transformed with Tel-Syk, Tel-Zap70 or Tel-KDR. Cells are maintained in RPMI/10% fetal calf serum (RPMI/FCS) supplemented with penicillin 50 μg/mL, streptomycin 50 μg/mL and L-glutamine 200 mM. Untransformed Ba/F3 cells are similarly maintained with the addition of murine recombinant IL3. Cells are dispensed into 384-well format plate at 5000 cell/well in 50 μL of culture medium. Compounds of the invention are dissolved and diluted in dimethylsufoxide (DMSO). Twelve points 1:3 serial dilutions are made into DMSO to create concentrations gradient ranging from 10 mM to 0.05 μM. Cells are added with 50 nL of diluted compounds and incubated for 48 hours in cell culture incubator. Luminiscent signal is measured following the addition of Bright glo® (Promega) luciferase substrate. IC_{50} values are calculated by linear regression analysis of the percentage inhibition of each compound at 12 concentrations.

Inhibition of enzymatic Syk and Zap70 kinase activity

[000279] Purified recombinant hSyk (full length) and Zap70 (kinase domain) diluted in assay buffer are dispensed in 384 well proxi-plates. Compounds of the invention are dissolved and diluted in dimethylsufoxide (DMSO). Twelve points 1:3 serial dilutions are made into DMSO to create concentrations gradient ranging from 10 mM to 0.05 μM. 50 nL of diluted compounds are added to the enzyme solutions and incubated for 30 min at room temperature, after which ATP and biotynilated peptide substrate are added. Substrate phosphorylation is a function of the HTRF signal measured following the addition of Cisbio-HTRF reagents. IC_{50} values are calculated by linear regression analysis of the percentage inhibition of each compound at 12 concentrations

Inhibition of cellular TrkA, TrkB or TrkC dependent proliferation

[000280] The cell line used is the Ba/F3 murine hematopoietic progenitor cell line transformed with human Tel-TrkA, Tel-TrkB or Tel-TrkC cDNAs (Ba/F3 EN A/B/C). These cells are maintained in RPMI/10% fetal bovine serum (RPMI/F B S) supplemented with penicillin 50 mg/mL, streptomycin 50 mg/mL and L-glutamine 200 mM. Untransformed Ba/F3 cells are similarly maintained with the addition 5 ng/ml of murine recombinant IL3.

[000281] 50 μl of a Ba/F3 or Ba/F3 EN A/B/C cell suspension are plated in Greiner 384 well

microplates (white) at a density of 2000 cells per well. 50nl of serially diluted test compound (1 0-0.0001 mM in DMSO solution) is added to each well. The cells are incubated for 48 hours at 37 °C, 5% CO2. 25µl of Bright glow is added to each well. The emited luminiscence is quantified using the ACQUEST™ luminescence system (Molecular Devices).

Effect on proliferation of various kinases dependent cells

[000282] Compounds of the invention are tested for their antiproliferative effect on Ba/F3 cells expressing either Tel-TrkA, Tel-TrkB or Tel-TrkC and an additional panel of 34 selected diverse kinases activated by fusion to the dimerizing partners Bcr or Tel (Abl, AlK, BMX, EphA3, EphB2, FGFR2, FGFR3, FGFR4, FGR, FLT1, FLT3, FLT4, FMS, IGF1R, InsR, JAK1, JAK2, JAK3, KDR, Kit, Lck, Lyn, MER, MET, PDGFRb, RET, RON, Ros-1, Src, Syk, TIE2, TYK2, Tie1, ZAP70) . The antiproliferative effect of these compounds on the different cell lines and on the non transformed cells were tested at 12 different concentrations of 3-fold serially diluted compounds in 384 well plates as described above (in media lacking IL3). The IC50 values of the compounds the different cell lines were determined from the dose response curves obtained as describe above.

FLT-3 (Enzymatic Assay)

[000283] Kinase activity assay with purified FLT-3 (Upstate) is carried out in a final volume of 10 µL containing 0.25 µg/mL of enzyme in kinase buffer (30 mM Tris-HCl pH7.5, 15 mM $MgCl_2$, 4.5 mM $MnCl_2$, 15 µM Na_3VO_4 and 50 µg/mL BSA), and substrates (5 µg/mL biotin-poly-EY(Glu, Tyr) (CIS-US, Inc.) and 3µM ATP). Two solutions are made: the first solution of 5 µl contains the FLT-3 enzyme in kinase buffer was first dispensed into 384-well format ProxiPlate® (Perkin-Elmer) followed by adding 50 nL of compounds dissolved in DMSO, then 5 µl of second solution contains the substrate (poly-EY) and ATP in kinase buffer was added to each wells. The reactions are incubated at room temperature for one hour, stopped by adding 10 µL of HTRF detection mixture, which contains 30 mM Tris-HCl pH 7.5, 0.5 M KF, 50 mM ETDA, 0.2 mg/mL BSA, 15 µg/mL streptavidin-XL665 (CIS-US, Inc.) and 150 ng/mL cryptate conjugated anti-phosphotyrosine antibody (CIS-US, Inc.). After one hour of room temperature incubation to allow for streptavidin-biotin interaction, time resolved florescent signals are read on Analyst GT (Molecular Devices Corp.). IC_{50} values are calculated by linear regression analysis of the percentage inhibition of each compound at 12 concentrations (1:3 dilution from 50 µM to 0.28 nM). In this assay, compounds of the invention have an IC_{50} in the range of 10 nM to 2 µM.

FLT-3 (Cellular Assay)

[000284] Compounds of the invention are tested for their ability to inhibit transformed Ba/F3-FLT3- ITD cell proliferation, which is depended on FLT-3 cellular kinase activity. Ba/F3-FLT3- ITD are cultured up to 800,000 cells/mL in suspension, with RPMI 1640 supplemented with 10% fetal bovine serum as the

culture medium. Cells are dispensed into 384-well format plate at 5000 cell/well in 50 μL culture medium. Compounds of the invention are dissolved and diluted in dimethylsulfoxide (DMSO). Twelve points 1:3 serial dilutions are made into DMSO to create concentrations gradient ranging typically from 10 mM to 0.05 μM. Cells are added with 50 nL of diluted compounds and incubated for 48 hours in cell culture incubator. AlamarBlue® (TREK Diagnostic Systems), which can be used to monitor the reducing environment created by proliferating cells, are added to cells at final concentration of 10%. After additional four hours of incubation in a 37 °C cell culture incubator, fluorescence signals from reduced AlamarBlue® (Excitation at 530 nm, Emission at 580 nm) are quantified on Analyst GT (Molecular Devices Corp.). IC_{50} values are calculated by linear regression analysis of the percentage inhibition of each compound at 12 concentrations

c-Kit – Proliferation Assay

[000285] Compounds were tested for their ability to inhibit the proliferation of wt Ba/F3 cells and Ba/F3 cells transformed with Tel c-Kit fused tyrosine kinases. Untransformed Ba/F3 cells are maintained in media containing recombinant IL3. Cells are plated into 384 well TC plates at 5,000 cells in 50ul media per well and test compound at 0.06 nM to 10 μM is added. The cells are then incubated for 48 hours at 37 °C, 5% CO_2. After incubating the cells, 25 μL of BRIGHT GLO® (Promega) is added to each well following manufacturer's instructions and the plates are read using Analyst GT – Luminescence mode – 50000 integration time in RLU. IC50 values, the concentration of compound required for 50% inhibition, are determined from a dose response curve.

cKit – Mo7e Assay

[000286] The compounds described herein are tested for inhibition of SCF dependent proliferation using Mo7e cells which endogenously express c-kit in a 96 well format. Briefly, two-fold serially diluted test compounds (Cmax=10μM) are evaluated for their antiproliferative activity of Mo7e cells stimulated with human recombinant SCF. After 48 hours of incubation at 37 °C, cell viability is measured by using a MTT colorimetric assay from Promega.

Upstate KinaseProfilerTM – Radio-enzymatic filter binding assay

[000287] Certain compounds of the invention are assessed for their ability to inhibit individual members of a panel of kinases (a partial, non-limiting list of kinases includes: Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-1R, Alk and c-FMS kinases). The compounds are tested in duplicates at a final concentration of 10 μM following this generic protocol. Note that the kinase buffer composition and the substrates vary for the different kinases included in the "Upstate KinaseProfiler™" panel. Kinase buffer (2.5 μL, 10x - containing $MnCl_2$ when required), active kinase (0.001-0.01 Units; 2.5 μL), specific or Poly(Glu4-Tyr) peptide (5-500 μM or .01 mg/ml) in kinase buffer and kinase buffer (50 μM; 5 μL) are mixed in an eppendorf on ice. A Mg/ATP mix (10 μL; 67.5 (or 33.75) mM $MgCl_2$, 450 (or 225) μM ATP

and 1 μCi/μl [γ-^{32}P]-ATP (3000Ci/mmol)) is added and the reaction is incubated at about 30 °C for about 10 minutes. The reaction mixture is spotted (20 μL) onto a 2cm x 2cm P81 (phosphocellulose, for positively charged peptide substrates) or Whatman No. 1 (for Poly (Glu4-Tyr) peptide substrate) paper square. The assay squares are washed 4 times, for 5 minutes each, with 0.75% phosphoric acid and washed once with acetone for 5 minutes. The assay squares are transferred to a scintillation vial, 5 ml scintillation cocktail are added and ^{32}P incorporation (cpm) to the peptide substrate is quantified with a Beckman scintillation counter. Percentage inhibition is calculated for each reaction.

[000288] In addition, compounds of Formula (I) were assessed for their ability to inhibit individual kinases utilizing Caliper Life Sciences' proprietary LabChip™ technology. A partial, non-limiting list of kinases includes: Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-1R, Alk and c-FMS kinases. The off-chip incubation mobility-shift kinase assay uses a microfluidic chip to measure the conversion of a fluorescent peptide substrate to a phosphorylated product. The reaction mixture, from a microtiter plate well, is introduced through a capillary sipper onto the chip, where the nonphosphorylated substrate and phosphorylated product are separated by electrophoresis and detected via laser induced fluorescence. The signature of the fluorescence signal over time reveals the extent of the reaction. The phosphorylated product migrates through the chip faster than the non-phosphorylated substrate, and signals from the two forms of the peptide appear as distinct peaks. Caliper's data analysis software (HTSWA) determines peak heights, from which the ratio of product to the peak sum P/(P+S) and percent (%) conversion is calculated. This value is used to compare compound wells to control wells present on the plate, and thereby determine the % inhibition values for the compound. The formula used to calculate % inhibition is as follows, where $C_{100\%}$ is the average % conversion of the 100% activity wells and $C_{0\%}$ is the average % conversion of the 0% activity wells: (1-(%conversionofsample – $C_{0\%}$)/($C_{100\%}$-$C_{0\%}$))*100.

[000289] Compounds (10 mM stocks in 100% DMSO) are diluted to a final concentration of 5 μM for single point inhibition experiments, and a series dilution of 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001, 0.0003, 0.0001, 0.00003 μM were made for IC_{50} determination. Generally, 12 μL of enzyme buffer containing purified kinase (various amount; various suppliers), 100 mM HEPES, pH 7.5, 1 mM DTT (Calbiochem, 2333153), 10 mM $MgCl_2$ (Sigma, M-1028) or 10 mM $MnCl_2$ (Sigma, M-1787) (assay specific), and 0.002% Brij-35 (Sigma, B4184) are added to each well. Compound and enzyme are allowed to pre-incubate for 15 minutes. 12 μL of peptide/ATP buffer containing 100 mM HEPES, pH 7.5, 1.5 μM fluorescein-labeled peptide (specific to kinase of interest), ATP (at K_M apparent, Sigma, A9187), and 0.002% Brij-35 is then added to each well to

initiate the reaction. The final concentration of DMSO in the well is 4%. Generally, reactions are incubated for 1 to 1.5 hours at room temperature to obtain adequate conversion of peptide to phosphorylated product in the linear range of the reaction. Reactions are terminated with the addition of 45 μL of Stop Buffer (containing 20 mM EDTA). Plates are then read on the LabChip 3000 using a 12-sipper LabChip. % conversion values and % inhibition values are obtained as described and IC_{50} curves of compounds are generated using GraphPad Prism Version 4 or 5.01, or XLfit Version 4.3.2. When using GraphPad Prism, a nonlinear curve fit using the sigmoidal dose response – variable slope fit was used to graph IC_{50} curves and determine IC_{50} values and hillslopes. When using XLfit, Fit Model 205 (4-Parameter Logistic Model) is used to generate and fit the IC_{50} curve.

[000290] In certain embodiments, compounds of Formula (I) in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, for example, as indicated by the *in vitro* tests described in this application. The IC_{50} value in those experiments is given as that concentration of the test compound in question that results in a cell count that is 50 % lower than that obtained using the control without inhibitor. In general, compounds of the invention have IC_{50} values from 1 nM to 10 μM. In some examples, compounds of the invention have IC_{50} values from 0.01 μM to 5 μM. In other examples, compounds of the invention have IC_{50} values from 0.01 μM to 1 μM, or more particularly from 1 nM to 1 μM. In yet other examples, compounds of the invention have IC_{50} values of less than 1 nM or more than 10 μM. In certain embodiments, compounds of Formula (I) exhibit a percentage inhibition of greater than 50%, or in other embodiments compounds of Formula (I) exhibit a percentage inhibition greater than about 70%, against one or more of the following kinases at 10 μM: Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-1R, Alk and c-FMS kinases.

Ceratin Assay Results

[000291] By way of example only, the compound 8-(4-morpholinophenylamino)-6-phenyl-2,7-naphthyridin-1(2H)-one (see table 1, compound 11) has an IC_{50} of 0.06μM and 50 μM in Syk and Zap70 enzymatic assay respectively. In addition, 8-(4-morpholinophenylamino)-6-phenyl-2,7-naphthyridin-1(2H)-one has an IC_{50} of 0.15 μM, 0.27 μM, 0.02 μM, 0.02 μM, 0.07 μM and in BaF_3/Tel-Syk, BaF_3/Tel-KDR, BaF_3/Tel-FMS, BaF_3/Tel-KIT and BaF_3/Tel-TRKA cellular assays, respectively. At a concentration of 5 μM, 8-(4-morpholinophenylamino)-6-phenyl-2,7-naphthyridin-1(2H)-one inhibits the following kinases by the percentage shown in brackets (for example, 100% means complete inhibition, 0% means no inhibition): Abl (100%), CHK2 (94%), FLT3 (100%), FMS (84%), JAK2 (96%), KDR (96%), RET (99%), TRKA (74%).

[000292] By way of example only, the compound 8-(4-morpholinophenylamino)-6-(4-ethylpiperazin-1-yl)-2,7-naphthyridin-1(2H)-one(see table 1, compound 83) has an IC_{50} of 0.01μM and 3.54 μM in Syk and

Zap70 enzymatic assays, respectively. In addition, 8-(4-morpholinophenylamino)-6-(4-ethylpiperazin-1-yl)-2,7-naphthyridin-1(2H)-one has an IC_{50} of 0.12 μM, 5.0 μM, 0.50 μM, 1.22 μM, 0.49 μM and 0.53 μM in BaF_3/Tel-Syk, BaF_3/Tel-KDR, BaF_3/Tel-FMS, BaF_3/Tel-KIT, BaF_3/Tel-TRKA and BaF_3/Tel-FLT3 cellular assays, respectively.

[000293] By way of example only, the IC_{50} for Syk inhibition by other compounds of Formula (I) are listed in Table 2 below. The compound No. corresponds to the compounds listed in Table 1.

Table 2

Compound No.	Syk HTRF
11	0.058
17	0.001
83	0.009
102	0.475
655	0.324
83	0.003
100	0.398
117	0.277
120	0.421
130	0.044
151	0.078
164	0.002
167	0.109
183	0.024
190	0.008
276	0.237
304	0.008
443	0.115
1124	0.048
580	0.22
589	0.079
610	0.292
643	0.031
637	0.046

[000294] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.

2009209304 21 Mar 2012

[000295] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[000296] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of Formula (Ia), pharmaceutically acceptable salt, pharmaceutically acceptable solvate thereof :



Formula

(Ia).

wherein:

R^2 and R^3 are independently selected from H, $(CH_2)_nR^{11}$, $-C(O)R^{12}$, $-CR^{12}=NOCR^{12}$, $-NR^8R^{10}$, halogen, R^{20}, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_1-C_6alkoxy, C_1-C_6alkylthio, hydroxyl-C_1-C_6alkyl, halo-substituted-C_1-C_6alkyl, and halo-substituted-C_1-C_6alkoxy, C_6-C_{14}aryl, C_3-C_{13}heteroaryl and C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_3-C_{13}heteroaryl, and C_2-C_{14}heterocycloalkyl of R^2 and R^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-NO_2$, $-OR^{12}$, $-OR^{10}$, =O, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-NR^{12}C(O)N(R^{12})_2$, $-NHS(O)_2R^{13}$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$,$-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy;

R^4 is H, C_1-C_6alkyl or $-(CR^{12}R^{12})_nR^{11}$;

R^5 is H or C_1-C_6alkyl;

R^6 is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_1-C_6alkyl, C_3-C_8cycloalkyl, halo-substituted C_1-C_6alkyl, $-(CH_2)_nR^9$, R^{20}, $-L^3R^9$ or $-Y^1$-L^1-R^{14}, wherein,

Y^1 is arylene, heteroarylene or heterocycloalkylene, and

L^1- is a bond, -O-, -C(O)-, -C(O)N(R^{11})-, -(C(R^{12})$_2$)$_n$- or -O(CH_2)$_n$-;

L^3 is a bond, C_1-C_6alkyl or C_1-C_6alkoxy; wherein the C_1-C_6alkyl and C_1-C_6alkoxy groups of L^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, –CN, -C_1-C_6alkyl, C_1-C_6alkoxy, -OR^{13}, -C(O)R^{13}, -OC(O)R^{13}, -C(O)OR^{13}, -N(R^{12})$_2$, -C(O)N(R^{12})$_2$, -N(R^{12})C(O)R^{13}, C_2-C_{14}heterocycloalkyl, –S(O)$_2$$R^{13}$, –S(O)$_2$ N(R^{12})$_2$, R^{13}, -(C(R^{12})$_2$)$_n$$R^{13}$, -(C($R^{12}$)$_2$)$_n$$R^{14}$, halo-substituted C_1–C_6alkyl and halo-substituted C_1–C_6alkoxy;

and wherein the C_6–C_{14}aryl, C_3–C_{13}heteroaryl, C_1–C_6alkyl, halo-substituted C_1-C_6alkyl, C_2–C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^6 and Y^1 are optionally substituted with 1 to 3 substituents independently selected from, halogen, –CN, –OR^{12}, –OR^{10}, -C(O)R^{12}, –OC(O)R^{12}, –C(O)OR^{12}, –N(R^{11})$_2$, –N(R^{12})$_2$, –N($R^{12}$$R^{10}$), –N($R^{12}$$R^{11}$), –(C$R^{12}$$R^{12}$)$_n$$R^{11}$, -S$R^8$, -N$R^{12}$C(O)N($R^{12}$)$_2$, -C(O)N($R^{12}$$R^{10}$), –N($R^{12}$)C(O)$R^{13}$, –C(O)N($R^{11}$)$_2$, -C(O)N($R^{12}$)$_2$, -(C$R^{12}$$R^{12}$)$_n$$R^{11}$, -(C$H_2$)$_n$$R^{12}$, -(C$H_2$)$_n$$R^{13}$, -O(C$H_2$)$_n$$R^{13}$, (C$H_2$)$_n$$R^{14}$, -O(C$H_2$)$_n$$R^{14}$, (C$H_2$)$_n$$R^{16}$, –S(O)$_2$$R^{12}$, –S(O)$_2$N($R^{11}$)$_2$, -S(O)$_2$N($R^{12}$)$_2$, R^{12}, R^{10}, -OR^{13}, -C(O)R^{13}, -OC(O)R^{13}, -C(O)OR^{13}, -S(O)$_2$$R^{13}$, –$R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^7 is H or C_1-C_6 alkyl;

R^8 is H or C_1-C_6 alkyl;

R^9 is R^{20}, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or Y^2-L^2-R^{14}, wherein,

Y^2 is bond, arylene, heteroarylene or heterocycloalkylene, and

L^2- is a bond, -O-, or -O(CH_2)$_n$-;

and wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl of R^9 and Y^2 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, =O, –OR^{12}, –OR^{10}, -C(O)R^{12}, -OC(O)R^{12}, -C(O)OR^{12}, -N(R^{11})$_2$, -N(R^{12})$_2$, -N($R^{12}$$R^{10}$), -N($R^{12}$$R^{11}$), -(C$R^{12}$$R^{12}$)$_n$$R^{11}$, -S$R^8$, –N$R^{12}$C(O)N($R^{12}$)$_2$, -C(O)N($R^{12}$$R^{10}$),

$-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^{10} is halo-substituted C_1-C_6alkyl, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or $-(CH_2)_nR^{11}$, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^{10} are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, hydroxl, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^{11} is $-N(R^{12})_2$, $-OR^{13}$, R^{20}, $-C(O)N(R^{12})_2$, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl, or C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl of R^{11} are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

each R^{12} is independently selected from H, C_1-C_6alkyl, C_2-C_6alkene, halo-substituted C_1-C_6alkyl and C_3-C_8cycloalkyl, or each R^{12} is independently a C_1-C_6alkyl that together with N they are attached to form a heterocycloalkyl;

R^{13} is H, C_1-C_6 alkyl, C_3-C_8cycloalkyl, halo-substituted C_1-C_6 alkyl or C_2-C_{14}heterocycloalkyl;

R^{14} is H, halogen, OR^{13}, R^{20}, -CN, $-S(O)_2N(R^{12})_2$, $-S(O)_2R^{13}$, $-C(O)N(R^{12})_2$, $N(R^{12})_2$, C_1-C_6alkyl, halo-substituted C_1-C_6alkyl, C_6-C_{14}aryl, heteroaryl or C_2-C_{14}heterocycloalkyl, wherein the C_2-C_{14}heterocycloalkyl, C_6-C_{14}aryl and C_3-C_{13}heteroaryl are optionally substituted with 1-3 substituents independently selected from halogen, –CN, C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_8cycloalkyl, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, $-C(O)(C(R^{12})_2)_nR^{16}$, $-C(O)N(R^{12})_2$, heterocycloalkyl, $-S(O)_2R^{13}$, $-S(O)_2N(R^{12})_2$, $-NHS(O)_2R^{13}$, R^{13}, R^{10}, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $-(C(R^{12})_2)_nR^{16}$, halo-substituted C_1-C_6alkyl and halo-substituted C_1-C_6alkoxy;

R^{15} is H, C_1-C_6alkyl, C_2-C_6alkenyl, -CN, halogen, R^{10},

R^{16} is H, halogen, OR^{13}, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-N(R^{12})_2$, -CN, $-S(O)_2N(R^{12})_2$, $-S(O)_2R^{13}$, $C(O)N(R^{12})_2$, $-NR^{12}C(O)(R^{12})$, halo-substituted C_1-C_6alkyl, or C_2-C_{14}heterocycloalkyl;

R^{20} is  , and

each n is independently 1, 2, 3, 4, 5 or 6.

2. The compound of claim 1, wherein R^6 is





wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

R^8 is H or C_1-C_6 alkyl;

n is 1, 2, 3 or 4, and

p is 0, 1, 2 or 3.

3. The compound of claim 1, wherein R^6 is

a) $-(CH_2)_nR^9$,

where R^9 is C_6-C_{14}aryl, C_3-C_{13}heteroaryl or C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl and C_2-C_{14}heterocycloalkyl are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and n is 1, 2, 3 or 4; or

b) $-L^3R^9$

where R^9 is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_8cycloalkyl or C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_3-C_8cycloalkyl and C_2-C_{14}heterocycloalkyl are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and

n is 1, 2, 3 or 4; or

c) $-Y^1-L^1-R^{14}$,

where Y^1 is arylene and R^{14} is C_2-C_{14}heterocycloalkyl optionally substituted with 1-3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and

n is 1, 2, 3 or 4; or

d) $-(CH_2)_nR^9$,

wherein R^9 is Y^2-L^2-R^{14} and Y^2 is arylene and R^{14} is C_2-C_{14}heterocycloalkyl optionally substituted with 1-3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and

n is 1, 2, 3 or 4; or

e) C_1-C_6alkyl or halo-substituted C_1-C_6alkyl

wherein the C_1-C_6alkyl and halo-substituted C_1-C_6alkyl of R^6 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and

n is 1, 2, 3 or 4.

4. The compound of any one of claims 1 to 3, wherein R^{13} is H or C_1-C_6 alkyl.

5. The compound of claim 3 or claim 4, wherein R^9 is



wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

n is 1, 2, 3 or 4;

m is 1, 2, 3 or 4, and

p is 0, 1, 2 or 3.

6. The compound of any one of claims 1 to 5, wherein R^2 is H, $(CH_2)_nR^{11}$, $-C(O)R^{12}$, $-CR^{12}$=NOCR^{12}, halogen, R^{20}, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_1-C_6alkoxy, C_1-C_6alkylthio, hydroxyl-C_1-C_6alkyl, halo-substituted-C_1-C_6alkyl, and halo-substituted-C_1-C_6alkoxy, C_6-C_{14}aryl, C_3-C_{13}heteroaryl and C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_2-C_6alkenyl, C_2-C_6alkynyl,C_3-C_{13}heteroaryl, and C_2-C_{14}heterocycloalkyl of

2009209304 21 Mar 2012

R^2 and R^3 are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-NO_2$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and

n is 1, 2, 3 or 4.

7. The compound of any one of claims 1 to 6, wherein R^2 is H, halogen, R^{20},





, wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

n is 1, 2, 3 or 4;

m is 1, 2, or 3 and

p is 0, 1, 2 or 3.

8. The compound of any one of claims 1 to 7, wherein the compound of Formula (Ia) is a compound of Formula (Ib), Formula (Ic) or Formula (Id):



(Ib)



(Ic)



(Id)

wherein,

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14}heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

n is 1, 2, 3 or 4, and

p is 0, 1, 2 or 3.

9. The compound of claim 8, wherein, R^{10} is C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl, C_3-C_8cycloalkyl or $-(CH_2)_nR^{11}$, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^{10} are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and n is 1, 2, 3 or 4.

10. The compound of claim 9, wherein, R^{10} is



, wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

n is 1, 2, 3 or 4;

m is 1, 2, or 3 and

p is 0, 1, 2 or 3.

11. The compound of claim 9, wherein R^{10} is $-(CH_2)_nR^{11}$.

12. The compound of any one of claims 8 to 11, wherein R^{11} is $-N(R^{12})_2$, $-OR^{13}$, $-C(O)N(R^{12})_2$, C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_1-C_6alkyl, C_3-C_8cycloalkyl, or C_2-C_{14}heterocycloalkyl, wherein the C_6-C_{14}aryl, C_3-C_{13}heteroaryl, C_2-C_{14}heterocycloalkyl and C_3-C_8cycloalkyl of R^{10} are optionally substituted with 1 to 3 substituents independently selected from halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$,

$-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and n is 1, 2, 3 or 4.

13. The compound of any one of claims 8 to 12, wherein R^{11} is $-N(R^{12})_2$,



, wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

n is 1, 2, 3 or 4, and

p is 0, 1, 2 or 3.

14. The compound of any one of claims 1 to 13, wherein R^{15} is H, halogen, C_2-C_6alkenyl, -CN,



wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-NHS(O)_2R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy, and

p is 0, 1, 2 or 3.

15. The compound of any one of claims 1 to 14, wherein R^{15} is H.

16. The compound of any one of claims 1 to 15, wherein R^4 is H.

17. The compound of any one of claims 1 to 16, wherein R^3 is H, -CN, halogen, C_2-C_6alkenyl,



wherein:

R^{21} is halogen, -CN, $-OR^{12}$, $-OR^{10}$, $-C(O)R^{12}$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-N(R^{11})_2$, $-N(R^{12})_2$, $-N(R^{12}R^{10})$, $-N(R^{12}R^{11})$, $-(CR^{12}R^{12})_nR^{11}$, $-SR^8$, $-NR^{12}C(O)N(R^{12})_2$, $-C(O)N(R^{12}R^{10})$, $-N(R^{12})C(O)R^{13}$, $-C(O)N(R^{11})_2$, $-C(O)N(R^{12})_2$, $-(CR^{12}R^{12})_nR^{11}$, $-(CH_2)_nR^{12}$, $-(CH_2)_nR^{13}$, $-O(CH_2)_nR^{13}$, $(CH_2)_nR^{14}$, $-O(CH_2)_nR^{14}$, $(CH_2)_nR^{16}$, $-S(O)_2R^{12}$, $-S(O)_2N(R^{11})_2$, $-S(O)_2N(R^{12})_2$, R^{12}, R^{10}, $-OR^{13}$, $-C(O)R^{13}$, $-OC(O)R^{13}$, $-C(O)OR^{13}$, $-S(O)_2R^{13}$, $-R^{13}$, C_2-C_{14} heterocycloalkyl, C_1-C_6alkyl, C_1-C_6alkoxy, hydroxyl-C_1-C_6alkyl, halo-substituted C_1-C_6alkyl or halo-substituted C_1-C_6alkoxy;

n is 1, 2, 3 or 4, and

p is 0, 1, 2 or 3.

18. The compound of any one of claims 1 to 17, wherein R^8 is H.

19. The compound of any one of claims 1 to 18, wherein R^3 is H.

20. The compound of any one of claims 1 to19, wherein R^2 is H or halogen.

21. The compound of claim 1 selected from:

3-(morpholin-4-yl)-N-(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)benzamide;

8-amino-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;

8-{[3-(morpholin-4-yl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;

N-(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)oxane-4-carboxamide

6-[(dimethylamino)methyl]-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-[(dimethylamino)methyl]-8-{[3-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-(2-phenylethyl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

8-{[3-(morpholin-4-yl)phenyl]amino}-6-(2-phenylethyl)-1,2-dihydro-2,7-naphthyridin-1-one;

6-[3-(trifluoromethyl)phenyl]-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-(2-aminoethyl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-(3-aminopropyl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-phenyl-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

8-{[4-(morpholin-4-yl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;

6-(pyridin-3-yl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

2-[2-(8-amino-1-oxo-1,2-dihydro-2,7-naphthyridin-3-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione;

6-(3-aminopropyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-(3-aminopropyl)-8-{[3-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[3-(dimethylamino)propyl]phenyl}amino)-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;
N-(3-methoxypropyl)-4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)amino]benzene-1-sulfonamide;
6-phenyl-8-{[3-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-aminopropyl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-3-(2-aminoethyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-aminobutyl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-aminobutyl)-8-{[3-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-aminopropyl)-8-{[4-methyl-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-(morpholin-4-yl)phenyl]amino}-6-(pyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-3-(3-aminopropyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-phenyl-8-{[4-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-aminopropyl)-8-{[4-methoxy-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-aminopropyl)-8-[(3,5-dimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-aminopropyl)-8-[(3,4-dimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-aminopropyl)-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-aminopropyl)-8-{[3-fluoro-4-(piperazin-1-ylmethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(3-bromophenyl)amino]-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-cyclohexyl-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-cyclohexyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-methoxyphenyl)amino]-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-phenyl-8-{[2-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[3-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(2-aminoethyl)amino]-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(2-aminoethyl)amino]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-aminopropyl)-8-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(3R)-piperidin-3-ylamino]-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[(3R)-piperidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[(3S)-piperidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[(3S)-pyrrolidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-{[(1S,2S)-2-aminocyclohexyl]amino}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[(3R)-pyrrolidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-{[(1S,2R)-2-aminocyclohexyl]amino}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-(piperidin-3-yloxy)-1,2-dihydro-2,7-naphthyridin-1-one;

6-[(2-aminoethyl)amino]-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-[(3S)-piperidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(benzylamino)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(2-aminoethyl)amino]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl 4-[4-({3-[(2-aminoethyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]piperidine-1-carboxylate;
6-[(2-aminoethyl)amino]-8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(pyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
2-(1-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzamide;
8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-{[(1S,2S)-2-aminocyclohexyl]amino}-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(2-aminoethyl)amino]-8-{[3-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-aminopiperidin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-{[(3-chlorophenyl)methyl]amino}-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(3R)-3-aminopyrrolidin-1-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-1-yl)phenyl]amino}-6-(pyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(2-aminoethyl)amino]-2-methyl-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-(pyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-chlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-({3-[(2-aminoethyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-(4-chlorophenyl)benzamide;
6-(3-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl 4-{4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)amino]phenyl}piperidine-1-carboxylate;
6-phenyl-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-hydroxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(2-aminoethyl)amino]-8-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-(1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3,5-dimethyl-1H-pyrazol-4-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
2-(1-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzonitrile
6-(4-methoxypyridin-3-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-(6-aminopyridin-3-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
3-(1-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzamide;
8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3,5-dimethyl-1,2-oxazol-4-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(furan-3-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-[4-({3-[(2-aminoethyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]-1,4-thiomorpholine-1,1-dione;
8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;
4-{4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)amino]phenyl}-1,4-thiomorpholine-1,1-dione;
6-(4-chlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-chlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3,4-dichlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-fluorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[3-(aminomethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[4-(piperazin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-(1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-(1H-pyrazol-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-hydroxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-hydroxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-hydroxypyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-(1-propyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[1-(1,3-dioxolan-2-ylmethyl)-1H-pyrazol-4-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
2-[4-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]acetic acid
6-(3,5-dimethyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

8-({4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}amino)-6-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}amino)-6-(3-hydroxyphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}amino)-6-(6-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1H-pyrazol-4-yl)-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-benzyl-1H-pyrazol-4-yl)-8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-fluorophenyl)amino]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-fluorophenyl)amino]-5-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
5-bromo-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-chloro-5-(pyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3,5-dimethyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
2-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzonitrile
5-(furan-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)amino]-N-propylbenzamide;
4-({3-[(2-aminoethyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-propylbenzamide;
4-(4-{[3-(4-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)-1,4-thiomorpholine-1,1-dione;
6-[2-(3-fluorophenyl)pyrrolidin-1-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methoxypyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-[4-({3-[6-(morpholin-4-yl)pyridin-3-yl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]-1,4-thiomorpholine-1,1-dione;
6-(4-methoxypyridin-3-yl)-8-{[4-(piperidin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[3-(dimethylamino)propyl]phenyl}amino)-6-(4-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(1-propyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(3-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(3-fluorophenyl)pyrrolidin-1-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
2-[4-(1-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]acetic acid
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(5-methyl-1H-pyrazol-3-yl)amino]-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-1,2-dihydro-2,7-naphthyridin-1-one;

6-(6-aminopyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(piperazin-1-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methylpiperazin-1-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-(piperidin-4-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[4-(piperidin-1-yl)piperidin-1-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-{[2-(morpholin-4-yl)ethyl]amino}-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-(6-aminopyridin-3-yl)-8-[(4-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
5-(6-aminopyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-(2-chloropyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-[4-(aminomethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-4-yl)benzamide;
5-iodo-8-[(4-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-methoxyphenyl)amino]-5-(3-phenylprop-1-yn-1-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
5-phenyl-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(2-chlorophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(3-chlorophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(4-chlorophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(2-methoxyphenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(3-methoxyphenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(4-methoxyphenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-benzyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-(phenylamino)-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-benzyl-1H-pyrazol-4-yl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-[1-(1,3-dioxolan-2-ylmethyl)-1H-pyrazol-4-yl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-methyl-1H-pyrazol-4-yl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(furan-3-yl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-[8-oxo-1-(phenylamino)-7,8-dihydro-2,7-naphthyridin-4-yl]furan-2-carbaldehyde
8-(phenylamino)-5-(pyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(2-chlorophenyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-chlorophenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N-[2-(morpholin-4-yl)ethyl]-4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)amino]benzamide;
N,N-diethyl-4-[(8-oxo-3-phenyl-7,8-dihydro-2,7-naphthyridin-1-yl)amino]benzamide;
6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(phenylamino)-5-[3-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-(phenylamino)-5-[4-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
5-(6-aminopyridin-3-yl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-[6-(morpholin-4-yl)pyridin-3-yl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(phenylamino)-5-[6-(piperazin-1-yl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
5-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(3-aminophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(4-aminophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(3-fluorophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(4-fluorophenyl)-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
4-[8-oxo-1-(phenylamino)-7,8-dihydro-2,7-naphthyridin-4-yl]benzamide;
8-(phenylamino)-5-[(1E)-3-phenylprop-1-en-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
5-[(E)-2-(2,4-difluorophenyl)ethenyl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
5-[(E)-2-cyclohexylethenyl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(phenylamino)-5-[(E)-2-[3-(trifluoromethyl)phenyl]ethenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-tert-butylpiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
3-[8-oxo-1-(phenylamino)-7,8-dihydro-2,7-naphthyridin-4-yl]benzonitrile
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[(2,2,2-trifluoroethyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methylpiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-ylcarbonyl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-phenyl-8-{[4-(piperazin-1-ylcarbonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-{[3-(4-methylpiperazin-1-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-[2-(morpholin-4-yl)ethyl]benzamide;
4-({3-[(2-aminoethyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-[2-(morpholin-4-yl)ethyl]benzamide;
4-{[3-(4-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-[2-(morpholin-4-yl)ethyl]benzamide;
6-(2-methoxyphenyl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-ethoxyphenyl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[2-(propan-2-yloxy)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-fluoro-2-methoxyphenyl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-{[5-(4-ethylpiperazin-1-yl)pyridin-2-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-{[4-(piperidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-{[4-(1-methylpiperidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-aminopropyl)-8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
5-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-[(E)-2-(3-methoxyphenyl)ethenyl]-8-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
4-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1,4-thiomorpholine-1,1-dione;
6-(4-acetylpiperazin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[4-(piperidin-1-yl)piperidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-hydroxypiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[4-(morpholin-4-yl)piperidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
4-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1,4-thiomorpholin-1-one;
6-(2-methoxypyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N-ethyl-4-(4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxamide
6-(5-methoxypyridin-3-yl)-8-({4-[1-(propan-2-yl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-cyclopentylpiperidin-4-yl)phenyl]amino}-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl}amino)-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-({4-[1-(3-oxobutyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
3-[4-(4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]propanenitrile
4-[(8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl)amino]-N-phenylbenzamide;
4-{[4-(1-methyl-1H-pyrazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-phenylbenzamide;
4-{[4-(1-methyl-1H-pyrazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide;
4-{[3-(4-methylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide;
4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide;
N-(2-hydroxyethyl)-4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
4-{[3-(cyclopropylamino)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide;
8-({4-[3-(dimethylamino)propyl]phenyl}amino)-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-fluorophenyl)amino]-5-(furan-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[(2,2,2-trifluoroethyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;

N-cyclopropyl-4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-chloro-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(1H-indazol-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(1H-indol-6-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(1H-indol-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(3-fluoropyridin-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(6-fluoropyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(2-methoxypyridin-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(6-fluoro-5-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
5-bromo-6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-hydroxypiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4,4-difluoropiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[3-(trifluoromethyl)piperidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[4-(hydroxymethyl)piperidin-1-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-({8-oxo-3-[(3R)-piperidin-3-ylamino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide;
6-(3-methoxyphenyl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[3-(trifluoromethoxy)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[2-(morpholin-4-yl)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(ethanesulfonyl)piperidin-4-yl]phenyl}amino)-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
ethyl 3-[4-(4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]propanoate
6-(3,3-difluoropiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[2-(trifluoromethyl)pyrrolidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[4-(trifluoromethyl)piperidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3,3-difluoropyrrolidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-fluoropiperidin-1-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

4-bromo-6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(3S)-3-fluoropyrrolidin-1-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-chloro-6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-4-iodo-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-ylcarbonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-iodo-6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-chloro-6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-{1-[(4-fluorophenyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-4-yl}furan-2-carbonitrile
6-(2-aminopyrimidin-5-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethoxypyrimidin-5-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[4-(propan-2-yl)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methanesulfonylpyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
ethyl 5-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carboxylate;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(morpholin-4-yl)pyrazin-2-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(4-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(2-methoxyphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-fluoropyridin-3-yl)-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[1-(1-methanesulfonylpiperidin-4-yl)-1H-pyrazol-4-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[1-(1-acetylpiperidin-4-yl)-1H-pyrazol-4-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N,2-dimethyl-2-(4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)propanamide
4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide;
8-{[4-(4-hydroxypiperidin-1-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
N-cyclopentyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
4-({8-oxo-3-[(2,2,2-trifluoroethyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-propylbenzamide;

N,2-dimethyl-2-[4-({8-oxo-3-[(2,2,2-trifluoroethyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]propanamide
8-[(4-fluorophenyl)amino]-5-(3-phenylpropyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1-oxo-1,2-dihydro-2,7-naphthyridine-4-carbonitrile
1-(benzylamino)-8-oxo-7,8-dihydro-2,7-naphthyridine-4-carbonitrile
6-(4-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-chloro-8-{[4-(pyridin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-chloro-8-[(4-{2H,3H-imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-chloro-8-{[4-(1H-imidazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-chloro-8-{[4-(1,3-oxazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methanesulfonylpyridin-3-yl)-8-{[4-(pyridin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2H,3H-imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)amino]-6-(5-methanesulfonylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1H-imidazol-4-yl)phenyl]amino}-6-(5-methanesulfonylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(6-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carbonitrile
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-[6-(piperidin-1-yl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(2-aminoethyl)amino]-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(oxan-4-yl)phenyl]amino}-6-[(3R)-piperidin-3-ylamino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-chlorophenyl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(3aS,6aS)-octahydropyrrolo[3,4-c]pyrrol-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-4-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-fluorophenyl)amino]-5-(3-hydroxy-3-phenylpropyl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-6-(3,3-difluoropyrrolidin-1-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-6-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
N-cyclopentyl-4-({8-oxo-3-[(2,2,2-trifluoroethyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide;
6-(2-methylpyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(dimethylamino)pyrimidin-5-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carbonitrile
N-methyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;

4-{[3-(2,6-dimethylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide;
4-({3-[2-(dimethylamino)pyrimidin-5-yl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-methylbenzamide;
8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-6-[4-(propan-2-yl)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
2-(4-{[3-(5-methanesulfonylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)-N,2-dimethylpropanamide
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(3,3-difluoropyrrolidin-1-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-chloro-8-[(2-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-chloro-8-[(2-methyl-3-oxo-2,3-dihydro-1H-isoindol-5-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-[(2-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-[(2-methyl-3-oxo-2,3-dihydro-1H-isoindol-5-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
3-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(2,6-difluoropyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-{imidazo[1,2-a]pyridin-6-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(5-fluoropyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
3-[(3-chloro-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl)amino]-N-methylbenzamide;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(6-fluoro-2-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-{[4-(1,3-oxazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-{1H-pyrrolo[2,3-b]pyridin-5-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-2-carbonitrile
6-(6-fluoro-2-methylpyridin-3-yl)-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,6-difluoropyridin-3-yl)-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-N-methylpyridine-2-carboxamide
6-chloro-8-{[4-(1-methanesulfonylpiperidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-chloro-8-{[4-(1-methanesulfonylpyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-chloro-8-{[4-(1-methylpyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-chloro-6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-chloro-6-(5-methoxypyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3,3-difluoropyrrolidin-1-yl)-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

4-({3-[4-(2-hydroxypropan-2-yl)piperidin-1-yl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-methylbenzamide;
4-{[3-(1-methyl-1H-pyrazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide;
4-({3-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-propylbenzamide;
4-[(3-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl)amino]-N-propylbenzamide;
4-({8-oxo-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-propylbenzamide;
4-{[3-(3-methyl-1H-pyrazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide;
N-methyl-4-{[3-(1-methyl-1H-pyrazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
N-methyl-4-({3-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide;
N-methyl-4-[(3-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl)amino]benzamide;
N-methyl-4-({8-oxo-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide;
N,2-dimethyl-2-[4-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]propanamide
N-ethyl-2-methyl-2-[4-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]propanamide
N,N,2-trimethyl-2-[4-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]propanamide
6-{1-[2-methyl-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl]-1H-pyrazol-4-yl}-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(5-methanesulfonylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
N-methyl-4-({8-oxo-3-[(2,2,2-trifluoroethyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide;
N,N-dimethyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
4-{[3-(5-methanesulfonylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide;
6-(2-aminopyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methanesulfonylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide;
N-methyl-4-{[3-(4-methylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
N-tert-butyl-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carboxamide
N-tert-butyl-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carboxamide
8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(4-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methanesulfonylpyrrolidin-3-yl)phenyl]amino}-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-{[4-(1-methylpyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,6-dimethylpyridin-3-yl)-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
5-bromo-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-5-(3-hydroxy-3-phenylpropyl)-1,2-dihydro-2,7-naphthyridin-1-one;
N-methyl-4-{[8-oxo-3-(2-oxopyrrolidin-1-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
N-methyl-4-{[8-oxo-3-(2-oxopiperidin-1-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
8-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-6-(2-oxopyrrolidin-1-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
6-{[2-(difluoromethane)sulfonylphenyl]amino}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-{[2-(propane-2-sulfonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-{[3-(2,4-dimethoxypyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N,2-dimethylbenzamide;
4-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N,2-dimethylbenzamide;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(5-methanesulfonylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methanesulfonylpiperidin-3-yl)phenyl]amino}-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
5-chloro-6-(5-methoxypyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}phenyl)amino]-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-[1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
N-methyl-4-({8-oxo-3-[1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide;
8-{[4-(oxan-4-yl)phenyl]amino}-6-[1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl}amino)-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3,3-difluoropiperidin-1-yl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methanesulfonylpyrrolidin-3-yl)phenyl]amino}-6-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methanesulfonylacetyl)piperidin-4-yl]phenyl}amino)-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

8-{[4-(morpholin-4-yl)phenyl]amino}-6-[5-(propane-2-sulfonyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-[5-(propane-2-sulfonyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
N-methyl-4-{[8-oxo-3-(2-oxoazepan-1-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
6-(3,3-difluoropyrrolidin-1-yl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-6-(3-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}amino)-6-(3-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
2-{[1-({6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]amino}benzene-1-sulfonamide;
4-({8-oxo-3-[(2-sulfamoylphenyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-propylbenzamide;
N,2-dimethyl-4-({8-oxo-3-[(2-sulfamoylphenyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzamide;
2-[(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzamide;
6-[(4-fluoro-2-methylphenyl)amino]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-{[2-(propane-2-sulfonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methanesulfonylphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-{[3-(3-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide;
N-ethyl-3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide;
8-{[4-(1-methanesulfonylpyrrolidin-3-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
3-{[3-(5-methoxypyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzene-1-sulfonamide;
6-[5-(ethanesulfonyl)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[5-(ethanesulfonyl)pyridin-3-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[5-(ethanesulfonyl)pyridin-3-yl]-8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-({3-[5-(ethanesulfonyl)pyridin-3-yl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)-N-methylbenzamide;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(propane-2-sulfonyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[5-(ethanesulfonyl)pyridin-3-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
2,2-dimethyl-6-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;
2,2-dimethyl-7-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;

7-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]-3,4-dihydro-2H-1,4-benzoxazin-3-one;
2,2-dimethyl-6-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]-3,4-dihydro-2H-1,4-benzoxazin-3-one;
N-methyl-2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzamide;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(2-methylpyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,3-dihydro-1H-indol-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-methyl-1H-pyrazol-4-yl)-8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
3-(1-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide;
6-[2-(methylsulfanyl)pyrimidin-5-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-{[2-(morpholin-4-yl)ethyl]amino}pyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-methyl-1H-pyrazol-4-yl)-8-{[6-(piperidin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methoxypyridin-3-yl)-8-{[6-(piperidin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-acetyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(1E)-1-(methoxyimino)ethyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
2-[(1-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
2-[(1-{[4-(oxan-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
2-[(1-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
2-{[1-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]amino}benzene-1-sulfonamide;
tert-butyl 4-(4-{[8-oxo-3-(1,3,5-trimethyl-1H-pyrazol-4-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate;
5-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-sulfonamide;
5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-sulfonamide;
5-(1-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-sulfonamide;
5-[1-({4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]pyridine-3-sulfonamide;
5-(1-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-sulfonamide;
N-methyl-4-{[8-oxo-3-(5-sulfamoylpyridin-3-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-(6-methylpyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-ethenyl-6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methylpyridin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-(pyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
4-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-3,4-dihydro-2H-1,4-benzothiazine-1,1-dione;
N-methyl-2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
N-ethyl-2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
6-[(2-methanesulfonylphenyl)amino]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
2-[(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
6-(2-aminopyrimidin-5-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
2-({1-[(2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl}amino)benzene-1-sulfonamide;
4-methoxy-2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
N,N,2-trimethyl-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide;
3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-N-(propan-2-yl)benzene-1-sulfonamide;
N-cyclopropyl-3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(3-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(3-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methanesulfonylphenyl)-8-{[4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N-[3-(1-{[2-methoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)phenyl]methanesulfonamide;
2-hydroxy-N-[3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)phenyl]ethane-1-sulfonamido
8-{[2-methoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}-6-(2-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,6-dimethoxypyridin-3-yl)-8-{[2-methoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methanesulfonylphenyl)-8-{[2-methoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(methylsulfanyl)pyrimidin-5-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-fluoropyridin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-(pyrimidin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-ethyl-1,3-thiazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-(5-methylpyridin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methylpyridin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(methylsulfanyl)pyrimidin-4-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
2-(4-{[3-(2-aminopyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)-N,2-dimethylpropanamide
2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]ethane-1-sulfonamide;
2-methyl-6-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
N,N-dimethyl-2-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
2,2-dimethyl-6-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;
N,2-dimethyl-2-[4-({8-oxo-3-[(2-sulfamoylphenyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]propanamide
2-[(1-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]-6-methylbenzene-1-sulfonamide;
6-(2-aminopyrimidin-5-yl)-8-{[4-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
3-{[3-(2-aminopyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzene-1-sulfonamide;
2,2-dimethyl-6-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one;
N-methyl-3-({8-oxo-3-[(2-sulfamoylphenyl)amino]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)benzene-1-sulfonamide;
6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-chlorophenyl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
N-ethoxy-4-{[3-(4-methylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
2-[(1-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
2-methyl-6-[(1-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
4-methyl-2-[(1-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
6-(1-methyl-1H-pyrazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-methyl-1H-pyrazol-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
2-methoxy-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide;
2-methoxy-N-methyl-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide;
tert-butyl 3-(4-{[3-(4-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)pyrrolidine-1-carboxylate;
6-(4-methanesulfonylphenyl)-8-{[4-(pyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl 4-(4-{[3-(4-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate;

6-(4-methanesulfonylphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({3-[2-(morpholin-4-yl)-2-oxoethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({4-methyl-3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3-hydroxy-4-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
3-{[3-(2-aminopyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide;
6-(2-methylpyrimidin-5-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-methyl-3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-6-(2-methylpyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methylpyridin-3-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,6-dimethylpyridin-3-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-(2-phenyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methanesulfonyl-4-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methanesulfonyl-4-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methanesulfonyl-4-methylpyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methanesulfonyl-4-methylpyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[3-(2-hydroxypropan-2-yl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[4-(2-hydroxypropan-2-yl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[3-methanesulfonyl-4-(morpholin-4-ylmethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[3-methanesulfonyl-4-(pyrrolidin-1-ylmethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-ethoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methanesulfonyl-4-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N-[5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridin-2-yl]acetamide
6-(4-methoxypyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-(6-amino-4-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-4-methylpyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
2-methyl-6-[(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
N-methyl-2-[(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-(1H-pyrazol-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
4-chloro-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
4,6-dichloro-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-(pyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[5-(propan-2-yloxy)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[5-methyl-6-(methylamino)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-methoxy-N-methyl-3-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-(1-propyl-1H-pyrazol-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[1-(2-phenylethyl)-1H-pyrazol-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[1-(propan-2-yl)-1H-pyrazol-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-benzyl-1H-pyrazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-tert-butyl-1H-pyrazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-sulfonamide;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[5-(trifluoromethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-[5-(trifluoromethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(trifluoromethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-fluoropyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-fluoropyridin-3-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(methylamino)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3,3-difluoropyrrolidin-1-yl)-8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;

8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-amino-4-methoxypyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N,2-dimethyl-2-(4-{[3-(2-methylpyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)propanamide
2-methyl-6-{[8-oxo-1-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-7,8-dihydro-2,7-naphthyridin-3-yl]amino}benzene-1-sulfonamide;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[5-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[5-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-fluoropyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-{[3-(6-fluoropyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-methylbenzamide;
6-[6-(methylamino)pyridin-3-yl]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(ethylamino)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methanesulfonyl-4-methoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methanesulfonyl-4-methylphenyl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N-[5-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridin-2-yl]acetamide
8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-6-[(2,2,2-trifluoroethyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
N-methyl-2-{[8-oxo-1-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-7,8-dihydro-2,7-naphthyridin-3-yl]amino}benzene-1-sulfonamide;
6-(2-amino-4-methoxypyrimidin-5-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-{[4-methyl-3-(methylamino)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methylpyrimidin-5-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-(pyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-aminopyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-2-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
2-[(1-{[4-(4-ethoxypiperidin-1-yl)-3-fluorophenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
6-(3,3-difluoropyrrolidin-1-yl)-8-{[4-(4-ethoxypiperidin-1-yl)-3-fluorophenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3,3-difluoropyrrolidin-1-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;

2-[(1-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
6-(3,3-difluoropyrrolidin-1-yl)-8-{[5-methyl-6-(morpholin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3,3-difluoropyrrolidin-1-yl)-8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(pyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-aminopyrazin-2-yl)-8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
4-{[3-(5-aminopyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide;
6-(6-methoxypyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methoxypyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-amino-4-methoxypyrimidin-5-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({4-[(2-methyl-1H-imidazol-1-yl)methyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3-methoxy-4-phenylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-{[3-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(4-{2-[3-(dimethylamino)pyrrolidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-butyl-1H-pyrazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[1-(2-hydroxyethyl)-1H-pyrazol-5-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
ethyl 2-[5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1H-pyrazol-1-yl]acetate
6-(2-methylpyrimidin-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methylpyridin-2-yl)-8-({4-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methylpyridin-2-yl)-8-({4-[1-(propan-2-yl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methanesulfonylpiperidin-4-yl)phenyl]amino}-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-amino-1,3-thiazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(methylamino)-1,3-thiazol-4-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methoxypyridin-3-yl)-8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-(1H-pyrazol-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-[5-methyl-6-(methylamino)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-6-ylamino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-({5-methyl-6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(4-ethoxypiperidin-1-yl)-3-fluorophenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
4-{[3-(2-aminopyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-(1-methylpiperidin-4-yl)benzamide;
N-(1-methylpiperidin-4-yl)-4-{[3-(2-methylpyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
6-(2-aminopyrimidin-5-yl)-8-({4-[3-(dimethylamino)pyrrolidin-1-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[3-(dimethylamino)pyrrolidin-1-yl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethoxypyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N-methyl-3-{[3-(2-methylpyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzene-1-sulfonamide;
2-methoxy-N-methyl-4-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide;
6-(6-hydrazinylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[6-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-hydroxy-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({5-methyl-6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
ethyl 4-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1,3-thiazole-2-carboxylate;

6-[2-(methanesulfonylmethyl)-1,3-thiazol-4-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl N-{2-[4-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-1,3-thiazol-2-yl]ethyl}carbamate
6-[2-(2-aminoethyl)-1,3-thiazol-4-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methylpyridin-2-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methylpyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-amino-4-methylpyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-amino-6-methylpyrimidin-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-{methyl[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-(morpholin-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(1-methylpiperidin-4-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-amino-4-methylpyrimidin-5-yl)-8-({4-[3-(dimethylamino)pyrrolidin-1-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-aminopyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-{5H-pyrrolo[2,3-b]pyrazin-2-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-aminopyridin-2-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-{5H-pyrrolo[2,3-b]pyrazin-2-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethyl-1,3-thiazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethyl-1,3-thiazol-5-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-[4-(propane-2-sulfonyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N,N-dimethyl-4-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide;
tert-butyl 4-[4-({8-oxo-3-[4-(propane-2-sulfonyl)phenyl]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]piperidine-1-carboxylate;
tert-butyl 4-[4-({3-[4-(dimethylsulfamoyl)phenyl]-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]piperidine-1-carboxylate;
tert-butyl 4-(4-{[3-(3-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate;
6-(5-amino-6-methylpyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-(6-aminopyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridazin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl}amino)-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-4-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-4-phenyl-1,2-dihydro-2,7-naphthyridin-1-one;
4-(2-chlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-methyl-1H-pyrazol-4-yl)-8-{methyl[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(2-aminopyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-{[4-(1-methanesulfonylpyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N-methyl-3-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzene-1-sulfonamide;
6-(2-aminopyrimidin-5-yl)-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[5-methyl-6-(methylamino)pyridin-3-yl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(propan-2-yloxy)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
4-methoxy-N-methyl-3-(1-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzene-1-sulfonamide;
6-[3-methanesulfonyl-4-(pyrrolidin-1-ylmethyl)phenyl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[3-methanesulfonyl-4-(morpholin-4-ylmethyl)phenyl]-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[5-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(propan-2-ylamino)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-methyl-1H-imidazol-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-2-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-(1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl 6-{[3-(4-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-1,2,3,4-tetrahydroisoquinoline-2-carboxylate;

6-(4-methanesulfonylphenyl)-8-(1,2,3,4-tetrahydroisoquinolin-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-[4-(propane-2-sulfonyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
4-(1-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-N,N-dimethylbenzene-1-sulfonamide;
6-[6-(4-methyl-1H-imidazol-1-yl)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(2-ethyl-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
benzyl 4-{1-[(4-{1-[(tert-butoxy)carbonyl]piperidin-4-yl}phenyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl}piperazine-1-carboxylate;
8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-{[(1S,2R)-2-aminocyclohexyl]amino}-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methylpyrazin-2-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-{[4-(2-methylpyridin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(6-amino-5-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-{[4-(4-methoxyphenyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-amino-4-methylpyrimidin-5-yl)-2-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-6-ylamino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methanesulfinyl-2-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(2-methanesulfonylethyl)({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl})amino]-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(4-methanesulfonylpiperazin-1-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)-2-methoxy-5-methylphenyl]amino}-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-6-ylamino)-6-[5-(propan-2-yloxy)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-6-ylamino)-6-[3-methanesulfonyl-4-(pyrrolidin-1-ylmethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-6-ylamino)-6-[3-methanesulfonyl-4-(morpholin-4-ylmethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-6-ylamino)-6-[6-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-6-ylamino)-6-[5-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;

3-(1-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-4-methoxy-N-methylbenzene-1-sulfonamide;
4-(1-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)-2-methoxy-N-methylbenzene-1-sulfonamide;
6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-6-ylamino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[5-methyl-6-(methylamino)pyridin-3-yl]-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-[2-(propan-2-yloxy)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-[2-(propan-2-yloxy)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-[5-methyl-6-(methylamino)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1H-indazol-6-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-6-(2-aminopyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methanesulfonylpiperazin-1-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(2-oxo-2,3-dihydro-1H-indol-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(2-oxo-2,3-dihydro-1H-indol-6-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(methylamino)pyridin-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(propylamino)pyridin-2-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(propan-2-ylamino)pyridin-2-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-{6-[(3-methoxypropyl)amino]pyridin-2-yl}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(dimethylamino)pyridin-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-8-{methyl[6-(morpholin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-(2,6-dimethylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
2-methyl-6-(1-methyl-1H-pyrazol-4-yl)-8-{methyl[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-{methyl[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-({4-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
4-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]pyridine-3-sulfonamide;
6-(6-methoxypyrazin-2-yl)-8-({3-methyl-4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;

2-(4-{[3-(6-amino-5-methylpyridin-3-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)-N,2-dimethylpropanamide
8-[(4-{2-[3-(dimethylamino)pyrrolidin-1-yl]ethyl}phenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-hydroxy-3-methylphenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-amino-6-methylpyrimidin-4-yl)-8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-(2,6-dichlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methoxypyridin-3-yl)-8-[(4-methanesulfonylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-methanesulfonylphenyl)amino]-6-[6-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-{imidazo[1,2-a]pyridin-6-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1H-indazol-6-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-{imidazo[1,2-a]pyridin-6-yl}-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-{1H-pyrrolo[2,3-b]pyridin-5-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-fluoro-2-methylpyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-fluoro-2-methylpyridin-3-yl)-8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-fluoro-2-methylpyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-(4-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(4-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridin-3-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridin-3-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;

8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methoxypyrazin-2-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridin-3-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-(6-methoxypyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(ethylamino)pyridin-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-2-methyl-8-{methyl[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(furan-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-5-ylamino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(4-hydroxyphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[4-(dimethylamino)phenyl]-8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(4-fluoro-2-methylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(4-fluoro-3-methoxyphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[4-(benzyloxy)phenyl]-8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-fluoropyridin-3-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(methylamino)pyridin-3-yl]-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(ethylamino)pyridin-3-yl]-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
2-methyl-6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-{[4-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(3-methoxy-4-phenylphenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-{[4-(2-methylpyridin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-[(4-{2-[3-(dimethylamino)pyrrolidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-{[4-(2-methylpyridin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-(6-amino-5-methylpyridin-3-yl)-8-{[4-(4-hydroxypiperidin-1-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-{[3-methyl-4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(2-aminopyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-2-sulfonamide;
N-methyl-5-(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-2-sulfonamide;
6-(3-methoxypyrazin-2-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(3-methoxy-4-methylphenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-methyl-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
2-methyl-8-(methylamino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-6-(2-aminopyrimidin-5-yl)-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-(methylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-(2-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methanesulfonylphenyl)-8-{[3-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-[2-(methylsulfanyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-[(2-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(3-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methanesulfonylphenyl)-8-{[3-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-6-[(2-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[4-(2-hydroxypropan-2-yl)phenyl]-8-(1H-indazol-5-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-8-(1H-indazol-5-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-5-ylamino)-6-[5-(propan-2-yloxy)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-fluoropyridin-3-yl)-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-6-ylamino)-6-[6-(methylamino)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(ethylamino)pyridin-3-yl]-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-[2-(dimethylamino)ethyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-{[4-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N-methyl-3-{[3-(2-methyl-1,3-thiazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
3-{[3-(2-methyl-1,3-thiazol-4-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide;
6-(2-methyl-1,3-thiazol-4-yl)-8-{[6-(piperidin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
N-(3-methoxypropyl)-4-{[3-(6-methoxypyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzene-1-sulfonamide;
6-(6-amino-5-methylpyridin-3-yl)-8-({4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-{[3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-ethyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-({3-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-({3-chloro-4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-fluoropyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-[6-(methylamino)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(ethylamino)pyridin-3-yl]-8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-5-ylamino)-6-[3-methanesulfonyl-4-(pyrrolidin-1-ylmethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-5-ylamino)-6-[3-methanesulfonyl-4-(morpholin-4-ylmethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-5-ylamino)-6-[5-(morpholin-4-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-5-ylamino)-6-[5-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[4-(2-hydroxypropan-2-yl)phenyl]-8-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3-methoxy-4-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
2-(2-methanesulfonylethyl)-8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl}amino)-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-chloro-2-(2-methanesulfonylethyl)-8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-chloro-8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-2-(2-methanesulfonylethyl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpiperidin-4-yl)phenyl]amino}-2-(2-methanesulfonylethyl)-6-(4-methanesulfonylphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
2-(2-methanesulfonylethyl)-6-(4-methanesulfonylphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-chloro-2-(2-methanesulfonylethyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl 4-(4-{[7-(2-methanesulfonylethyl)-3-(4-methanesulfonylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate;
tert-butyl 4-(4-{[3-chloro-7-(2-methanesulfonylethyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate;

6-(6-methoxypyridin-2-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridin-2-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methoxypyrazin-2-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-methoxypyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(3-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-fluoro-4-(morpholin-4-yl)phenyl]amino}-6-(3-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-(1H-indazol-6-ylamino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(pyrimidin-5-yl)-8-[(2,2,2-trifluoroethyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-[(2,2,2-trifluoroethyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-[2-(dimethylamino)ethyl]-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-4-methylpyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-({6-[(2S)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({6-[(2S)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-(2-methoxyethyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
2-[2-(dimethylamino)ethyl]-6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(2-aminopyrimidin-5-yl)-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridin-2-yl)-8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(6-methoxypyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(3-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethoxypyrimidin-5-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethoxypyrimidin-5-yl)-8-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethoxypyrimidin-5-yl)-8-({4-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-({4-[2-(4-ethylpiperazin-1-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;

6-(2,4-dimethoxypyrimidin-5-yl)-8-({4-[2-(4-ethylpiperazin-1-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(4-ethylpiperazin-1-yl)ethyl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-8-{[4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-6-(5-amino-6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-({4-[2-(4-ethylpiperazin-1-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-[(4-{2-[4-(morpholin-4-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-[(4-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2S)-2-methylmorpholin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-({3-methyl-4-[(2S)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-{6-[2-(pyrrolidin-1-yl)ethoxy]pyridin-2-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-ethoxypyrimidin-5-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(4-methylpiperazin-1-yl)pyridin-2-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(morpholin-4-yl)pyridin-2-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-[6-(pyrrolidin-1-yl)pyridin-2-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-ethoxypyrimidin-5-yl)-8-({6-[(2S)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-ethoxypyrimidin-5-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-ethoxypyrimidin-5-yl)-8-({3-methyl-4-[(2S)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-({[4-(morpholin-4-yl)phenyl]methyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-({3-methyl-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-aminopyridin-3-yl)-8-{[4-(oxan-4-yloxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(methylamino)pyrimidin-5-yl]-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(methylamino)pyrimidin-5-yl]-8-[(4-{2-[4-(morpholin-4-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;

6-[2-(methylamino)pyrimidin-5-yl]-8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(methylamino)pyrimidin-5-yl]-8-{[4-(oxan-4-yloxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(methylamino)pyrimidin-5-yl]-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-(2-methoxyethyl)-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-[(2-methyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]phenyl}amino)-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(4-{2-[4-(dimethylamino)piperidin-1-yl]ethyl}phenyl)amino]-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(2-methylpyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl}phenyl)amino]-6-(2-methyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-({[4-(morpholin-4-yl)phenyl]methyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-{[2-(propane-2-sulfonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methyl-1,3-thiazol-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-{[2-(methylsulfanyl)phenyl]amino}-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methylpyridin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(3-phenoxyphenyl)amino]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methylpyridin-2-yl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(2-ethoxyphenyl)amino]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-[(3-methyl-1H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-[(3-methyl-1H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;

8-[(3-methyl-1H-indazol-6-yl)amino]-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(3-methyl-1H-indazol-6-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl]-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-[6-(morpholin-4-yl)pyridin-2-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(dimethylamino)pyridin-2-yl]-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(3-methoxypyrazin-2-yl)-8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-{[3-methyl-4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-[(5-methoxy-2-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-{[2-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-{[2-methoxy-5-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-(1H-indazol-6-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-[(2-methoxy-5-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
N-(3-{[1-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]amino}-4-methoxyphenyl)acetamide
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-{[2-methoxy-4-(phenylamino)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(5-chloro-2-methoxyphenyl)amino]-8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-[(2-methoxy-5-nitrophenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-{[3-(trifluoromethoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(3-methoxy-4-phenylphenyl)amino]-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-6-[(3-methoxy-4-phenylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-[(2-methyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-{[6-(oxan-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-6-(3-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethoxypyrimidin-5-yl)-8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethoxypyrimidin-5-yl)-8-{[3-methyl-4-(2-methylmorpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methylpyrazin-2-yl)-8-[(2,3-dimethyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-{[3-methyl-4-(2-methylmorpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-2-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-8-({3-methyl-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-{6-[2-(pyrrolidin-1-yl)ethoxy]pyridin-2-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-8-({3-methyl-4-[(2S)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[4-(dimethylamino)piperidin-1-yl]ethyl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(oxan-4-yloxy)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
N-{4-[1-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]phenyl}acetamide
8-({2-[(2R)-2-methylmorpholin-4-yl]pyrimidin-5-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl}phenyl)amino]-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-6-(2-methyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[4-(dimethylamino)piperidin-1-yl]ethyl}phenyl)amino]-6-(2-methyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[1-(propan-2-yl)piperidin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-8-({6-[(2S)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-methyl-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[6-(piperazin-1-yl)pyridin-3-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

8-[(4-{2-[4-(morpholin-4-yl)piperidin-1-yl]ethyl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(3-fluoropropyl)piperidin-4-yl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(3-fluoropropyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methoxyethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-{[3-methyl-4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-({3-methyl-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({4-[1-(3-fluoropropyl)piperidin-4-yl]-3-methylphenyl}amino)-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-({3-methyl-4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methylpyridin-2-yl)-8-[(4-{2-[4-(morpholin-4-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methylpyridin-2-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methylpyridin-2-yl)-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-[(4-{2-[4-(morpholin-4-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-[(2-methyl-2H-indazol-6-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-(2-methyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-fluoro-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-fluoro-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-cyclopropylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[4-(dimethylamino)piperidin-1-yl]ethyl}phenyl)amino]-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl}phenyl)amino]-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(methylamino)pyrimidin-5-yl]-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(3-fluoropropyl)piperidin-4-yl]phenyl}amino)-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methylpyrimidin-5-yl)-8-{[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-{[3-methyl-4-(oxan-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-({2-methyl-5-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({2-methyl-5-[2-(morpholin-4-yl)ethoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
4-{[3-(6-methoxypyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N,2-dimethylbenzamide;
8-[(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}phenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-[(4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methyl-1,3-thiazol-4-yl)-8-{[4-(oxan-4-yloxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(3-fluoropropyl)piperidin-4-yl]phenyl}amino)-6-(2-methyl-1,3-thiazol-4-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methylpyridin-2-yl)-8-{[4-(oxan-4-yloxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(3-fluoropropyl)piperidin-4-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methyl-1,3-thiazol-2-yl)-8-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methyl-1,3-thiazol-2-yl)-8-{[4-(oxan-4-yloxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(4-hydroxypiperidin-1-yl)ethyl]phenyl}amino)-6-(4-methyl-1,3-thiazol-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-methyl-1,3-thiazol-2-yl)-8-({4-[1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;

6-(4-methyl-1,3-thiazol-2-yl)-8-({2-[(2R)-2-methylmorpholin-4-yl]pyrimidin-5-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-fluoro-5-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-fluoro-5-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-fluoro-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-fluoro-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[6-(1-methylpiperidin-4-yl)pyridin-3-yl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-{[6-(1-methylpiperidin-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,6-dimethylphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl 4-(4-{[3-(2-butoxyphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate;
6-(2-butoxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl 4-(4-{[3-(2-ethoxy-5-methylphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate;
6-(2-ethoxy-5-methylphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl 4-(4-{[8-oxo-3-(2-propoxyphenyl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-(2-propoxyphenyl)-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl 4-[4-({8-oxo-3-[2-(propan-2-yloxy)phenyl]-7,8-dihydro-2,7-naphthyridin-1-yl}amino)phenyl]piperidine-1-carboxylate;
8-{[4-(piperidin-4-yl)phenyl]amino}-6-[2-(propan-2-yloxy)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl 4-(4-{[8-oxo-3-(2-phenoxyphenyl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate;
6-(2-phenoxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[2-(methylamino)pyrimidin-5-yl]-8-[(4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-6-[2-(methylamino)pyrimidin-5-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-8-({4-[2-(morpholin-4-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methylpyrazin-2-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-8-({3-methyl-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-8-({3-methyl-4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-(2-methanesulfonylethyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-({6-[(2S)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;

8-({3-fluoro-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
4-{[3-(6-methoxypyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-N-propylbenzamide;
8-({4-[1-(2,3-dihydroxypropyl)piperidin-4-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methylpyridin-2-yl)-8-[(4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
N,2-dimethyl-4-{[3-(6-methylpyridin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}benzamide;
6-(2-aminopyrimidin-5-yl)-8-[(3-chlorophenyl)amino]-2-(2-methoxyethyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-(2-methoxyethyl)-8-[(3-methylphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methoxypyrazin-2-yl)-2-(2-methoxyethyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3-methoxyphenyl)amino]-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3-methylphenyl)amino]-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3-chlorophenyl)amino]-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(1-methyl-1H-pyrazol-4-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(2-methanesulfonyl-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(2-methanesulfonyl-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(2,2-dimethylmorpholin-4-yl)-3-methylphenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(2,2-dimethylmorpholin-4-yl)-3-methylphenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethoxypyrimidin-5-yl)-8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-{[4-(pyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,4-dimethoxypyrimidin-5-yl)-8-({4-[1-(2-methoxyethyl)pyrrolidin-3-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methoxyethyl)pyrrolidin-3-yl]phenyl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[6-(oxan-4-yl)pyridin-3-yl]amino}-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-({4-[1-(4,4,4-trifluorobutyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrazin-2-yl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-ethylpyrrolidin-3-yl)phenyl]amino}-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

4-(4-methoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
N-methyl-4-(8-{[4-(morpholin-4-yl)phenyl]amino}-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzamide;
8-{[4-(morpholin-4-yl)phenyl]amino}-4-[3-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
4-[3-(dimethylamino)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-(4-chlorophenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(morpholin-4-yl)phenyl]amino}-4-[4-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-ethyl-8-{[4-(1-ethylpyrrolidin-3-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2,6-dimethoxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
tert-butyl 4-(4-{[3-(2,6-dimethoxyphenyl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidine-1-carboxylate;
8-{[2-(3-methylbutoxy)phenyl]amino}-6-(phenylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-({4-[(4-ethylpiperazin-1-yl)methyl]phenyl}amino)-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-(3-methylbutoxy)phenyl]amino}-6-{[2-(propane-2-sulfonyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-(3-methylbutoxy)phenyl]amino}-6-(pyridin-3-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-(3-methylbutoxy)phenyl]amino}-6-{[3-(piperidin-1-ylmethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(2-methoxy-5-phenoxyphenyl)amino]-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-(3-methylbutoxy)phenyl]amino}-6-{[3-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-(3-methylbutoxy)phenyl]amino}-6-{[2-(methylsulfanyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-(3-methylbutoxy)phenyl]amino}-6-[3-(pyrrolidin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
5-(1-{[2-(3-methylbutoxy)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)pyridine-3-carbonitrile
6-{2-[(dimethylamino)methyl]phenyl}-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-(3-methylbutoxy)phenyl]amino}-6-[3-(morpholin-4-ylcarbonyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
4-methoxy-3-(1-{[2-(3-methylbutoxy)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzaldehyde
6-(2,6-dimethoxyphenyl)-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-ethoxypyridin-3-yl)-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
3-methoxy-2-(1-{[2-(3-methylbutoxy)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzonitrile
3-methoxy-2-(1-{[2-(3-methylbutoxy)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)benzamide;
2-methyl-5-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
3-[(1-{[4-(morpholin-4-yl)phenyl]amino}-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]benzene-1-sulfonamide;
8-{[2-(3-methylbutoxy)phenyl]amino}-6-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;

8-{[2-(3-methylbutoxy)phenyl]amino}-6-[4-(piperazin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-{[4-(4-aminopiperidin-1-yl)pyridin-3-yl]amino}-8-{[2-(3-methylbutoxy)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-(3-methylbutoxy)phenyl]amino}-6-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
3-methoxy-2-(8-oxo-1-{[4-(piperidin-4-yl)phenyl]amino}-7,8-dihydro-2,7-naphthyridin-3-yl)benzamide;
6-{2-[(dimethylamino)methyl]phenyl}-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-chloro-6-methoxyphenyl)-8-{[4-(piperidin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(1-methyl-1H-pyrazol-4-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-[(1-methyl-1H-pyrazol-4-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridin-2-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-4-methylpyridin-2-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
1-[2-(4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)ethyl]piperidine-3-carboxylic acid
8-{[1-(piperidin-4-yl)-1H-pyrazol-4-yl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
1-[2-(4-{[3-(2-methoxypyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)ethyl]piperidine-3-carboxylic acid
6-(6-amino-5-methylpyridin-3-yl)-8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-6-(2-methylpyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-cyclopropylpiperidin-4-yl)-3-methylphenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-cyclopropylpiperidin-4-yl)-3-methylphenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
4-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-[2-methyl-4-(trifluoromethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-(4-methoxy-2-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-(5-methoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[3-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-6-[6-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-6-[6-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2-dihydro-2,7-naphthyridin-1-one;

6-(6-methylpyridin-3-yl)-8-{[4-(piperidin-4-yl)-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-{[4-(piperidin-4-yl)-3-(trifluoromethyl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-cyclopropylpiperidin-4-yl)-3-methylphenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({6-[(2R)-2-methylmorpholin-4-yl]pyridin-3-yl}amino)-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(2,2-dimethylmorpholin-4-yl)-3-methylphenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)-3-(trifluoromethyl)phenyl]amino}-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
1-[2-(4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)ethyl]piperidine-4-carboxylic acid
1-[2-(4-{[3-(2-methoxypyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)ethyl]piperidine-4-carboxylic acid
8-({6-[1-(2-methoxyethyl)piperidin-4-yl]pyridin-3-yl}amino)-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-{[1-(piperidin-4-yl)-1H-pyrazol-4-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({6-[1-(2-methoxyethyl)piperidin-4-yl]pyridin-3-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-hydroxypyrimidin-5-yl)-8-{[1-(piperidin-4-yl)-1H-pyrazol-4-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-amino-5-methylpyridin-3-yl)-8-{[6-(oxan-4-yl)pyridin-3-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[(3-fluorophenyl)methyl]amino}-6-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(1-methyl-1H-pyrazol-4-yl)amino]-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-1,2-dihydro-2,7-naphthyridin-1-one;
3-[4-(2-methyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]propanenitrile
6-(2-aminopyrimidin-5-yl)-8-[(3-methoxyphenyl)amino]-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one;
4-(3-chloro-2-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(oxan-4-yl)-1,3-thiazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(piperidin-3-yl)-1,3-thiazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(2-aminoethyl)-1,3-thiazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[2-(pyridin-3-yl)-1,3-thiazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-methyl-4-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

8-({3-methyl-4-[6-(piperazin-1-yl)pyridin-3-yl]phenyl}amino)-6-(6-methylpyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(piperidin-4-yl)-3-(trifluoromethyl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-acetylpiperidin-4-yl)-3-methylphenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1-methylpiperidin-4-yl)-3-(trifluoromethyl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
5-[1-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]pyridine-2-carbonitrile
6-(6-methoxypyridin-2-yl)-8-({4-[1-(4,4,4-trifluorobutyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methoxyethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(6-methoxypyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methoxyethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(5-methoxypyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
2-(2-aminoethyl)-6-(2-aminopyrimidin-5-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-6-(6-methoxypyridin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(5-amino-6-methylpyrazin-2-yl)-8-({4-[1-(2-methoxyethyl)piperidin-4-yl]-3-methylphenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{1-[2-(dimethylamino)acetyl]pyrrolidin-3-yl}phenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyrimidin-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(6-methoxypyridin-2-yl)-8-({3-methyl-4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
4-phenyl-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
4-(4-methoxyphenyl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
4-(4-chlorophenyl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-4-[4-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-4-[3-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
4-[3-(dimethylamino)phenyl]-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
4-(4-methoxy-2-methylphenyl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
4-[2-methyl-4-(trifluoromethyl)phenyl]-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
4-(1-methyl-1H-pyrazol-4-yl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
4-(5-methoxypyridin-3-yl)-8-[(4-{2-[4-(pyrrolidin-1-yl)piperidin-1-yl]ethyl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-methyl-6-(pyrimidin-4-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;

8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methanesulfonylethyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(1-methyl-1H-pyrazol-4-yl)-8-[(3-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
3-[4-(4-{[3-(2-methoxypyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-2-methylphenyl)piperidin-1-yl]propanenitrile
6-(2-aminopyrimidin-5-yl)-2-(2-hydroxy-3-methoxypropyl)-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-[3-(dimethylamino)propyl]-8-[(3-methoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
2-[4-(2-methyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]acetonitrile
2-[4-(2-methyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]acetamide
8-({4-[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]-3-methylphenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3-methoxyphenyl)amino]-2-(3-methoxypropyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3,5-dimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3,5-dimethoxyphenyl)amino]-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3,4,5-trimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(hydroxymethyl)pyridin-3-yl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-[6-(hydroxymethyl)pyridin-3-yl]-8-({3-methyl-4-[(2R)-2-methylmorpholin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[4-(1,2-dimethylpiperidin-4-yl)-3-fluorophenyl]amino}-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(2-methylphenyl)amino]-6-[3-(pyrrolidin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(2-methoxyphenyl)amino]-6-[3-(pyrrolidin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(2-ethoxyphenyl)amino]-6-[3-(pyrrolidin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-(propan-2-yloxy)phenyl]amino}-6-[3-(pyrrolidin-1-yl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3,5-dimethoxyphenyl)amino]-2-(2-methoxyethyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3,5-dimethoxyphenyl)amino]-2-[2-(dimethylamino)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one;
8-({1-[1-(2-methoxyethyl)piperidin-4-yl]-1H-pyrazol-4-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({1-[1-(2-methanesulfonylethyl)piperidin-4-yl]-1H-pyrazol-4-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-[(1-methyl-1H-pyrazol-4-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-[(3,4,5-trimethoxyphenyl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
4-[6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl]-N-methylbenzamide;

6-(4-ethylpiperazin-1-yl)-4-(4-methoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
4-(4-chlorophenyl)-6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-4-[4-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-4-[3-(trifluoromethyl)phenyl]-1,2-dihydro-2,7-naphthyridin-1-one;
4-[3-(dimethylamino)phenyl]-6-(4-ethylpiperazin-1-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-4-(4-methoxy-2-methylphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-4-[2-methyl-4-(trifluoromethyl)phenyl]-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-4-(1-methyl-1H-pyrazol-4-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(4-ethylpiperazin-1-yl)-4-(5-methoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-methyl-6-(pyridin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}phenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{1-[2-(ethylamino)acetyl]piperidin-4-yl}phenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(4-{1-[2-(ethylamino)acetyl]piperidin-4-yl}phenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
N-[3-(2-aminopyrimidin-5-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]-4-fluorobenzamide;
4-fluoro-N-[3-(6-methoxypyrazin-2-yl)-8-oxo-7,8-dihydro-2,7-naphthyridin-1-yl]benzamide;
6-(2-amino-6-methylpyrimidin-4-yl)-8-({4-[1-(2-methoxyethyl)piperidin-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-(2-hydroxyethyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-[(dimethylamino)methyl]-1H-indazol-6-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-[(dimethylamino)methyl]-1H-indazol-6-yl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({3-[(dimethylamino)methyl]-1H-indazol-6-yl}amino)-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(2-methanesulfonyl-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]-6-(6-methylpyridin-3-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-[(2-methanesulfonyl-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-methyl-6-[(5-methylpyridin-2-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-methyl-6-[(3-methylpyridin-2-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(1-amino-7-methyl-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]pyridine-3-carbonitrile
6-[(1-amino-7-methyl-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl)amino]pyridine-3-carboxamide
8-amino-2-methyl-6-[(1-methyl-1H-pyrazol-3-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-methyl-6-(1,3-thiazol-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-methyl-6-(pyridazin-3-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-methyl-6-(pyrazin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-benzyl-6-(pyrimidin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-methyl-6-(pyrimidin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;

2-[4-(4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}-1H-pyrazol-1-yl)piperidin-1-yl]acetonitrile
8-({4-[1-(2,3-dihydroxypropyl)piperidin-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2,3-dihydroxypropyl)piperidin-4-yl]phenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)-6-(2-methoxypyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-({1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}amino)-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-({1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-2-(2-methoxyethyl)-1,2-dihydro-2,7-naphthyridin-1-one;
2-[6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-1-oxo-1,2-dihydro-2,7-naphthyridin-2-yl]acetonitrile
8-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-methoxypyrimidin-5-yl)-8-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-2-[2-(dimethylamino)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-[(3,4-dimethoxyphenyl)amino]-2-(2-hydroxy-3-methoxypropyl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-({4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-({1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-2-methyl-8-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-(2-aminopyrimidin-5-yl)-8-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]amino}-2-[2-(morpholin-4-yl)ethyl]-1,2-dihydro-2,7-naphthyridin-1-one;
N-methyl-2-[4-(2-methyl-4-{[8-oxo-3-(pyrimidin-5-yl)-7,8-dihydro-2,7-naphthyridin-1-yl]amino}phenyl)piperidin-1-yl]acetamide
8-[(2-acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
8-{[2-(2-methoxyethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]amino}-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;
6-(pyrimidin-5-yl)-8-{[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazol-6-yl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-{imidazo[1,2-a]pyrimidin-6-yl}-2-methyl-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-{8-methylimidazo[1,2-a]pyrazin-6-yl}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

6-{imidazo[1,2-a]pyrimidin-6-yl}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;

2-({1-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}-3-methylphenyl)amino]-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl}amino)-6-methylbenzene-1-sulfonamide;

2-{[1-({4-[1-(2-methoxyethyl)piperidin-4-yl]-3-methylphenyl}amino)-8-oxo-7,8-dihydro-2,7-naphthyridin-3-yl]amino}-6-methylbenzene-1-sulfonamide;

8-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}-3-methylphenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

8-[(4-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}-3-methylphenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

8-[(4-{1-[2-(ethylamino)acetyl]piperidin-4-yl}-3-methylphenyl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

8-[(4-{1-[2-(ethylamino)acetyl]piperidin-4-yl}-3-methylphenyl)amino]-6-(6-methoxypyrazin-2-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

8-[(6-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}pyridin-3-yl)amino]-6-(pyrimidin-5-yl)-1,2-dihydro-2,7-naphthyridin-1-one;

6-(6-methoxypyrazin-2-yl)-8-({4-[2-(4-methylpiperazin-1-yl)ethyl]phenyl}amino)-1,2-dihydro-2,7-naphthyridin-1-one;

6-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-2-methyl-8-(propan-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;

6-(2-aminopyrimidin-5-yl)-2-methyl-8-(propan-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;

8-amino-2-benzyl-6-(pyrimidin-4-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;

8-amino-2-benzyl-6-(pyridin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;

8-amino-2-benzyl-6-[(5-methylpyridin-2-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;

8-amino-2-benzyl-6-[(3-methylpyridin-2-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;

2009209304 21 Mar 2012

8-amino-2-benzyl-6-(pyridazin-3-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one;
4-{6-[(2-methoxyethyl)amino]-8-{[4-(morpholin-4-yl)phenyl]amino}-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl}-N-methylbenzamide;
6-[(2-methoxyethyl)amino]-4-(4-methoxyphenyl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-benzyl-6-[(1-methyl-1H-pyrazol-3-yl)amino]-1,2-dihydro-2,7-naphthyridin-1-one;
6-[(2-methoxyethyl)amino]-4-(5-methoxypyridin-3-yl)-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
6-{8-methylimidazo[1,2-a]pyridin-6-yl}-8-{[4-(morpholin-4-yl)phenyl]amino}-1,2-dihydro-2,7-naphthyridin-1-one;
8-amino-2-benzyl-6-(pyrazin-2-ylamino)-1,2-dihydro-2,7-naphthyridin-1-one, and
8-{[4-(morpholin-4-yl)phenyl]amino}-6-{1H,2H,3H-pyrrolo[2,3-b]pyridin-5-yl}-1,2-dihydro-2,7-naphthyridin-1-one.

22. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1 to 21 and a pharmaceutically acceptable carrier.

23. Use of a compound of any one of claims 1 to 21 in the manufacture of a medicament for treating a Syk-mediated disease or condition, wherein the disease or condition is asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohns disease, bronchitis, dermatitis, allergic rhinitis, psoriasis, scleroderma, urticaria, rheumatoid arthritis, multiple sclerosis, cancer, breast cancer, HIV, lupus, lymphoma, osteosarcoma, melanoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.

24. A method for treating a Syk-mediated disease or condition, comprising administering to a system or subject in need of such treatment an effective amount of a compound of any one of claims 1 to 21, or pharmaceutically acceptable salts or pharmaceutical compositions thereof.

25. The method of claim 24, wherein the disease or condition is an inflammatory disease, a respiratory disease, a cell-proliferative disease or an autoimmune disease.

26. The method of claim 25, wherein the disease or condition is asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohns disease, bronchitis, dermatitis, allergic rhinitis, psoriasis, scleroderma, urticaria, rheumatoid arthritis, multiple sclerosis, cancer, breast cancer, HIV, lupus, lymphoma, osteosarcoma, melanoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.

27. Compound according to claim 1, composition according to claim 22, use according to claim 23 or method according to claim 24 substantially as hereinbefore described with reference to any one of the examples.